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Abstract 
Depression is a common condition, affecting around one in 20 people worldwide. 
It is challenging conceptually and clinically, with treatment being ineffective for 
many, and significant consequences for individuals and societies alike. 
Depression is particularly problematic during pregnancy, where it is no less 
common, but poses additional difficulties. Both depression and its 
pharmacological treatments are associated with a range of short- and longer-
term sequelae for offspring, and current data is insufficient to allow fully 
informed decisions to be made by mothers, midwives, or doctors. 
Research is affected by practical, ethical, and methodological issues, and a 
myriad of confounding factors, which combine to increase uncertainties over the 
risks and benefits of prescribing (or not). Retrospective and prospective 
observational studies accompany epidemiological data linkage and meta-
analyses involving millions of subjects, in contributing to both current knowledge 
and testable hypotheses to inform future directions for research, while clinical 
and preclinical studies with smaller sample sizes provide invaluable and 
complementary details. However, significant gaps remain, not least in delivering 
optimal care to each individual mother and baby.   
While the overall emerging picture appears reassuring to some, others 
acknowledge that we do not even possess all the pieces of the puzzle yet. There 
remains an urgent need for more comprehensive and relevant data. This thesis 
presents the findings from a series of pilot studies on evaluating the 
characteristics and consequences of antenatal exposure to selective serotonin 
reuptake inhibitors. Up to one in 10 women in the general Scottish population 
may be exposed to an antidepressant at some point during pregnancy, but 
adverse outcomes may be related more to underlying maternal depression, 
rather than its pharmacological treatment. We highlight areas of both 
intelligence and ignorance, and make proposals for future research. 
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Preface 
The various components of this project were presaged in August 2006, when my 
Supervisor, Professor Jonathan Cavanagh (then Senior Lecturer in Psychiatry at 
the University of Glasgow), invited the new Higher Trainees in Psychiatry (of 
which I was one) to speak to him if they were interested in research. 
After doing so I agreed to process data on antenatal prescribing for patients 
receiving care via the local specialist Perinatal Mental Health Service, with a 
view to establishing baseline characteristics and informing clinical care. Through 
subsequent collaboration with various colleagues in the University of Glasgow 
and the University of Columbia, and in light of existing concerns about the 
potential sequelae of early exposure to pharmacological perturbation of 
serotonin-mediated processes, we progressed to imaging neonates via magnetic 
resonance, in an attempt to identify neurodevelopmental consequences of 
exposure to antenatal antidepressants, specifically selective serotonin reuptake 
inhibitors. 
I registered as a doctoral student in October 2008, with the aim of completing 
the scanning as a pilot study. However, circumstances intervened (e.g. scanning 
was stopped in early 2012 by a change in local NHS services), and our pilot 
became a feasibility study instead. Concurrently we had been reanalysing the 
data on antenatal exposure to antidepressants in the specialist Perinatal Mental 
Health Service, and extended our methodology to a local general maternity 
service, thus allowing more representative characterisation of prescribing 
patterns in the population. We then expanded this work to include both a check 
on accuracy of our existing data, and to identify what data on early clinical 
outcomes could be established. 
This thesis presents our findings. 
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Chapter 1 - Perinatal depression: An overview 
 
 “Depression is the cruelest disease in the world.” 
“Postpartum depression is a stunning example of its cruelty.” 
Phil Baumann 
	
 
Depression is pandemic. 
Recently described in Nature as “the biggest blight on human society — bar 
none”, that “hits people with a double-whammy” of the suffering caused by the 
“agony of the symptoms”, as well as “the way in which those symptoms 
interfere with how the person would otherwise like to live”, depression remains 
under-diagnosed, under-treated, and stigmatised compared with other 
conditions, with treatment being underfunded (Nature, 2014; Smith, 2014). This 
is related to depressive disorders being poorly understood, and research 
underfunded, too, particularly in contrast with cancers (Ledford, 2014). At 
worst, depression has been perceived as lacking both validity as a medical 
diagnosis and effective treatments (attitudes not without empirical support), 
and has certainly lacked the level of advocacy witnessed in cancer (Hyman, 
2014; Ledford, 2014). Comparisons with cancer are commonplace, with those 
who have suffered both making statements such as, “Depression is worse than 
cancer”, and “I would rather have terminal cancer than depression”, on the 
grounds that depression has no guaranteed end, friends and family withdraw 
rather than rally round, and one feels dead already, even while still alive 
(Goddard, 2008; lonesomeroad, 2014). Professor Lewis Wolpert famously 
described his experience of depression as a “dark destroyer”, admitting with 
shame that, “It was the worst experience of my life. More terrible even than 
watching my wife die of cancer” (Wolpert, 1999; Wolpert, 2010). 
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According to the World Health Organization (WHO) (2012), depressive disorders 
are one of the leading direct causes of disability worldwide, and major 
contributors to the global burden of disease, including that attributable to 
ischaemic heart disease and suicide (WHO, 2012; Ferrari et al., 2013). They are 
“responsible for more ‘years lost’ to disability than any other condition”, due to 
both their prevalence and chronicity (Smith, 2014). Estimated to affect more 
than 350 million people internationally (~5% of the world’s population), unipolar 
depression is associated with greater ill health than other major chronic diseases 
such as ischaemic heart disease and diabetes, and is projected to become the 
leading contributor to the global burden of disease by 2030 (Moussavi et al., 
2007; WHO, 2011). It is well established that women are affected 
disproportionately and, due to complex gene-environment interactions, are at 
around twice the risk of suffering depression than men (Kessler, 2003; Kendler 
et al., 1995). Lépine and Briley (2011) provide a helpful review of the 
prevalence and consequences of depressive illness. 
As a poorly understood complex acute and chronic brain condition, depression 
poses a multiplicity of challenges to researchers as well as sufferers and carers. 
Firstly, in addition to the practical problems associated with its prevalence and 
impact, depression is challenging conceptually. In the broadest sense depression 
is a ubiquitous human experience, such that it would be highly abnormal for 
anyone never to experience low mood, albeit usually appropriate to the external 
environment. There appears to be no satisfactory answer to the critical 
question, when does unhappiness become a clinical condition? In particular, 
context, psychopathology, pragmatism, and/or severity, cannot be used to 
determine thresholds or criteria for diagnosis, nor can response to treatment 
even demonstrate the validity or presence of depression as a diagnosable illness, 
as it appears that it is the minority of those with recurrent episodes who achieve 
remission as traditionally defined (Trivedi et al., 2006; Parker, 2009; Maj, 2011). 
While the term “major depressive disorder” is frequently employed to signify a 
syndrome of sufficient severity to require clinical intervention, the word 
“depression” will be used hereafter to refer to all depressive experiences, both 
“major” and “minor”, in light of the difficulties of more precise definition.  
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Depressive illness is formulated as a mental disorder characterised by dysthymia, 
anhedonia and anergia, with these core features being accompanied by a range 
of other psychological and physical problems (WHO, 1992; American Psychiatric 
Association, 2013). However, despite the term being used as if it is a well-
circumscribed unitary phenomenon, it is acknowledged that depression is a 
neurocognitively-mediated clinical syndrome, a heterogeneous group of 
disorders associated with a complex array of biological, psychological and social 
factors, with unclear boundaries (Parker, 2000; Antonijevic, 2006; Horwitz & 
Wakefield, 2007). Depression is not simply a singular shared experience directly 
attributable to one discrete neuropathology, and therefore cannot be 
conceptualised in a reductionist manner. Some have pointed out that depression 
is analogous to other clinical phenomena with a range of aetiologies such as pain 
or fever, explaining why categorisation and treatment remain suboptimal 
(Parker, 2009; Ledford, 2014). Nevertheless, despite these challenges to 
elucidating the neurobiological correlates of depressive psychopathology for the 
purpose of identifying specific targeted therapies, safe, (broadly speaking) 
effective, and (reasonably) well-tolerated pharmacological interventions for 
treating major depressive disorder have been available for several decades; 
arguably, however, there have been no radical advances since the 1950s (Bauer 
et al., 2002a; Bauer et al., 2002b; Cleare et al., 2015; Hyman, 2014). 
Secondly, depression remains challenging clinically. Perhaps closely related to 
the underlying conceptual and aetiological uncertainties, acute depressive 
illness not infrequently progresses to recurrent and chronic depressive illness, 
accompanied by the phenomena of “kindling” and increasing treatment 
resistance, particularly in those with genetic risk factors and stressful life events 
(Kendler, Thornton & Gardner, 2000; Kendler, Thornton & Gardner 2001; Monroe 
& Harkness, 2005). It is well recognised that outcomes for patients can be poor, 
with perhaps less than 50% achieving sustained remission and recovery (Trivedi 
et al., 2006; Pigott et al., 2010). And, like other conditions, depression of any 
severity is associated with increased mortality, both directly via suicide, and 
indirectly via medical comorbidities (Miret et al., 2013; Cuijpers et al., 2013). It 
is significant to note that depression is known to place a disproportionate burden 
on those in the age range 15-44, i.e. women of childbearing potential (WHO, 
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2013). The usual morbidity and mortality of untreated depression are 
complicated in pregnancy by additional risks to the developing fetus such as 
intrauterine growth retardation, low birth weight, preterm delivery, and longer-
term educational and neurocognitive difficulties (American College of 
Obstetricians & Gynaecologists [ACOG], 2008; Stein et al., 2014). 
And thirdly, depression is also challenging with regards to its costs to the 
individual sufferer, his or her family, health services, and society, in terms of 
personal identity and wellbeing, years lived with disability, care, healthcare 
interventions, and financial issues related to employment and benefits. Nowhere 
are these issues more apparent than when depression affects young women in 
the perinatal period, when the “double” becomes at least a “triple whammy”, 
with immediate and longer term consequences on offspring, too (Centre for 
Maternal and Child Enquiries, 2011). 
 
Perinatal mental health problems 
Although traditionally thought of as protective against mental disorder (including 
suicide), pregnancy and in particular the postnatal period are now recognised to 
be associated with significant mental health problems, including psychotic, 
affective, and neurotic disorders (Oates, 2003). Postpartum psychosis, a 
condition that affects between one and two per thousand women, was described 
by Hippocrates almost 2,500 years ago, but it was not until the 19th century that 
Marcé published his classic treatise (Doyle, Carballedo & O’Keane, 2015). Over 
100 years later Kendell et al’s seminal study demonstrated a striking increase in 
the risk of admission to psychiatric hospital due to mental illnesses in the early 
puerperium, with the risk being greatest for psychotic illness, in primiparous 
women, in the first 30 postnatal days (relative risk 35.0) (Kendell et al., 1987). 
These findings have recently been replicated, confirmed, and extended in 
Scotland, and similar admission patterns for non-psychotic major depression in 
perinatal women reported in Australia (Xu et al., 2012; Langan Martin et al., 
2016). 
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Postnatal maternal admission to psychiatry is not the most concerning risk 
associated with perinatal mental illness, however. Suicide, although mercifully 
rare, is also a significant risk associated with perinatal mood disorders (Oates, 
2003). Alongside several high profile tragedies involving acutely psychiatrically 
unwell mothers killing their infants along with themselves (e.g. Daksha Emson, a 
consultant psychiatrist with bipolar affective disorder), the recent heightened 
awareness of perinatal mental health issues was also driven by the serial 
Confidential Enquiries into Maternal and Child Health (CEMACH), now conducted 
via the Centre for Maternal and Child Enquiries (CMACE) (North East London 
Strategic Health Authority, 2003; Jones & Craddock, 2005). The CEMACH/CMACE 
reports identified suicide as the leading cause of maternal death during 
pregnancy and within the first postnatal year from the Fifth Report (covering 
1997-99) until the Seventh Report (2003-5) (Lewis & Drife [eds], 2001; Lewis 
[ed], 2004; Lewis [ed], 2007) (Table 1-1). These findings were based on careful 
analyses of data not hitherto included in such projects, and included deaths up 
to one year postpartum, taking account of so-called late maternal deaths, 
including those due to indirect (psychiatric) causes. The reports made and 
precipitated numerous recommendations regarding the provision of specialist 
services for women suffering from mental illnesses in the perinatal period, 
including the National Institute for Health and Clinical Excellence (NICE), the 
Royal College of Obstetricians and Gynaecologists (RCOG), and the Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines. (NICE CG45, 2007 [updated 
2014]); RCOG, 2011; SIGN, 2012). Perinatal mental health care, including via 
mother and baby units, became a national priority in Scotland, enshrined in the 
Mental Health (Care and Treatment) (Scotland) Act (MHA) 2003 (Lewis [ed], 
2004). In particular, Scottish Health Boards became obligated to provide mothers 
of children less than one year old who require inpatient care “such services and 
accommodation as are necessary to ensure that the woman is able, if she 
wishes, to care for the child in hospital” (so long as this “is not likely to 
endanger the health or welfare of the child”), whether detained or not (MHA, 
2003 p14: Part 4, Chapter 1, S24). Given that psychiatric admissions in the 
puerperium are likely to be required soon after delivery (especially for puerperal 
psychosis, which peaks within the first postnatal week), that separating babies 
from their primary care-giver is likely to adversely affect attachment, and that 
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such separation may well feed in to any persecutory maternal delusions, it is 
desirable that mothers can continue to care for their infants as much as 
possible. 
 
Table 1-1 – Maternal death rates and suicides 
 Maternal mortality  
Suicides 
 
 Rate per 100,000 maternities1 (N) Rate per 100,000 maternities (N) 
2000-2 13.07 (261) 1.10 (22) 
2003-5 13.95 (295) 0.95 (20) 
2006-8 11.39 (261) 1.27 (29) 
 
1 Direct and indirect causes combined 
 
However, despite the seriousness of postpartum psychosis, perinatal depression 
may be considered to pose equal if not greater problems, in terms of both 
prevalence and potential sequelae for mothers and progeny. Moreover, new 
onset depression during pregnancy can herald the start of persisting or chronic 
recurrent illness, with around two thirds of women experiencing more than one 
episode (Rahman & Creed, 2007; Pawlby et al., 2009; Reay et al., 2011; 
Woolhouse et al., 2014). Perinatal anxiety disorders are common, too, and 
neurotic and stress-related symptoms share similarities with perinatal 
depression, with overlapping obstetric and offspring consequences, being 
frequently comorbid (Ross & McLean, 2006; Alder et al., 2007; Kingston, Tough 
& Whitfield, 2012).  In addition to the clinical concerns, recent analyses 
concluded that perinatal mental health problems cost British society more than 
£8 billion per annual birth cohort in the long term, with more than two thirds of 
this attributable to sequelae for the child (Bauer et al., 2014). To put this in 
context, it is estimated that one episode of postnatal depression costs the 
United Kingdom’s (UK) National Health Service (NHS) around £74,000 on 
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average, equating to approximately £10,000 for every single UK birth. Using 
complex modelling, maternal and offspring lifetime costs of perinatal depression 
(due to health and social care, education, health-related quality of life losses, 
productivity losses, parents’ out-of-pocket expenditure, criminal justice, crime 
victim costs) are estimated to be largely attributable to the children’s adverse 
outcomes (pre-term birth, infant death, emotional problems, conduct problems, 
special educational needs, and leaving school without qualifications) (Bauer, 
Knapp & Parsonage, 2016). Unfortunately, and despite the financial motivators 
to provide clinically effective interventions for perinatal depression, significant 
uncertainty remains about cost effectiveness, mainly due to the lack of 
adequate research (Morrell et al., 2016). Moreover, an investigation into NHS 
service provision for postnatal depressions services by The Patients Association 
via a Freedom of Information request demonstrated widespread failings, with 
the majority of Primary Care Trusts who responded acknowledging that they did 
not even know the incidence of postnatal depression in their region (The 
Patients Association, 2011).  Notwithstanding these challenges to addressing the 
economic challenges, recent recommendations and commitments to invest in 
perinatal mental health services are welcome (National Maternity Review report, 
2016; BBC, 2016). 
The increasing awareness of the significance of the characteristics and 
consequences of perinatal depression is reflected by the exponential growth in 
associated research and publications. A PubMed search for “[*natal OR pregnan* 
or *partum] AND depression” in September 2015 yielded more than 12,000 
results, increasing from one paper published in 1939 to 822 in 2014 (Figure 1-1). 
However, these include numerous studies of small sample size and varying 
methodologies reporting an array of inconsistent findings (Wisner et al., 2009; 
Howard et al., 2014). 
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Figure 1-1 – Number of publications on perinatal depression by year 
 
 
Perinatal depression 
Perinatal mental illness is defined as those psychiatric disorders occurring during 
pregnancy and up to one year postpartum (O’Hara, Wisner & Asher, 2014). 
Historically, clinical and research focus has been on postnatal psychosis and 
depression, with more recent characterisation of other disorders both 
antenatally and postnatally (Waters et al., 2014). Paschetta et al. (2014) classify 
common perinatal mental disorders as depicted in Figure 1-2, indicating that 
both new onset and relapse in existing illness are included. At least in part due 
to the close temporal relationship between childbirth and low mood, postnatal 
depression was originally suspected to be nosologically distinct from depressive 
illness outwith the puerperium, a notion now largely abandoned, although 
uncertainties remain (Di Florio & Meltzer-Brody, 2015). On behalf of the 
Nosology Working Group of the Perinatal Section of the Royal College of 
Psychiatrists, Jones and Cantwell (2010) made five recommendations on the 
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classification of perinatal mood disorders with regards to potential future 
revisions to both DSM and ICD, seeking to harmonise the challenges in 
emphasising continuity with illness episodes outwith the perinatal period, while 
acknowledging the distinct timing and characteristics of antenatal and postnatal 
elation and depression.  
 
 
Figure 1-2 – Classification of common perinatal mental disorders 
 
Reprinted from American Journal of Obstetrics and Gynecology, Volume 210; Elena Paschetta, 
Giles Berrisford, Floriana Coccia, Jennifer Whitmore, Amanda G Wood, Sam Pretlove, Khaled MK 
Ismail; Perinatal psychiatric disorders: an overview, Pages 501-509.e6, Copyright Mosby, Inc. 
(2014), with permission from Elsevier. 
https://www.sciencedirect.com/journal/american-journal-of-obstetrics-and-gynecology  
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Distinguishing between puerperal psychosis and perinatal (antenatal and 
postnatal) non-psychotic depression is critical, as despite similarities there are 
significant differences in epidemiology, clinical management, risks, outcomes, 
and aetiology. For example, while there is no time in a woman’s life that she is 
more at risk of developing affective psychosis than immediately after delivery, 
particularly if she has a personal or family history of significant mental illness, 
the risk of significant new onset or relapse in pre-existing illness may be reduced 
during pregnancy itself (Kendell et al., 1987; Wieck et al., 1991; Robertson et 
al., 2005; Xu et al., 2012). In contrast, depressive symptoms (although not 
necessarily depressive illness) appear to be common both antenatally and 
postnatally, with up to 70% and 84% of women affected, respectively (Henshaw, 
2003; ACOG, 2008). Discriminating between antenatal and postnatal depression 
is not straightforward, as the two are closely related (approximately half of 
postnatal depressive episodes begin during pregnancy and, empirically as well as 
logically, antenatal episodes persist postpartum), and they pose overlapping 
risks to mother and offspring in both the short and longer term (Robertson et 
al., 2004; Rahman & Creed, 2007; Reay et al., 2011; Parker et al., 2015). 
 
Risk factors for perinatal depression 
Numerous biological, psychological, and social factors are associated with 
increased risk of both antenatal and postnatal depression. Howard et al. (2014) 
summarise key findings from 12 systematic reviews in their recent overview of 
non-psychotic perinatal psychiatric disorders, comparing and contrasting the 
overlapping and discrete profiles of depression during and following pregnancy. 
They lament the quality of the data available, highlighting the relative lack of 
systematic reviews, and the rarity of studies based on valid diagnoses, 
longitudinal perspectives, comparison groups, and representative population 
samples from which meaningful generalisable and ultimately clinical useful 
inferences can be reached. Notwithstanding, a number of relevant papers, 
including original research and review articles, report consistent conclusions, 
summarised helpfully in the systematic review by Lancaster et al. (2010) and 
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presented in Table 1-2 (Logsdon & Usui, 2001; Robertson et al., 2004; Howell et 
al., 2005; Ryan, Milis & Misri, 2005; Leigh & Milgrom, 2008; Pearlstein et al., 
2009; Ross & Dennis, 2009; Paschetta et al., 2014). 
Not all factors are specific either to discrete disorders, nor the perinatal period, 
and several are strongly interrelated and/or demonstrate a bidirectional 
relationship with depression. For example, maternal age is linked with 
socioeconomic status and social/partner support, and personal mental illness is 
associated with family history, substance misuse, and unintended pregnancy. 
Moreover, absence of evidence is not evidence of absence – it would seem odd if 
immigrant status or substance misuse were not associated with antenatal as well 
as postnatal depression. Risks are also culture-sensitive – while there is no 
association between offspring gender and postnatal depression in western 
populations, paternal negativity towards having a baby girl may be linked with 
postnatal depression in some populations (Robertson et al., 2004). 
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Table 1-2 – Risk factors for perinatal depression 
 Antenatal depression Postnatal depression 
Physical abuse/violence/trauma ü ü 
Sexual abuse  ü 
Stress/negative life events ü ü 
Socioeconomic deprivation ü ü 
Poor social support 
(including relationship with partner) 
ü ü 
Unintended pregnancy ü ü 
Immigrant status  ü 
Ethnicity  ü 
History of psychiatric disorder (especially depression) ü ü 
Anxiety during pregnancy ü ü 
Depression/unhappiness during pregnancy  ü 
Personality traits (including trait neuroticism) ü ü 
Substance misuse  ü 
Family history of psychiatric disorder  ü 
Young maternal age (<18) ü  
Previous miscarriages ü  
Hyperemesis gravidarum ü  
Multiparity  ü 
Multiple births  ü 
Chronic illness  ü 
Medical comorbidity ü ü 
Preterm birth  ü 
Low birthweight  ü 
Premenstrual tension/dysphoria  ü 
Neonatal complications  ü 
Infant temperament/ 
childcare stress  
ü 
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The prevalence of antenatal and postnatal depression 
There appears to be no clear or final answer to the question, how common is 
perinatal depression? The prevalence of perinatal depressive illness, a term 
encompassing both antenatal (prenatal) and postnatal depression, has been 
reported to be comparable to that of depression at other times of life, affecting 
around one in ten women, while other studies suggest increased rates in the 
childbearing years (Cooper & Murray, 1998; Kessler et al., 2003). However, 
attempts to more clearly delineate the incidence, point prevalence, and period 
prevalence of depression during and after pregnancy have been affected by the 
conceptual and methodological limitations of diagnosis, and the time periods 
studied: reported figures have been based on various approaches, ranging from 
retrospective self-reports to structured interviews and rating scales, for 
different perinatal stages and intervals (Gaynes et al., 2005; O’Hara et al., 
2014). In light of how common perinatal depressive features are, discriminating 
between symptoms and illness, and estimating severity, are clearly vital in 
reaching meaningful conclusions, and making relevant recommendations. 
Due to the huge volume of studies and publications on perinatal depression 
alone (with an average of one new paper indexed every 12 hours), high quality, 
relevant, and up-to-date systematic reviews are invaluable in informing valid 
inferences with regards to the prevalence and consequences of perinatal 
depression. 
Two systematic reviews of studies on the extent of perinatal depressive illness 
reached important conclusions; Bennett et al. (2004a), and Gavin et al. (2005). 
Bennett et al. (2004a) concluded from 21 studies of 19,284 pregnant women 
from the general population (including more than 12,000 from one English study) 
that rates of depression (defined as either reaching cut-off scores on the Beck 
Depression Inventory [BDI or BDI-II] or Edinburgh Postnatal Depression Scale 
[EPDS], or diagnosed via structured clinical interview [SCI]) were 7.4%, 12.8%, 
and 12.0% in the first, second, and third trimesters, respectively (Evans et al., 
2001). Interestingly, it appeared that studies using the BDI/BDI-II reported 
higher rates of depression, while those using the EPDS and SCIs were 
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comparable, despite both the EPDS and BDI having been validated in obstetric 
populations (Murray & Cox, 1990; Holcomb et al., 1996). It should be noted that 
studies used different cut-off scores, ranging from >12 to ≥15 for the EPDS, and 
>9 to ≥16	for the BDI/BDI-II. 
Holcomb et al. (1996) specifically recommended using a higher cut-off point of 
>16 for the BDI during pregnancy, to avoid false positives. However, Ji et al. 
(2011) concluded that while the BDI and EPDS are suitable instruments to screen 
for depression during pregnancy (as compared to the “gold standard” Hamilton 
Rating Scale for Depression [HRSD] for rating severity, and the Mood Module of 
the Structured Clinical Interview for DSM-IV Axis I Disorders [SCID] for 
diagnosing), different cut-off points are required at different time points for 
optimal sensitivity and specificity (Table 1-3) (Hamilton, 1960; First et al., 
2002). Remarkably, although specificity reduces during pregnancy (as they 
predicted, due to the increasing somatic symptoms of pregnancy that overlap 
with those of depression), lower cut-off scores are indicated. They suggested 
that this could be due to women’s own interpretation of the aetiology of their 
symptoms, i.e. not rating symptoms that they attributed to pregnancy rather 
then depression when completing the rating scales. (Consistent with this, one 
additional finding of interest was that multigravida women scored more highly 
than primigravida during the third trimester, and consequently required higher 
cut-off points to maintain adequate sensitivity – this may be explained by their 
previous experiences of pregnancy informing more nuanced interpretations of 
physical symptoms as not due to pregnancy, and hence increased reporting, and 
not a direct effect of multiparity per se.) 
Gavin et al. (2005) reported from 28 studies (including three with a comparison 
group) of 14,835 patients that the combined rate of minor and major depression 
(diagnosed via SCIs either during pregnancy or within the 12 months following 
delivery) was 19.2% in the first three months after delivery, although 
significantly less at 7.1% for major depression only. While they were unable to 
provide accurate estimations of incidence or period prevalence for the 
trimesters of pregnancy, point prevalence for combined depression (major 
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depression only) was 11.0% (3.8%), 8.5% (4.9%), and 8.5% (3.1%) for the first, 
second, and third trimesters, respectively. 
 
Table 1-3 – Optimal cut-off points for screening for the BDI and EPDS 
 BDI EPDS 
Preconception 17 18 
Trimester 1 15 12 
Trimester 2 13 9 
Trimester 3 12 15 
Early postpartum 14 11 
Late postpartum 14 12 
Overall 13 11 
 
 
Gavin et al. (2005) noted that their reported rates were slightly lower than 
those of others, attributing this to their methodology of including only recent 
studies of “higher quality” (associated with lower prevalence of depression), 
excluding studies based on patient-reported screening measures, differentiating 
between major and combined major/minor depression, and using point rather 
than period prevalence. (However, their second trimester rate was still higher 
than that found by Andersson et al. [2003], who reported the point prevalence 
of major depression as 3.3%, using the DSM-IV-based PRIME-MD structured 
clinical interview and patient questionnaire in 1,734 consecutive women 
attending for routine care.) Gavin et al. (2005) also observed that there were no 
statistically significant differences between the rates of depression in perinatal 
and non-pregnant control subjects, save for one paper reporting a three-fold 
increased risk of developing depression of any severity in the first five weeks 
postpartum (Cox, Murray & Chapman, 1993). However, they drew attention to 
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the inconsistencies in the published literature, as illustrated by the wide 
confidence intervals, advising caution in interpreting their conclusions, and 
highlighting a number of challenges in comparing the identified studies. In 
particular, they raised the issue of potential confounders, such as higher rates of 
minor depression in more socioeconomically deprived populations, and 
differences in the specific SCIs used – further research using bigger samples (to 
allow subgroup analyses), more representative populations (to include ethnic 
and racial heterogeneity), and comparator control groups of non-pregnant 
women is warranted. 
More recently, Woolhouse et al. (2014) conducted a prospective cohort study of 
1,507 pregnant nulliparous women, using a cut-off of EPDS ≥13 to define 
depressive symptoms. They found rates of perinatal depression similar to Gavin -
et al. (2005), but follow-up at four years postnatally yielded a prevalence of 
depressive symptoms of 14.5%, higher than at any point during the first 
postnatal year. Women with one child at four years reported the highest rates of 
depressive symptoms (22.9% versus 11.3% for those with two or more children), 
an intriguing finding which suggest that environmental adversity contributed 
greater risk than multiparity with or without recurrent episodes of perinatal 
depression. 
Of relevance to estimating rates of perinatal depression is the recent paper by 
Parker et al. (2015). They “diagnosed” 756 pregnant women in the third 
trimester and again at three months postnatally using both a SCI (the MINI 
International Psychiatric Review, which assesses DSM-IV criteria for major 
depression), and the EPDS with a cut-off of ≥10, yielding rates of antenatal 
depression “diagnosed” via the MINI and the EPDS of 3.2% and 18.5% 
(respectively), and 6.5% and 15.4% postnatally, comparable to those reported by 
Gavin et al. (2005) for major depression only, and combined major and minor 
depression. In other words, estimating perinatal depression prevalence is 
strongly influenced by the measure used, and as the EPDS is a quantitative 
dimensional rating of depressive symptomatology rather than a qualitative 
categorical discriminator of “caseness”, using a cut-off score risks both false 
positives and negatives – lower cut-off points sacrifice specificity for sensitivity, 
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and vice-versa. Moreover, the EPDS includes items that relate more to anxiety 
and general distress, thus diluting its ability to discriminate between depression 
and related but distinct phenomena. 
However, in addition to the concerns over the limitations of the EPDS in 
accurately “diagnosing” perinatal depression, the validity of using DSM criteria 
has also been questioned. Matthey and Ross-Hamid (2011) used the MINI in 118 
women in the second and early third trimesters, establishing a rate of DSM-IV 
major depressive disorder of 6.8%. However, when they asked those meeting 
criteria for major depression if they thought that their symptoms were due to 
pregnancy or mood, 66% attributed them to pregnancy, reducing point 
prevalence to 1.7%. This study suggests that establishing rates of depression 
using even SCIs and DSM operational criteria may not be accurate in the 
perinatal period due to including the physical symptoms associated with 
pregnancy, leading to artificially inflated estimates of point prevalence. 
Assuming that women’s attribution of symptoms to pregnancy rather than 
mental illness was correct even half the time, this study suggests that we may 
be in danger of being “ridiculous”, and “pathologising women for being 
pregnant”. They note the potential harm associated with current screening 
practices, particularly given that rating scales used (e.g. the EPDS) are also 
validated with reference to DSM criteria, and suggest that the low utilisation of 
clinical care following screening positive for depression may reflect women’s 
attribution of their symptoms as being due to pregnancy, and not indicative of a 
significant psychiatric disorder (Sit et al., 2009). Matthey and colleagues have 
explored related concerns in other studies, noting that around half of pregnancy 
women who screen “high” for emotional distress (i.e. depressive or anxiety 
symptoms) on the EPDS no longer do so within two weeks, indicating transient 
distress resolving spontaneously, rather than severe and enduring mental illness 
requiring intervention; and that the EPDS appears to rate symptoms of anxiety 
and not just specifically depression, concluding that diagnosing and treating 
perinatal depression after one high score on a self-reported rating scale has the 
potential to over-pathologise, and result in unnecessary clinical activity 
(Matthey, 2010; Matthey & Ross-Hamid, 2012; Matthey, Fisher & Rowe, 2013). 
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Notwithstanding, Matthey et al. acknowledge that mothers who score >13 on the 
EPDS, either antenatally or in the early postnatal period, continue to self-report 
distress up to two years later, associated with poorer relationships with their 
partners and mother-infant relationships, particularly those who screened 
positive on more than one occasion (Reay et al., 2011). Despite concerns about 
over-pathologising, it is noteworthy that normalising depressive symptoms during 
pregnancy has reported to be a barrier to women accessing mental health 
services (Kingston et al., 2015). 
Overall, despite the challenges and uncertainties in establishing how common 
perinatal depression actually is, the summary by Oates and Cantwell bears 
repeating: 
“The majority of women who develop mental health problems during 
pregnancy or following delivery suffer from mild depressive illness, often 
with accompanying anxiety. Such conditions are probably no more common 
than at other times. In contrast, the risk of developing a serious mental 
illness (bipolar disorder, other affective psychoses and severe depressive 
illness) is reduced during pregnancy but markedly elevated following 
childbirth, particularly during the first 3 months.” (CMACE, 2011.) 
Nevertheless, whether or not depression within the perinatal period differs 
qualitatively or quantitatively from that without, it remains clear that a 
significant proportion of mothers and babies are exposed to depressive 
symptoms, which are in turn linked with significant sequelae for both, both 
immediately and over time. In this regard, it is significant to note that even 
“unhappiness during pregnancy” has been reported to be a risk factor for 
postnatal depression, with all its associated consequences (Ramchandani et al. 
2009). 
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Consequences of (untreated) perinatal depression 
For many years it has been known that maternal depression in the postnatal 
period can have adverse effects on offspring, in addition to negative maternal 
effects (Murray & Cooper, 1997). However, although historically clinical concern 
was focused on postnatal depression and its consequences, more recently there 
has been increasing awareness of antenatal depression, too, not least as a major 
predictor of postnatal depression (Lee et al., 2007; Waters et al., 2014). 
Again, the literature on outcomes for those “diagnosed” with antenatal and 
postnatal non-psychotic depression is voluminous and growing, and defies simple 
summary. Several reviews, both systematic and narrative, reach similar, 
overlapping, and complementary conclusions. In addition to the usual personal 
biopsychosocial consequences of untreated depression outwith pregnancy, a 
myriad of maternal, obstetric/fetal, neonatal, and long term sequelae for 
offspring have been established, with some reported adverse outcomes being 
inconsistently replicated (Wisner et al., 2009; Hanley & Oberlander, 2014). This 
is unsurprising, given the twin challenges of diagnostic heterogeneity, and the 
multitude of known and unknown confounding factors. 
Maternal correlates of untreated perinatal depression include subjective 
suffering and negative cognitive biases; poor self-care and worse general health; 
poor nutrition and reduced maternal weight gain; obesity; increased use of 
tobacco, alcohol and substances; reduced use of antenatal care; social isolation; 
reduced breastfeeding; bonding, parenting, and childcare deficits; and even 
suicide and infanticide (Pearlstein et al., 2009; CMACE, 2011; O’Hara & McCabe, 
2013; Epstein, Moore & Bobo, 2014; Paschetta et al., 2014).  Obstetric/fetal 
features span spontaneous and elective abortion; placental abnormalities; 
reduced fetal growth; pre-eclampsia and eclampsia; pre-term and earlier 
deliveries; operative deliveries; low birthweight; DNA methylation 
abnormalities; congenital abnormalities; and stillbirth (Field, Diego & 
Hernandez-Reif, 2006; ACOG, 2008; Ban et al., 2012; Ban et al., 2014; Hanley & 
Oberlander, 2014; Gentile, 2015; Staneva et al., 2015). Neonatal problems have 
been reported as low APGAR scores; respiratory distress; persistent pulmonary 
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hypertension of the newborn; increased rates of admission to neonatal care 
units; and perinatal death (ACOG, 2008; Ban et al., 2014; Epstein, Moore & 
Bobo, 2014). Longer term sequelae for offspring include neuroendocrine 
dysregulation and physiological abnormalities; attachment difficulties, 
temperament and personality; neurodevelopmental delay and deficits; socio-
emotional, psychomotor, cognitive, academic, intellectual, and behavioural 
problems; general health complications; and increased risks of 
childhood/adolescent/adulthood psychopathology and mental health problems, 
including depression (Grace, Evindar & Stewart, 2003; Murray et al., 2006; 
Deave et al., 2008; Pearlstein et al., 2009; Murray et al., 2010; Murray et al., 
2011; Davalos, Yadon & Tregellas, 2012; Kingston, Tough & Whitfield, 2012; 
O’Hara & McCabe, 2013; Pearson et al., 2013; Csaszar, Melichercikova & 
Dubovicky, 2014; Suri et al., 2014; Waters et al., 2014; Gentile, 2015). 
Two key reviews of the literature on the consequences of antenatal depression 
are those provided by Field, Diego & Hernandez-Reif (2006), and Waters et al., 
(2014), which, in addition to contributing to the findings summarised above, 
highlight several important points. 
Field, Diego & Hernandez-Reif (2006) reviewed fetal and neonatal sequelae of 
exposure to antenatal depression. They draw attention to the obvious conclusion 
that as fetuses exhibit abnormalities, at least some adverse effects of exposure 
to maternal depression commence in utero. They discuss possible mechanisms, 
including that some consequences of exposure to antenatal depression may be 
mediated via elevated maternal cortisol and norepinephrine, which are 
associated with persisting hypothalamic-pituitary-adrenal (HPA) axis and 
sympatho-adrenal hyperactivation in offspring, in addition to structural brain 
abnormalities (Weinstock, 2001). They acknowledge, however, that potential 
confounders include maternal anxiety and stress, as antenatal depression, 
anxiety and perceived stress interact in complex ways with one another and 
other risk factors for adverse outcomes, to exert direct and indirect effects on 
pregnancy outcomes (Weinstock, 2008; Woods et al., 2010; Staneva et al., 
2015). 
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Waters et al. (2014) performed a systematic review of publications on antenatal 
depression and longer term developmental outcomes. They observe that 
prenatal maternal stress can have long lasting adverse effects on offspring, and 
explore potential mechanisms as per Field, Diego & Hernandez-Reif (2006). With 
regards to neuroendocrine dysregulation, although the influences of HPA axis 
dysregulation and overactivation on the developing fetus are not fully 
understood, Water et al’s conclusions resonate with the aphorism that “a 
stressed mum equals a stressed baby” (Davis et al., 2011). However, Waters et 
al. (2014) point out that hypercortisolaemia and antenatal depression are often 
independently linked with offspring outcomes. They highlight the possible 
contribution of epigenetic phenomena, including altered DNA methylation and 
histone modification. Moreover, they suggest that changes in placental gene 
expression and endocrine function may mediate the fetal consequences of 
antenatal maternal stress. They also note that aspects of the postnatal 
environment may act to accentuate or indeed buffer the effects of stress in 
utero on offspring. Importantly, they emphasise that associations do not 
establish causality, and that exposure to antenatal depression is heavily 
confounded by a variety of interrelated biopsychosocial prenatal and postnatal 
risk factors. 
In summary, therefore, not only is perinatal depression common, it is associated 
with a wide range of significant adverse outcomes for both mothers and 
progeny. 
 
Characteristics and consequences of antenatal antidepressants 
It is in this context that the pharmacological treatment of perinatal psychiatric 
disorders has attracted greater attention over the last few years, with regards to 
clarifying issues surrounding the safety and efficacy of antenatal psychotropics, 
particularly antidepressants, and especially selective serotonin reuptake 
inhibitors (SSRIs), given the extent of their use (e.g. Oberlander et al., 2008; 
Udechuku et al., 2010; Grzeskowiak, Gilbert & Morrison, 2011; Bromley et al., 
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2012; Malm, 2012; Bourke, Stowe & Owens, 2014; El Marroun et al., 2014; 
McDonagh et al., 2014; Forray, Blackwell & Yonkers, 2015; Robinson, 2015). It 
appears clear from a number of studies that a significant proportion of women in 
the UK are prescribed antidepressants during their childbearing years, including 
during pregnancy. Margulis, Kang & Hammad (2014) reported that 4.7% were 
prescribed an antidepressant, mostly SSRIs, before pregnancy, falling to 2.8% in 
the first trimester, and 1.3% thereafter, returning to 5.5% postpartum. However, 
these figures were averaged for pregnant women over a period of 22 years 
(1989-2010), and as antenatal prescribing of SSRIs has been reported to have 
increased significantly during this time, it seems likely that recent rates of 
exposure may be higher. Petersen et al. (2011) described similar period 
prevalence before and during the trimesters of pregnancy (4.8%, 2.4%, 1.0%, and 
1.0%, respectively), noting however that overall exposure rates during pregnancy 
increased more than fourfold from 0.8% in 1992 to 3.3% in 2006. This trend 
suggests that recent exposure rates during pregnancy may have increased 
further in the past 10 years, and be closer to American estimates of 13.4% in 
2003 (Cooper et al., 2007). 
Charlton et al. (2015) recently compared perinatal rates of SSRI prescribing in 
six European populations between 2004 and 2010, and found these to be highest 
in the UK, especially in Wales. While 4.5% of Welsh women were prescribed an 
SSRI during pregnancy, the average for the six regions was 2.3%, with rates of 
1.2-1.6% in Italy, and 2.3% in Denmark and the Netherlands. The relatively high 
rates of antenatal exposure in the UK were attributed to the higher pre-
pregnancy prescribing rates (8.8-9.6% versus 3.3-4.4% in other areas), leading to 
increased first trimester exposure in particular. Most studies converge on 
reporting a “J-shaped” curve, of exposure reducing markedly from 
periconception through the first and second trimesters, before returning 
to/exceeding pre-pregnancy levels following delivery. Characteristics of 
exposure to antenatal psychotropics in the UK are discussed in more detail in 
Chapters 2 and 4. 
Given that many women are prescribed antidepressants in their fertile years, 
and that a significant proportion of pregnancies are unexpected, it follows that a 
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sizeable number of fetuses are at risk of unintended exposure in the first 
trimester. Early concerns centred on congenital malformations due to first 
trimester exposure, but progressed to include short term maternal/obstetric and 
fetal/neonatal risks following exposure later in pregnancy (Chambers et al., 
1996; Wisner et al., 2009). Although accumulating data reassuringly suggests 
that exposure to many commonly used antidepressants during organogenesis in 
the first trimester is not clearly linked with clinically significant major 
congenital malformations, it is acknowledged that current evidence remains 
inadequate to allow informed decisions, particularly given the extent and 
potential consequences of perinatal depression and its antenatal 
pharmacological management (McDonagh et al., 2014; Ornoy & Koren, 2014; 
Furu et al., 2015). Moreover, uncertainties about the longer term 
neurobehavioural consequences of both untreated depression and 
antidepressants on the developing brain remain, despite recent reassurances 
(Grzeskowiak et al., 2015). 
One major challenge in this area is the lack of randomised controlled trials of 
interventions, due to the ethical issues involved, leaving observational and 
epidemiological database linkage studies to fill the gap, with all their associated 
limitations, including inability to establish causal relationships (Grzeskowiak, 
Gilbert & Morrison, 2011; Einarson, Egberts & Heerdink, 2015). Notwithstanding, 
the volume of literature available suggests that inferential quantity has been 
substituted for empirical quality. Barbui and Ostuzzi (2014) observe that 
“antidepressants are the most studied drugs during pregnancy, with more than 
30,000 neonatal outcomes following exposure . . . documented in the peer-
reviewed literature”. Although no consistent associations between commonly 
used antidepressants and major congenital malformations have been 
demonstrated, different studies have linked drugs with a variety of adverse 
pregnancy outcomes (Ban et al., 2012; Andrade, 2014; Ban et al., 2014; 
Jimenez-Solem, 2014; Furu et al., 2015; Reefhuis et al., 2015). These include, 
but are not limited to, spontaneous and elective abortion, obstetric 
complications, teratogenicity and birth defects, pre-term delivery and low birth 
weight (both independently associated with long term health problems), 
neonatal adaptation syndrome, feeding difficulties and failure to thrive, specific 
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uncommon conditions such as persistent pulmonary hypertension of the 
newborn, and structural brain abnormalities  (Simoncelli, Martin & Bérard, 2010; 
Grigoriadis et al., 2014; Knickmeyer et al., 2014; Huybrechts et al., 2015). 
However, although statistically significant associations between antenatal 
exposure to antidepressants and sequelae have been reported, these are not 
always clinically significant (Ray & Stowe, 2014). 
The robustness and finality of the conclusions based on the current literature is 
weakened by several factors. One major problem is heterogeneity. The 
definitions of exposure vary from study to study with regards to drug type, 
timing, and duration, and consequences have frequently been lumped together, 
with the potential for true associations to be obscured via dilution. For example, 
Reefhuis et al. (2015) found clear associations between specific birth defects 
and certain SSRIs, illustrating that drugs (even SSRIs) are not all the same 
(Gentile, 2015). This suggests that proportionately greater exposure to “safer” 
drugs (e.g. Sertraline) may mask the effects of less commonly used “riskier” 
SSRIs (e.g. Paroxetine), if analysed together as a single exposure. Furthermore, 
the overlap with consequences of exposure to antenatal depression is at least 
partially explained by the observation that not all studies take account of 
underlying illness type, timing, duration, and severity, nor known confounding 
factors (Grzeskowiak, Gilbert & Morrison, 2011). Research has increasingly taken 
account of theses issued over the past 20 years, and initial reports of 
consequences of antenatal exposure to antidepressants have not infrequently 
been refined and/or negated by improved methodology, e.g. propensity score 
matching (Oberlander et al., 2008; Margulis et al., 2013; Bourke, Stowe & 
Owens, 2014). 
Despite the generally reassuring data and clinical experience accrued over 
decades, and millions of exposures worldwide, the potential impact of antenatal 
antidepressants on neurodevelopment and later functioning remains largely 
unknown, and therefore complacency is ill-advised. Findings from preclinical 
animal studies indicate that fetal brain exposure to drugs with monoaminergic 
effects has a range of anatomical and functional correlates (Kiryanova, 
McAllister & Dyck, 2013). Hermansen and Melinder (2014) consider that prenatal 
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SSRI exposure may have latent deleterious effects on cognition and behaviour 
that studies with only short-term follow-up may miss. Kepser and Homberg 
(2015) reviewed neurodevelopmental effects of early exposure to 
antidepressants in rodents and humans, concluding that pharmacological 
perturbation of serotonin-dependent neurodevelopmental processes may be 
associated with mood disorder in adulthood. A critical question emerges – in an 
attempt to reduce adverse outcomes for both mother and baby, could treating 
maternal depression during pregnancy with antidepressants actually increase the 
risks of later depression and anxiety for offspring? Despite the rodent data, Gur, 
Kim and Eperson (2013) opine that while the existing literature indicates the 
urgent need for further research, nevertheless it should not dissuade from the 
appropriate use of antenatal SSRIs, given the known risks of untreated antenatal 
depression. 
 
SSRIs and the developing brain 
Kepser and Homberg (2015) note that consequences of exposure are time-
sensitive, with both shared and differential outcomes for prenatal, early 
postnatal, and late postnatal exposure. In light of this, it is noteworthy that 
there has also been widely publicised concern over the potential dangers of 
prescribing antidepressants for children and adolescents, particularly with 
regards to increased suicidality (Stone et al., 2009; Wijlaars, Nazareth & 
Petersen, 2012). However, a more recent analysis of the data did not support 
this association (Gibbons et al., 2012). It remains unclear exactly if and when 
the developing brain may be especially vulnerable to SSRIs, but it is plausible 
that there may be critical periods of neurodevelopment when altered 
serotonergic function results in potentially long-term undesirable consequences 
(Olivier et al., 2011). 
It is well-established that SSRIs not only cross the placenta in humans, they are 
also present in amniotic fluid and the fetal circulation, rendering the immature 
central nervous system vulnerable to neurobiological toxicity from exogenous 
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drug exposure during the prenatal and early postnatal periods (Ababneh, Ritchie 
& Wesbter, 2012; Bourke, Stowe & Owens, 2014; Ray & Stowe, 2014). A 
significant proportion of infants born to mothers taking SSRIs during pregnancy 
do display signs of a putative neurochemically-mediated initial antidepressant 
withdrawal syndrome, the “neonatal adaptation syndrome”, in keeping with 
concerns that the fetus is exposed to neurobiologically relevant doses of these 
drugs (Sanz et al., 2005). Oberlander et al. (2005) reported alterations in pain 
sensitivity and heart rate variability in infants exposed to SSRIs in utero, 
suggesting abnormal autonomic neurodevelopment, as well as increased risk of 
low birth weight and respiratory distress. 
Findings from genetic and pharmacological studies indicate that serotonin 
signaling during early life is critically involved in regulating the development of 
brain circuits that modulate adult emotional behaviour (Whitaker-Azmitia, 
2001). Rodent work indicates that neonatal exposure to SSRIs can disrupt the 
normal maturation of the serotonin system, and alter serotonin-dependent 
neuronal processes, including the regulatory pathways in the ascending serotonin 
projections (Maciag et al., 2006a). These effects are mediated via the serotonin 
transporter (see below). Other rodent studies have shown that early exposure to 
serotonergically-active antidepressants are associated with persistent 
neurobehavioural abnormalities in adults (Kepser & Homberg, 2015). These data 
all add weight to the hypothesis that disrupted serotonergic function during 
neurodevelopment are related to structural and functional brain abnormalities in 
the adult brain (Oberlander et al., 2012). 
 
SSRIs and the serotonin transporter 
The exact mechanism(s) via which SSRIs are therapeutic in depression remain as 
unclear as the pathophysiology of the disorder itself (Walker, 2013). 
Notwithstanding, one of their major effects is blockade of the presynaptic 
membrane protein known as the serotonin transporter (SERT). SERT blockade 
precipitates a transient increase in serotonin in the synaptic cleft, leading to an 
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early net reduction in serotonergic transmission, due to activation of presynaptic 
inhibitory autoreceptors. This results in desensitization of the presynaptic 
receptors and upregulation of the postsynaptic receptors, phenomena that 
emerge over days to weeks. Consequently, enhanced activation of G-protein-
coupled postsynaptic receptors increases intracellular messaging, gene 
expression, and the production of neurotrophic factors, including brain-derived 
neurotrophic factor (BDNF), which has been linked with the clinical response to 
antidepressants via hippocampal neurogenesis and synaptic plasticity (Krishnan 
& Nestler, 2008; Haase & Brown, 2015). 
The SERT gene is located on the short arm of chromosome 17 (17q11.2), and has 
several allelic variants. The best know, and perhaps most clinically important, is 
a polymorphism in the promoter region (5-HTTLPR), consisting of a 44 base pair 
insertion or deletion, referred to as long (L) and short (S), respectively. This 
polymorphism is linked with varying degrees of reduced SERT expression and 
function. When compared to the long allele, the short allele is associated with 
less efficient transcription of the SERT, and less than half the basal activity and 
serotonin uptake. Adults with one or more short alleles appear to be more prone 
to trait neuroticism, anxiety and depression, in addition to other phenotypic 
abnormalities (Murphy et al., 2008). Complementary studies have suggested that 
the short allele mediates an increased risk of depression in response to stressful 
life events and physical illness, and is associated with attenuated response to 
SSRIs and increased side-effects, although findings are conflicting (Serretti et 
al., 2007; Kato & Serretti, 2010; Karg et al., 2011; McGuffin, Alsabban & Uher, 
2011; Queirazza & Cavanagh, 2014). 
 
The “serotonin paradox” 
This appears counterintuitive. If individuals with reduced endogenous SERT 
function are at increased risk of depression, why should SSRI-induced SERT 
blockade be therapeutic? In other words, there is an apparent “serotonin 
paradox”, in that while iatrogenic pharmacological inhibition of the SERT in the 
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adult brain can be antidepressant, genetically-mediated SERT stultification may 
have contrary effects (Homberg, Schubert & Gaspar, 2009). 
 
Serotonin and neurodevelopment 
Healthy adults carrying one or more “S” alleles (or variants with comparable 
functionality) have been found to have significantly reduced amygdalar and 
hippocampal volumes, compared to those homozygous for the long allele (Frodl 
et al., 2008a; Frodl et al., 2008b). Moreover, possessing one or more “S” alleles 
is associated with smaller hippocampal volume, which is in turn linked with 
increased risk of developing depression in adolescence (Little et al., 2014). 
Pezawas et al. (2005) and Kobiella et al. (2011) also described reduced 
amygdalar volumes in “S” carriers, in addition to associated functional 
abnormalities, with a dysregulated over-sensitive “fear response” circuit. In 
other words, congenital SERT hypofunction is associated with structural and 
functional limbic abnormalities that may result in excessive prolonged fear 
responses during neurodevelopment, resulting in trait neuroticism and 
susceptibility to depression (Hariri & Weinberger, 2003; Keightley et al., 2003). 
Ansorge et al. (2004) found that transient exposure of mice to an SSRI during a 
neurodevelopmental period corresponding to the third trimester and neonatal 
period in humans mimicked the emotionally abnormal phenotype of mice 
carrying one or more short alleles. This suggests that perturbation of 
serotonergic function during critical phases of early neurodevelopment, whether 
mediated genetically or pharmacologically, adversely affects the maturation of 
the neural circuitry responsible for emotional regulation in the adult brain. 
Ansorge et al. (2008) further reported that it is the SERT and not the 
noradrenaline transporter (NAT) that is relevant with regards to pharmacological 
effects on neurobehavioural development. However, other studies using 
different models of depression report somewhat contradictory findings, 
implicating the dopamine transporter (DAT) more than either the SERT or NAT 
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(Perona et al., 2008). Interestingly, Maciag et al. (2006b) reported that chronic 
adult administration of the SERT/NAT inhibitor imipramine reversed the 
neurobehavioural consequences of neonatal exposure to the SSRI citalopram in 
rats. A comprehensive account of the relationships between monoamines and 
neurodevelopment, SERT, NAT and DAT genotypes, early exposure to 
serotonergically-, noradrenergically- and dopaminergically-active ligands, and 
subsequent affective dysregulation remains elusive. 
Despite the difficulties in reconciling the apparently discordant findings, it 
appears clear that timing is important. The adverse effects of SERT inhibition 
appear to be dependent on early life exposure as evidenced by the observation 
that the effects of SERT inhibition on behaviour were not maintained if this 
inhibition occurred at a later time period (Ansorge et al., 2008). Taken together, 
these findings indicate that the effects of SSRI-mediated inhibition of the SERT 
on neural circuitry are not merely sustained withdrawal phenomena. Rather, 
they are dependent on the timing of treatment, representing a “critical period” 
in neurodevelopment. 
 
Imaging the neurodevelopmental consequences of antenatal SSRIs 
Given that early exposure to Fluoxetine mimics the “S/S” genotype in mice, and 
structural and functional brain abnormalities are associated with “S” genotypes 
in otherwise healthy human adults, can similar findings be demonstrated in 
human infants exposed to antenatal SSRIs? 
Detailed neuroimaging studies of the developing human brain remain rare, and 
any exploring the effects of antenatal exposure to maternal depression or SSRIs 
are yet to be published. This is due in large part to the difficulties in performing 
scans on neonates and young children (see Chapter 5). Notwithstanding, several 
such projects have been undertaken, including Knickmeyer et al. (2008) 
completing structural magnetic resonance imaging (MRI) on infants from two 
weeks to two years postpartum, Choe et al. (2013) reporting on serial scans 
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between three and 13 months, and Holland et al. (2014) presenting findings 
from the first three postnatal months.  Two review articles provide a synthesis 
of findings to date, with the main findings being that there is significant early 
postnatal growth mainly due to grey matter, with total brain volume more than 
doubling in the first year alone (Silk & Wood, 2011; Dennis & Thompson, 2014). 
The cerebellum grows more and faster than other regions, more than doubling in 
volume in the first three postnatal months, and increasing in size by 240% over 
the first two years of life. Although Gilmore et al. (2012) and Holland et al. 
(2014) were able to evaluate the hippocampus, reporting a slow rate of growth 
in the first 12 months compared to other regions, Knickmeyer et al. (2008) were 
unable to identify the hippocampus reliably in neonates, and only presented 
findings from the second year of life. Guo et al. (2014) outline the technical and 
methodological challenges in imaging the hippocampus in the early postnatal 
months, discussed further in Chapter 5. 
It is theoretically possible, therefore, to look for structural abnormalities in the 
brains of neonates exposed to depression and SSRIs in utero. However, it is 
crucial to finalise which regions of the brain to evaluate, not least due to 
heterogeneity in the rates of neonatal brain development and the difficulties in 
measuring subcortical nuclei. For example, limbic structures with rich 
serotonergic innervation involved in mood regulation such as the amygdala and 
hippocampus are obvious targets for comparative neuroimaging in adults, but 
their small size in the neonatal brain limits their usefulness for this purpose. 
Other structures such as the cerebellum are therefore worthy of study. 
 
Neonatal neuroimaging and the cerebellum 
Human brain growth begins antenatally, peaks at term and continues beyond 30 
months postnatally (Dobbing & Sands, 1973). In addition to an increase in brain 
mass, synaptogenesis and glia proliferation in humans begin during the second 
and third trimesters and continue throughout childhood and adolescence (de 
Graaf-Peters & Hadders-Algra, 2006). Although the relationship between 
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anatomical volume and cognitive function is neither clear nor necessarily linear, 
size can influence performance of modality-specific behaviour (Leingärtner et 
al., 2007). The cerebellum grows faster and proportionately more than other 
brain regions, and its long term functions increasingly have become the focus of 
attention (Knickmeyer et al., 2008; Holland et al., 2014). It is now established 
that, in addition to its traditionally understood contributions to motor and 
sensory activity, the cerebellum is important in a wide variety of cognitive tasks, 
including planning, abstract reasoning, and visuospatial organisation (Baillieux et 
al., 2008). This is unsurprising as the cognitive regions of the cerebellum are 
known to have reciprocal connections with non-primary frontal, occipito-parietal 
and temporal cortical associative areas (Bugalho et al., 2006). 
The cerebellum is also implicated in mood disorders, with the cerebellar-
cognitive-affective syndrome described by Schmahmann, and reduced cerebellar 
volume, increased cerebellar activity, and abnormal connectivity being reported 
in depression (Gordon, 2007; Tavano et al., 2007; Phillips et al., 2015). In light 
of this, it is noteworthy that serotonin plays roles in cerebellar development and 
functioning, albeit poorly understood (Oostland & van Hooft, 2013; Saitow, 
Hirono & Suzuki, 2013). Due to its exponential growth and development over the 
first year of postnatal life, the cerebellum is potentially especially vulnerable to 
environmental insults. Consistent with this, Gilmore et al. (2010) reported that, 
of all brain regions studied in twins, the heritability of cerebellar volume is 
significantly lower than the others. Interestingly, Knickmeyer et al. (2014) found 
that around one in five children exposed to SSRIs in utero develop a Chiari I 
malformation, where the cerebellar tonsils herniate through the foramen 
magnum during the first decade of life. Together, these observations make the 
cerebellum a potential area of interest for comparative structural neuroimaging. 
In particular, diffusion tensor imaging (DTI) studies of developing connections 
between the cerebellum and other brain regions may also help shed light on 
potential areas of abnormality at an early stage in life. 
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Research proposals 
Significant numbers of fetuses are exposed to maternal depression and/or SSRIs, 
whose long-term consequences remain insufficiently characterised to allow fully 
informed clinical decisions. Evidence suggests that, in addition to clinical 
outcomes, both antenatal maternal depression and its pharmacological 
treatment may be associated with structural brain differences, which could 
serve as biomarkers for future risk. We therefore proposed to complete a series 
of pilot studies, intended to explore some of the issues discussed above. 
We undertook to investigate early neurodevelopmental consequences of 
exposure to depression/SSRIs via structural MRI, DTI, and magnetic resonance 
spectroscopy (MRS), a significant body of work presented in Chapter 7. 
Concurrently, in preparation for neuroimaging, and as the consequences of 
antenatal exposure to SSRIs are intimately related to its characteristics, we 
completed a systematic review on characteristics of antenatal exposure to SSRIs 
in the UK, detailed in Chapter 2. We also reviewed local records in a general 
maternity unit, and two specialist perinatal mental health services, to establish 
details of medication usage during pregnancy, subsequently evaluating the 
utility and accuracy of the clinical records in comparison with national 
epidemiological data (Chapters 3 and 4). Thereafter we investigated select 
outcomes of exposure in the general maternity unit and one specialist service 
(Chapter 5). Chapter 6 outlines key methodological challenges in researching 
characteristics and consequences of antenatal exposure to SSRIs, and Chapter 8 
provides a synthesis of our findings, with discussion and recommendations for 
future research. 
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Chapter 2 - Characteristics of antenatal exposure to SSRIs in 
the UK: A systematic review 
 
Within the last 10 years, the American College of Obstetricians and 
Gynecologists (ACOG) stated that “an estimated one third of all pregnant women 
are exposed to a psychotropic medication at some point during pregnancy” 
(ACOG, 2008). This projection was made with reference to a 30 year old study of 
168 mums-to-be receiving care from a university teaching hospital in Florida, 
USA (Doering & Stewart, 1978). This study also reported that all patients 
consumed at least two drugs during pregnancy, with over 90% taking five or 
more drugs, and an average of 11 drugs being used per participant. (13.2% used 
illicit drugs, mainly Marijuana.) Doering and Stewart based their findings on 
patients’ retrospective accounts of their drug use, and included over-the-
counter medicines and nutritional supplements such as iron and vitamins, which 
may explain the concerningly high rates of antenatal exposure to drugs in 
general. However, it is not clear from Doering and Stewart’s paper, nor from the 
ACOG report, to which psychotropics the ACOG estimate refers. 
Assuming that psychotropic medication indicates mainly antidepressants, mood 
stabilisers, and antipsychotics, the ACOG conclusion seems at odds with current 
clinical practice and experience in the UK. In 2008, anecdotal evidence 
indicated that a more likely figure for our local population would be ~1 in 20, 
i.e. ~5% of women in the West of Scotland are exposed to a psychotropic 
medication during pregnancy, as found during an audit at the Queen Mother’s 
Hospital in Glasgow in the early 2000s (Dr Roch Cantwell, personal 
communication).  However, a subsequent retrospective analysis of the records of 
women attending the specialist Glasgow Perinatal Mental Health Service (PMHS) 
did find that 57.3% (118/206) were documented as receiving at least one 
antidepressant, mood stabiliser, or antipsychotic drug at some point during 
pregnancy, with 50.8% (60/118) of these exposed to SSRIs (59.4% of those 
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exposed to antidepressants [60/101]), i.e. 29.1% (60/206) of the total sample 
(Julyan, Cavanagh & Cantwell, 2009). 
Data from the Avon Longitudinal Study of Parents and Children (ALSPAC) suggest 
that (in the UK at least) more than 80% of women take prescribed medication 
(other than nutritional supplements) at least once during pregnancy, while more 
recent American studies indicate that up to one in eight fetuses may be exposed 
to antidepressant medication (Headley et al., 2004; Cooper et al., 2007; Yonkers 
et al., 2009). Reports from both sides of the Atlantic raise concerns that rates of 
antidepressant prescribing during pregnancy have risen recently, up to fourfold 
in the UK (Cooper et al., 2007; Andrade et al., 2008; Petersen et al., 2011; 
Jimenez-Solem, 2014). Mirroring patterns in the non-pregnant population, and as 
per guidelines, the bulk of prescriptions for antenatal psychotropics are for SSRIs 
(Margulis, Kang & Hammad, 2014; NICE, 2014). 
As outlined in Chapter 1, the short, medium and long term advantages and 
disadvantages for both mothers and babies of using antidepressants to treat 
perinatal depressive disorders require careful consideration. In particular, the 
numerous potentially significant sequelae of fetal exposure to SSRIs must be 
weighed against those of untreated ante- and post-natal depression. Clarifying 
current patterns of perinatal prescribing is a critical prerequisite for evaluating 
outcomes, and therefore informing future practice to minimise risks and 
maximise benefits for mothers and babies. Key characteristics to note include 
the frequency of prescriptions for SSRIs during pregnancy, and for which drugs, 
at what doses, when, for how long, and for what indications, in addition to types 
and severity of maternal illness, and the myriad of known and unknown 
confounding factors. We therefore undertook a systematic review to address this 
gap in the literature. 
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Research question 
What are the characteristics of antenatal exposure to SSRIs in the UK, with 
specific reference to prevalence, type, dose, timing, and duration? 
 
Methods 
Search strategy and study selection 
We used PRISMA criteria for conducting a systematic review, and a professional 
librarian (JW) working in the local mental health library within NHS Ayrshire & 
Arran advised on and ran the search strategy (Moher et al., 2009). Electronic 
databases (including MEDLINE®, EMBASE, the Cochrane Database of Systematic 
Reviews, the PROSPERO International Prospective Register of Systematic 
Reviews, the Web of Science/Knowledge, Trip and OpenGrey) were searched 
from their respective inceptions to 7 October 2016. 
Keyword combinations utilised included: selective serotonin reuptake inhibitors 
or SSRIs, citalopram or cipramil, dapoxetine or prilegy, escitalopram or cipralex, 
fluoxetine or prozac or oxactin, fluvoxamine or faverin, paroxetine or seroxat, 
sertraline or lustral, pregnan*, fetal or fetus or foetal, pr*natal or ant*natal, and 
in utero or intr*uterine (see Appendix 1 for full details). A filter was applied to 
limit results to UK studies. 
 
Inclusion and exclusion criteria 
We included English language publications reporting original data from 
observational studies on the UK population (or representative samples) that 
directly addressed the research question. Papers that indirectly covered 
relevant data were also included, e.g. those stating prevalence and 
characteristics of antenatal exposure to SSRIs en route to reporting outcomes. 
Page 49 of 365 
We excluded interventional trials and case-control studies, as well as review and 
educational articles, abstracts, conference proceedings and unpublished data, 
although employed these in identifying subsequent peer-reviewed publications. 
 
Data extraction and analysis 
Three psychiatrists (EJ, TK and AS) independently screened the titles and 
abstracts of all studies identified through the search strategy, identified 
pertinent papers, and obtained the full text of each for more detailed analysis. 
Articles likely to contain references to other relevant publications were also 
accessed. 
We extracted data from each included study into an Excel® worksheet under the 
following headings: date range, data source, number of pregnancies, inclusion 
criteria, exclusion criteria, definition of antenatal exposure to SSRIs, and 
characteristics of exposure. This allowed the prevalence of antenatal exposure 
to SSRIs in the UK to be calculated, including more detailed estimates of 
exposure rates preconception, in each trimester and postnatally. 
 
Contributors 
EJ (consultant psychiatrist) planned, supervised and contributed to each part of 
the systematic review, including defining the research question, planning the 
search strategy, reviewing all titles and abstracts, reviewing references in 
relevant articles, extracting and analysing data, and writing up. JW (professional 
librarian) advised on and ran the search strategy, and acquired copies of 
relevant articles. TK (speciality psychiatric trainee) and AS (core psychiatric 
trainee) independently reviewed all titles and abstracts, reviewed references in 
relevant articles, and extracted data, with support from EJ as required. 
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Results 
Following electronic removal of duplicates, our search strategy identified 587 
publications across the medical databases Figure 2-1). The “grey literature” 
search yielded no relevant articles, and PROSPERO identified 23 registered 
systematic review protocols. Ninety-three articles were selected as potentially 
relevant by the three reviewers, with five meeting the inclusion criteria (Table 
2-1 studies 1-4 & 6), and hand-searching of references identified two further 
papers, one of which was relevant (Table 2-1 study 5). Two of the studies 
primarily and directly (albeit partially) addressed our research question 
(Margulis, Kang & Hammad, 2014; Charlton et al., 2015), with a third focusing on 
antidepressant discontinuation during pregnancy (Petersen et al., 2011). The 
others reported briefly on antenatal SSRI prescribing rates in the context of their 
primary aims of exploring outcomes of fetal exposure to antidepressants, and 
are included for completeness (Table 2-1, studies 2-4 & 7) (Ban et al., 2012; 
Margulis et al., 2013; Ban et al., 2014). None of the studies identified via 
PROSPERO met inclusion criteria.  
 
 
Table 2-1 – Studies meeting inclusion & exclusion criteria 
Study Authors (year) Date range Data source 
Number of 
pregnancies 
1 Petersen et al. (2011) 1992-2006 THIN 145,532 
2 Ban et al. (2012) 1990-2009 THIN 512,574 
3 Margulis et al. (2013) 1996-2010 CPRD 149,464 
4 Ban et al. (2014) 1990-2009 THIN1 349,127 
5 Margulis et al. (2014) 1989-2010 CPRD 421,645 
6a (UK) 
Charlton et al. (2015) 2004-2010 
CPRD2 182,9203 
6b (Wales) SAIL4 58,1065 
1The Health Improvement Network; 2Clinical Practice Research Datalink; 3excluding subjects 
registered with GPs in Wales; 4Secure Anonymised Information Linkage Databank; 5Welsh subjects 
only 	  
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Figure 2-1 - PRISMA flow diagram 
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One of the final six studies also reported on data from outwith the UK: Charlton 
et al. (2015) compared data from UK-wide and Welsh databases with data from 
four other European areas (Denmark, the Netherlands, and two Italian regions). 
All seven studies utilised either THIN (The Health Improvement Network) or 
CPRD (the Clinical Practice Research Datalink [formerly the General Practice 
Research Database]), with Charlton et al. (2015) also including data from SAIL 
(the Secure Anonymised Information Linkage Databank). Characteristics of THIN, 
CRPD and SAIL datasets have been described by Blak et al. (2011), Lewis et al. 
(2007), Wood & Martinez (2004), Ford et al. (2009) and Lyons et al. (2009), 
respectively. THIN is a large primary care database that (by 2016) included data 
from over 11 million patients registered with more than 560 general practices in 
the UK, while the comparable CPRD covers over five million patients registered 
with more than 630 general practices. Specific to Wales, SAIL similarly includes 
data from over two million patients, covering more than 40% of the Welsh 
population. These datasets are considered to be representative of the general 
British and Welsh populations. All studies pooled their results, averaging 
prescribing rates for the years covered, with Petersen et al. (2011) charting an 
increase in the rates of antidepressant prescribing in women both before and 
during pregnancy by year (Figure 2-2). 
Table 2-2 summarises inclusion and exclusion criteria used by each study, while 
Table 2-3 presents their definitions of pregnancy and fetal exposure to SSRIs. 
Table 2-4 lists the period prevalence of putative maternal exposure to SSRIs 
before (T0) and after (T4) pregnancy, and maternal-fetal exposure during the 
three trimesters (T1, T2 and T3), as well as overall during pregnancy. 
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Figure 2-2 - Time trends of the prevalence of antidepressant prescribing 
(from Petersen et al., 2011) 
 
 
 
Irene Petersen, Ruth E Gilbert, Stephen J W Evans, Shuk-Li Man, Irwin Nazareth; Pregnancy as a 
Major Determinant for Discontinuation of Antidepressants: An Analysis of Data From The Health 
Improvement Network; The Journal of Clinical Psychiatry; 72(7); p979-985; 2011. Copyright 
2011; Physicians Postgraduate Press. Reprinted by permission. 
http://www.psychiatrist.com/jcp/article/Pages/2011/v72n07/v72n0715.aspx    
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Table 2-2 – Inclusion & exclusion criteria for each study 
Study Inclusion criteria Exclusion criteria 
1 Live births to different mothers, between 
1992 and 2006, with data for mothers for 
at least 6 months before pregnancy until 
delivery 
In mothers with more than 1 pregnancy, 1 
was selected at random; mothers prescribed 
antidepressants at presumed subtherapeutic 
doses 
2 All singleton pregnancies ending in live 
birth, stillbirth, miscarriage or TOP1, in 
mothers aged 15-45, between 1990 and 
2009 
Pregnancies in mothers with 
psychotic/bipolar illness; pregnancies in 
women registered in Northern Ireland (due 
to different abortion legislation) 
3 All singleton live births, to mothers aged 
12-49, with linked mother-child data from 
15 months before pregnancy, between 1 
January 1996 and 30 November 2010 
Mother-child dyads for whom dates were 
anomalous and/or could not be reconciled; 
mothers prescribed non-contraceptive FDA2-
pregnancy category X drugs between 15 
months preconception and delivery; infants 
with chromosomal abnormalities, sequences 
or single-gene inherited diseases 
4 All singleton live births, to mothers aged 
15-45, with linked mother-child data from 
1 year before and throughout pregnancy 
available, between 1990 and 2009 
Births to mothers with psychotic/bipolar 
illness or anti-manic/-psychotic drugs 
antenatally 
5 All pregnancies resulting in live birth(s), 
between 1 January 1989 and 31 December 
2010, with linked mother-child data from 6 
months before pregnancy until 3 months 
after delivery 
Nil in addition to inclusion criteria 
6 All pregnancies resulting in live birth or 
stillbirth, beginning and ending between 1 
January 2004 and 31 December 2010, with 
data available from 1 year before 
pregnancy until 1 year after delivery. 
Nil in addition to inclusion criteria 
 
1TOP = termination of pregnancy 
2FDA = Food and Drug Administration  
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Table 2-3 – Definitions of pregnancy, & maternal & fetal exposure to SSRIs 
Study Definitions of pregnancy 
Definitions of fetal exposure 
to SSRIs 
1 Live birth; length of pregnancy estimated from gestation 
at birth, LMP and free text entries, or assumed to be 280 
days if data missing (including for preterm births) 
Prescription for SSRI during 
pregnancy 
2 Singleton pregnancy ending in live birth, stillbirth, 
miscarriage or TOP; conception estimated from several 
variables (expected delivery date, maturity estimates, 
timing of routine monitoring events) – where data was 
missing, delivery assumed to be at 40 weeks, and 
miscarriage and TOP at 10 weeks 
Prescription for SSRI in 
maternal records within first 
90 days following conception 
3 Singleton delivery; delivery dates estimated, as accurate 
birth dates not recorded, start of pregnancy estimated 
from LMP for term deliveries (pregnancy assumed to last 
273 days if data missing), and from records if preterm 
(pregnancy assumed to last 258 days if data missing) 
Prescription for SSRI issued 
during T1 or T2, or before 
pregnancy where the number 
of days supplied would 
overlap with T1  
4 Singleton live birth Prescription for SSRI in 
maternal records from 4 
weeks before to 12 weeks 
after first day of LMP 
5 Live birth, multifetal classified as one pregnancy; start of 
pregnancy estimated by LMP or codes for preterm 
delivery; length of pregnancy calculated from gestation 
at birth, and assumed to be 273 days for term deliveries 
and 258 days for preterm deliveries if data missing 
Prescription for SSRI issued 
during gestational periods (3 
months before pregnancy, 
T1, T2, T3, and 3 months 
after delivery) 
6 Pregnancy resulting in live birth or stillbirth; “the best 
estimate of the start of pregnancy was calculated” (no 
details provided) 
Prescription for SSRI issued 
during pregnancy 
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Table 2-4 – Period prevalence of perinatal exposure to SSRIs 
Study T0 T1 T2 T3 T4 Any stage during pregnancy 
1 4.8% 1.9% 0.77% 0.75% - 2.11% 
2 - 2.77% - - - - 
3 - - - - - [2.15%]2 
4 - 2.281 - - - - 
5 3.43% 2.06% 0.94% 0.99% 4.44% - 
6a (UK) 8.8% - - - 12.9% 3.7 
6b (Wales) 9.6% - - - 15.0% 4.5% 
 
1(2.20% SSRIs only, 0.08% SSRI co-prescribed with non-SSRI AD) 
2Prescriptions during T3 not included 
 
 
Prevalence and timing of exposure to antenatal SSRIs 
As summarised in Table 2-4, two studies either stated or described data 
sufficient to calculate overall exposure rates to SSRIs at any stage during 
pregnancy (Petersen et al., 2011; Charlton et al., 2015), with a third providing 
figures permitting a similar calculation but omitting prescriptions issued in T3 (a 
reasonable estimate of overall exposure, as studies indicated that few women 
were commenced on SSRIs de novo in the third trimester) (Margulis et al., 2013). 
Ban et al. (2012) and Ban et al. (2014) gave exposure rates during T1 only. While 
neither detailing nor describing data to allow estimation of overall exposure 
during pregnancy, Margulis et al. (2014) did define SSRI exposure rates for each 
of the individual trimesters. 
Petersen et al. (2011) based their study on UK data for 145,532 pregnancies in 
114,999 women who had a live birth between 1992 and 2006, identified via 
THIN. The researchers identified all pregnant women issued with at least two 
consecutive prescriptions for an antidepressant, with at least one of these being 
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in the three months prior to the date of conception (calculated from baby’s 
gestational age at the time of birth, and information on the last menstrual 
period). (Drugs classified as antidepressants, but prescribed at doses lower than 
what would be generally be considered the minimum effective dose were 
excluded from their analysis, mainly due to the assumption that these 
prescriptions were likely to be for indications other than depression, e.g. “low 
dose” Amitriptyline for pain.) They also identified women who received only one 
prescription for an antidepressant during pregnancy, to allow comparison with 
other studies employing this methodology. A comparison group of 22,677 non-
pregnant women was employed to provide an estimate of baseline prescribing in 
the general population. Rates of antidepressant prescribing per year were 
plotted graphically (Figure 2-2, reproduced with permission), ranging from 0.8% 
in 1992 to 3.3% in 2006, mirroring the greater than four-fold increase in 
antidepressant use in non-pregnant women from 1.2% in 1992 to 5.3% in 2006. 
Overall, from 1992 to 2006, 4.8% women were prescribed an antidepressant in 
the 6 months before conceiving, with almost half (2.3%) continuing into 
pregnancy. 78.5% of those on an antidepressant during pregnancy received an 
SSRI (although not necessarily SSRI monotherapy). The main focus of Petersen et 
al’s study was to establish rates of and reasons for antidepressant 
discontinuation during pregnancy, and they therefore looked at rates of 
antidepressants prescribed during different stages, rather than overall exposure 
(Table 2-4). Nevertheless, they concluded that, overall, around 2.7% of British 
women were prescribed an antidepressant at some point during pregnancy (2.1% 
SSRIs). It was not clear whether these data referred to women receiving only one 
prescription, or the stricter criteria for those receiving at least two prescriptions 
within three months. 
Margulis, Kang and Hammad (2014) used the CPRD’s Mother-Baby Link to identify 
mothers with a live birth between 1 January 1989 and 31 December 2010 
(inclusive), with the aim of delineating longitudinal patterns for perinatal 
psychotropic prescriptions. Women who were registered from six months before 
pregnancy through until three months postpartum were included, 421,645 out of 
907,642 deliveries (46.5%). The researchers calculated the beginning of 
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pregnancy using gestational age at birth for the 22% for whom this was available, 
and estimated the rest depending on whether they were term or preterm births, 
for which they used 273 days and 258 days, respectively.  Period prevalence for 
antidepressants (and antipsychotics) was calculated for five epochs: three 
months preconception (T0); trimesters one, two, and three (T1-3); and three 
months postpartum (T4) (Table 2-4). 21,363 subjects issued with a prescription 
in T0 and/or T3 were assigned to one of six discrete categories: (1) treatment 
discontinuation (all drugs discontinued); (2) treatment simplification (some 
drugs discontinued, or dose lowered); (3) no change in drugs or dose; (4) drug 
switch; (5) treatment intensification (drugs added to prior treatment, or dose 
increased); and (6) treatment start. The necessity of using so many categories 
when considering prescriptions for only one medication type illustrates the 
challenges in characterising perinatal psychotropic prescription patterns. 
Margulis, Kang and Hammad reported that of 19,774 women prescribed any 
antidepressant (i.e. not just SSRIs) in T0, 79.6% discontinued in T1, and 0.4% of 
those not prescribed an antidepressant in T0 had started by T3. 
Charlton et al. (2015) compared perinatal rates of SSRI prescribing in six 
European populations between 2004 and 2010 (Denmark, two Italian regions, the 
Netherlands, the UK and Wales), utilising the CPRD (with Welsh data excluded) 
and SAIL. Rates of prescribing were highest in the UK, and especially in Wales - 
4.5% of Welsh and 3.7% of other British women were prescribed an SSRI during 
pregnancy, while the average for the six regions reported to be 2.3%, with rates 
of 1.2-1.6% in Italy, and 2.3% in both Denmark and the Netherlands (Table 2-4). 
The relatively high rates of antenatal exposure in the UK were attributed to the 
higher pre-pregnancy prescribing rates (8.8-9.6% versus 3.3-4.4% in other areas), 
leading to increased first trimester exposure in particular. As per Margulis, Kang 
and Hammad (2014), the period prevalence of antidepressants followed a “J-
shaped” curve, of prescribing rates reducing markedly from periconception 
through the first and second trimesters, before increasing postnatally, as 
summarised in Figures 2-3 and 2-4, similar to Petersen et al. (2011), as well as 
American and Danish findings reported by Reefhuis, Rasmussen and Friedman 
(2006) and Jimenez-Solem et al. (2013), respectively. 
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Characteristics of exposure to antenatal psychotropics are discussed in more 
detail in Chapter 5. 
Figure 2-3 – Period prevalence of perinatal antidepressants 1989-2010 (from 
Margulis, Kang & Hammad, 2014) 
 
‘Because some women used more than one class of antidepressants, the prevalence of use of any 
antidepressant may be lower than the addition of SSRIs, TCAs and other antidepressants. AD 
antidepressant, CPRD Clinical Practice Research Datalink, SSRIs selective serotonin reuptake 
inhibitors, TCAs tricyclic antidepressants, T0 the 3 months before pregnancy, T1 first gestational 
trimester, T2 second gestational trimester, T3 third gestational trimester, T4 3 months after 
delivery.’ 
Reprinted by permission from Springer Customer Service Centre GmbH: Springer; Maternal and 
Child Health Journal; 18:1742-1752; Patterns of Prescription of Antidepressants and 
Antipsychotics Across and Within Pregnancies in a Population-Based UK Cohort; Andrea V 
Margulis, Elizabeth M Kang, Tarek A Hammad; Figure 1; Copyright 2014. 
https://link.springer.com/article/10.1007%2Fs10995-013-1419-2  
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Figure 2-4 – Period prevalence of perinatal SSRIs 2004-2010 (from Charlton et 
al., 2015) 
 
 
* Excluding Wales 
John Wiley and Sons, BJOG 2015;122:1010-1020, Selective serotonin reuptake inhibitor 
prescribing before, during and after pregnancy: a population-based study in six European 
regions, Rachel A Charlton et al., Figure 1, © John Wiley and Sons. 
https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.13143  
 
Figure 2-5 – Prescribing patterns during pregnancy (from Charlton et al., 
2015) 
 
John Wiley and Sons, BJOG 2015;122:1010-1020, Selective serotonin reuptake inhibitor 
prescribing before, during and after pregnancy: a population-based study in six European 
regions, Rachel A Charlton et al., Figure 2, © John Wiley and Sons. 
https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.13143  
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Types of SSRIs prescribed 
Two studies (Petersen et al., 2011; Charlton et al., 2015) provided data on 
individual SSRIs prescribed during pregnancy as a whole (Figure 2-6), with 
Fluoxetine and Citalopram the most commonly used, and Sertraline, Paroxetine 
and Escitalopram vying for third place (Fluovoxamine was rarely prescribed). Ban 
et al. (2014) provided limited data on SSRIs prescribed in the first trimester, 
with Petersen et al. (2011) describing individual SSRI prescribing rates in each 
trimester (Table 2-5).  Although Charlton et al. (2015) did not give exact 
numbers, presenting their data in chart form, Dr Charlton kindly provided the 
raw data on request (personal communication). Citalopram appeared more 
popular than Fluoxetine in Wales during the study period, although the CPRD 
dataset indicated that Fluoxetine use was more prevalent in England and 
Scotland. 
 
Figure 2-6 – Prevalence of antenatal exposure to individual SSRIs (%) 
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Table 2-5 – Prevalence of antenatal exposure to individual SSRIs by trimester 
SSRI/study T1 T2 T3 Any stage during pregnancy 
Citalopram 
1 0.4% 0.16% 0.15% 0.50% 
4 0.6% - - - 
6a (UK) - - - 1.60% 
6b (Wales) - - - 2.13% 
Escitalopram 
1 0.1% 0.01% 0.01% 0.10% 
4 0.1% - - - 
6a (UK) - - - 0.27% 
6b (Wales) - - - 0.29% 
Fluoxetine 
1 0.8% 0.33% 0.33% 0.92% 
4 0.9% - - - 
6a (UK) - - - 1.70% 
6b (Wales) - - - 1.50% 
Fluvoxamine 
1 <0.1% 0.00 0.00 <0.1% 
4 - - - - 
6a (UK) - - - 0.01% 
6b (Wales) - - - 0.004% 
Paroxetine 
1 0.4% 0.2% 0.17% 0.44% 
4 0.3% - - - 
6a (UK) - - - 0.27% 
6b (Wales) - - - 0.23% 
Sertraline 
1 0.2% 0.1% 0.09% 0.25% 
4 0.2% - - - 
6a (UK) - - - 0.58% 
6b (Wales) - - - 0.38% 
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Doses of SSRIs prescribed 
None of the studies described doses in any detail, although Margulis et al. (2014) 
noted that 5.1% of women prescribed an antidepressant in the three months 
before pregnancy who continued medication during pregnancy “simplified” their 
treatment – this included 4.0% who switched to a lower dose (with an additional 
0.01% “unclassified”, having increased and/or decreased some doses during 
pregnancy). 
 
Timing and duration of antenatal SSRIs (Tables 2-4 and 2-5) 
Ban et al. (2012) reported that 50.8% of women potentially exposed to SSRIs in 
T1 discontinued them in T1. While not giving raw data, Charlton et al. (2015) 
again charted several different exposure patterns, with around 20% of those 
prescribed an SSRI in T0 discontinuing in T1, roughly 1% stopping in T2 or T3, and 
approximately 10% continuing throughout pregnancy (Figure 2-4). Petersen et al. 
(2011) described an overall reduction in exposure to SSRIs from 4.85% in T0, to 
1.86% in T1, 0.77% in T2 and 0.75% in T3, while Margulis, Kang and Hammad 
(2014) reported a similar pattern of a decrease in exposure from 3.43% in T0, to 
2.06% in T1, 0.94% in T2 and 0.99% in T3 (Figure 2-2). Margulis, Kang and 
Hammad (2014) and Charlton et al. (2015) also found significant increases in 
rates of SSRIS prescribed postnatally, to 4.4%, and 12.9% (UK) and 15.0% (Wales), 
respectively. Owing to varying methodologies, primary purposes and reporting 
formats, detailed comparisons and conclusions could not be realised. 
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Discussion 
It was striking that, despite historical awareness of perinatal mental health 
problems and contemporary concerns about fetal outcomes, a non-systematic 
review of the medical literature at the outset of this body of work in 2008 had 
not identified any publications with a primary focus on the characteristics of 
antenatal exposure to SSRIs in the UK. Apart from a few studies mentioning 
psychotropics in the context of antenatal exposure to medication in general 
(e.g. Headley et al., 2004), it was not until 2009 that Durrani and Cantwell 
(2009) reported on the general characteristics of patients attending the Glasgow 
Perinatal Mental Health Service (PMHS), devoting a total of 160 words to 
describing and commenting briefly on issues relating to psychotropic medication. 
The first study specifically describing patterns of antidepressant prescribing 
during pregnancy in the UK did not appear until 2011 (Petersen et al., 2011). 
 
Data quality and methodological considerations 
Together, the six studies that met criteria for our systematic review included 
more than 20 years of data on nearly two million pregnancies, although given 
that studies explored overlapping years and converged on the same databases, 
the extent to which subjects overlapped across the studies is likely to be high, 
and impossible to determine from the published reports. The studies were 
heterogeneous, varying in how they defined subjects for inclusion, with most but 
not all requiring singleton pregnancies, and some focusing on live births while 
others included stillbirths, miscarriages and terminations of pregnancy (TOPs). 
Maternal age ranges were not restrictive, and all studies required data for both 
mothers and offspring to be available throughout pregnancy, with several 
requiring data pre- and post-pregnancy, too. The datasets used had face 
validity, given that over 98% of the UK population are registered with a GP, and 
less than 0.01% of patients opt out of having their clinical details included. It 
appears likely that all scripts for SSRIs issued via the patients’ GPs would have 
been captured (unless handwritten). 
Page 65 of 365 
However, the possibility of bias and confounding cannot be excluded, as patients 
who were not registered with a GP, did not consent to being included in THIN, 
CPRD or SAIL, or had data missing (e.g. due to poor attendance at antenatal 
appointments, being removed from their practice for non-attendance, relocating 
during the study periods, or receiving prescriptions via specialist services not 
included in the primary care databases, such as those provided for homeless, 
abused, addicted or vulnerable women) would not be included in the data; 
characteristics potentially associated with significant depressive illness, as 
depressed women may be less likely to engage effectively with antenatal care 
(Bennett et al., 2004b; Marcus & Heringhausen, 2009; Walsh, 2009; Ludermir et 
al., 2010; Beydoun et al., 2012; Grzeskowiak, Gilbert & Morrison, 2012a; Bassuk 
& Beardslee, 2014).  
While the absolute number of patients in these categories is likely to have been 
low, nevertheless, they may have been overrepresented among those prescribed 
antenatal SSRIs, leading to underestimates of prevalence. Similarly, bias may be 
introduced through including only live births, if exposure to antenatal SSRIs is 
associated with early or late miscarriage, TOP or stillbirth; as may including 
multiple and/or serial pregnancies in the same women, given that multiparity is 
a potential confounding factor for both maternal and progenic outcomes (see 
Chapter 6) (Louis et al., 2006; Ban et al., 2012; Grzeskowiak, Gilbert & 
Morrison, 2012a; Redshaw & Henderson, 2013; Sockol & Battle, 2013; Lahti et 
al., 2014). 
 
Challenges in defining pregnancy, and antenatal exposure to SSRIs 
The challenges in defining the start, duration and even end of pregnancy from 
retrospective data that were not collected primarily with this end in mind have 
been highlighted above, outlined in Table 2-3, and are explored further in 
Chapter 6. With regards to pregnancy, the gold standard would be to know both 
the child’s date of birth and gestation at delivery (as estimated by antenatal 
ultrasound scan), thus allowing accurate calculation of the date of conception. 
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However, these data were not available for all subjects in the included studies, 
leading to the different researchers resorting to alternative methods to 
compensate, e.g. (in order of decreasing preference) estimating the start of 
pregnancy from the LMP or “free text entries”, or simply assigning standard 
lengths of pregnancy to so-called “term” and  “preterm” deliveries (Table 2-3). 
Overestimating length of pregnancy may lead to overestimating early exposure 
to drugs prescribed periconception, while underestimating length of pregnancy 
leads to the opposite error. While most studies gave details of their 
methodology, Charlton et al. (2015) stated simply that “the best estimate of the 
start of pregnancy was calculated” without giving further details. 
Defining antenatal exposure to SSRIs is similarly fraught. Most studies used the 
date the prescription was issued to specify timing of exposure, but this does not 
necessarily indicate that this was the date the prescription was dispensed. 
Moreover, neither issuing nor dispensing proves when or even if the medication 
was actually taken and, given that most prescriptions usually cover at least a 28 
day period, simply using the date of issue will tend to underestimate antenatal 
exposure in women who received a prescription less than 28 days before 
conception, which provided sufficient tablets from them to persist into the first 
trimester, only to stop when they discover they are pregnant. Similar issues 
affect estimations of exposure and timing across the trimesters, as well as 
contributing to potential overestimations of third trimester exposure, when 
prescriptions for medicines planned to start postnatally are issued before 
delivery. 
Moreover, there is no agreed definition of the trimesters of pregnancy, hence 
references to exposure by trimester may not be identical across studies 
(Appendix 5). Notwithstanding, Petersen et al. (2011) did describe how they 
defined trimesters, “as the first day of the last menstrual period to 14 weeks 
and 6 days (first trimester); 15 weeks to 27 weeks and 6 days (second trimester); 
and 28 weeks to delivery (third trimester)”. 
Furthermore, estimating actual fetal exposure to SSRIs is even more 
problematic, when one takes into account maternal adherence and dose taken, 
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in addition to issues such as maternal absorption, placental transfer, maternal 
and fetal genotypes, and epigenetic factors. 
One significant issue is that all studies pooled data over the years of the study 
periods, meaning that the overall rates of antenatal exposure may be an 
underestimate. For example, while Petersen et al. (2011) reported that 2.69% of 
pregnancies between 1992 and 2006 were exposed to an antidepressant, the 
actual rates of antidepressant prescribing increased more than fourfold from 
0.8% in 1992 to 3.3% in 2006. This suggests that averaging exposure rates over 
the years may be misleading, by more recent rates being artificially suppressed 
by those from a decade or more ago. Moreover, if the trend described by 
Petersen et al. (2011) continued, even at a slower pace, then current rates will 
be higher still – Charlton et al. (2015) indicated that rates of fetal exposure to 
SSRIs increased by more than 40% over a five year period (2004-9), from 3.5% to 
5.0% in Wales, and from 3.4% to 4.1% in the rest of the UK (plotted together in 
Figure 2-7) (raw data kindly provided by Dr Charlton). Increasing rates are 
strongly correlated with years (Spearman’s rank correlation coefficient 
rho=0.843, p=0.000582). This trend towards increasing antenatal exposure to 
SSRIs over time may be driven by various factors, including a general increase in 
prescriptions for antidepressants in general, and SSRIs in particular, in the 
population (including in women of childbearing age), and a shift towards 
continuing antidepressants into and throughout pregnancy rather than stopping. 
These developments were concurrent with phenomena such as campaigns to 
promote awareness, recognition and treatment of depression, with increased 
media coverage and reduced stigma surrounding depression and antidepressants; 
and changes in the delivery of antenatal mental health care, including increasing 
access to specialist perinatal services, more evidence on which to base 
guidelines and treatment decisions (e.g. relapse rates in those stopping 
antidepressants during pregnancy, and the relatively low risk of adverse 
consequences of fetal exposure in contrast to those of untreated maternal 
antenatal depression), and therefore more women continuing to be prescribed 
antidepressants (particularly SSRIs) throughout the perinatal period. 
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Notwithstanding the above, the included studies appeared complementary in 
their definitions of pregnancy and exposure, and their broad agreement on 
prevalence and types of SSRIs prescribed, and “J-shaped” patterns of exposure 
from T0 through T4 (Figures 2-3 and 2-4). 
  
Figure 2-7 – Rates of exposure to antidepressants and SSRIs 1992-2008 
 
 
Prevalence of antenatal SSRIs 
Despite the methodological issues, and although varying by a factor of more than 
two, the studies from which the prevalence of exposure to SSRIs during 
pregnancy could be calculated were comparable in the range ~2.1& to 4.5%, 
with a clear trend towards prescribing rates increasing over time (Table 2-4; 
Figure 2-2; Figure 2-7).  Indeed, NHS Digital recently reported that, for the 
fourth consecutive year, prescriptions for antidepressants in England alone 
increased more than other drugs, with an increase of 6.0% from 2015-6 alone, 
contributing to an overall doubling of antidepressant items dispensed since 2006 
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(from 31.0 million to 64.7 million) (NHS Digital, 2017). The situation in Scotland 
appears similar, with Lockhart and Guthrie (2011) describing a threefold 
increase in antidepressant prescribing between 1995-6 and 2006-7 (attributable 
to “a complex mixture of more patients being prescribed SSRI and ‘other’ 
antidepressants, the use of higher doses, and longer durations of treatment, 
with the balance changing over time”), consistent with news reports of a ~30% 
increase in antidepressant prescribing between 2009 and 2015, and a ~5% 
increase from 2014-5 alone (BBC, 2015). 
However, these observations require cautious interpretation in light of McCrea 
et al’s 2016 study using THIN, where new prescriptions for SSRIs doubled 
between 1995 and 2001, but remained stable thereafter through 2012. McCrea 
et al. (2016) did find, however, that the apparent duration of treatment rose 
from a median of 112 days for those commencing in 1995 to 169 days in 2010, 
suggesting that at least some of the increases reported by NHS Digital (2017) 
may be attributable to patients and/or prescribers continuing SSRIs for longer 
rather than more individuals starting them, as per Moore et al. (2009). However, 
other sources report rates of increase of more than 50% in the number of under 
18s prescribed antidepressants between 2005 and 2012, with a proportionately 
greater fourfold increase in under 13s between 2009 and 2016 (Bachmann et al., 
2016; BBC, 2017). This inverse relationships between age and prescribing rates 
may explain in part why SSRI exposure appeared to be higher in Wales than in 
the rest of the UK, as Charlton et al. (2015) noted that the mean age of the 
Welsh mothers was statistically significantly lower than their English and Scottish 
counterparts. However, lower socioeconomic status in Wales is likely to have 
been an contributing factor. 
Prescriptions for SSRIs (and antidepressants in general) reduced from 3.43%-9.6% 
in T0 to ~1.5%-2.77% in T1 (reductions of between ~40% and ~70%), representing 
significant rates of discontinuation, presumably when women found themselves 
to be pregnant and decided, or were advised, to stop (Petersen et al., 2011). 
Rates of exposure reduced again in the second trimester (to between <1% and 
~1.5%), but remained fairly constant into the third trimester, rising again 
significantly to exceed pre-pregnancy rates in the year following delivery (4.4%-
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15.0%). While period prevalence for the whole of pregnancy was predictably 
higher than in T1 (due to a small number of women commencing SSRIs during 
pregnancy after the first trimester), nevertheless, T1 rates appeared 
comparable in the one study that reported data for both (Petersen et al., 2011). 
The rates of antenatal SSRIs of ~5% by 2009 are not out of kilter with the 
reported rates of antenatal major depression of ~2-10% (discussed in Chapter 1), 
particularly when taken in the context of GPs having been found to issue 
antidepressant prescriptions for around 50% of those who score as “probable 
depression” using the Hospital Anxiety and Depression Scale (HADS) (Cameron, 
Lawton & Reid, 2009). 
The rates of exposure reported by Charlton et al. (2015) were significantly 
higher than those reported in other studies. A plausible explanation is that while 
all other papers pooled results from 1989-96 until 2006-11, Charlton et al. (2015) 
included only data from more recent years, 2004-10, reflecting the increase in 
prescribing rates over the years described above. It follows that fetal exposure 
to SSRIs in the UK may now be higher still, and vary by demographic, given that 
rates of increase appear to be inversely proportional to age. 
 
 
Types and doses of SSRIs 
As per Table 2-5 and Figure 2-6, Fluoxetine was the most common SSRI 
prescribed (except in Wales). Citalopram was the next most prevalent (the front 
runner in Wales), with Sertraline and Paroxetine alternating for third and fourth 
place, and Escitalopram and Fluvoxamine fifth and sixth, respectively. These 
findings mirror clinical experience in the UK, and reflect clinical guidelines – 
although historically tricyclic antidepressants were used during pregnancy due to 
experience and reasonably reassuring data and clinical experience regarding 
safety, in line with the general shift towards SSRIs (due to their comparable 
efficacy, but superior tolerability) GPs, NICE and other bodies came to 
recommend Fluoxetine as the antidepressant of choice in pregnancy during the 
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years included and, arguably, Citalopram remains the antidepressant most 
commonly prescribed by GPs (NICE CG45, 2007 [updated 2014]); Cipriani et al., 
2009; Taylor, Paton & Kapur, 2015; personal observation). Paroxetine was also 
frequently used by GPs and in secondary care, but following the US Food and 
Drug Administration’s warning in 2005 about Paroxetine’s potential for 
teratogenic effects (but not other SSRIs), prescribers moved away from using 
Paroxetine in pregnancy, and its prominence in the studies above is likely to 
represent a historical artifact of the years to which their data belong (Stone et 
al., 2009). Sertraline gained popularity in the latter years of the included 
studies, likely due to its preferable safety, efficacy and tolerability profile, and 
prominence as perhaps the SSRI (and antidepressant) of choice in breastfeeding, 
hence promoting its suitability for antenatal use (SIGN, 2012). Escitalopram was 
relatively less commonly prescribed, presumably at least in part due to its 
greater cost under patent until 2014, and Fluovoxamine was rarely used in the 
UK. None of the studies included gave a detailed account or analysis  
 
International context and comparisons 
Our six included studies indicated that antenatal exposure to antidepressants in 
the UK was significantly less common than in some general maternity 
populations in America, where rates of up to 13.4% of pregnant women on 
antidepressants were reported (10.2% for SSRIs alone) (Cooper et al., 2007). 
However, the exposure rates were not inconsistent with other international 
estimates, with rates of SSRI prescribing during pregnancy in North America, 
Europe and Australia between 1976 and 2010 between 0.44% and 10.2%, a 23-
fold difference (Table 2-6). It should be noted, however, that sample sizes 
ranged from 805 to 848,786, and most studies reported rates averaged over 
years. These data are summarised in Table 2-6, alongside our findings discussed 
in Chapters 4 and 5 (Taylor, Cameron & Julyan, 2010; Wood, Cameron & Julyan, 
2015). Papers which included longitudinal comparisons demonstrated increases 
in prescribing over time consistent with Petersen et al. (2011) and Charlton et 
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Table 2-6 – International rates of antenatal SSRIs 
Study Country Pregnancies Year(s) SSRIs 
Oberlander et al. (2006) Canada 119547 1997-2002 5.0% 
Reefhuis, Rasmussen & Friedman (2006) USA 4,094 1997-8 1.5% 
1999-2000 2.8% 
2001-2 2.3% 
Cooper et al. (2007) USA 105,335 1999 2.9% 
2003 10.2% 
Ramos et al. (2007) Canada 97,680 1998-2002 3.7% 
Andrade et al. (2008) USA 118,935 1996 1.5% 
2005 6.2% 
Bakker et al. (2008) Netherlands 14,902 1995-2004 2.1% 
Wichman et al. (2008) USA 27,908 1993 0.44% 
2007 6.61% 
Taylor, Cameron & Julyan (2010) UK 805 2010 2.36% 
Alwan et al. (2011) USA 6,582 1998-2005 3.8% 
Colvin et al. (2011) Australia 123,405 2002-5 3.0% 
Mitchell et al. (2011) USA 25,313 1976-2008 5.8% 
Petersen et al. (2011) UK 114,999 1992-2006 2.11% 
Jimenez-Solem et al. (2012) Denmark 848,786 2004 1.4% 
2007 2.4% 
Hanley & Mintzes (2014) USA 343,299 2006-11 5.1% 
Charlton et al. (2015) Denmark 320,846 2004-10 2.3% 
 Italy: Emilia Romagna 129.220  1.2% 
 Italy: Tuscany 157,916  1.6% 
 Netherlands 13.935  2.3% 
 UK 182,920  3.7% 
 Wales 58,106  4.5% 
Wood, Cameron & Julyan (2015) UK 875 2012 7.89% 
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al. (2015) (Reefhuis, Rasmussen & Friedman, 2006; Cooper et al., 2007; Andrade 
et al., 2008; Wichman et al., 2008; Jimenez-Solem et al., 2012) 
Charlton et al. (2015) provided a direct comparison of six European regions, with 
the striking finding that SSRIs were significantly more commonly prescribed in 
the UK before, during and after pregnancy than in other regions, almost fourfold 
higher than some (Table 2-6). While the non-UK databases reporting 
prescriptions dispensed rather than prescriptions issued may have “magnified” 
differences, this appears unlikely to be a sufficient explanation, especially given 
the differences between Wales and the rest of the UK. Other possible 
explanations include that the UK’s continental neighbours favour non-SSRI 
antidepressants or are more circumspect about prescribing, or that UK regions 
diagnose, prescribe for, or actually have more depressed residents. 
 
Timing of antenatal psychotropics 
The findings of Petersen et al. (2011), Margulis, Kang and Hammad (2014) and 
Charlton et al. (2015) are broadly consistent with other studies in Australia, 
Denmark, Finland, Germany, the Netherlands, Canada, Norway, and the USA 
reporting on rates of antidepressants (not just SSRIs) during T1, T2 and T3 (Malm 
et al., 2003; Egen-Lappe & Hasford, 2004; Reefhuis, Rasmussen & Friedman, 
2006; Ververs et al., 2006; Ramos et al., 2007; Engeland et al., 2008; Hanley & 
Mintzes, 2014; Jimenez-Solem, 2014) (Table 2-7). Numerous studies report that 
many women prescribed antidepressants periconception discontinue during 
pregnancy, most commonly in the first trimester, although with ongoing 
reductions in the second and third trimesters. In fact, most reports (except for 
Ververs et al. [2006]) suggest that it is the minority of women who continue 
antidepressants throughout pregnancy.  
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 Table 2-7 – International rates of antidepressants by stage of pregnancy 
Authors Country Pregnancies Year(s) Overall 
Trimester 
1 2 3 
Malm et al. (2003) Finland 43,470 1999 1.0% 0.8% 0.3% 0.3% 
Egen-Lappe & Hasford 
(2004) 
Germany 41,293 2000-1 - - - 0.08% 
Ververs et al. (2006) Netherlands 29,005 2000-3 - 2.0% 1.8% 1.8% 
Cooper et al. (2007) USA ~20,000 2003 13.3% 10.0% 6.4% 5.9% 
Ramos et al. (2007) Canada 97,680 1998-
2002 
- 3.7% 1.6% 1.1% 
Andrade et al. (2008) USA 118,935 1996-
2005 
6.6% 5.1% 3.8% 4.1% 
Engeland et al. (2008) Norway 106,329 2004-6 2.6% 1.1% 0.5% 0.4% 
Taylor, Cameron & 
Julyan (2010) 
UK 805 2010 2.86% 2.48% 2.24% 2.48% 
Alwan et al. (2011) USA 6,582 1998-
2005 
4.5% 3.1% 2.2% 2.3% 
Colvin et al. (2011)1 Australia 123,405 2002-5 3.0%1 1.7%1 1.5%1 1.5%1 
Petersen et al. (2011) UK 114,999 1992-
2006 
2.7% 2.4% 1.04% 0.99% 
Hanley & Mintzes 
(2014) 
USA 343,299 2006-11 6.5% 5.0% 3.6% 3.5% 
Margulis, Kang & 
Hammad (2014) 
UK 421,645 1989-
2010 
- 2.81% 1.31% 1.34% 
Wood, Cameron & 
Julyan (2015) 
UK 875 2012 9.83% 9.14% 4.69% 3.89% 
1SSRIs only 
 
Tables 2-6 and 2-7 imply that perinatal antidepressant prescribing rates vary 
from country to country - this is likely to be attributable to a number of factors. 
A full account would require a further systematic review (which is beyond the 
scope of this thesis), but in anticipation of the more detailed discussion of 
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methodological issues discussed in Chapter 6, it is worthwhile summarising them 
briefly here. 
The studies in Tables 2-7 and 2-8 were conducted using different databases in 
each country, which ranged from those including the whole population to others 
based on subsets, defined by those with certain types of health insurance or 
benefits, whether private or state-funded. Moreover, some studies excluded 
those with missing data, over half of the initial number identified in some cases. 
These aspects had the potential to lead to biases relating to issues such as 
socioeconomic deprivation and funded access to specialist services or 
medication. Indeed, as noted by Andrade et al. (2008), rates varied between 
5.5% and 9.1% in different health plans in 2005, while Hanley and Mintzes (2014) 
found that rates varied between 6% and 15% in different American states. 
Some studies included all pregnancies, whereas other were based only on live 
births, i.e. they excluded women with pregnancies ending in spontaneous or 
elective termination, a stillbirth, or birth defects. If antidepressants or the 
conditions they were being used to treat were associated with increased fetal 
loss or teratogenicity, this could lead to under-estimates. 
Studies varied in defining number of subjects, with some referring to individuals, 
others pregnancies, and still others live births.  This meant that some women 
with multiple pregnancies during the study period (up to 22 years for Margulis, 
Kang and Hammad [2014]) were included more than once, leading to potential 
bias given the association between perinatal depression (and therefore 
antidepressant use) and multiparity (Redshaw & Henderson, 2013; Sockol & 
Battle, 2013; Lahti et al., 2014). 
Different epochs were used for analysis, with some studies reporting results for 
specific years, while others averaged their findings over several years. The 
longer the period over which figures were combined and averaged, the less 
contemporary relevance they have, given the significant increases in 
prescriptions for antidepressants (particularly SSRIs) in recent years. 
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Some studies defined prescriptions as those issued, while others referred to 
drugs dispensed or reimbursed. It is entirely possible that some prescriptions 
may not have been captured, particularly those not issued electronically, or by 
the patients’ registered doctor. 
Few studies took account of the dynamic nature of antenatal prescriptions, 
which can include continuing, stopping, pausing/restarting, adding or switching 
drugs; or maintaining, increasing, or reducing doses; suggesting that using period 
prevalence alone to define fetal exposure to antidepressants may miss some 
importance variations in timing, duration, and continuity. The study by Colvin et 
al. (2011) serves to highlight some of the complexity of perinatal prescribing 
patterns, as illustrated in Figure 2-8. It is important to note that, as with 
depressive symptoms, prescriptions for antidepressants may come and go for 
many women during pregnancy (Colvin et al., 2011; Parker et al., 2015). 
In addition to defining the start and end of pregnancy to allow an estimate of at 
what gestational stage(s) medication was taken as noted above, another issue 
critical to identifying clinically significant fetal exposure to SSRIs is the 
condition(s) for they were prescribed, and their severity, chronicity and 
response. It has already been acknowledged that the underlying illnesses for 
which antenatal psychotropics are prescribed share some sequelae with their 
pharmacological treatments and hence, for example, low dose tricyclics for pain 
are not directly comparable to higher dose SSRIs for major depression. 
Notwithstanding, studies were broadly consistent in reporting a slight or 
significant reduction in antidepressant prescribing in T1 as compared to T0, with 
further reductions in T2 and T3 (Table 2-7). However, as per our findings, this 
was not a universal phenomenon, and some found either no change between T2 
and T3, or a small but potentially significant increase. It has already been noted 
that many estimates were based on when prescriptions were either issued or 
dispensed, but this does not necessarily indicate if, when, or how consistently 
medication was taken, nor therefore define fetal exposure. 
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Figure 2-8 – Prescribing patterns during pregnancy (from Colvin et al., 2011) 
 
© 2011 Wiley-Liss, Inc. Birth Defects Research (Part A): Clinical and Molecular Teratology 
91:142-152, Dispensing patterns and pregnancy outcomes for women dispensed selective 
serotonin reuptake inhibitors in pregnancy, Lyn Colvin et al., Figure 1. 
https://onlinelibrary.wiley.com/doi/abs/10.1002/bdra.20773  
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Key points 
• Three studies provided significant details of characteristics of antenatal 
exposure to SSRIs in the UK 
• Findings were influenced by methodological heterogeneity 
• Prescriptions for SSRIs before, during and after pregnancy have been 
increasing from 1992 through 2010 
• By 2010 up to 1 in 20 British women were exposed to an SSRI at some point 
during pregnancy 
• Prescriptions for SSRIs fell significantly during the first trimester, and again to 
a lesser degree through the second and third trimesters, before increasing 
again to postnatal levels higher than those prenatally 
• Although most women discontinued SSRIs in the first trimester, some 
continued throughout pregnancy, some who discontinued restarted in the 
second or third trimester, and some started de novo during pregnancy 
• The most common SSRIs prescribed were Fluoxetine and Citalopram, with 
Sertraline becoming more popular in recent years, and Paroxetine less 
• These UK data are comparable to international reports 
• Minimal data on the changing patterns, timing and duration of SSRI exposure 
through the perinatal period were reported, with no details on doses 
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Chapter 3 - Characteristics of antenatal exposure to SSRIs in a 
specialist perinatal mental health service 
 
Specialist perinatal mental health services are appropriate settings in which to 
explore patterns of perinatal prescribing. We extended our analysis of the data 
from our existing review of the records of patients attending the Glasgow PMHS, 
to clarify issues surrounding local antenatal psychotropic prescribing, to address 
the gaps in the literature, and to provide a realistic basis for our proposed 
scanning study. 
 
Research questions 
(1) What proportion of women attending the PMHS was seen during pregnancy? 
(2) At what stage of pregnancy were they seen? 
(3) How many were prescribed psychotropic medication? 
(4) What was prescribed, including at what doses, and when? 
(5) With which diagnoses were psychotropics associated? 
(6) How many had a primary diagnosis of depression? 
(7) How many had a diagnosis of depression, were receiving SSRI monotherapy 
during pregnancy, and attended in the first or second trimesters, i.e. how 
many potential scanning participants could be recruited from the PMHS? 
	  
Page 80 of 365 
Methods 
 
Setting and subjects 
The Glasgow PMHS was formally established in October 2004 to provide specialist 
inpatient care for women and babies in the West of Scotland (~25,000 live births 
per annum) during pregnancy and up to 1 year postnatally, in addition to 
community/liaison input to the Greater Glasgow area (~10,000 live births per 
annum) (ISD Births in Scottish Hospitals, 2014). Annual referrals increased from 
around 250 initially to more than 1,100 by 2017, received from both Primary and 
Secondary Care, for a variety of reasons, from preconception advice through to 
tertiary inpatient care. Patients attending the service are from a range of 
socioeconomic backgrounds and, although several areas of Glasgow are among 
the most deprived in the UK, there are also patients demographically similar to 
those reported by the Centre for Maternal and Child Enquiries (CMACE) in the 
Confidential Enquiries (CMACE, 2011). 
 
Data sources 
Data collection forms are routinely completed by clinicians for all patients 
attending the PMHS – these collate clinically relevant details to facilitate audit, 
and to provide a basis for research (Appendix 2). Two researchers reviewed all 
data collection forms available between 2007 and 2009. Anonymised details 
were entered into a Microsoft® Excel® spreadsheet for descriptive analysis, 
including age, diagnosis, date/gestation seen, and psychotropic and other 
medication during pregnancy. A key was established to define how to interpret 
ambiguities, and agreement reached through discussion where necessary. We 
annotated each form after its contents had been transferred to the spreadsheet, 
and noted any uncertainties or missing data, to be verified later with PMHS staff 
and/or the clinical records. Each form was allocated a unique study number to 
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allow accurate identification of not only unique subjects, but also discrete 
episodes of care, as some patients attended the PMHS more than once during 
different pregnancies. The details harvested from the data collection sheets 
were not cross-checked with each patient’s PMHS record, as our initial audit had 
not found this fruitful in terms of clarifying ambiguities nor influencing 
conclusions to any significant degree (Julyan, Cavanagh & Cantwell, 2009). 
Psychotropics were defined as antidepressants, antipsychotics (oral or long-
acting injectable), or mood stabilisers described in the British National 
Formulary (BNF) Sections 4.3, 4.2 and 4.2.3 (excluding Benzodiazepines, but 
including Lamotrigine [Section 4.8.1]), with prescribed Methadone being 
recorded separately from psychotropics and non-psychotropics, to allow discrete 
analysis (Appendix 3) (BNF 60, September 2010). Co-prescribing of psychotropics 
with other psychotropics, non-psychotropics and Methadone was identified. 
Psychotropic prescribing patterns were categorised according to drug type and 
timing of exposure to allow analysis via descriptive statistics, including early and 
late exposure to psychotropics in general, and antidepressants and SSRIs in 
particular, as per Chambers et al. (1996) and Oberlander et al. (2008), i.e. any 
exposure in the first and second trimesters that ended before the third trimester 
was defined as “early”, and any exposure in the third trimester was designated 
“late”. Excel’s® inbuilt functions were utilised to calculate median ages at the 
time of delivery, and filter/sort and analyse data by category.  
 
Contributors 
RC (PMHS consultant psychiatrist) arranged access to the data, and helped to 
refine EJ’s research questions. After completing the audit on the first 206 
patients, EJ processed a further ~200 data collection sheets; transferred the 
relevant data to Excel®; trained, supervised and supported RC (medical student) 
to process an additional ~200 sheets, and transfer to Excel®; and completed 
descriptive statistical analysis.  
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Results 
Summary sheets were available for 627 women seen between 28 October 2002 
and 24 September 2009. Most forms had missing, incomplete, inconsistent, or 
illegible entries in a variety of data fields (see below). Notwithstanding, we 
analysed the available information carefully, to answer our research questions as 
far as the records allowed. 
 
Age at estimated date of delivery 
The median age at estimated date of delivery (EDD) in our sample was 31 (range 
16-45). We were unable to calculate the age for 34.0% (213/627) women, due to 
data being unrecorded or unspecified, incomplete or illegible, or self-evidently 
incorrect (Table 3-1). 
 
Table 3-1 – Missing data 
Data Recorded (%) (N) 
Not recorded/ 
Specified (%) (N) 
Incomplete/ 
Illegible (%) (N) Incorrect (N) 
DOB 96.3 (604) 3.7 (23) 0 (0) 0 (0) 
EDD 68.4 (429) 29.7 (186) 1.6 (10) 0.3 (2) 
Date seen 97.8 (613) 1.3 (8) 1.0 (6) 0 (0) 
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Dates of birth (DOBs) were missing in 3.7% (23/627), of which five also had EDD 
missing (three were described as “Delivered”, one as “Planning”, and one 
blank). Of the 31.6% (198/627) EDDs that were unavailable or erroneous, 4.6% 
(29/627) had no entry, 22.0% (138/627) were recorded as “Delivered”, 2.7% 
(17/627) as “Planning”, 0.2% (1/627) as “Miscarriage”, and 0.2% (1/627) as TOP 
(termination of pregnancy); 1.6% (10/627) had one or more digits missing or 
illegible (e.g. ??/03/05); and two were mistakes (“00/01/08” and 
“16/07/20098”), presumably typographical errors made when entering data into 
Excel® (Table 3-1).  
Calculating age when first seen at the PMHS reduced the number of missing 
values to 4.5% (28/627), and yielded identical median age and age range. 
 
Stage seen 
“Date seen” was completed for 97.8% (429/627), with 1.3% (8/627) having no 
entry, and 1.0% (6/627) being incomplete/illegible, e.g. one digit being 
ambiguous (Table 3-1). In addition to the stages indicated by entries under 
“EDD”, comparison of the “Date seen” with “EDD” yielded the breakdown 
summarised in Table 3-2. Stage seen was accurately identified under “EDD” in 
85.0% (17/20) as preconception, and in 78.9% (138/175) as postnatal. However, 
stage seen remained unknown and incalculable in 6.2% (39/627), due to a 
mixture of missing/incomplete “Date seen” and/or “EDD”. Overall, 62.4% 
(391/627) were pregnant at the time of initial contact, with the majority being 
seen later in pregnancy. 
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Table 3-2 - Stage first seen at the PMHS 
Stage first seen % (N) 
Preconception  3.2 (20) 
Pregnant 62.4 (391) 
First trimester 3.7 (23) 
Second trimester 25.5 (160) 
Third trimester 33.2 (208) 
Postnatal 27.9 (175) 
Post-miscarriage1 0.2 (1) 
Post-TOP2 0.2 (1) 
Unknown 6.2 (39) 
 
1 Miscarriage at 11 weeks, seen at the PMHS 3 weeks later 
2 Termination of pregnancy due to Trisomy 21 (Down’s syndrome) 
(Neither were documented as taking psychotropic medication during pregnancy) 
 
Diagnoses 
The primary diagnoses are shown in Table 3-3, alongside those reported by 
Durrani and Cantwell (2009), confirming that 49.1% (308/627) were diagnosed 
with an affective disorder, 41.3% (259/627) with a depressive episode or 
recurrent unipolar depression (15.9% [100/627], and 25.4% [159/627], 
respectively), or bipolar affective disorder (6.1%, 38/627). 
 
Types and rates of antenatal psychotropics 
Prescribing data for all 627 women are summarised in Table 3-4, showing that 
42.1% (264/627) of the women were documented as taking a psychotropic at 
some point during pregnancy, with 35.2% (93/264) of these co-prescribed non-
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psychotropic drugs. Overall, 51.8% (325/627) were documented as having been 
prescribed at least one drug antenatally, whether a psychotropic or a non-
psychotropic. Methadone prescriptions were documented for 4.0% (25/627), and 
co-prescribed with psychotropics in 3.0% (19/627), representing 7.2% of those on 
psychotropics (19/264), 6.8% of those prescribed antidepressants (16/235), and 
5.7% of those exposed to SSRIs (10/175). Generally speaking, drugs were 
specified, with only one described as an “antidepressant”. Doses were less 
consistently documented. 
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Table 3-3 - Primary psychiatric diagnoses 
ICD-10 Description % (N) Durrani & 
Cantwell 
(2009) (%) 
F0x Organic, including symptomatic, mental disorders 0.2 (1) 0.4 
F1x Mental & behavioural disorders due to psychoactive substance use 1.6 (10) 2.5 
F2x Schizophrenia, schizotypal and delusional disorders 3.0 (19) 4.7 
F20 Schizophrenia 1.1 (7) 1.4 
F21 Schizotypal disorder 0.2 (1) 0.4 
F22 Persistent delusional disorders 0.3 (2) 0.4 
F23 Acute and transient psychotic disorders 1.0 (6) 1.4 
F25 Schizoaffective disorder 0.3 (2) 1.1 
F29 Unspecified non-organic psychosis 0.2 (1) - 
F3x Mood (affective) disorders 49.1 (308) 33.6 
F30 Manic episode 0.2 (1) - 
F31 Bipolar affective disorder 6.1 (38) 5.1 
F32 Depressive episode 15.9 (100) 14.8 
F33 Recurrent depressive disorder 25.4 (159) 11.9 
F34 Persistent mood [affective] disorders 1.8 (11) 1.8 
F4x Neurotic, stress-related & somatoform disorders 18.8 (118) 16.2 
F40 Phobic anxiety disorders 1.3 (8) 1.1 
F41 Other anxiety disorders 6.9 (43) 6.5 
F42 Obsessive-compulsive disorder 1.4 (9) 2.9 
F43 Reaction to severe stress, and adjustment 
disorders 
9.1 (57) 5.4 
F45 Somatoform disorders 0.2 (1) 0.4 
F5x Behavioural syndromes associated with physiological disturbances and physical factors 0.6 (4) 0.4 
F50 Eating disorders 0.3 (2) - 
F51.0 Non-organic insomnia 0.2 (1) - 
F53 Mental and behavioural disorders associated 
with the puerperium, not elsewhere classified 
0.2 (1) - 
F6x Disorders of adult personality & behaviour 2.4 (15) 3.6 
F60 Specific personality disorder (unspecified) 0.2 (1) - 
F60.3 Emotionally unstable personality disorder 2.1 (13) 3.2 
F68.1 
Intentional production or feigning of symptoms 
or disabilities, either physical or psychological 
[factitious disorder] 
0.2 (1) - 
F7x Mental retardation 0.6 (4) 0.4 
N94.3 Premenstrual tension syndrome 0.2 (1) - 
Zx Factors influencing health status and contact with health services 3.7 (23) - 
Unknown Diagnosis not recorded 19.6 (123) - 
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Table 3-4 – Proportion of women prescribed antenatal medication1 
Antenatal medication + non-psychotropics + Methadone 
  % (N) % (N) % (N) 
No psychotropics 57.9 (363) 9.4 (59) 1.0 (6) 
Psychotropics 42.1 (264) 14.8 (93) 3.0 (19) 
Any antidepressant 37.5 (235) 13.2 (83) 2.6 (16) 
Antidepressants only 33.5 (210) 11.5 (72) 2.2 (14) 
Any SSRI 27.9 (175) 9.4 (59) 1.6 (10) 
SSRIs only 23.0 (144) 15.9 (100) 1.0 (6) 
SSRI monotherapy 20.9 (131) 6.2 (39) 0.3 (2) 
Citalopram 5.7 (36) 1.8 (11) 0 (0) 
Escitalopram 0.5 (3) 0.2 (1) 0 (0) 
Fluoxetine 8.8 (55) 2.2 (14) 0.3 (2) 
Paroxetine 2.1 (13) 0.8 (5) 0 (0) 
Sertraline 3.8 (24) 1.3 (8) 0 (0) 
Any TCA 6.7 (42) 3.2 (20) 0.6 (4) 
Any SNRI 3.5 (22) 1.0 (6) 0.3 (2) 
Other ADs 3.2 (20) 1.8 (11) 0.5 (3) 
>1 AD 5.1 (32) 2.2 (14) 0.5 (3) 
Any mood stabiliser 3.3 (21) 1.0 (6) 0.3 (2) 
Mood stabilisers only 1.3 (8) 0.3 (2) 0 (0) 
Any antipsychotic 6.4 (40) 2.6 (16) 0.3 (2) 
Antipsychotics only 2.7 (17) 1.1 (7) 0.3 (2) 
AD = antidepressant, TCA = tricyclic, SNRI = serotonin noradrenaline reuptake 
inhibitor 
1 Rows and categories do not always add up consistently, due to some patients 
being co-prescribed non-psychotropics and/or Methadone, and those on mood 
stabilisers and/or antipsychotics being omitted from the “only” and 
“monotherapy” categories. 
 
Table 3-4 illustrates the complexity of the prescribing, with the 264 women on 
psychotropics receiving a mixture of concurrent and consecutive psychotropics 
and non-psychotropics in patterns defying simple categorisation. 
Notwithstanding, in essence (and ignoring co-prescriptions for non-
psychotropics, mood stabilisers, antipsychotics, and Methadone) 37.5% (235/627) 
were prescribed at least one antenatal antidepressant, 27.9% (175/627) at least 
one SSRI, and 20.6% (129/627) SSRI monotherapy only. A further 1.4% (9/627) 
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women were exposed to two consecutive SSRIs, and no other drugs, but they 
were not classed as receiving strict SSRI monotherapy – the type of antenatal 
psychotropic prescribing desirable for our proposed scanning project. 
Table 3-5 shows the numbers prescribed each type of psychotropic, whether 
receiving co-prescriptions for non-psychotropics or not (omitting patients also 
taking non-psychotropics would have excluded more than one third of the 
sample). Each row includes any exposure to a psychotropic within that category, 
regardless of co-prescriptions, unless already counted in a row above. For 
example, a patient exposed to an SSRI and a TCA would appear in the “Any SSRI” 
row under the “TCAs” column, but then not in the “Any TCA” row below – the 
shaded boxes have been left blank to minimize repetition and redundancy. 
Of the 32 women exposed to more than one antidepressant, 1.4% (9/627) were 
exposed to two consecutive SSRIs; 1.3% (8/627) an SSRI and an TCA 
consecutively; 0.2% (1/627) to two consecutive SSRIs and then a TCA; 0.5% 
(3/627) an SSRI and an SNRI consecutively; 0.5% (3/627) an SSRI and Trazodone 
concurrently; 0.2% (1/627) an SSRI following Mirtazapine; 0.2% (1/627) an SSRI 
and Bupropion concurrently; 0.5% (3/627) a TCA and Mirtazapine, or Reboxetine, 
or an unspecified antidepressant (respectively); 0.2% (1/627) a TCA and an SNRI 
consecutively; and 0.2% (1/627) a TCA following concurrent exposure to an SNRI 
and Reboxetine. 
The TCAs consisted of Lofepramine (23/627), Amitriptyline (10/627), 
Clomipramine (5/627), Dosulepin (2/627), Imipramine (1/627), and Trimipramine 
(1/672); SNRIs Venlafaxine (20/627) and Duloxetine (2/627); and other 
antidepressants Mirtazapine (9/627), Trazodone (4/627), Reboxetine (3/627), 
Bupropion (1/627), and Moclobemide (1/627). 
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Table 3-5 – Psychotropic co-prescribing1 
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Any AD (235) 175 42 22 20 32 9 2 4 1 2 19 8 13 16 
Any SSRI2 (175)  12 3 3 27 6 2 3 0 1 12 7 7 10 
Any TCA (42)   2 4 17 4 0 2 1 1 5 1 4 4 
Any SNRI (22)    1 5 1 0 1 0 0 2 0 1 2 
Other (20)     11 1 0 1 0 0 2 1 2 3 
>1 AD (32)      2 0 2 0 0 2 1 2 3 
Any MS (21)       6 7 2 7 7 3 5 2 
Lithium (6)        0 0 0 3 1 3 0 
Carbamazepine (7)         0 0 0 0 0 0 
Lamotrigine (2)          1 0 0 0 0 
Valproate (7)           4 2 2 2 
Any AP (40)            21 23 4 
"Typicals" (21)             3 4 
"Atypicals" (23)              0 
AD = antidepressant, TCA = tricyclic, SNRI = serotonin noradrenaline reuptake 
inhibitor, MS = mood stabiliser, AP = antipsychotic. 
1 Figures indicate co-prescribing of the two drugs/classes intersecting, and 
include patients prescribed other drugs. For example, if a patient was 
prescribed an SSRI, a TCA, and a mood stabiliser, they would be included in SSRI-
TCA, SSRI-MS and TCA-MS. Hence, given the complexity of some of the 
prescribing patterns, some subjects are represented multiple times in several 
different places. For simplicity, numbers do not take into account concurrent 
non-psychotropics. 
2 Includes 10 patients exposed to two different SSRIs (consecutively), with one of 
these also prescribed a TCA.  
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Timing of antenatal psychotropics 
Again, the data fields defining timing of exposure were frequently incomplete. 
Reasons for this were not specified, although at least some of the time it 
appeared to be because patients were seen only once during pregnancy, hence 
subsequent details were not available. Where drugs were documented in the 
first trimester, but there was no entry for the second or third trimesters, it was 
taken that they were stopped in the first trimester. Of the 57 women to whom 
this applied, 94.7% (54/57) either had a separate entry confirming that the 
medication was discontinued in the first trimester, or they were seen in the 
second trimester or later. Conversely, when drugs were commenced in the 
second or third trimesters, but not mentioned thereafter, we assumed that they 
were continued until delivery, unless otherwise specified. This was the case for 
49 women, 29 of which received SSRI monotherapy (of whom 10 also took non-
psychotropics). 
Rather than using a priori categories into which the data was made to fit, we 
employed a mixture of stage started, stage stopped, and stage restarted to 
describe the prescribing patterns (Table 3-6). Thus, P was used to refer to 
medicines commenced preconception, and 1, 2, or 3, if commenced in the first, 
second, or third trimesters, respectively. A small “s” was used to identify when 
medication stopped, with 1, 2, 3 to indicate in which trimester, and “r” to 
indicate when restarted. For example, Ps1 indicated that a drug taken 
preconception was stopped in the first trimester, while P signified that the drug 
was taken throughout pregnancy. 
Of the 264 women on antenatal psychotropics, 78.4% (207/264) were taking 
medication before conception, with 31.0% (82/264) continuing throughout 
pregnancy, and 36.7% (97/264) stopping in the first trimester (Table 3-6). A 
number of patients stopped and restarted drugs during pregnancy, several more 
than once, with 20.5% (54/264) commencing in the second and third trimesters 
(11.0% [29/264], and 9.5% [25/264], respectively). This pattern was similar for 
antidepressants in general, and SSRI monotherapy in particular, including the 
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13.1% (82/627) depressed women receiving only one SSRI. Thus the majority of 
women taking psychotropics during pregnancy commenced before conceiving. 
Table 3-7 presents the same data from a different perspective, indicating the 
actual numbers of those exposed to psychotropics before and during the three 
trimesters of pregnancy. Overall, the pattern for SSRI monotherapy was 
comparable to that of psychotropics in general. Exposure to one SSRI only, i.e. 
no mood stabilisers, no antipsychotics, and no Methadone (although 
prescriptions for other non-psychotropics, including benzodiazepines were not 
excluded) was characterised as follows. 
35.2% (94/627) of the total cohort were prescribed SSRI monotherapy before 
pregnancy, with the majority receiving Fluoxetine (43.6%, 41/94), Citalopram 
(34.0%, 32/94), or Sertraline (11.7%, 11/94). Overall, 64.9% (61/94) of those 
exposed to SSRI monotherapy preconception stopped during the first trimester, 
while 35.1% (33/94) continued. Of those who stopped, two restarted in trimester 
one, one restarted in trimester two, and two restarted in trimester three. 
Another woman started and subsequently stopped in the first trimester. Two 
others started in trimester one, and continued thereafter until delivery. There 
was variation between individual SSRIs, in that 73.2% (30/41), 63.6% (7/11), and 
62.5% (20/32) of those on Fluoxetine, Sertraline, and Citalopram (respectively) 
stopped, while 37.5% (12/32), 36.4% (4/11), and 26.8% (11/41) of those on 
Citalopram, Sertraline, and Fluoxetine (respectively) continued.  
The overall numbers exposed to psychotropics obscure some of the detail as 
depicted in Tables 3-6 and 3-7, in that while the majority (67.4%, 87/129) of 
those exposed to SSRI monotherapy at any point during pregnancy fell into the 
categories of either commencing preconception and continuing throughout 
pregnancy (P), or stopping in the first trimester (Ps1), almost one third followed 
a different, frequently complicated pattern. The first trimester represented the 
stage during which women were most likely to stop and least likely to start an 
SSRI; the converse was true for the second and third trimesters. 
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Table 3-6 – Timing of exposure to antenatal psychotropics  
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Any 
psychotropic (264) 82 97 3 13 1 6 2 1 2 2 1 24 3 2 25 104 160 93 19 
Any AD (235) 68 88 3 12 1 6 1 1 2 2 1 23 3 2 22 94 141 83 16 
ADs only (196) 55 72 3 10 1 5 1 1 2 2 1 20 3 1 19 78 118 63 - 
Any SSRI (175) 47 66 3 9 0 4 0 1 2 2 1 17 2 2 19 69 106 59 10 
SSRIs only (138) 35 56 2 5 0 3 0 0 2 2 1 13 2 1 16 59 79 40 - 
SSRI 
monotherapy (129) 31 56 2 1 0 2 0 0 2 2 1 14 2 1 15 59 70 38 - 
Citalopram (36) 11 19 1 0 0 0 0 0 1 0 1 2 0 0 3 20 18 11 - 
Escitalopram (3) 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 3 - 
Fluoxetine (53) 9 26 1 1 0 2 0 0 1 1 0 5 1 0 5 27 25 53 - 
Paroxetine (13) 5 3 0 0 0 0 0 0 0 1 0 1 0 0 3 3 10 13 - 
Sertraline (24) 4 7 0 0 0 0 0 0 0 0 0 6 1 1 5 8 16 24 - 
Depressed 
+ any SSRI (82) 20 30 1 1 0 1 0 0 2 2 1 10 1 0 13 32 50 19 - 
 
 
In the second trimester, 28.7% (37/129) continued their SSRI, 13.2% (17/129) 
started, and 0.8% (1/129) restarted, while 1.6% (2/129) stopped, with a similar 
pattern in the third trimester; 38.8% (50/129) continued, 11.6% (15/129) started 
and 1.6% (2/129) restarted, while 2.3% (3/129) stopped. These observations 
were complemented by the overall proportion of women exposed to any SSRI 
monotherapy during pregnancy, 15.5% (97/627) in the first trimester, 8.6% 
(54/627) in the second trimester, and 11.2% (70/627) in the third. Thus, while 
most discontinued in the first trimester, this was also when most were exposed, 
with the reduced rate of exposure in the second trimester gradually increasing 
into the third trimester.  
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Table 3-7 – Stage of exposure to antenatal psychotropics 
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(N) 
(264) (235) (175) (138) (129) (36) (3) (53) (13) (24) 
Before pregnancy 207 182 132 103 94 32 2 41 8 11 
Trimester 
1 
Continued1 87 72 50 35 33 12 1 11 5 4 
Started 3 3 3 3 3 1 0 1 1 0 
Stopped 121 111 83 69 62 21 1 30 3 7 
Restarted 3 3 3 3 2 1 0 1 0 0 
Total 210 190 135 106 97 33 2 42 9 11 
Trimester 
2 
Continued 89 75 54 40 37 13 1 13 6 4 
Started 29 28 21 17 17 2 0 5 1 8 
Stopped 7 6 3 2 2 0 0 1 0 1 
Restarted 15 14 10 6 1 0 0 1 0 0 
Total 135 118 85 63 55 15 1 20 7 12 
Trimester 
3 
Continued 125 109 79 58 50 14 1 18 7 10 
Started 25 22 19 15 15 1 1 5 3 5 
Stopped 4 4 4 3 3 1 0 1 0 1 
Restarted 6 6 4 3 2 0 0 2 0 0 
Total 160 141 106 79 70 16 2 26 10 16 
1 “Continued” refers to those already on the relevant drug at the start of the 
trimester, and who remained on it throughout that trimester without stopping. 
 
Early and late exposure to antenatal psychotropics 
Of those who received a psychotropic during pregnancy, 39.4% (104/264) were 
exposed in the first and second trimesters only, with 60.6% (160/264) exposed in 
the third trimester (Table 3-6). With regards to the 129 women receiving SSRI 
monotherapy, 45.7% (59/129) were exposed in early pregnancy, and 54.3% 
(70/129) in late pregnancy. Due to lack of precise dates and gestation for 
starting and stopping each medication, the exact durations of exposure could 
not be determined. 
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Timing of exposure to SSRI monotherapy, and stage first seen at the PMHS 
With regards to women exposed to SSRI monotherapy, their stage first seen at 
the PMHS is shown in Table 3-8. Most were seen after the first trimester, i.e. 
after the majority of prescribing decisions. However, most of those commencing 
an SSRI in the second or third trimesters were first seen via the PMHS at that 
stage. 
 
Table 3-8 – Timing of exposure to SSRI monotherapy by stage seen 
  Stage of pregnancy first seen at the PMHS 
  Trimester 1 Trimester 2 Trimester 3 Other 
 (N) (1) (51) (48) (29) 
P (31) 0 11 12 8 
Ps1 (56) 1 19 19 17 
Ps1r1 (2) 0 1 1 0 
Ps1r2 (1) 0 1 0 0 
Ps1r3 (2) 0 1 0 1 
Ps3 (2) 0 1 1 0 
1 (2) 0 1 0 1 
1s1 (1) 0 0 1 0 
2 (13) 0 10 2 1 
2s2 (2) 0 2 0 0 
2s3 (1) 0 1 0 0 
3 (16) 0 3 12 1 
Early (59) 1 21 20 17 
Late (70) 0 30 28 12 
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Type of exposure by diagnosis 
Type of exposure to antenatal psychotropics for all diagnoses is shown in Table 
3-9. As per antidepressants only, almost two thirds of those exposed to SSRI 
monotherapy had a primary diagnosis of depression, and around one fifth a 
primary diagnosis of a neurotic, stress-related, or somatoform disorder. 
 
Table 3-9 – Antenatal psychotropic exposure by diagnosis1 
 
 
Psychoses	 Bipolar	 Depression	 Neuroses	 Other	
 (N) 
(19)	 (38)	 (259)	 (118)	 (193)	
No 
psychotropics (363) 2.8	 5.2	 33.6	 20.7	 37.7	
Any 
psychotropic (264) 3.4	 7.2	 51.9	 16.3	 21.2	
Any AD (235) 1.3	 3.8	 56.6	 17.9	 20.4	
ADs only (196) 0	 2.6	 61.2	 18.9	 17.3	
Any SSRI (175) 1.1	 4.0	 58.9	 19.4	 16.6	
SSRIs only (138) 0	 2.2	 63.8	 20.3	 13.8	
SSRI 
monotherapy (129) 
0	 2.3	 63.6	 19.4	 14.7	
Citalopram (36) 0	 5.6	 63.9	 19.4	 11.1	
Escitalopram (3) 0	 0	 66.7	 33.3	 0	
Fluoxetine (53) 0	 1.9	 62.3	 15.1	 20.8	
Paroxetine (13) 0	 0	 61.5	 23.1	 15.4	
Sertraline (24) 0	 0	 66.7	 25.0	 8.3	
1 expressed as a percentage of those exposed to each type of drug, i.e. each row 
totals 100% 
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Of the 259 women with a primary diagnosis of depression, 31.7% (82/259) were 
exposed to SSRI monotherapy (Table 3-10), with 78.0% (64/82) of these seen 
during pregnancy, 48.4% (31/64) in trimester two, and 51.6% (33/64) in 
trimester 3 (Table 3-11). 
 
Table 3-10 - Proportion of women receiving SSRI monotherapy with a primary 
diagnosis of depression 
Diagnosis % (N) 
F32  18.6 (24) 
F33 45.0 (58) 
 
 
Table 3-11 – Stage first seen for all women receiving SSRI monotherapy, for 
all diagnosis, and those with a primary diagnosis of depression 
 All diagnoses Depression 
Stage first seen % (N) % (N) 
Preconception  1.6 (2) - (0) 
Pregnant 77.5 (100) - (0) 
First trimester 0.8 (1) - (0) 
Second trimester 39.5 (51) 24.0 (31) 
Third trimester 37.2 (48) 25.6 (33) 
Postnatal 16.3 (21) 10.9 (14) 
Unknown 4.7 (6) 3.1 (4) 
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Table 3-11 reveals that 10.2% (64/627) of the total PMHS sample who received 
SSRI monotherapy for depression were seen during pregnancy. Of these, more 
than half attended in the third trimester, possibly too late to be recruited to the 
scanning study, leaving 31 women seen in the second trimester. 1.8% (11/6.27) 
were exposed in early pregnancy, and 3.2% (20/627) in late pregnancy. Table 3-
12 summarises the prescribing patterns for the 31 women who would have been 
potential participants in our scanning study. 
 
 
Table 3-12 – Timing and duration of exposure to SSRI monotherapy for woman 
with a primary diagnosis of depression attending the PMHS during pregnancy 
  Timing (%) Exposure (%) 
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Any SSRI1 (31) 5.4 7.8 0.8 0.8 0.8 0.8 4.7 0.8 2.3 41.9 58.1 
Citalopram (5) 0.8 1.6 0.8 0.0 0.8 0 0 0 0 40.0 60.0 
Escitalopram (0) - - - - - - - - - - - 
Fluoxetine (15) 3.1 3.9 0 0.8 0 0 2.3 0.8 2.3 40.0 60.0 
Paroxetine (3) 0.8 0.0 0 0 0 0.8 0 0 2.3 33.3 66.7 
Sertraline (8) 0.8 2.3 0 0 0 0 2.3 0 0.8 50.0 50.0 
 
1 SSRI monotherapy, i.e. no other antidepressants, mood stabilisers, 
antipsychotics, or Methadone 
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Results summary 
(1) 62.4% (391/627) of women attending the PMHS were seen during 
pregnancy, the majority in the second and third trimesters (Table 3-4). 
(2) 3.7% (23/627) were seen in the first trimester, 25.5% (160/627) in the 
second trimester, and 33.2% (208/627) in the third trimester (Table 3-2). 
(3) 42.1% (264/627) were exposed to a psychotropic medication during 
pregnancy (Table 3-4). 
(4) Of those exposed to a psychotropic, 89.0% (235/264) were exposed to an 
antidepressant, 74.2% (196/264) to antidepressants only, 66.3% (175/264) 
to an SSRI, 52.3% (138/264) to SSRIs only, and 48.9% (129/264) to SSRI 
monotherapy. Of those exposed to SSRI monotherapy, 42.6% (55/129) took 
Fluoxetine, 27.9% (36/129) Citalopram, 18.6% (24/129) Sertraline, 10.1% 
(13/129) Paroxetine 13/129, and 2.3% (3/129) Escitalopram. Doses were 
neither clearly nor consistently specified. Co-prescribing was common, 
35.2% (93/264) with non-psychotropics, and 7.2% (19/264) with Methadone. 
Of those prescribed an antidepressant, 13.6% (32/235) were exposed to 
more than one antidepressant, and 10.6% (25/235) were exposed to at least 
one mood stabiliser and/or an antipsychotic. With regards to those taking 
SSRI monotherapy, 72.9% (94/129) were exposed at conception, of whom 
33.0% (31/94) continued throughout pregnancy, and 67.0% (63/94) stopped 
during pregnancy; 64.9% (61/94) in the first trimester, and 2.1% (2/94) in 
the third. A few women who stopped in the first trimester subsequently 
restarted, 2.1% (2/94) in the first trimester, 1.1% (1/94) in the second, and 
2.1% (2/94) in the third. Of those on SSRI monotherapy, 45.7% (59/129) 
were exposed “early” in pregnancy, and 54.3% (70/129) “late”. There were 
a range of prescribing patterns, with 2.3% (3/129) starting in the first 
trimester (one stopped almost immediately, and returned to Duloxetine), 
13.2% (17/129) starting in the second (with three subsequently stopping), 
and 11.6% (15/129) starting in the third and continuing until delivery. The 
SSRIs most commonly started during pregnancy were Fluoxetine and 
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Sertraline, in 9.3% (12/129) and 10.1% (13/129), respectively (Tables 3-4, 
3-5, and 3-6). 
(5) The majority of those exposed to psychotropics had a primary diagnosis of 
depression, and more than 60% of those prescribed antidepressants only 
(Table 3-9). 
(6) 41.3% (259/627) had a primary diagnosis of depression (Table 3-3). 
(7) Over the seven years under scrutiny, 4.9% (31/627) women had a primary 
diagnosis of depression, were exposed to SSRI monotherapy during 
pregnancy, and attended the PMHS in the first or second trimesters, i.e. 
were seen early enough to be invited to participate in scanning. 
 
 
Discussion 
These findings represent a detailed analysis of antenatal psychotropic 
prescribing patterns in a sizeable cohort of patients attending a specialist 
perinatal mental health service over several years. We have been unable to find 
comparable published data from the UK. Several findings of both general 
importance and specific relevance to the scanning study emerged. 
 
Data integrity 
There were significant challenges posed by the partial and ambiguous nature of 
much of the data. Consistent with the findings of Durrani and Cantwell (2009) 
(who reported that 79% of forms had some sections incomplete), the majority of 
the data collection forms analysed had one or more blank fields. Despite the 
intended content of the information fields in the PMHS data collection forms 
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appearing self-evident, many were completed (or not) in ways that did not 
provide the kind of detail necessary for accurate and comprehensive analysis. 
Although the PMHS did not formally open until 2004, we were able to access 
forms from 2002 onwards. This was because the lead Consultant Psychiatrist had 
been providing specialist perinatal care and advice via general psychiatry 
services in a consultation-liaison model, and had established the practice of 
collecting and organising clinically relevant data via his bespoke forms alongside 
the clinical records, to facilitate informed audit, and to provide a basis for 
research even before the PMHS opened (Appendix 2). These forms were partially 
mined, to answer some basic questions about the PMHS’s clinical activity and 
practice, as subsequently reported by Durrani and Cantwell (2009). However, 
when we started processing the forms in 2007 this data had not yet been fully 
analysed, reported nor published, hence our pre-study assumptions were largely 
based on anecdotal evidence – that most referrals were from maternity services; 
that most patients were pregnant when seen; that affective disorders were the 
most common diagnostic category; that around half received prescribed 
medication; and that SSRIs were the single most common type of drugs 
prescribed. 
The forms did provide data in a more organised, concise, efficient and relevant 
way than the clinical records. However, as they had not been designed 
specifically to answer the questions we were asking, they posed challenges to 
forensic analysis, particularly with regards to exact timing and amount of 
exposure to prescribed and other medication, and confounding factors such as 
alcohol, smoking, and illicit drugs. This appeared partly related to how the 
forms were laid out, and the amount of space provided to update details of 
drugs before, during and after pregnancy. 
In addition, the forms did not facilitate a longitudinal perspective, with multiple 
contacts being documented in an easily identifiable way, but rather a snapshot 
of (mainly) the initial clinical encounter. It was not always clear whether the 
patients had attended only once, or had been seen multiple times, nor if the 
forms had been updated by clinical staff at each subsequent attendance, hence 
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uncertainties over exactly when drugs were started and stopped, and therefore 
exactly when and for how long fetuses had been exposed. Moreover, patients 
were seen and forms completed by a variety of clinicians, some of whom were 
less experienced and only working with the PMHS for short periods, e.g. core 
psychiatry trainees. It is plausible that their completion of the forms was less 
detailed and/or relevant than that of the more experienced permanent PMHS 
staff, and the Consultant Psychiatrist who had initiated the forms. 
Furthermore, the data collection forms were simply a summary of the clinical 
encounter, i.e. information affected by a mixture of patients’ recall bias, 
availability and accuracy of records, the clinician’s interpretation, and the time 
available for documentation (staff were expected to complete forms in addition 
to the standard clinical entries). We verified the first 206 forms with the clinical 
records, which clarified some, but not all, of the issues. Overall, cross-checking 
added little to the details contained in the forms, and did not result in subjects 
changing categories for analysis, hence was not deemed necessary for the 
remainder.  
Issues of interpretation were seen most clearly in the sections dedicated to 
smoking, alcohol, and drug use. For example, as alcohol use was documented by 
stating the number of units consumed each week, it is plausible that figures 
represented an over- or under-estimate by either patients or clinicians, whether 
by intention or error. It has been established that women may significantly 
under-report alcohol use within pregnancy, and that doctors and nurses in 
general, and psychiatric staff in particular, do not display universally accurate 
knowledge of units (Ernhart et al., 1988; Anderson, Flanigan & Jauhar, 1999; 
Webster-Harrison et al., 2001; Das et al., 2009; Das et al., 2014). 
Another unexpected challenge was the dynamic nature of the data. Early in the 
project we were puzzled by the weekly appearance of new forms amongst those 
already competed, and the disappearance of forms already processed. Forms 
were stored alphabetically by surname in a folder, and it emerged that the 
administrative system involved new forms being added as new patients were 
seen, and old forms belonging to patients discharged from the PMHS being 
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removed and archived in a separate folder. Moreover, forms for patients who 
were returning to clinic for review were (sometimes, but not always) removed 
temporarily to allow them to be updated, then returned to the folder. 
Furthermore, as forms accrued it became impossible to file them all in one 
folder, necessitating transfer to further folders, by year seen. This made it 
difficult to ensure that our cohort was composed of consecutive attendees, and 
included all patients, to avoid confounding via non-random sampling, e.g. 
missing those attending for frequent review. 
Although the overall impact of data quality issues was difficult to estimate, we 
found that even minor parameters such as calculating age at EDD or stage seen 
at the PMHS were affected by missing information. However, we discerned no 
reason to suspect that the available details were biased, nor unrepresentative of 
the true facts. 
 
Stage first seen at the PMHS, diagnoses, and the extent of antenatal 
psychotropics 
Perhaps unsurprisingly due to the period prevalence of perinatal mental health 
problems, more than one third (37.6%, 236/627) of women attending the PMHS 
for whom data collection forms were available were seen outwith pregnancy, 
with most of these receiving postnatal care (74.2%, 175/236). This contrasts 
somewhat with the proportion reported by Battle et al. (2006), who found that 
63.7% (318/500) of women attending specialist perinatal mental health services 
in Rhode Island, USA, attended outwith pregnancy, all postpartum. This suggests 
different emphases between Battle et al’s services (encompassing both 
outpatients and day hospital attendees) and the Glasgow PMHS, and may simply 
reflect the increasing awareness of psychiatric disorders during pregnancy and 
the development of specialist perinatal mental health services over time, as 
Battle et al’s sample were seen between 1999 and 2002. 
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Similarly, while Battle et al. established that 80.6% (403/500) of their cohort 
had a primary diagnosis of depression (55.9% (57) of the 102 outpatients, and 
86.9% (346) of the 398 day hospital attendees), the PMHS had a rate of only half 
that. As Battle et al. did not give a comprehensive breakdown of all diagnoses, it 
is difficult to comment further, although the smaller proportion of depressed 
patients in our sample may be attributable to a variety of factors, including 
demographic and diagnostic issues, service progression, or more patients being 
seen during pregnancy – Battle et al’s rates for bipolar affective disorder and 
neurotic, stress-related and somatoform disorders were substantially lower at 
2.0%, and ~11.6%, respectively (although these combined figures mask some 
differences between their outpatients and day hospital attendees). 
Despite the specialist nature of the PMHS, more than half of those attending 
were not documented as having been prescribed a psychotropic during 
pregnancy (58.0%, 363/627), including those seen during pregnancy (53.5%, 
209/391). While both Durrani and Cantwell (2009) and Julyan, Cavanagh and 
Cantwell (2009) reported that around 60% of the PMHS attendees were exposed 
to a psychotropic at some point during pregnancy, this analysis of a larger 
sample refined this figure down to around 40%. The explanation for this is 
unclear, although may be due to our sample including women seen later in the 
development of the PMHS, from 28 October 2002 to 24 September 2009, while 
Julyan, Cavanagh and Cantwell’s sample spanned 30 June 1999 to 27 August 
2003, and Durrani and Cantwell covered 1 April 2005 to 31 April 2006. 
It could be assumed that most women attending a specialist PMHS would be 
moderately to severely ill, and therefore require psychotropics. Referrals for 
milder, uncomplicated cases (in which medication is less likely to be indicated) 
are generally redirected to the patient’s General Practitioner (GP) or sector 
Community Mental Health Team (CMHT), while those seen via the PMHS tend to 
be more severely unwell, or have complicated diagnostic or management needs 
(Dr Cantwell, personal communication). There are several possible explanations 
why less than half of those attending the PMHS were prescribed a psychotropic, 
discussed below. 
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Notwithstanding, we took our findings as being broadly credible and as having 
face validity, given the experience of the clinicians involved, and the published 
literature – a significant proportion of pregnant women attending the PMHS, and 
thus their fetuses, are exposed to psychotropic drugs at some point, and the 
most common antenatal drugs are antidepressants, especially SSRIs. It followed 
that our enquiries should be extended to pregnant women in the general 
population, and that attempts should be made to address the inaccuracies 
inherent in the data. 
 
Types of antenatal psychotropics 
We found examples of women prescribed psychiatric drugs from every available 
class, including antidepressants, mood stabilisers, and (oral and long-acting 
injectable) antipsychotics. It proved difficult to know how best to categorise 
drugs such as Methadone, benzodiazepines, and anticonvulsants as, although 
they are psychoactive and associated with adverse outcomes for mothers and 
babies, they are not strictly speaking psychiatric drugs prescribed only for 
psychiatric illnesses. We chose to classify only antidepressants, mood stabilisers 
(including Lamotrigine), and antipsychotics as psychotropics, with 
benzodiazepines being categorised as non-psychotropics, and Methadone being 
analysed separately. The lack of comparable studies in other specialist perinatal 
populations has already been noted, although the rates of psychotropic 
prescribing in the PMHS differed somewhat from those of Battle et al. (2006), 
who reported that 25.4% (127/500) from their sample took a psychotropic, with 
83.5% (106/127) of these prescribed an antidepressant. It should be noted, 
however, that Battle et al. reported only “medications at intake”, i.e. point 
prevalence, mainly postpartum, and our figures referred to total prevalence, 
hence could reasonably be expected to be higher. 
Consistent with the published literature, SSRIs were the single most commonly 
prescribed psychotropics, with patients on SSRI monotherapy comprising 48.9% 
(129/264) of all patients exposed to a psychotropic, 55.0% (129/235) of those 
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prescribed an antidepressant and 65.8% (129/196) of those receiving 
antidepressants only (Margulis, Kang & Hammad, 2014).  This is in keeping with 
current guidelines on the pharmacological management of depressive illness in 
the non-pregnant population, where SSRIs are recommended as first line agents 
due to their safety, efficacy and tolerability (NICE CG90, 2009). Largely due to 
the amount of available data, Fluoxetine has been recommended as the 
antidepressant of choice during pregnancy, and Sertraline postnatally, due to its 
relatively low excretion in breast milk – these two SSRIs made up 60.0% (77/129) 
of SSRI monotherapy, with Citalopram and Paroxetine being the next most 
commonly used SSRIs (27.9% [36/129] and 10.1% [13/129], respectively). It was 
noteworthy that when an SSRI was commenced during pregnancy, the most 
commonly used were Fluoxetine and Sertraline, each comprising 35.5% (11/31) 
of those starting SSRI monotherapy (Table 3-13). 
 
Timing of antenatal psychotropics 
Given the myriad of psychotropics, prescribed at different doses and for 
different indications, alongside other drugs (including non-psychotropics and 
Methadone), at different times and for different durations, it proved challenging 
to know how to categorise prescribing patterns. For the purposes of this study 
we elected simply to describe each patient’s prescribing details, for exposure to 
all psychotropics combined, as well as their classes (antidepressants, mood 
stabilisers, and antipsychotics), antidepressants only, and SSRIs monotherapy, 
including for each specific SSRI (Tables 3-6 and Table 3-12). This allowed us to 
identify any patterns without pre-specification, to avoid imposition of biases or 
suppositions. 
Antenatal psychotropic prescribing patterns appeared to fall into six main 
categories, shown in Table 3-13.  
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Table 3-13 – Categories of antenatal psychotropic prescribing 
  Timing 
 (N) P Ps
1 
1 2 3 O
th
er
 
Any psychotropic (264) 82 97 2 24 25 34 
Any AD (235) 68 88 2 23 22 32 
ADs only (196) 55 72 2 20 19 28 
Any SSRI (175) 47 66 2 17 19 24 
SSRIs only (138) 35 56 2 14 16 16 
SSRI monotherapy (129) 31 56 2 14 15 11 
Citalopram (36) 11 19 0 2 3 3 
Escitalopram (3) 1 1 0 0 1 0 
Fluoxetine (53) 9 26 1 5 5 6 
Paroxetine (13) 5 3 1 1 3 0 
Sertraline (24) 4 7 0 6 5 2 
Depressed + any SSRI (82) 20 30 2 10 13 7 
 
 
In order of frequency, the most common patterns of prescribing for SSRI 
monotherapy were 43.4% (56/129) exposed periconception and stopping in the 
first trimester, 24.0% (31/129) exposed periconception and continuing 
throughout pregnancy, 11.6% (15/129) commencing in the third trimester, 10.9% 
(14/129) commencing in the second trimester, 8.5% (11/129) following various 
“stop-start” sequences, and 1.6% (2/129) commencing in the first trimester. Five 
of those who were exposed periconception and stopped in the first trimester 
subsequently restarted and continued until delivery; two in the first trimester 
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(one Fluoxetine, one Citalopram), one in the second (Fluoxetine), and two in the 
third (both Fluoxetine). 
Of the women prescribed psychotropics before conception, less than one third 
were documented as continuing these medicines throughout pregnancy (31.1%, 
82/264), and less than one quarter of those exposed to SSRI monotherapy 
(24.0%, 31/129).  This is consistent with other studies in non-specialist 
populations, which have reported that more than half of those taking an 
antidepressant before pregnancy stop in the first trimester, with others 
discontinuing in the second or third (Ververs et al., 2006; Ramos et al., 2007; 
Petersen et al., 2011; Jimenez-Solem, 2014; Margulis, Kang & Hammad, 2014; 
Charlton et al., 2015). The relatively low rates of prescribing in the PMHS 
appeared counterintuitive, in that one might have expected women seen via the 
specialist PMHS, who are presumably more unwell or have more complex needs, 
to be more likely to require psychiatric medication throughout pregnancy, with 
the opposite being true for women who can be managed in primary care, or by 
their general psychiatry team. There are several possible explanations, including 
that pregnant women are more likely to stop psychotropic medication if referred 
to a specialist perinatal mental health service. Conversely, it may be that 
pregnant women on psychotropics who wish to stop are more likely to be 
referred for specialist assessment and advice. However, as Cohen et al. (2006) 
found that around two thirds of remitted depressed women who discontinued 
antidepressants perinconception subsequently relapsed during pregnancy, this 
may explain why those who stopped medication in the first trimester required 
specialist psychiatric follow-up. 
Women receiving care via the PMHS are not representative of the general 
population, but are an asymmetrically skewed cohort. For example, pregnant 
women prescribed SSRI monotherapy for “mild” “uncomplicated” depression are 
generally not seen by the PMHS, nor those with stable severe mental illnesses 
already in contact with mental health services. Thus the PMHS sample is more 
likely to be comprised of “atypical” or “complicated” patients with diagnoses 
other than unipolar depression, including those with severe current and/or 
historical perinatal psychiatric disorders. In this regard, it may be expected that 
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psychotropic prescribing, including polypharmacy, would be common. However, 
there may be differences in the clinical management of patients attending the 
PMHS, compared to that provided by CMHTs. Several factors are of potential 
explanatory relevance, including those specifically relating to patients, 
referrers, the PMHS clinicians and interventions, and the data itself. 
Firstly, patient factors. It may be that women referred to PMHS are more 
motivated to seek help, and therefore more open to considering alternatives to 
medication, even if driven mainly by anxiety over possible teratogenicity (Koren, 
2014). Indeed, some may seek referral specifically in an attempt to identify non-
pharmacological options for their symptoms. It is certainly not the case that 
everyone referred to or seen via the PMHS is severely or acutely unwell, and 
only a small proportion of pregnant women on psychotropics from the referable 
population are referred to or attend the PMHS (Dr Cantwell, personal 
communication). 
Secondly, referrer factors. As most referrals to the PMHS originate from 
maternity services, it is plausible that some may be motivated to link with the 
PMHS when they suspect that antenatal psychotropics are not necessary, and 
could be safely discontinued (Durrani & Cantwell, 2009). (The corollary is that 
mums-to-be with more severe mental health problems, who are stable on long 
term psychotropics, and who are receiving care from a general psychiatry 
service or CMHT, may be less likely to be referred, due to the perception that 
this would not change management.) Moreover, as the PMHS became known over 
time, and midwives and others became more aware of and screened for 
perinatal mental health problems, it is also possible that the increasing number 
of referrals included women who did not require medical treatment. For 
example, while 48.3% (232/480) of those with an ICD-10 “F” code (indicating a 
mental, behavioural, or neurodevelopmental diagnosis) received a psychotropic 
during pregnancy, only 21.8% (32/147) with other/no diagnosis were exposed. 
(These 147 women comprised 24 with an ICD-10 “N” or “Z” code, of whom 12.5% 
[3/24] were on a psychotropic, and 123 with no diagnosis recorded, of whom 
23.6% [29/123] were exposed to psychiatric medication.) In other words, around 
50% of those with a psychiatric diagnosis were prescribed a psychotropic, 
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although this included conditions for which psychiatric medication is not 
necessarily indicated nor routinely prescribed. 
Thirdly, PMHS factors. The PMHS clinicians have special experience in managing 
perinatal mental health problems, and hence might have different thresholds for 
starting and stopping psychiatric drugs during pregnancy. Furthermore, the 
availability of non-pharmacological interventions offered by the specialist PMHS 
may have the potential to enable women to stop medication due to the 
psychosocial support available, in contrast to the more limited therapies 
available via GPs or CMHTs. It is also conceivable that expectant mothers may be 
more willing to try stopping their medication if they are confident that they will 
be closely followed-up, and monitored for relapse. 
Fourthly, data quality. The apparent low rates of prescribing may be explained 
simply by the data being inaccurate. As intimated above, in the early stages of 
data collection we crosschecked the contents of the first 206 data collection 
forms with each patient’s PMHS records, as most sheets had sections that had 
not been completed, and some of the information was ambiguous. Even then not 
all queries could be addressed, and several issues emerged. Firstly, the data 
collection forms were not specifically designed to collect information in a way 
that allowed us to answer the specific questions we posed, particularly with 
regards to timing of exposure to medication throughout pregnancy. Secondly, 
while the forms were generally populated to some extent at patients’ first 
contact, they were not necessarily completed nor updated at subsequent 
appointments. Thus the data was incomplete, leading to a potential under- or 
over-estimate of prescribing rates, e.g. if a patient commenced a psychotropic 
after being seen by or discharged from the PMHS, this would not have been 
captured by our methods, and vice versa.  Thirdly, the data were ultimately 
based on patients’ self-reporting of what medication they were taking, 
introducing potential recall bias, and inaccuracies relating to patients’ 
knowledge and adherence to treatment as prescribed, i.e. what drug, at which 
dose, for how long, and at what stage(s) of pregnancy. However, we did not 
attempt to harmonise the data from the following 421 sheets with the clinical 
records, as the anticipated inaccuracies appeared unlikely to influence our 
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overall conclusions and subsequent actions at this stage, in addition to 
medicolegal, ethical and information governance considerations related to 
accessing the PMHS patients’ clinical records. 
Notwithstanding, we noted that despite the apparent reduction in ongoing 
exposure to SSRI monotherapy in this sample from 15.0% (94/627) periconception 
to 8.8% (55/627) by the second trimester due to patients discontinuing in the 
first trimester, there was an increase back to 11.2% (70/627) by the third 
trimester, mainly due to patients starting an antidepressant for the first time 
during pregnancy (Table 3-7). This trend was reflected in the rates for other 
antidepressants and psychotropics, and is consistent with the twin observations 
that women attending the PMHS are seen later in pregnancy, and are more likely 
to be unwell, thus requiring medical treatment. This is a finding that contrasts 
somewhat with those reported in general (non-specialist) perinatal populations 
as outlined in Chapter 2, and appears related both to the different samples, and 
the different methodologies employed to estimate exposure, discussed further in 
Chapters 6 and 8 (see Figures 2-3, 2-4, 2-5 and 8-5). 
 
Categories of exposure to antenatal psychotropics 
The ultimate aim of characterising antenatal exposure to psychotropic 
medication is to identify which types of exposure are associated with which 
sequelae, and to establish valid predictor variables for specific outcomes. 
Studies exploring the progenic consequences of antenatal antidepressants have 
frequently dichotomised the exposure type into fetuses exposed during the first 
trimester, and those exposed later in pregnancy, with the former generally 
being evaluated with regards to miscarriage and/or congenital malformations, 
and the latter for neonatal and longer term neurobehavioural outcomes (e.g. 
Maschi et al., 2007; Ramos et al., 2008; Nakhai-Pour, Broy & Bérard, 2010; Ban 
et al., 2012; Ban et al., 2014). Some researchers have investigated 
length/duration of exposure as a related but distinct variable, concluding that 
this may be a better predictor of adverse birth outcomes than timing of 
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exposure (e.g. Oberlander et al., 2008; Casper et al., 2011), discussed further in 
Chapters 5 and 6. 
We were unable to calculate the length of exposure accurately from the data 
available. This was not critical for our conclusions above, as we were not 
exploring consequences of exposure at this stage of our enquiries. Nevertheless, 
as exploring outcomes of exposure was a planned future step, we used the 
definition of “early” and “late” exposure used by Chambers et al. (1996) to 
estimate how many neonates may be at increased risk of short term sequelae 
(Table 3-6). 
Whether considering all antenatal psychotropics together, antidepressants only, 
or SSRI monotherapy, (with the exception of Fluoxetine) we found that at least 
half of the women prescribed drugs were exposed later in pregnancy. In other 
words, given that fetal exposure to SSRIs longer and later in pregnancy may 
convey a higher risk of early complications, it is possible that a sizeable 
proportion of women seen at the PMHS will deliver babies with neonatal 
complications that may or may not require specialist intervention, or be at 
longer term risk of adverse outcomes. 
However, duration of exposure is related to several other factors, including 
timing and severity of illness, access to medical advice and care, maternal 
preferences and adherence to prescribed drugs, and intertwined issues such as 
medication efficacy and tolerability. Decisions on when to start, stop and 
continue medication are made personally and clinically, taking into account 
each individual patient’s presentation and preferences, in addition to their 
doctor’s experience, with a joint weighing of the potential advantages and 
disadvantages. Furthermore, while it is likely that patients with more severe 
illness will persist with prescribed medication for longer, illness severity and 
duration itself may contribute to at least some of the risks associated with 
duration of exposure (Oberlander et al., 2008). 
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Prescribing decisions 
It was noteworthy that while the majority of prescribing decisions were made in 
the first trimester (including whether to stop or continue medication), most 
women were not seen in the PMHS until the second or third trimester (Tables 3-2 
and 3-8). This is in keeping with Durrani and Cantwell’s finding that the majority 
of referrals originated from maternity services, where women are usually seen 
for “booking” towards the end of the first trimester. This does indicate, 
however, that potentially significant specialist input with regards to the risks 
and benefits of stopping, continuing or commencing medication may not be 
accessed by most women either before, or early enough within, pregnancy.  
Notwithstanding, many of those who stopped or started medication during 
pregnancy were seen before or during the trimester of change; it appeared that 
around 20-25% of prescription changes may have been made alongside PMHS 
involvement. 
 
Identifying potential participants for scanning 
One aim of our analysis was to estimate how many depressed women on SSRI 
monotherapy we would be able to recruit for our proposed scanning study. Only 
4.9% (31/627) of the sample would have been potential participants, although a 
further 5.3% (33/627) may have been suitable, save for attending the PMHS in 
the third trimester, possibly too late to take part. This suggested that 5-10% of 
the >200 women who attend the PMHS each year may be eligible, perhaps up to 
20 women each year, 1-2 per month. However, as we also sought depressed 
unmedicated women as well as healthy unmedicated controls, we agreed that 
we may need to look outwith the PMHS to recruit, and consider seeking subjects 
from general maternity services, as well as from GPs and CMHTs. 
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Challenges to analysis 
The above account of different antenatal psychotropic drugs - alone and in 
combination with other psychotropics, non-psychotropics, and Methadone; at 
different stages of pregnancy; for varying lengths of time; and in heterogeneous 
maternal clinical states - illustrates the complexity of this area of enquiry (see 
also Figure 2-8). Yet for a full understanding of the consequences, a detailed 
and nuanced awareness of antenatal exposure to psychotropics is necessary, in 
conjunction with other parameters influencing offspring’s neurodevelopment, 
including paternal factors (e.g. genotype; age at conception; mental health), 
maternal factors (e.g. genotype; mental illness type, timing, severity, and 
functional impact; adherence to medication; drug metabolism/serum levels; 
substance misuse; personality; lifestyle), obstetric factors (e.g. placental 
transfer; complications) and fetal factors (e.g. genotype; birthweight). 
 
Future work 
Given that the above findings were specific to a specialist perinatal population, 
we progressed to undertake a pilot study into establishing the characteristics of 
antenatal exposure to psychotropic medication in a general maternity sample.  
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Key points 
• ~2 in 3 women attending the PMHS were seen during pregnancy, mainly in the 
second and third trimesters. 
• ~2 in 5 took psychotropic medication at some point during pregnancy, with ~1 
in 4 exposed to SSRI monotherapy. 
• ~2 in 5 attending the PMHS had a primary diagnosis of unipolar depression. 
• ~1 in 2 with depression were exposed to a psychotropic (virtually all 
antidepressants), and ~1 in 3 to SSRI monotherapy. 
• ~2 in 3 exposed to SSRI monotherapy had a primary diagnosis of unipolar 
depression. 
• Attending the PMHS was associated with an increased rate of exposure to 
psychotropics in general, and SSRIs in particular, as pregnancy progresses, 
presumably because those seen are referred due to significant mental health 
problems. 
• PMHS data collection forms were not necessarily complete or accurate. 
• Our findings are not likely to be fully representative of the general 
population. 
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Chapter 4 - Characteristics of antenatal exposure to SSRIs in a 
general maternity sample  
 
Phase 1 Antenatal psychotropics in a general maternity sample  
Given that our findings in the Glasgow PMHS were unlikely to be representative 
of the non-specialist population, we set out to establish the characteristics of 
psychotropic prescribing during pregnancy in women attending a general 
maternity service. It was agreed to repeat the methodology employed within the 
PMHS, as far as the general maternity data would allow, to address our research 
questions (below). We also aimed to establish what relevant data could be 
extracted from routine clinical records. 
 
Research questions 
(1) What proportion of women was prescribed psychotropic medication during 
pregnancy? 
(2) What was prescribed, at what doses, and when? 
(3) With which diagnoses were psychotropics associated? 
 
Methods 
Subjects and setting 
Ayrshire Maternity Unit (AMU) was selected as a suitable site for this pilot study. 
Established in 2006, AMU serves the whole of Ayrshire (a relatively stable 
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population of around 370,000), oversees ~3,800 live births annually, and collects 
electronic data on all patients, that can be linked to their mental health records 
and other databases, including the Information Services Division (ISD) of the 
National Health Service in Scotland. AMU is located within University Hospital 
Crosshouse, and is served by a psychiatric Maternity Liaison Service (MLS), also 
established in 2006. Effective working relationships between AMU and the MLS 
clinical staff have been developed, with the MLS raising awareness of perinatal 
mental health issues, providing education on perinatal mental health to the 
midwives, and supporting obstetric staff in identifying women with current and 
historical psychiatric disorders, and those at increased risk of new onset illness, 
e.g. those with a family history or bipolar affective disorder or puerperal 
psychosis (NICE CG45, 2007). The MLS has access to Eclipse, the electronic 
patient record and database used by AMU (see below). We interrogated Eclipse 
using its built-in reporting tools, to identify all postnatal women discharged from 
AMU within a three month period (24 May to 23 August 2010, inclusive), 
reviewing details of frequency, type and timing of antenatal psychotropics 
(defined as per Chakrabarti, Julyan & Cantwell, 2010; Appendix 3), in addition 
to any referrals to the MLS. These data were exported to a Microsoft® Excel® 
worksheet, anonymised, and descriptive statistical analysis, using Excel’s® 
inbuilt functions. We registered the project via Healthcare Quality, who 
confirmed that formal R&D/ethical approval was not required. 
 
Eclipse 
Eclipse, the System C Medway Maternity Information System 
www.systemc.com/our-solutions/medway-maternity/, is used to register and 
store information on all women receiving obstetric care in AMU, and has fields 
specifically dedicated to historical and current mental health problems, and 
medication, explicitly including psychotropics, in addition to sections for 
standard comprehensive obstetric assessment and management. A new Eclipse 
record is generated for every woman who registers (‘books’) to receive 
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antenatal care and/or deliver at AMU, and clinical details are entered and 
updated following outpatient and inpatient contact. 
 
Contributors 
EJ generated the research questions; planned the methodology; arranged access 
to Eclipse via MC (MLS consultant psychiatrist); trained, supervised and 
supported RT (elective medical student) in transferring relevant data to Excel®; 
and completed descriptive statistical analysis. 
 
Results 
A total of 805 postnatal women discharged from AMU during the study period 
were identified, but similar to the PMHS data collection forms, not all relevant 
data fields in Eclipse were consistently populated. Furthermore, it was not clear 
that Eclipse had been updated following each clinical contact. Due to these 
uncertainties over the accuracy of the data, it was not possible to establish full 
details, and we were unable to verify details with the patients’ clinical records 
post hoc, as the information had been anonymised as it was entered. In 
particular, it was not possible to determine maternal diagnoses, details for all 
psychotropics, nor particulars of non-psychotropics prescribed. Notwithstanding, 
several findings emerged. 
 
Type of drug  
Table 4-1 summarises prescribing data for all 805 women, showing that 3.0% 
(24/805) of the women were documented as having been prescribed a 
psychotropic medication during pregnancy. All but one received an 
antidepressant (95.8%, 23/24), and 87.5% (21/24) of those on psychotropics were 
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exposed to antidepressant monotherapy, with 75.0% (18/24) prescribed one SSRI 
only. In other words, 2.2% (18/805) of the whole cohort were exposed to SSRI 
monotherapy at some point during pregnancy. Of the other three women on non-
SSRI antidepressant monotherapy, one was prescribed a tricyclic, and two 
received another class of antidepressant (one Duloxetine, one unspecified), as 
detailed in Table 4-2. The three women not on antidepressant monotherapy 
(0.4% of the total sample) received ‘atypical’ antipsychotics – one received 
Aripiprazole monotherapy, and two were co-prescribed Olanzapine alongside an 
antidepressant (one Amitriptyline, and one Sertraline). None were documented 
as having received a mood stabiliser. The most common drugs prescribed were 
the SSRIs Fluoxetine, Citalopram, and Sertraline, taken by 41.7%, 16.7%, and 
12.5% (10/24, 4/24, and 3/24), respectively. 
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Table 4-1 – Proportion of women prescribed antenatal medication 
Antenatal medication 
 % (N) 
No psychotropics 97.0 (781) 
Psychotropics 3.0 (24) 
Any antidepressant 2.9 (23) 
Antidepressants only 2.6 (21) 
Any SSRI 2.4 (19) 
SSRIs only 2.4 (19) 
SSRI monotherapy 2.2 (18) 
Citalopram 0.5 (4) 
Escitalopram 0.1 (1) 
Fluoxetine 1.2 (10) 
Paroxetine 0.0 (0) 
Sertraline 0.4 (3) 
Any TCA 0.2 (2) 
Any SNRI 0.1 (1) 
Other ADs 0.1 (1) 
>1 AD 0 (0) 
Any mood stabiliser 0 (0) 
Mood stabilisers only 0 (0) 
Any antipsychotic 0.4 (3) 
Antipsychotics only 0.1 (1) 
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Table 4-2 - Type, dose, timing and duration of antenatal psychotropics, and 
referrals to MLS 
Subject Type Dose Timing Exposure Referred to MLS 
14 Fluoxetine 60mg P Late Yes 
23 Fluoxetine ? Ps1 Early No 
96 Aripiprazole 20mg 3 Late No 
108 Escitalopram 20mg P Late No 
131 Fluoxetine 20mg Ps1r1 Late No 
135 Fluoxetine 20mg P Late No 
153 Sertraline 50mg 1 Late Yes 
185 Amitriptyline 20mg P Late No 
240 Duloxetine 60mg P Late No 
251 Citalopram 20mg P Late No 
262 Fluoxetine 20mg P Late Yes 
263 Antidepressant (unspecified) ? Ps1 Early Yes 
266 Sertraline 50mg P Late Yes 
329 Amitriptyline 
Olanzapine 
50mg 
5mg 
P Late Yes 
361 Sertraline 
Olanzapine 
? 
10mg P Late No 
376 Sertraline 25mg P Late No 
404 Fluoxetine 20mg P Late No 
413 Fluoxetine 20mg P Late No 
419 Fluoxetine 20mg P Late No 
433 Citalopram 20mg 3 Late No 
597 Fluoxetine 20mg P Late No 
680 Fluoxetine 20mg P Late No 
787 Citalopram ? ? ? No 
789 Citalopram 20mg 3 Late Yes 
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Timing of drug  
Eclipse indicated that 79.2% (19/24) of the women exposed to a psychotropic 
during pregnancy started prior to conception, with 66.7% (16/24) continuing 
throughout pregnancy, and 12.5% (3/24) stopping in the first trimester (Table 4-
3). One of the latter restarted in the first trimester (4.2%, 1/24), with another 
woman starting in the first trimester (4.2%, 1/24), and three in the third 
trimester (12.5%, 3/24). Details of dose and timing were unclear for one subject 
on SSRI monotherapy (Citalopram). Overall 16.7% (4/24) commenced medication 
during pregnancy, 4.2% (1/24) in the first trimester and 12.5% (3/24) in the third 
trimester, and all continued until term. In keeping with the PMHS findings, the 
timing of exposure to SSRIs was similar to that of psychotropics overall (Table 4-
3). 
Table 4-4 summarises the actual numbers of those exposed to psychotropics 
before and during the three trimesters of pregnancy, showing little variation 
throughout pregnancy, as although three women stopped medication in the first 
trimester, one restarted shortly thereafter, and three additional patients 
commenced a psychotropic in the third trimester - two patients commenced SSRI 
monotherapy (Citalopram), and one started antipsychotic monotherapy 
(Aripiprazole). 2.2% (18/805) of the sample were prescribed SSRI monotherapy 
before pregnancy, with the majority receiving Fluoxetine (55.6%, 10/18), 
Citalopram (22.2%, 4/18), or Sertraline (16.7%, 3/18). Overall, 16.7% (3/18) of 
those exposed to SSRI monotherapy preconception stopped during the first 
trimester, while 80.0% (8/10), 66.7%  (2/3), and 25.0% (1/4) of those on 
Fluoxetine, Sertraline, and Citalopram (respectively) continued. 54.2% (13/24) 
of those on SSRI monotherapy commenced preconception and either continued 
throughout pregnancy, or stopped in the first trimester. Of the others, one was 
exposed preconception, stopped in the first trimester, and then restarted, 
continuing thereafter until delivery; one commenced in the first trimester; two 
commenced in the third trimester; and details were not available for the fourth. 
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Table 4-3 – Timing of exposure, and referrals to MLS, by type of 
psychotropic1 
   Timing  Exposure Referred to MLS 
 (N)  P Ps
1 
Ps
1r
1 
1 3  Ea
rl
y 
La
te
  
Any psychotropic (24)  16 2 1 1 3  2 21 7 
Any AD (23)  16 2 1 1 2  2 20 7 
ADs only (21)  14 2 1 1 2  2 18 6 
Any SSRI (19)  13 1 1 1 2  1 17 5 
SSRIs only (19)  12 1 1 1 2  1 16 5 
SSRI monotherapy (18)  12 1 1 1 2  1 16 5 
Citalopram (4)  1 0 0 0 2  0 3 1 
Escitalopram (1)  1 0 0 0 0  0 1 0 
Fluoxetine (10)  8 1 1 0 0  1 9 2 
Paroxetine (0)  0 0 0 0 0  0 0 0 
Sertraline (3)  2 0 0 1 0  0 3 1 
1 Details for one patient taking Citalopram were not specified, and one 
antidepressant type was unknown. 
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Table 4-4 – Stage of exposure to antenatal psychotropics1 
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e 
(N) (24) (23) (19) (19) (18) (4) (1) (10) (0) (3) 
Before pregnancy 19 19 15 15 14 1 1 10 0 2 
Trimester 1 Continued2 16 16 13 13 12 1 1 8 0 2 
Started 1 1 1 1 1 0 0 0 0 1 
Stopped 3 3 2 2 2 0 0 2 0 0 
Restarted 1 1 1 1 1 0 0 1 0 0 
Total 20 20 16 16 15 1 1 10 0 3 
Trimester 2 Continued 18 18 15 15 14 1 1 9 0 3 
Started 0 0 0 0 0 0 0 0 0 0 
Stopped 0 0 0 0 0 0 0 0 0 0 
Restarted 0 0 0 0 0 0 0 0 0 0 
Total 18 18 15 15 14 1 1 9 0 3 
Trimester 3 Continued 18 18 15 15 14 1 1 9 0 3 
Started 3 2 2 2 2 2 0 0 0 0 
Stopped 0 0 0 0 0 0 0 0 0 0 
Restarted 0 0 0 0 0 0 0 0 0 0 
Total 21 20 17 17 16 3 1 9 0 3 
1 Details for one patient taking Citalopram were not specified, and one 
antidepressant type was unknown. 
2 ‘Continued’ refers to those already on the relevant drug at the start of the 
trimester, and who remained on it throughout that trimester without stopping. 
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Early and late exposure to antenatal psychotropics 
As per Tables 4-3 and 4-4, Eclipse implied that of those who were prescribed a 
psychotropic during pregnancy, 8.3% (2/24) were exposed in the first and second 
trimesters only, while 87.5% (21/24) were exposed in the third trimester. A 
similar pattern emerged for those on SSRI monotherapy, with 5.6% (1/18) 
exposed in early pregnancy, and 88.9% (16/18) in late pregnancy. The exact 
durations of exposure in days could not be determined from the Eclipse data. 
 
Referrals to the MLS  
According to Eclipse, 1.6% (13/805) of the total sample were referred to the MLS 
(Table 4-5). Although 53.8% (7/13) of these were prescribed psychotropic 
medication during pregnancy, 70.8% (17/24) of those on psychotropics were not 
referred to the MLS, i.e. 2.1%  (17/805) of the total sample, including two taking 
antipsychotics, one of whom commenced their antipsychotic in the third 
trimester. In other words, the majority of pregnant women documented by their 
midwives as receiving psychiatric medication were not referred for specialist 
mental health review, and around half of those referred to the MLS were not 
receiving psychotropics. Of the three patients commencing psychotropic 
monotherapy in the third trimester (one Aripiprazole, and two Citalopram), one 
of those started on Citalopram was documented as having been referred to the 
MLS. 
 
Table 4-5 - Referrals to the MLS 
 Referred to the MLS 
Not referred 
to the MLS 
Total 
(%) 
Exposed to psychotropics 7 17 24 
Not exposed to psychotropics 6 775 781 
Total 13 792 805 
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Results summary 
(1) 3.0% (24/805) of women who delivered at AMU were documented as being 
exposed to a psychotropic medication during pregnancy, and 2.4% (19/805) 
to an SSRI (Table 4-1). 
(2) Of those exposed to a psychotropic, 95.8% (23/24) were exposed to an 
antidepressant, 87.5% (21/24) to antidepressants only, 79.2% (19/24) to an 
SSRI, 79.2% (19/24) to SSRIs only, and 75.0% (18/24) to SSRI monotherapy. 
Of those exposed to SSRI monotherapy, 55.6% (10/18) took Fluoxetine, 
22.2% (4/18) Citalopram, 16.7% (3/18) Sertraline, 5.6% (1/18) Escitalopram, 
and none Paroxetine. Type and dose were not specified for one 
antidepressant, and details of dose and timing were not documented for 
one woman on SSRI monotherapy (Citalopram). Doses were specified for all 
but four antidepressants (three SSRIs, and one unknown, Table 4-2), and 
both women exposed to a tricyclic received low dose Amitriptyline (50mg, 
and 20mg), suggesting an indication other than depression. Co-prescribing 
was less common than in the PMHS, with (2/24) receiving an antidepressant 
and an antipsychotic. None were exposed to more than one antidepressant 
during pregnancy. Of those prescribed SSRI monotherapy, 77.8% (14/18) 
were exposed at conception, of whom 85.7% (12/14) continued throughout 
pregnancy. 14.3% (2/14) stopped during pregnancy, both in the first 
trimester, one of whom restarted in the first trimester. Of those on SSRI 
monotherapy, 5.6% (1/18) were exposed “early” in pregnancy, and 88.9% 
(16/18) “late” (Table 4-3). Prescribing patterns were less varied than in the 
PMHS, with 5.6% (1/18) starting in the first trimester, none in the second, 
and 11.1% (2/18) in the third – all who commenced during pregnancy 
continued until delivery. The SSRIs started during pregnancy were 
Citalopram and Sertraline, in 11.1% (2/18) and 5.6% (1/18), respectively 
(Tables 4-2 and 4-3). Exposure rates to antidepressants [SSRIs] in trimesters 
one, two, three, and pregnancy as a whole were 2.5% (20/805) [2.0%, 
16/805], 2.2% (18/805) [1.9%, 15/805], 2.5% (20/805) [2.1%, 17/805], and 
2.9% (23/805) [2.4%, 19/805], respectively. 
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(3) Diagnoses were not available. 
 
Discussion 
These data provide a retrospective estimate of antenatal psychotropic 
prescribing patterns in a sample of women representative of the general 
population. As expected, rates of prescribing were significantly less than those 
found in the Glasgow PMHS, and prescribing patterns less varied. 
 
Data integrity 
However, as with the PMHS data collection forms, numerous fields in Eclipse 
were unpopulated, and it was not clear that information was updated following 
each clinical contact. Therefore, the details may be incomplete and hence 
inaccurate. As discussed in Chapter 6, this could lead to an under- or over-
estimate of antenatal prescribing, due to failure to identify medication started 
or stopped after booking, respectively. Moreover, anonymising the data as it was 
processed had the unintended consequence of rendering us unable to clarify any 
ambiguities or omissions from the clinical records, or indeed, even calculate 
ages. As before, issues such as patients forgetting, misremembering, or not 
disclosing information about psychotropics may also have influenced our 
findings, in addition to the quality of assessment and documentation by AMU 
staff. Furthermore, given the number of different fields used to record details in 
Eclipse, it is possible that we missed some references to antenatal 
psychotropics, despite the care taken. 
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Types and rates of antenatal psychotropics 
Nevertheless, our findings of 2.9% and 2.4% exposed to antenatal antidepressants 
and SSRIs (respectively) were not inconsistent with other UK and international 
reports, as discussed in Chapter 2 (our figures included as Taylor, Cameron & 
Julyan [2010] to two decimal places for comparison in Tables 2-6 and 2-7). 
Our prevalence rates were broadly comparable for T1, but appeared 
proportionately significantly higher in T2 and T3 than those reported by Petersen 
et al. (2011) and Margulis, Kang and Hammad (2014) (Table 2-7). The latter 
study in particular is worthy of discussion in this context. As per our findings 
that 84.2% (16/19) of those taking antidepressants periconception continued 
throughout pregnancy and only 15.8% (3/19) stopped in T1, and in contrast to 
Margulis, Kang and Hammad’s (2014) report that 79.6% stopped in T1, Eclipse 
indicated that antenatal exposure reduced slightly from T1 to T2, but returned 
to (and slightly exceeded) T0 levels by T3 (Table 4-4). 
This difference may be attributable to various factors influencing both our and 
Margulis, Kang and Hammad’s methodologies. As noted in relation to the PMHS in 
Chapter 3, we may have under- or over-estimated prevalence, due to patients’ 
reports, clinicians’ assessments and documentation, and inadequate updating of 
data at follow-up. As Margulis, Kang and Hammad interrogated a high quality 
inclusive electronic database, it could be assumed that their findings were more 
accurate. However, a number of factors may also have influenced their 
conclusions, some (but not all) of which they acknowledge and discuss. 
Firstly, their sample may not be truly representative of the general population, 
as their inclusion criteria effectively excluded over half of the relevant sample. 
This was considered necessary for the sake of data quality, and ensuring that 
details of patients’ prescriptions for all time periods studied were available. 
However, it was not clear whether the requirement to be registered from six 
months before pregnancy until three months postpartum referred to registration 
with any participating practice, or the CPRD itself. This may have systematically 
excluded certain subsets of the population, e.g. those who moved frequently, or 
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who were removed from practices for non-attendance, leading to an 
underestimate of prevalence, as depressed women may be less likely to attend 
antenatal appointments (Walsh, 2009; Grzeskowiak, Gilbert & Morrison, 2012a). 
The AMU sample was representative, albeit small in size. 
Secondly, the prescribing data was based on prescriptions issued, as recorded in 
the CPRD. This is one step removed from prescriptions actually being dispensed, 
and yet further from medication actually being taken as prescribed. Estimates 
suggest that around 90% of prescriptions issued are dispensed (Jick, Jick & 
Derby, 1991). Skurtveit et al. (2014) compared self-reported use of prescribed 
medication during pregnancy (established from MoBa, a large population-based 
prospective pregnancy cohort study of >90,000 mothers) with the national 
Norwegian Prescription Database (NorPD) (which includes all drugs dispensed to 
outpatients). They found that while there was good agreement between the 
MoBa and NorPD, in that both yielded a figure of 1.0% for antidepressants taken 
during pregnancy, the NorPD figure increased to 1.3%, then 1.5%, when 30 days 
and 60 days before pregnancy, respectively, were also taken into account. This 
indicates that issues surrounding estimating exactly when pregnancy begin, and 
thus defining the exact stage at which perinatal prescriptions are issued, 
dispensed, and actually taken, are critical in estimating exposure rates. (The 
difficulties in identifying the date of conception and hence stage of gestation 
from databases are well-recognised, and are discussed further in Chapter 6 
(Margulis et al., 2013; Margulis et al., 2015). One important matter is how 
definitions of exposure such as that used by Margulis, Kang and Hammad can 
influence estimates of exposure rates – if a one or two month supply of 
medication is issued in T0 but not thereafter, the early fetus may be exposed in 
T1, even though no prescription was issued in that epoch (Grzeskowiak, Gilbert 
& Morrison, 2012b; Grzeskowiak, Gilbert & Morrison, 2013). Conversely, and as 
they acknowledge, prescriptions issued in T3 may be intended for T4 use, and 
hence artificially inflate T3 prevalence. The AMU data were prone to other 
limitations, including that they were based on what midwives established from 
patients, encompassing issues such as the adequacy and detail of history taking, 
and patients’ knowledge and recall. 
Page 129 of 365 
Thirdly, a related issue is the difficulty in interpreting exactly what prescriptions 
represent. In an ideal world, patients would pick up monthly prescriptions for 
unambiguous quantities of medication. However, this is frequently not the 
reality. Timing, dose, and quantity can affect interpretation, as can potential 
duplicates. For example, if a patient is prescribed 84 Fluoxetine 20mg tablets, 
this could represent a three month supply of Fluoxetine 20mg daily, or a one 
month supply of Fluoxetine 60mg daily, or even a two month supply of 
Fluoxetine 20mg daily for one month, followed by titration to 40mg daily 
thereafter. Prescriptions issued or dispensed earlier or later than anticipated 
may either indicate lost scripts, dose changes, or inconsistent adherence. 
Moreover, they do not necessarily reveal when the drugs were actually taken. In 
the absence of other data, interpreting exactly what was taken, at what dose, 
and when, can be largely a matter of guesswork, no matter how intelligent or 
informed. On this basis Margulis, Kang and Hammad (2014) excluded all 
prescriptions that were not for tablets or capsules with clearly defined doses, 
representing 7.4% of the sample, and a further 0.8% that appeared to be 
duplicate scripts. Again, the AMU data were dependent on clinical assessment, 
interpretation and documentation. 
Fourthly, as the CPRD included only electronic prescriptions issued in primary 
care, any medicines prescribed via handwritten scripts or provided by secondary 
care specialists would be missed. These would be most likely to include new 
episodes of treatment, or medicines such as long-acting antipsychotic injections, 
Lithium or Clozapine. Of particular concern is that prescriptions for 
antidepressants (or antipsychotics) provided via specialist perinatal mental 
health services may have been excluded, thus resulting in an underestimate of 
prevalence. The AMU data were not affected by this. 
Fifthly, as only pregnancies resulting in one or more live births were included, 
any pregnancies resulting in miscarriage, elective termination, or stillbirth 
would not be counted. Given that antidepressants have been linked with an 
increased risk of spontaneous and therapeutic abortion, this factor may also 
have contributed to an underestimate of perinatal antidepressant prevalence 
(Nakhai-Pour, Broy & Bérard, 2010; Kieler et al., 2014). (It should be noted, 
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however, that antidepressants are not independently associated with 
miscarriage in women with a diagnosis of depression [Kjaersgaard et al., 2013].) 
The AMU data were similarly derived from live births only. 
Sixthly, Margulis, Kang and Hammad basing their longitudinal analysis on those 
who received a prescription in either T0 or T3 meant that any who started in T1 
or T2, and stopped before T3 would be missed. Although this is likely to be a low 
absolute number (there were none in our AMU sample, and only 3 [0.5%] in the 
PMHS population), nevertheless, to provide a truly comprehensive account of the 
longitudinal course of antidepressants in pregnancy, one should take account of 
all patients and prescriptions. The corresponding AMU limitation was that we 
were unable to confirm if the data were updated timeously, fully, accurately or 
at all – they were likely to represent a “snapshot” at the time of the clinical 
encounter, rather than a comprehensive dynamic account of exposure 
throughout pregnancy. 
Seventhly, Margulis, Kang and Hammad (2014) discuss the challenges they 
encountered in interpreting medication changes, and thus allocating subjects to 
their categories. They acknowledged that changes in drug type or dose may 
signify altered illness severity or pharmacokinetic changes due to pregnancy, 
thus confounding attempts to attribute outcomes to prescriptions rather than 
pathology. 
 
Timing of antenatal psychotropics 
As per Table 2-7, the majority of women prescribed antidepressants 
periconception discontinue during pregnancy, most commonly in the first 
trimester, with only a minority continuing throughout pregnancy, similar to our 
findings in the PMHS. This raises significant questions about our AMU data, 
derived from Eclipse. If details about timing were incorrect, even if simply due 
to records not being updated to reflect antidepressants being discontinued after 
booking, it follows that our findings may not be accurate. 
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However, our main findings were not inconsistent with the literature, and within 
the estimated international ranges, with the majority of pregnant women on 
antidepressants being exposed to SSRI monotherapy. The types and proportions 
of psychotropics were also broadly comparable with the PMHS sample. 
 
Early and late exposure to antenatal psychotropics, and access to specialist 
care 
We found a relatively low rate of antenatal psychotropics prescribed locally. 
While this was somewhat reassuring in terms of concerns over safety, it 
nevertheless suggests that of the approximately 750,000 babies born each year 
in the UK, >20,000 may have been exposed antenatally to psychotropic drugs, 
with more than 100 fetuses exposed to antidepressants in Ayrshire annually 
(Office for National Statistics, 2015; National Records of Scotland, 2015). 
Moreover, it appears that women receiving antenatal care in Ayrshire may be 
more likely to continue antidepressants throughout pregnancy than women in 
some other countries and settings, and the relative proportion of fetuses 
exposed to antidepressants late in pregnancy was higher than that found in the 
PMHS (87.0% [20/23] versus 60.0% [141/235]), as was the percentage exposed 
throughout pregnancy (69.6% [16/23] versus 28.9% [68/235]). Late fetal 
exposure has been linked with increased risks for early adverse outcomes in a 
number of studies (Chambers et al., 1996; McElhattan et al., 1996; Cohen et al., 
2000; Simon, Cunningham & Davis, 2002; Kallen, 2004; Moses-Kolko et al., 2005; 
Boucher, Bairam & Beaulac-Baillargeon, 2008; Grigoriadis et al., 2014; 
Huybrechts et al., 2015). However, other studies have challenged these findings, 
e.g. Jimenez-Solem et al. (2013), Furu et al. (2015), and Grzeskowiak et al., 
(2015), and the seminal study published by Oberlander et al. (2008) implicated 
duration of exposure more than timing. 
Also concerning, and possibly linked to how long women receiving antenatal care 
in Ayrshire appear to take antidepressants during pregnancy, is the prospect that 
many pregnant women on psychotropics may not access specialist psychiatric 
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input – less than one third of those on psychotropics during pregnancy were 
documented as being referred to the MLS (7/24, 29.2%). It is possible that these 
women were already being seen in general adult psychiatry, especially those on 
antipsychotics (it seems unlikely that a non-psychiatrist would prescribed 
antipsychotics during pregnancy, or that midwives would not refer such patients 
if not being seen by a specialist). It is also plausible if not likely that referrals 
from AMU to the MLS may not have been documented in Eclipse, as discussed 
below – in any given three month period MLS would expect to see ~25 expectant 
mums, with the bulk of these being referred from AMU; significantly more than 
the 13 women suggested by the sample. Unfortunately, as our data were 
anonymised we were unable to identify individuals post hoc to allow verification 
with their psychiatric case-records, and therefore could not investigate further.  
While the contrast between AMU and the PMHS re: proportions of women taking 
antidepressants throughout pregnancy (less than one third of those attending the 
PMHS, but more than two thirds of those attending AMU) could suggest that 
access to specialist perinatal psychiatric care reduces antenatal medication 
usage, the finding that only 14.3% (1/7) of the women on psychotropics referred 
to the MLS stopped medication during pregnancy (in the first trimester) casts 
doubt on this. Of the others, 57.1% (4/7) took psychotropics preconception and 
continued throughout pregnancy, while 28.6% (2/7) started medication during 
pregnancy, one in the first trimester, and one in the third. In other words, 80.0% 
(4/5) of those prescribed medication before conceiving who were referred to the 
MLS continued throughout pregnancy. Similarly, 92.3% (12/13) of those receiving 
a psychotropic but not referred to the MLS continued throughout pregnancy 
(Table 4-6). Attendance at the MLS appeared to have little effect on whether 
psychotropics stopped or started, with similar patterns being seen whether 
referred or not. Again, however, because our data was anonymised, it was not 
sufficiently detailed to allow in-depth analysis of individual cases - further work 
is indicated to establish more details via analysis of a larger sample. 
Furthermore, as we did not have details about the stage(s) of pregnancy when 
women were seen at the MLS, we were unable to identify when prescriptions for 
antenatal psychotropics were stopped or started, i.e. what difference(s) 
attendance at the MLS made. 
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Closer scrutiny of the PMHS data showed that although it was the minority of 
attendees who continued antidepressants throughout pregnancy, those who 
stopped did so before being seen in the specialist service, and 12.9% (81/627) 
started or restarted during pregnancy, compared with 15.4% (2/13) of the MLS 
mothers (Table 4-6). In other words, women who received care from the PMHS 
were more likely to have stopped medication before being seen than those 
referred to the MLS, suggesting that there were factors that resulted in referral 
rather than attendance resulting in medication being stopped. It would be useful 
to clarify what proportion of those who stopped or started psychotropics did so 
as a consequence of their attendance at the PMHS and the MLS, but we were 
unable to establish this from our data. 
 
Table 4-6 – Psychotropic timing, and referrals to the MLS 
 Referred to MLS Not referred to MLS Total 
Continued psychotropics throughout 
pregnancy 4 (0.5%) 12 (1.5%) 16 (2.0%) 
Stopped psychotropics during 
pregnancy 1 (0.1%) 1 (0.1%) 2 (0.2%) 
Started psychotropics during 
pregnancy 2 (0.2%) 2 (0.2%) 4 (0.5%) 
Total 7 (0.9%) 15 (1.9%) 221 
1 the total is 22 rather than 24, as one subject stopped medication in the first trimester, but 
restarted, and the details for another subject were unspecified 
 
As previously intimated, differences may simply be due to the incompleteness 
and hence inaccuracy of the data from either or both the PMHS and AMU. 
However, they may also be explained by reference to patient-, referrer-, 
clinician- or service-specific factors, and these differences between the MLS and 
the PMHS require confirmation and explanation. It should be noted that the MLS 
and the PMHS are not identical services, and absolute numbers attending the 
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MLS are low than the PMHS, but an intriguing possibility is that receiving 
specialist care via a dedicated and well-resourced perinatal mental health 
service enables more women to stop psychotropic medication during pregnancy. 
This is not supported by our findings, given that most stopped before attending 
the PMHS. However, as discontinuation of antidepressants during pregnancy is 
associated with younger maternal age, commencing an antidepressant shortly 
before pregnancy, and being prescribed only one antidepressant, the PMHS and 
the MLS data could be analysed further to detect any systematic differences in 
their attendees with regards to these factors (Petersen et al., 2011; Margulis, 
Kang & Hammad, 2014). It is possible, of course, that these factors are simply 
proxy markers for chronicity, severity, or treatment-resistance of underlying 
illness. 
Nevertheless, it seems like uncontroversial common sense for GPs, obstetricians 
and midwives to be encouraged to consider referring all pregnant women on 
psychotropics for psychiatric review, at the very least by a general adult 
psychiatrist. Indeed, this is now recommended by the updated NICE guidelines 
on antenatal and postnatal mental health (NICE CG192, 2014). However, the 
issues raised by the AMU and the PMHS data indicated that further work was 
needed, both to check the accuracy of our findings thus far, and to explore what 
sequelae of antenatal psychotropics could be identified, so that women of 
childbearing potential prescribed psychotropic medication can make more 
informed choices. We therefore agreed to repeat and extend our methodology, 
this time without anonymisation, and with the addition of external validation via 
reference to other “gold standard” datasets. 
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Key points 
• ~1 in 30 women attending AMU were documented as being prescribed a 
psychotropic medication during pregnancy, the majority SSRI monotherapy. 
• ~2 in 3 of those on psychotropics at conception, and ~1 in 2 of those on SSRI 
monotherapy, continued throughout pregnancy. 
• ~9 in 10 women on psychotropics, and 15 in 16 on SSRI monotherapy, were 
exposed late in pregnancy. 
• Not all women receiving antenatal psychotropics were referred to the MLS, 
but referral was not associated with significant differences in prescribing. 
• The AMU data were not necessarily complete or accurate. 
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Phase 2 Accuracy of data 
The questions re: data quality raised by our findings in the PMHS and AMU 
indicated that further work in this area was necessary. In light of the 
incompleteness of both the PMHS data collection forms and Eclipse fields, it was 
agreed to repeat the AMU study, but this time Eclipse data would be verified 
with accurate external sources, while establishing what information would be 
available to explore select neonatal outcomes of exposure to antenatal 
psychotropics. 
The first step was to agree how best to verify Eclipse data. As Eclipse also 
specifies each patient’s GP surgery we considered contacting individual 
practices to request all prescribing data for their patients, whose names and 
Community Health Index numbers (CHIs) we would be able to provide. (CHIs are 
unique identifiers allocated to all individuals born or receiving planned 
healthcare in Scotland, and are 10 digit numbers usually made up by the first 6 
digits representing date of birth, with four additional numbers, e.g. 
DDMMYY1234). However, these primary care data are not necessarily 
straightforward to extract, and we suspected that at least some of our GP 
colleagues might not participate. Moreover, this would not necessarily capture 
all prescribing data, as drugs such as Methadone and some psychotropics 
(including Clozapine and long-acting injectable antipsychotics [depots]) are not 
prescribed by Primary Care – this effectively excluded utilising the regional 
Primary Care Prescribing Database, too, in addition to its data not always being 
straightforward to interpret or analyse (Mario Hair, personal communication). 
Prescriptions issued by psychiatrists would not be included, either. Hence, after 
consultation with local colleagues we decided to access prescribing data held by 
the Information Services Division of the NHS in Scotland (ISD). 
As we planned a more detailed project on antenatal psychotropics, taking into 
account select neonatal outcomes, we considered which other psychoactive 
prescription medicines to include. As opiate dependence is associated with 
significant psychiatric comorbidity, and maintenance prescribing is overseen by 
the NHS addictions service in Ayrshire, we therefore agreed to include 
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Methadone in this phase. Methadone is a mainstay of the pharmacological 
management of opiate dependence, and is a potentially significant (albeit 
heavily confounded) risk factor for poor neonatal outcomes, being associated 
with a well known postnatal abstinence syndrome (Jones et al., 2010; Desai et 
al., 2015). We therefore elected to establish accurate information on Methadone 
prescriptions during pregnancy via the NHS Ayrshire & Arran Shared Addiction 
Management System database (SAMS). Simultaneously, the MLS records and the 
NHS Ayrshire & Arran Mental Health Services electronic patient records and 
database (FACE), would be interrogated to corroborate Eclipse entries (and 
omissions) on past and current mental health problems and care. The Mental 
Health Services Pharmacy was unable to identify prescriptions for Clozapine and 
depots retrospectively. 
 
Research questions 
(1) How accurate was Eclipse, in comparison with ISD, SAMS, and FACE? 
(2) What proportion of women was prescribed psychotropic medication during 
pregnancy? 
(3) What was prescribed, at what doses, and when? 
 
Methods 
We accessed Eclipse to identify all women who delivered in AMU within a three 
month period (1 January to 31 March 2012, inclusive), in addition to information 
on psychotropics prescribed during pregnancy, those referred to MLS, and those 
screened for historical and current mental health problems, use of illicit 
substances, and substitute prescribing (Methadone). Psychotropics were defined 
as per Chakrabarti, Julyan and Cantwell (2010) (Appendix 3). These data were 
entered into a Microsoft® Excel® worksheet for descriptive statistical analysis, 
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using Excel’s® inbuilt functions. Excel’s® “Advanced filter” function was 
employed to identify and remove any duplicate records. As we planned to use 
CHI numbers to integrate data from various sources, subjects were sorted in 
order of their CHIs (thus allowing complementary datasets to be sorted in the 
same order). Once sorted, we allocated an ID number to each subject in CHI 
order, to allow anonymisation after matching and harmonising the various data 
sources. As some CHIs start with “0”, and Excel® processes data defined as 
numbers by removing initial zeros, we ensured that CHIs were formatted as text. 
Excel’s® “VLOOKUP” function was used to indicate where CHIs from different 
sources matched, and outcomes were dichotomised where possible into “0” or 
“1” to facilitate descriptive statistical analysis. All sources were interrogated for 
the 12 months prior to and during the three month study period, to ensure that 
all psychotropic prescriptions and psychiatric/addictions input both 
periconception and antenatally were identified. The project was registered with 
Healthcare Quality, who confirmed that formal R&D/ethical approval was not 
required. However, as ISD required approval from an appropriate sponsor within 
NHS Ayrshire & Arran, and SAMS also required approval, this was sought and 
obtained from the NHS Ayrshire & Arran Caldicott Guardian via Information 
Governance. 
 
Data sources 
ISD 
As part of NHS National Services Scotland, ISD was set up to support the various 
parts of the NHS in Scotland, through providing statistical information to 
facilitate research, and ultimately improve patient care (www.isdscotland.org). 
ISD collects and retains information on diverse Scottish NHS data, and produces 
reports on a range of issues, available via their website. Details for all 
community NHS prescriptions dispensed (‘filled’) are available, traceable to 
each patient by their CHI number and date issued. ISD holds details of all drugs 
actually dispensed via the NHS in Scotland, not just prescribed, i.e. one step 
Page 139 of 365 
closer to actually being taken – this data includes type, dose, amount and date 
of medication dispensed. 
ISD agreed to provide prescribing data for psychotropics for the specified period 
free of charge, subject to approval from the NHS Ayrshire & Arran Caldicott 
Guardian. We emailed CHIs for the patients in our sample securely to ISD via NHS 
email (www.nhs.net), and received the relevant data in Excel® format, with 
CHIs anonymised via alphanumerical substitution (the key was emailed 
separately). A script was devised to convert the ISD codes back to CHIs, in 
addition to being verified manually. 
 
SAMS 
Colleagues in the local NHS addictions service confirmed that the information we 
sought was available via SAMS, an electronic database containing details of all 
Methadone scripts issued in Ayrshire, again coded by reference to CHI. We 
submitted all CHIs to the SAMS database manager, who provided dates and 
quantities of Methadone prescribed to any relevant patients. Supervised 
dispensing ensured that prescriptions issued equated to Methadone consumed. 
 
MLS 
Given that screening for past and present mental health issues by obstetric staff 
is recommended by national guidelines, and that Phase 1 had included referrals 
to the MLS from AMU, we elected to compare Eclipse entries about mental 
health with both the MLS and general psychiatry data sources. The MLS keeps a 
record of all patients referred via those offered an appointment, including 
details on name, date of birth, and date and source of referral, but not CHI. This 
information is stored in a Microsoft® Word® document in tabular format, which 
we imported to Excel®. MLS clinicians also complete data collection forms 
similar to those used in the Glasgow PMHS, but with some modifications, to 
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allow more accurate recording of medication by date/gestation started and 
stopped, via update at each clinical encounter (Appendix 4). 
FACE 
FACE has been used by Mental Health Services in NHS Ayrshire & Arran since 
2004, and has become the primary clinical record for all disciplines (with the 
exception of medical staff, who still use paper for making contemporaneous 
notes, although all their official correspondence is uploaded and copied to a 
FACE record). FACE is a software solution to support clinical staff in managing 
information pertinent to the assessment and management of patients, with 
extensive options to produce reports, if data are appropriately tagged during 
entry. The FACE graphical user interface interrogates a SQL database. 
Confirming Eclipse with FACE initially appeared to be a straightforward but 
laborious and time-consuming process, requiring that we access FACE manually 
for each subject’s CHI, to ascertain firstly if they had a record, and secondly 
where and when they were seen. However, assuming an average of 5 minutes to 
check each record, this alone would have taken almost 70 hours, even before 
the ethical issues involved in accessing patient records were taken into account. 
We therefore discussed our requirements re: data extraction with the local FACE 
team, who arranged for appropriate scripts to be provided by FACE Europe, and 
run on Ayrshire data. FACE Europe provided two scripts to identify all women 
with a FACE entry for Adult Mental Health and Addictions (1) during the study 
period, i.e. perinatally, and (2) before the study period, to allow accurate 
identification of current and historical contact, although this could not 
distinguish between attendance for mental health or addictions. 
 
Contributors 
EJ generated the research questions; planned the methodology; arranged access 
to Eclipse (via MC), FACE, SAMS and ISD; trained, supervised and supported CW 
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(a medical student with a background in Information Technology) in processing 
relevant data in Excel®; and completed descriptive statistical analysis. 
 
Results 
The data fields included are shown in Table 4-7, alongside the percentage of 
records with an entry in that field.  
 
Eclipse data 
875 women who delivered during the study period were identified, with a 
median age of 28 (range 16 to 46), and a median of one previous pregnancy 
(range 0 to 13). It proved challenging to locate all details sought, as there were 
numerous different data fields associated with medication, with undefined 
purpose and scope, and the majority were left blank (Table 4-7). Therefore, 
rather than examining only the “Medication” and “Medication history” fields, we 
scanned all sections for each of the 875 records individually, in addition to using 
Excel’s® search function to find “antidepressant”, and the generic and brand 
names of individual SSRIs (“cipralex”, “cipramil”, “citalopram”, “escitalopram”, 
“faverin”, “fluoxetine”, “fluvoxamine”, “lustral”, “paroxetine”, “prozac”, 
“seroxat”, and “sertraline”). This permitted a degree of confidence that all 
women recorded as having taken a psychotropic antenatally were identified, 
although it is possible that some entries were missed, especially as there were 
numerous spelling mistakes in the records, e.g. “cirtalopram” and 
“Mwthodone”. 1.0% (9/875) of the women were documented as being prescribed 
a psychotropic medication during pregnancy, all SSRI monotherapy (six 
Fluoxetine, two Citalopram, and one Sertraline), with 0.3% (3/875) prescribed 
Methadone. 0.8% (6/875) appeared to have been referred or already known to 
the MLS, although some documentation was ambiguous. “Dr Cameron” (the MLS 
Consultant Liaison Psychiatrist) was mentioned specifically for six women.  
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Table 4-7 – Eclipse data fields and completion rates 
Eclipse data field Completed (%) Affirmative (%) 
Last name 100 - 
First name 100 - 
CHI number 100 - 
Date of birth 100 - 
Pregnancy number 67.2 - 
Date and time of delivery 100 - 
Medication  4.7 - 
Medication Category 4.6 - 
Medication Dose 4.5 - 
Medication Form 3.2 - 
Medication Frequency 4.6 - 
Medication Instructions 0.8 - 
Medication history 5 - 
Medication history Category 4 - 
Medication history Comments 1.1 - 
Problem or health issue 83.3 - 
Problem or health issue Category 39 - 
Problem or health issue Comments 33.4 - 
Feeling down depressed or hopeless 17.6 3.2 
Feeling down depressed or hopeless Comments 0.5 - 
Feeling little interest / pleasure in doing things 17.5 2.6 
Feeling little interest / pleasure in doing things Comments 0.3 - 
Feels she needs or wants help with low mood 2.5 22.7 
Involvement with mental health services 17.6 17.5 
Involvement with mental health services Comments 1.8 - 
Perinatal mental health lead 0.3 - 
Perinatal mental health lead Contact telephone number 0 - 
Perinatal mental health lead Role 0.1 - 
Plans and referrals 70.6 - 
Plans and referrals Assigned to 1.7 - 
Plans and referrals Comments 23.2 - 
Plans and referrals Due on 37.1 - 
Plans and referrals Priority 17.7 - 
History of substance misuse 12.8 6.2 
History of substance misuse Comments 0.7 - 
History of substance misuse Last taken 0.7 - 
Chemist for prescribed controlled drugs 0.2 - 
Feel she needs or wants help with substance misuse 1 22.2 
Involvement with substance misuse services 13.3 3.4 
Involvement with substance misuse services Comments 0.2 - 
Comments for perinatal mental health referral 0 - 
Perinatal Mental health services referral sent to 0.2 - 
Consent to perinatal mental health referral 0 - 
Consent to perinatal mental health referral Comments 0 - 
Comments for substance misuse referral 0 - 
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A seventh patient had “To see Dr” recorded in the “Plans and referrals” data 
field - she had a history of postnatal depression, and had stopped medication 
“two months” prior to booking, i.e. in the first trimester – the context suggested 
that the Dr was the MLS consultant, but may simply have indicated the obstetric 
consultant – there was no subsequent record of her being seen via the MLS. 
It was unclear how many were screened for current or past mental health 
problems, as only 17.6% (154/875) had relevant fields completed – 17.0% 
(149/875) had “No” entered, while one of the remaining five was feeling sad due 
to bereavement, and four were identified as potentially having a current mental 
health problem (Table 4-7). Three of these four had an action clearly 
documented, with two being referred to the MLS (although this was described 
specifically as a referral for cognitive-behavioural therapy for one, and a 
referral to “Dr Cameron” for the other), and one being advised to see her GP in 
six weeks. Similarly, 13.1% (115/875) had screening for substance misuse 
documented – 105 had “No history of substance misuse” and seven had details of 
various substances recorded in the “History of substance misuse” field, with 
three having “None” recorded in the “Involvement with substance misuse 
services” field. In one case, prescribed Methadone in the absence of illicit drug 
use was recorded via the “History of substance misuse” section. 0.3% (3/875) 
were identified as being prescribed Methadone. 
With regards to “Involvement with mental health services”, 1.0% (9/875) were 
documented as being currently involved, all of whom were asked about current 
symptoms of depression – two screened positive for “Feeling down depressed or 
hopeless”, and both were to be referred to the MLS. 1.8% (16/875) were 
recorded as having previous involvement with mental health services, and again 
all were asked about current depression – one screened positive, but did not 
think that any additional input was required (they had recently defaulted from 
psychiatry clinic). 0.2% (2/875) were “Not asked at this time”, with no reason 
given, but screening negative for current depression, 14.5% (127/875) were 
documented as having no mental health input, and 82.4% (721/875) had no 
entry. Of the nine women receiving a psychotropic, two were documented as to 
be referred to the MLS, entered in the “Plans and referrals” field, three were 
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recorded as having ongoing current input from a Community Psychiatric Nurse 
(CPN), one was attending a Consultant Psychiatrist, two were noted as having 
had previous involvement with mental health services, and one was “Not asked 
at this time”. 
It proved challenging to find and interpret the data due to the variety of 
overlapping fields, and the rather fragmented and haphazard manner in which 
entries appeared to have been made. There were several duplications, entries 
made in fields that did not always appear particularly clear as to their scope and 
purpose, and some entries consisted of apparently random characters (e.g. “#’), 
presumably typographical errors. Nevertheless, Eclipse data was compared with 
other sources to the best of our abilities, as described below, and summarised in 
Table 4-8. 
 
Table 4-8 - Eclipse compared to other data sources 
 Eclipse ISD MLS FACE SAMS 
Number of relevant records 875 141 26 105 10 
Antenatal psychotropics 9 89 - - - 
Methadone 3 - - - 10 
Referred/known to MLS 6 - 26 - - 
Potential mental health problem 5 - - - - 
Current psychiatry contact 9 - - 105 - 
Historical psychiatry contact 16 - - 58 - 
Substance misuse 3 - - - - 
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Eclipse compared with ISD 
In contrast to Eclipse, ISD data indicated that 16.1% (141/875) had had a 
prescription for a psychotropic (so defined) dispensed between 1 January 2011 
and 31 March 2012 (inclusive) (Table 4-9). Of these, 3.1% (27/875) appeared to 
have finished the medication before conceiving, and 2.9% (25/875) to have 
started postnatally (see discussion). Of the 10.2% (89/875) who were exposed 
during pregnancy, 0.3% (3/875) received anticonvulsant monotherapy only (two 
Lamotrigine, and one Carbamazepine), and 1.3% (11/875) were prescribed 
Amitriptyline at a dose of less than 75mg daily, suggesting non-psychiatric 
indications, e.g. epilepsy and neuropathic pain, respectively. Although Petersen 
et al. (2011) excluded those on “low dose” Amitriptyline from their analyses, in 
the absence of access to the diagnostic justification, we included all as 
psychotropics for the purpose of our investigation. Therefore, 10.2% (89/875) 
women were exposed to an antenatal psychotropic, although at most 8.6% 
(75/875) appeared to have been prescribed medication for a psychiatric 
indication, all of whom received antidepressants (Table 4-9). 7.0% (61/875) were 
on SSRI monotherapy, 0.1% (1/875) was prescribed 2 different consecutive SSRIs 
(i.e. not simultaneously) in addition to a tricyclic, 0.1% (1/875) received SNRI 
monotherapy, 1.0% (9/875) took tricyclic monotherapy, 0.6% (5/875) were given 
Mirtazapine monotherapy, and 1.4% (12/875) were prescribed a combination of 
different concurrent and consecutive antidepressants, antipsychotics and/or 
mood stabilisers. 
 
Table 4-9 - Eclipse compared with ISD 
 Eclipse ISD 
Number of relevant records 875 141 
Antenatal psychotropics 9 89 
SSRI monotherapy 9 61 
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Eclipse compared with MLS 
The MLS records proved difficult to interrogate for a number of reasons. CHIs 
had not been used to identify individual patients, and this, combined with 
missing or incorrect DOBs, forenames and surnames being stored in the same 
field, and several individuals having their names spelled in up to three different 
ways, meant that it was challenging to compare entries with Eclipse and ISD. To 
resolve this we reviewed each MLS record by hand, matching patients with their 
CHIs on Eclipse by means of their name and DOB. According to the MLS records, 
190 patients were offered appointments between 1 January 2011 and 31 March 
2012 (inclusive), although details for October 2011 were unavailable. Again, as 
the MLS records included both new and review appointments, with multiple 
different appointments for several patients (up to eight for one woman) during 
the study period, it took time to establish who attended when, and if this was 
before, during or after the index pregnancy. 13.7% (26/190) corresponded to our 
Eclipse sample, of whom 23 attended MLS at least once. Four of the six 
identified by ECLIPSE as being referred to the MLS were offered an appointment, 
and of the nine identified by ECLIPSE as being on a psychotropic, three were 
offered and attended an appointment with MLS, although only one had a data 
collection form completed. 
 
Eclipse compared with FACE 
FACE revealed that 12.0% (105/875) of the women had had contact with Adult 
Mental Health & Addictions (including the MLS) during the study period, with an 
additional 6.6% (58/875) having had previous (but not ongoing) contact. We were 
unable to reconcile these figures with Eclipse. Of the 721 women not 
documented as being screened for mental health issues, 9.6% (69/721) were 
found to be prescribed a psychotropic during pregnancy, 11.1% (80/721) were in 
current contact with psychiatric services, and 17.6% (127/721) were known to 
have previous contact. Moreover, of the 89 prescribed a psychotropic during 
pregnancy according to ISD, only 21.3% (19/89) were referred to the MLS, and 
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36.8% (7/19) of these did not have antenatal psychotropic medication 
documented by the MLS (including the two who did not attend). 
 
Eclipse compared with SAMS 
The Addictions’ database confirmed that 1.1% (10/875) were prescribed 
Methadone antenatally, including all three correctly identified on ECLIPSE. 
  
MLS compared with ISD, FACE and SAMS 
ISD data showed that of the 23 women seen by the MLS, 1.8% (17/875) were 
prescribed a psychotropic during pregnancy. (19 of the 26 offered an 
appointment were exposed to antenatal psychotropics, i.e. two of the three who 
did not attend their MLS appointment were also on medication.) Of those who 
attended, 4.3% (1/23) were seen in the first trimester, 43.5% (10/23) in the 
second, and 52.2% (12/23) in the third. None of those who attended the MLS 
were prescribed Methadone, and contemporary FACE records existed for 14 of 
the 15 MLS patients. 
 
Types and rates of antenatal psychotropics from ISD and SAMS 
ISD data yielded comprehensive information about type, dose, timing and co-
prescribing of psychotropics dispensed. Table 4-10 shows the breakdown of 
different psychotropics, and as drugs were prescribed alone and in combination, 
both concurrently and consecutively, simple categorisation proved impossible, 
even in this relatively small sample. Nevertheless, it can be see that 0.8% 
(86/875) were prescribed at least one antenatal antidepressant, 7.9% (69/875) 
at least one SSRI, and 7.0% (61/875) SSRI monotherapy only. The only woman 
exposed to more than SSRI was also exposed to a tricyclic (Citalopram 20mg 
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daily and Amitriptyline 20mg daily periconception, stopping in the first 
trimester, then Fluoxetine 20mg daily commenced towards the end of the first 
trimester, but apparently only dispensed once – this patient was not identified 
on Eclipse as having mental health problems, nor as having been on psychotropic 
medication, and was not seen by the MLS). 
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Table 4-10 - Proportion of women prescribed antenatal medication 
Antenatal medication Methadone1 
 % (N) % (N) 
No psychotropics 89.8 (786) 0.9 (8) 
Psychotropics 10.2 (89) 0.2 (2) 
Any antidepressant 9.8 (86) 0.2 (2) 
Antidepressants only 9.5 (83) 0.2 (2) 
Any SSRI 7.9 (69) - - 
SSRIs only 7.0 (61) - - 
SSRI monotherapy 7.0 (61) - - 
Citalopram 2.7 (24) - - 
Escitalopram 0.2 (2) - - 
Fluoxetine 3.2 (28) - - 
Paroxetine 0.1 (1) - - 
Sertraline 0.7 (6) - - 
Any TCA 1.5 (13) 0.1 (1) 
Any SNRI 0.3 (3) - - 
Other ADs 1.0 (9) 0.1 (1) 
>1 AD 0.9 (8) - - 
Any mood stabiliser 0.5 (4) - - 
Mood stabilisers only 0.3 (3) - - 
Any antipsychotic 0.2 (2) - - 
Antipsychotics only 0 (0) - - 
1 According to SAMS 
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Table 4-11 outlines the actual number of women prescribed each type of 
psychotropic, in addition to details of co-prescribing. (All women on SSRIs only 
were exposed to SSRI monotherapy, but the two categories continue to be shown 
to allow comparison with results from the PMHS and AMU.) Of the eight women 
exposed to more than one antidepressant, 0.1% (1/875) was exposed to two 
consecutive SSRIs with a concurrent TCA (described above), 0.1% (1/875) an SSRI 
and a TCA concurrently, 0.1% (1/875) a TCA then an SSRI consecutively, 0.1% 
(1/875) an SNRI then an SSRI consecutively, 0.1% (1/875) an SSRI then Trazodone 
consecutively, 0.1% (1/875) an SSRI then Mirtazapine consecutively (with 
concurrent Quetiapine), 0.1% (1/875) Trazodone followed by Mirtazapine then an 
SSRI consecutively (with an SNRI prescribed ~10 weeks before conceiving, hence 
take to have finished before pregnancy), and 0.1% (1/875) an SNRI then 
Trazodone consecutively. 
The TCAs consisted of Amitriptyline (12/875 – in 11 cases the dose appeared to 
be less than 75mg daily, although two of these were also exposed to SSRIs), and 
Clomipramine (1/875 – although 84 25mg tablets were dispensed monthly at the 
start of pregnancy suggesting a daily dose of 75mg, the dose appeared to reduce 
to 50mg and then 25mg daily during the second trimester); the SNRIs of 
Venlafaxine  (2/875) and Duloxetine (1/875); and other antidepressants 
Mirtazapine (7/875), and Trazodone (3/875). The single biggest category of 
psychotropic was SSRIs, comprising 77.5% (69/89) of those exposed to any 
psychotropic, and 92.0% (69/75) of those exposed to an antidepressant at a 
therapeutic dose.  
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Table 4-11 – Psychotropic co-prescribing 
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Any AD (86) 69 13 3 9 8 1 0 0 1 2 1 1 3 
Any SSRI (69)  3 1 3 7 1 0 0 1 1 0 1 0 
Any TCA (13)   0 0 3 0 0 0 0 1 1 0 1 
Any SNRI (3) 
   
1 2 0 0 0 0 0 0 0 0 
Other (9)     4 0 0 0 0 1 0 1 2 
>1 AD (8) 
     
0 0 0 0 1 0 1 0 
Any MS (4)       1 2 1 0 0 0 0 
Carbamazepine (1)        0 0 0 0 0 0 
Lamotrigine (2)         0 0 0 0 0 
Valproate (1)          0 0 0 0 
Any AP (2) 
          
1 1 0 
‘Typicals’ (1)            0 0 
‘Atypicals’ (1) 
            
0 
 
 
Timing of antenatal psychotropics from ISD and SAMS 
ISD gave clear details of each prescription for the psychotropics under study, 
linked to CHI numbers. Data fields included the “Approved” and “Prescribable 
item name” for each drug, along with “Date prescription was prescribed”, “Date 
prescription was dispensed”, “Date prescription was paid”, “BNF Section Code”, 
“Drug Strength”, “Drug Formulation”, “Drug Description”, “Number of Dispensed 
items”, “Dispensed Quantity”, and “Gross ingredient cost (£)”. 
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However, a degree of interpretation was still required for two reasons. Firstly, it 
was not always clear exactly what dose was being taken by each patient, as only 
the strength and quantity of the tablets were defined. Using the example of the 
patient prescribed Clomipramine (described briefly above), her details were as 
summarised in Table 4-12 (her baby was born on 9 January 2012, indicating that 
pregnancy started circa 4 April 2011, assuming a term delivery, i.e. 280 days 
gestation). As can be seen, neither the prescribing nor the dispensing occurred 
in a regular pattern, and although it appears that the first two repeat 
prescriptions were picked up one month after the preceding prescriptions and 
thus were for 75mg daily, this changes to a two month gap, and then a three 
month gap for the next two prescriptions, suggesting a reduction in daily dose to 
50mg daily, and then 25mg daily as the second trimester progressed. These 
conclusions are predicated on the assumption that the patient actually took 
Clomipramine on a daily basis. This illustrates the difficulty in interpreting 
quantities of tablets in multiples of 28 according to frequency of dispensing, and 
several patients had much more irregular gaps between prescriptions being 
dispensed than this particular individual. 
 
Table 4-12 – Sample ISD prescribing data 
Date prescribed Date dispensed Drug Strength Dispensed Quantity 
25 May 2011 30 June 2011 25mg 84 
31 May 2011 31 May 2011 25mg 84 
11 July 2011 31 July 2011 25mg 84 
5 September 2011 30 September 2011 25mg 84 
19 December 2011 31 December 2011 25mg 84 
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Secondly, and even more critically than knowing daily dose, establishing if 
antenatal exposure had taken place also required accurate gestational age at 
birth, in the absence of knowing either the estimated delivery date (EDD) by 
ultrasound scan, or the last menstrual period (LMP), both of which would allow 
gestation to be calculated, if date of delivery was known. Gestational age at 
birth was necessary to determine length of pregnancy, and hence whether drugs 
prescribed/dispensed had ended before conception (in the same way that date 
of delivery showed if drugs were taken until delivery, or not commenced until 
afterwards). 
In contrast, it proved straightforward to characterise the timing of exposure to 
Methadone – all patients were prescribed Methadone before conceiving, and 
continued into the postnatal period. Notwithstanding the challenges in 
interpreting the ISD data, our interpretation of the timing details by drug type 
are summarised in Table 4-13. Of the 89 women exposed to antenatal 
psychotropics, 66.3% (59/89) were taking medication before conception, with 
16.9% (15/89) continuing throughout pregnancy, and 31.5% (28/89) stopping for 
good in the first trimester. 1.1% (1/89) started in the first trimester, 2.2% (2/89) 
in the second, and 1.1% (1/89) in the third, who all continued until delivery, 
leaving 47.2% (42/89) who followed a different stop-start pattern – 18.0% 
(16/89) who commenced preconception, 25.8% (23/89) in the first trimester, 
and 3.4% (3/89) in the second trimester, who subsequently stopped +/- 
restarted. Again, the pattern was similar for antidepressants in general, and 
SSRIs in particular.  
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Table 4-13 – Timing of exposure to antenatal psychotropics 
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Table 4-14 presents the numbers exposed to psychotropics before and during the 
three trimesters of pregnancy, showing a trend towards an increase in period 
prevalence of around 50% in the first trimester, followed by a reduction of 
around 50% in the second trimester, and a further slight reduction in the third 
trimester. There was significant stopping and starting, and focusing on SSRI 
monotherapy revealed the following observations. 
The most common patterns were exposure preconception and stopping finally in 
the first trimester, exposure preconception and continuing until delivery, or 
commencing in the first trimester and continuing until delivery, in 31.1% 
(19/61), 14.8% (9/61), and 13.1% (8/61), respectively. 5.0% (40/805) of the total 
cohort were exposed to SSRI monotherapy at conception, with the majority 
(55.7%, 34/61) receiving either Citalopram or Fluoxetine (both 27.9%, 17/61), 
4.9% (3/61) Sertraline, 3.3% (2/61) Escitalopram, and 1.6% (1/61) Paroxetine. 
With regards to the first trimester, 65.0% (26/40) of those exposed to SSRI 
monotherapy at conception stopped, while 35.0% (14/40) continued, 22.5% 
(9/40) until delivery, and 12.5% (5/40) into the second trimester. There was 
variation between individual SSRIs, with 54.2% (13/24) on Citalopram, 100.0% 
(2/2) on Escitalopram, 28.6% (8/28) on Fluoxetine, 100.0% (1/1) on Paroxetine, 
and 33.3% (2/6) on Sertraline stopping in the first trimester. The most common 
SSRI monotherapies commenced during pregnancy were Fluoxetine (1.4%, 
11/805), Citalopram (0.9%, 7/805), and Sertraline (0.4%, 3/805). 
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Table 4-14 – Stages of exposure to antenatal psychotropics 
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(N) (89) (86) (69) (61) (61) (24) (2) (28) (1) (6) 
Before pregnancy 59 58 47 40 40 17 2 17 1 3 
Trimester 1 Continued* 23 22 18 14 14 4 0 9 0 1 
Started 24 22 18 17 17 5 0 10 0 2 
Stopped 53 51 41 37 37 15 2 16 1 3 
Restarted 5 5 5 4 4 3 0 0 1 0 
Total 83 80 65 57 57 22 2 27 1 5 
Trimester 2 Continued 19 19 13 11 11 6 0 5 0 1 
Started 5 5 3 3 3 2 0 1 0 0 
Stopped 20 20 16 15 15 4 0 9 1 1 
Restarted 3 3 2 2 2 0 0 2 0 0 
Total 42 41 34 29 29 11 0 14 1 2 
Trimester 3 Continued 18 17 14 12 12 6 0 5 0 1 
Started 1 1 1 1 1 0 0 0 0 1 
Stopped 8 8 7 5 5 2 0 2 0 1 
Restarted 14 14 13 12 12 1 0 8 1 2 
Total 35 34 30 24 24 8 0 13 1 4 
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Early and late exposure to antenatal psychotropics 
Of those prescribed a psychotropic during pregnancy, 60.7% (54/89) were 
exposed in the first and second trimesters only, while 39.3% (35/89) were 
exposed in the third trimester (Table 4-13). A similar pattern emerged for those 
on SSRI monotherapy, with 57.4% (35/61) exposed in early pregnancy, and 
42.6%% (26/61) in late pregnancy. Again, the exact durations of exposure in days 
could not be determined from the ISD data, due to the difficulties in 
interpretation highlighted above. 
 
Detailed comparison of MLS data collection forms with ISD 
The MLS records indicated that 26 women from our cohort were offered an 
appointment, and 23 attended (Table 4-15). 66.7% (2/3) of those who did not 
attend were prescribed an SSRI during pregnancy according to ISD; one woman 
commenced Citalopram in the second trimester, and the other started Sertraline 
in the third, with both continuing until delivery. 43.5% (10/23) of those who 
attended the MLS did not have a data collection form completed. Conclusions 
based on the MLS data collection forms regarding antidepressant type and timing 
matched with those based on the ISD data for 61.5% (8/13) subjects. In the other 
five cases, there were examples of each source offering more detail than the 
other (IDs “55”, “283”, “296”, “574”, and “669” in Table 3-18). For example, 
the timing for subject “55” was ambiguous in the ISD data, but the clinician 
assessing the patient clearly documented that she stopped Fluoxetine in the first 
trimester, and restarted in the second. It appeared that while the ISD data were 
correct with regards to dispensing, details of timing could be more accurately 
derived from the MLS forms, due to assumptions about gestation (see Chapter 
6). Overall, those attending the MLS did differ from those who did not: 73.9% 
(17/23) were exposed to a psychotropic during pregnancy; none exposed at 
conception stopped in the first trimester, and 82.4% (14/17) were exposed late 
in pregnancy. 
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Table 4-15 – MLS data collection forms compared with ISD 
ID MLS ISD 
Seen Form Type Timing Type Timing 
91 No No ?2 ? Sert 3 
29 Yes Yes Cit P Cit P 
55 Yes Yes Flu Ps1r2 Flu P? 
59 Yes Yes Flu P Flu P 
116 Yes No ? ? Sert Ps1r3s3 
117 Yes Yes Flu Ps1r3 Flu Ps1r3 
128 Yes No ? ? 0 0 
140 Yes Yes Flu P Flu P 
169 Yes No ? ? 0 0 
282 Yes No ? ? Cit, AMT 1s1 
283 Yes Yes Mtz P Sert, Mtz, Quet P 
296 Yes Yes Cit ? Cit 2 
418 No No ? ? 0 0 
429 Yes No ? ? Flu 1s1 
460 Yes Yes 0 0 0 0 
517 Yes Yes Cit P Cit P 
522 Yes No ? ? Dul P 
574 Yes Yes Flu 2 Flu 2s2r3 
597 No No ? ? Cit 2 
618 Yes No ? ? Flu Ps2 
650 Yes No ? ? Cit P 
669 Yes Yes Clom, Flup Ps3, P Clom 1s2r2s3r3 
727 Yes Yes 0 0 0 0 
733 Yes No ? ? 0 0 
803 Yes No ? ? 0 0 
860 Yes Yes Ven P Ven P 
1 Subjects who did not attend, or for whom a data collection form was not available, are shaded 
in grey 
2 Missing or ambiguous data are represented by ‘?’ 
Cit = Citalopram; Clom = Clomipramine; Dul = Duloxetine; Flu = Fluoxetine; Flup = Flupentixol; 
Mtz = Mirtazapine; Quet = Quetiapine MR; Sert = Sertraline; Ven = Venlafaxine  
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Results summary 
(1) Eclipse data was incomplete, identifying only 10.1% (9/89) of those actually 
prescribed a psychotropic according to ISD, and 30.0% (3/10) of those 
taking Methadone according to SAMS. Eclipse could not be reconciled with 
FACE. 
(2) 10.2% (89/875) of women who delivered at AMU were recorded as having 
been dispensed a psychotropic likely taken during pregnancy (Table 4-10). 
(3) Of those exposed to a psychotropic, 96.6% (86/89) were exposed to an 
antidepressant, 93.3% (83/89) to antidepressants only, 77.5% (69/89) to an 
SSRI, and 68.5% (61/89) to SSRIs only (all monotherapy). Of those exposed 
to SSRI monotherapy, 45.9% (28/61) took Fluoxetine, 39.3% (24/61) 
Citalopram, 9.8% (6/61) Sertraline, 3.3% (2/61) Escitalopram, and 1.6% 
(1/61) Paroxetine. 84.6% (11/13) exposed to a tricyclic received low dose 
Amitriptyline (<20mg), suggesting an indication other than depression, with 
the others taking Amitriptyline 200mg daily, and Clomipramine 75mg daily. 
Co-prescribing was less common than in the PMHS, with (3/86) receiving an 
antidepressant and a mood stabiliser or an antipsychotic. 9.3% (8/86) were 
exposed to more than one antidepressant during pregnancy. Of those 
prescribed SSRI monotherapy, 65.6% (40/61) were exposed at conception, 
of whom 22.5% (9/40) continued throughout pregnancy, and 47.5% (19/40) 
stopped for good in the first trimester. Of the others exposed 
periconception, 7.5% (3/40) stopped in the second trimester, and 22.5% 
(9/40) stopped and restarted at least once at different stages during 
pregnancy. Of those on SSRI monotherapy, 57.4% (35/61) were exposed 
‘early’ in pregnancy, and 42.6% (26/61) ‘late’ (Table 4-13). Prescribing 
patterns appeared more varied than in the PMHS, with 27.9% (17/61) 
starting in the first trimester, 4.9% (3/61) in the second, and 1.6% (1/61) in 
the third – 19.0% (4/21) who commenced during pregnancy continued until 
delivery. The SSRIs started during pregnancy were Fluoxetine, Citalopram 
and Sertraline, in 18.0% (11/61), 11.5% (7/61) and 4.9% (3/61), respectively 
(Tables 4-13 and 4-14). Exposure rates to antidepressants [SSRIs] in 
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trimesters one, two, three, and pregnancy as a whole were 9.1% (80/875) 
[7.4%, 65/875], 4.7% (41/875) [3.9%, 34/875], 3.9% (34/875) [3.4%, 
30/875], and 9.8% (86/875) [7.9%, 69/875], respectively. 
 
Discussion 
This pilot allowed not only data integrity to be compared between local clinical 
and central administrative sources, but also an estimate of recent rates of 
antenatal psychotropic prescribing in a sample likely to be representative of the 
general Scottish population. 
 
Data integrity – Eclipse, ISD, SAMS, FACE and MLS 
There was evidence of good local clinical practice, in that the AMU Eclipse 
record includes fields for documenting psychotropic medication, substance 
misuse and Methadone, as well as screening for ongoing and past contact with 
psychiatric services, and current evidence of potential mental health problems. 
There was also an active and accessible MLS, and evidence of shared awareness 
of the importance of identifying and managing women at increased risk of 
perinatal mental illness. 
However, Eclipse documentation was patchy, with many fields left blank, and 
data regarding findings and action(s) taken (e.g. referral to MLS) entered 
inconsistently across unrelated and overlapping fields. Moreover, there were 
numerous examples of requests made by MLS for an alert to be put on Eclipse to 
trigger a request for postnatal review being missed. The vast majority of 
pregnant women who were prescribed a psychotropic or Methadone were not 
identified accurately via AMU records, nor was there evidence of adequate 
screening for mental health issues. This may represent incomplete 
documentation at the time of initial booking and/or lack of updating of records 
throughout the remainder of pregnancy. Midwives may also be unaware of the 
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consequences of both perinatal mental illness and its treatment on mothers and 
babies. 
It was clear that while Eclipse was a reliable and accurate means of identifying 
pregnant women delivering in AMU, it was not a complete clinical record that 
could be used to establish either the extent or characteristics of exposure to 
antenatal psychotropics. The 10-fold discrepancy between the nine women 
documented as having taken a psychotropic (all SSRI monotherapy) and the 89 
revealed by ISD to have been dispensed psychotropics likely to have been taken 
during pregnancy (a range of different antidepressants, mood stabilisers, and 
antipsychotics, both singly, consecutively and concurrently) was striking, and 
cause for clinical concern. However, discussion with AMU staff revealed that 
Eclipse is not used as the primary record of antenatal care, including booking, 
and paper notes remain the mainstay of documentation informing care. The 
exceptions to this are labour and delivery, with a range of data on peripartum 
interventions and outcomes being entered on Eclipse. 
The non-universal utilisation of Eclipse essentially invalidates it as a source of 
data for detailed exploration of perinatal exposures and outcomes. However, it 
does explain the marked difference between the estimates of antenatal 
psychotropic exposure based on the AMU data in comparison to ISD. In 
particular, our findings should not be interpreted as implying that pregnant 
women are not being screened for mental health problems, and not being 
referred appropriately; at least, not on the basis of Eclipse alone. 
(It follows that while Eclipse is a trustworthy way to identify those delivering in 
AMU, whether live or stillbirths, it cannot be used to identify those who 
experience spontaneous or induced abortion, or ectopic pregnancy, with the 
attendant issues of possible biases in basing epidemiological analyses on its 
contents. One further issue of note is that Eclipse therefore cannot be used to 
explore any influences of psychotropics on fecundity, either.) 
Although the ISD data had significant face validity, nevertheless some issues 
emerged. In contrast to the SAMS database, where prescriptions for specified 
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daily doses of Methadone were dispensed at regular intervals for (generally) 
supervised ingestion, a significant degree of interpretation was required with 
regards to exactly when dispensed tablets started, what daily doses were taken, 
for how long medication was taken, and any gaps. Furthermore, it was not 
possible to time prescriptions with the exact gestation medication was taken, as 
although dates of birth were known, using an average pregnancy length of 280 
days to determine fetal exposure retrospectively may have resulted in an under- 
or overestimate. For example, as deliveries from 37 weeks gestation onwards 
are taken as “term”, a neonate born after 37 completed weeks (with a 
gestational age of 260 days, Appendix 5) would not have been exposed to 
medication that finished 265 days before birth, but would have been classified 
as such via our methodology. Moreover, as reduced gestational age (including 
preterm delivery) is associated with exposure to antenatal antidepressants, 
there remains the potential for significant misinterpretation of outcomes, via 
those with preterm deliveries being excluded from relevant studies (Oberlander 
et al., 2008; Ross et al., 2013). 
Nevertheless, our findings regarding the extent of perinatal psychotropic 
prescribing (as well as type and timing of drugs) are broadly comparable with 
the current literature, summarised for SSRIs in Table 4-16 alongside the recent 
figures relevant to the UK (see Chapter 2). Again, there was a significant trend 
towards reduced rates as pregnancies progressed. It should be noted that 
although we identified psychotropics dispensed within at least the three months 
before conception, we did not specifically calculate the total prevalence pre-
pregnancy and, in comparison with Margulis, Kang and Hammad (2014), our 
methodology had the potential to allow more accurate estimation of exposure by 
trimester, by using date and quantity of tablets dispensed to project actual 
gestation taken, rather than just when prescriptions were issued. This may 
explain our higher figures for T1 prevalence: as many women discontinue 
medication in the first trimester after realising they are pregnant, Margulis, 
Kang and Hammad (2014) reported a lower prevalence due to fewer 
prescriptions being issued in T1, but this did not take account of those who were 
prescribed sufficient quantities of drugs just before conceiving, and who 
therefore were exposed early post-conception, particularly if there was any 
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delay between dispensing and commencing. Current data suggest that such 
short-lived early exposure may not to be of clinical significance, although this is 
not absolutely certain – for example, miscarriage is associated with antenatal 
antidepressants, although this may be due to underlying disease severity (Ban et 
al., 2012; Ban et al., 2014; Furu et al., 2015). 
 
Table 4-16 – Prevalence of SSRIs during pregnancy 
 T0 T1 T2 T3 T4 Overall 
Petersen et al. (2011) 4.8% 1.9% 0.77% 0.75% - 2.11% 
Margulis, Kang & Hammad (2014) 3.43% 2.06% 0.94% 0.99% 4.44% - 
Charlton et al. (2015) (UK) 8.8% - - - 12.9% 3.7% 
Charlton et al. (2015) Wales) 9.6% - - - 15.0% 4.5% 
Wood, Cameron & Julyan (2015) - 7.43% 3.89% 3.43% - 7.89% 
Figures represent percentage of women exposed to antidepressants during 
pregnancy, with percentage exposed to SSRIs in parenthesis. 
 
 
Categories of exposure 
Classifying different types of exposure for the purpose of allocating to discrete 
categories to facilitate statistical analysis of associations poses significant 
challenges. Pregnant women are exposed to different types and combinations of 
psychotropics, at different gestations, for varying durations, and for different 
indications. Given the difficulties in diagnosing depression and rating its 
severity, it proves difficult to take account of these potential confounding 
factors when exploring outcomes in relationship to exposure, even before other 
known, and indeed unknown, confounding factors are taken into account. 
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Notwithstanding, almost all of those prescribed antenatal psychotropics in our 
general maternity population were exposed to antidepressants (96.6%, 86/89), 
mostly to SSRIs (77.5%, 69/89). More than 85% of those on SSRI monotherapy 
took either Fluoxetine or Citalopram. The trends for timing and duration of 
exposure to psychotropics as a whole, antidepressants in general, and SSRI 
monotherapy in particular were similar – around 30% were exposed 
periconception and discontinued in the first trimester; around 15% were exposed 
periconception and continued until delivery; around 15% commenced and then 
stopped in the first trimester; and the others followed a range of patterns (Table 
4-13). Most prescribing changes took place in the first trimester, presumably 
with many women deciding to stop medication when they discovered they were 
pregnant. These decisions are likely to be taken without the benefits of 
specialist advice, hence the critical importance of giving appropriate 
anticipatory information and advice to all women of childbearing potential 
receiving a prescription for any medication – pregnancy is frequently 
unexpected, and even non-prescription drugs commonly used antenatally may be 
associated with as yet unknown risks. For example, even Paracetamol (which is 
estimated to be taken by >65% of pregnant women), has recently been 
highlighted as potentially increasing the risk of cryptorchidism (van den Driesche 
et al., 2015). 
As the MLS provides specialist psychiatric input to AMU, several issues emerged 
from our findings. Firstly, CHIs and Excel should ideally be used to record 
referrals, appointments, and attendance, to provide a comprehensive, accurate, 
and useful source of basic data. Secondly, data collection forms are not 
completed for all patients, and the relevant processes therefore need to be 
optimised, to eradicate variation between clinicians. However, the MLS forms 
appeared to have some advantages over the PMHS forms, in that data from 
follow-up visits were entered to update the forms, and the use of dates to 
specify exactly when medication started and stopped allowed more accurate 
characterisation of exposure, comparable to ISD. 
Having established the above, we progressed to exploring select outcomes, and 
establishing what could be gleaned from clinical records. 
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Key points 
• ~1 in 10 women attending AMU were dispensed a psychotropic medication 
likely taken during pregnancy, the majority SSRI monotherapy. 
• ~1 in 6 of those on psychotropics at conception, and ~1 in 7 of those on SSRI 
monotherapy, continued throughout pregnancy. 
• ~2 in 5 women on psychotropics were exposed late in pregnancy. 
• Not all women receiving antenatal psychotropics were referred to the MLS. 
• Those attending the MLS differed from the general cohort in being more likely 
to be exposed to medication (mainly SSRIs), continue medication throughout 
pregnancy, and exposed late in pregnancy.  
• The AMU and MLS data were not complete, not fully accurate, and therefore 
not a reliable source for research purposes. 
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Chapter 5 - Consequences of antenatal exposure to SSRIs: 
Clinical outcomes 
 
Phase 1 Admissions to the neonatal unit 
Given our findings that almost one in 10 women in the general population were 
prescribed a psychotropic antenatally, with around one in six of these continuing 
medication throughout pregnancy, and in light of concerns about potential 
neurodevelopmental toxicity, comprehensive and accurate data about 
consequences of antenatal exposure to psychotropics is of paramount 
importance, not least in supporting mothers and their clinicians in making 
necessary decisions about care. 
In keeping with other studies, we established that the most common type of 
antenatal psychotropic exposure was to SSRIs. Despite researchers reaching 
reassuring conclusions regarding their overall safety, a number of inconsistent 
findings have been reported. For example, in 2015 alone, although Reefhuis et 
al. reported no association between Sertraline and birth defects (including 
cardiac abnormalities and craniosystosis) in 440 women exposed in the first 
trimester, Bérard, Zhao and Sheehy did find that Sertraline was linked with 
cardiac abnormalities and craniosystosis in 366 depressed/anxious women with 
similar exposure. (Significantly, Sertraline was not associated with an increased 
risk of malformations overall in comparison to depressed/anxious women not 
exposed to antidepressants, but only when specific defects were analysed 
individually.) These conflicting conclusions illustrate the challenging 
complexities of assessing antenatal exposures, as references can be produced to 
support apparently opposite conclusions about most drugs. 
Some inconsistencies in the literature may be attributable to heterogeneous 
samples and/or different methodologies, both relevant to the above example. 
However, in view of the difficulties in accessing and analysing relevant data 
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highlighted by our work in the PMHS and AMU, what register-based meta-analytic 
linkage studies gain in power from interrogating large datasets may be offset by 
the fine detail of individual clinical care, and extensive confounding. For 
example, in order to clarify the consequences of antenatal exposure to a 
particular drug, one should ideally take account of each individual medication’s 
pharmacokinetic and pharmacodynamic characteristics, and the dose, 
gestational stage, and duration prescribed, in addition to the same factors for 
any co-prescribed drugs, as well as any known or unknown interactions. These 
data are not easily accessible, nor straightforward to interpret, categorise, or 
analyse. Moreover, due to the small absolute numbers of fetuses exposed, and 
the potentially subtle sequelae of exposure, in conjunction with any 
inaccuracies in the data, or unwarranted assumptions in its analysis, and the 
countless confounders, the use of retrospective proxy markers for exposure (e.g. 
the date medication was dispensed) introduces a bewildering array of complex 
challenges.  
Numerous other factors also contribute to outcomes for offspring, including 
general maternal health and the diagnoses for which medication is prescribed, 
illness severity, time course, and response to intervention(s), other treatment 
modalities (e.g. psychological), consistency of adherence to medication, drug 
metabolism and serum levels achieved, degree of placental transfer, maternal 
genotype and phenotype, fetal genotype (and therefore paternal genotype and 
age at conception), obstetric insults, and the myriad of environmental 
influences, both alone and in combination. Drawing clinically significant 
inferences from statistical associations in this area is far from straightforward. 
Early exposure to psychotropic medication may exert different influences on 
progeny at different stages of life. For example, some early outcomes may be 
more related to direct developmental and teratogenic effects of the drug(s) in 
question, including epigenetic factors, while longer term outcomes may be 
related more to direct and indirect neurodevelopmental pathways, with greater 
likelihood of complex gene:environment interactions contributing over time, 
especially psychosocial factors (Oberlander et al., 2008). 
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For these reasons, examining naturalistic outcomes of clinical and personal 
relevance is of value to parents, children, and healthcare workers alike. What do 
prospective mothers and antenatal prescribers need to know? 
The relationship between neonatal admission, antenatal depression, and 
antenatal antidepressants is complex. For example, in a prospective 
observational cohort study of 959 women, Chung et al. (2001) found that 
admission rate increased from 19% to 24% in those with BDI scores >14.5, while 
Engelstad et al. (2014), who retrospectively compared select outcomes from a 
cohort of 254 women with diagnoses of depression with 222 matched controls, 
reported that antenatal depression (but not SSRIs) was independently associated 
with an increased risk of admission, from 24% to 42%. Maschi et al. (2008) found 
no association between antidepressants (including SSRIs) and neonatal 
admission, whereas Lund, Pedersen and Henriksen (2009) established that 
exposure to SSRIs increased the admission rate to 16.4% from 9.0% (7.4%) in 
those with a psychiatric history (no psychiatric history) but not exposed to 
antidepressants. Similarly, in a retrospective register-based analysis of 511,938 
deliveries, Räisänen et al. (2014) described an increased risk of neonatal 
admission associated with exposure to antenatal depression, but were unable to 
account for medication. Conversely, in a study of 76 exposed and 90 unexposed 
women, Ferreira et al. (2007) did not find an independent association between 
admission and exposure to SSRIs or SNRIs, but did not control for maternal 
depression. Sutter-Dallay et al. (2015) investigated antenatal exposure to 
different psychotropics in 1,071 women admitted to 13 French Mother-Baby 
Units providing psychiatric care, and found an association between 
antidepressants and admission, but did not control for underlying illnesses. 
Lastly, Wisner et al. (2009) reported that neonatal admission rates were 8%, 
19%, and 21%, in healthy controls, those exposed to SSRIs, and those exposed to 
unmedicated depression, respectively. Again, the influences of heterogeneous 
unrepresentative samples, varying methodologies, and lack of accounting for 
confounders are evident. 
Moreover, the mechanisms by which antenatal exposure to depression and 
antidepressants may precipitate neonatal admission remain unclear. It is 
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possible that indirect factors such as preterm delivery are relevant, as well as 
pharmacological issues such as poor neonatal adaptation, which is closely linked 
with admission (Craighead & Elswick, 2014; Kocherlakota, 2014; Kieviet et al., 
2015). 
Although the validity of using admission to neonatal intensive care units as an 
outcome measure and surrogate for morbidity has been criticised (mainly on the 
basis of non-comparability of different units), it can serve as a relevant proxy 
marker of early distress and/or adversity, and therefore we undertook to 
explore any such association in our sample (Wiegerinck et al., 2014). 
 
Research questions 
(1) What proportion of neonates required admission to the local neonatal unit 
(NNU)? 
(2) Did exposure to antenatal psychotropics in general, and SSRIs in particular, 
increase the risk of admission? 
(3) Which types of exposure were associated with the greatest risk of 
admission? 
 
Methods 
AMU is located within University Hospital Crosshouse, a large district general 
hospital serving Ayrshire. All neonates requiring special care are admitted to the 
local NNU, unless beds are unavailable, or tertiary-level specialist intervention is 
indicated. As there was no electronic database at that time, the lead NNU 
paediatrician arranged for administrative staff to provide details of all 
admissions between 1 January and 31 March 2012, including linked CHIs for 
mothers and babies. Neonatal CHIs, DOBs, and gestation at birth were matched 
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to maternal CHIs, and entered in to an Excel® spreadsheet for statistical 
analysis. Approval was granted via Information Governance and the Caldicott 
Guardian, and Healthcare Quality and R&D confirmed that formal ethical 
approval was not required. 
 
Contributors 
EJ generated the research questions; planned the methodology; arranged access 
to NNU data via SK (NNU consultant); entered and processed relevant data in 
Excel®; and completed descriptive statistical analysis. 
 
Results 
Neonates from 101 mothers in our cohort were admitted to NNU between 1 
January and 31 March 2012 (inclusive), i.e. overall admission rate 11.5% 
(101/875) (none were admitted after 31 March). 19.8% (20/101) had potentially 
been exposed to a psychotropic during the study period according to ISD. 
However, eight of these had not been exposed during pregnancy (six exposed 
preconception only, and two postnatally). SAMS indicated that 40.0% (4/10) had 
been exposed to Methadone throughout pregnancy. Diagnoses were not 
immediately available, due to the lack of an established database. 
Knowing the gestation allowed us to review the timing of exposure for each 
neonate both exposed to an antenatal psychotropic and admitted to NNU, 
resulting in three subjects changing category due to pregnancies lasting less 
then the assumed 280 days: “92” (exposed to Mirtazapine) changed from 2s2 to 
1s2 (gestation 266 days), “174” (Citalopram) from 1s3 to Ps2 (gestation 231 
days), and “295” (Fluoxetine) from Ps1 to 0 (gestation 230 days), i.e. exposed 
preconception only. In other words, 25.0% (3/12) changed timing category as a 
result of gestation being known. 
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This left 11 neonates exposed to antenatal psychotropics and subsequently 
admitted to NNU, all exposed to antidepressants only, and none co-prescribed 
Methadone, as detailed in Table 5-1. 90.9% (10/11) were exposed to an SSRI 
(81.8% [9/11] to SSRI monotherapy), 18.2% (2/11) were exposed in the first 
trimester only, and 27.3% (3/11) throughout pregnancy, with 36.4% (4/11) 
exposed early and 63.6% (7/11) late in pregnancy. 27.3% (3/11) were born 
before 37 weeks completed gestation. Significantly, two subjects commenced 
apparently “high” doses of SSRIs; “398” who commenced Sertraline 100mg in the 
first trimester, and “569” who commenced Fluoxetine 40mg daily in the first 
trimester.  
 
Table 5-1 – Neonates exposed to antenatal antidepressants, and admitted to 
NNU 
Subject Gestation 
(days) 
Gestation 
category 
Drug(s) Dose1 Timing Exposure 
 
Actual 
duration 
92 266 Term Mirtazapine 15mg 1s2 Early 28 
117 273 Term Fluoxetine 20mg Ps1r3 Late 75 + 12 
140 184 Pre-term Fluoxetine 20mg P Late 184 
174 231 Pre-term Citalopram 40mg Ps2 Early 168? 
311 275 Term Fluoxetine 20mg Ps2r3 Late 164 + 16 
398 275 Term Sertraline 100mg2 1s2r3 Late 56 + 56 
442 280 Term Citalopram 20mg Ps1 Early 17 
466 271 Term Citalopram 20mg 1s1 Early 28 
495 231 Pre-term Sertraline 100mg P Late 231 
522 287 Term Trazodone, 
Mirtazapine, 
then Citalopram 
150mg, 
45mg, 
 20mg 
P Late 287 
569 273 Term Fluoxetine 40mg3 1 Late 245 
1 Highest daily dose achieved 
2 Apparently commenced on Sertraline 100mg daily at day 55 – no ISD prescription in preceding 9 
months 
3 Apparently commenced on Fluoxetine 40mg daily at day 28 – no ISD prescription in preceding 9 
months 
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Admission rates for different exposure types are summarised in Table 5-2, with 
statistical significance calculated using Fisher’s exact test. The admission rates 
for those exposed antenatally to any psychotropic, any antidepressant, any SSRI, 
and SSRI monotherapy were 12.5%, 12.9%, 14.7%, and 15.0%, respectively. 
Detailed subgroup analyses were not appropriate due to the low absolute 
numbers, but there appeared to be a trend towards increased risk of admission 
to the NNU being associated with late exposure to antidepressants in general, 
exposure to SSRIs in particular, and also ‘exposure’ to the MLS. Several 
exposures were significantly associated with admission to the NNU, including 
Methadone, and exposure to an antidepressant until delivery. Again, there was a 
trend towards exposure to SSRIs in particular up until delivery being strongly 
associated with admission. Exposure to antenatal psychotropics that was limited 
to the first trimester only was significantly associated with a reduced risk of 
admission to the NNU. There was no statistically significant relationship between 
gestation at birth and exposure to psychotropics found (Mann Whitney U 2-tailed 
test). 
 
Results summary 
(1) ~1 in 10 babies required admission to the NNU. 
(2) Exposure to antenatal psychotropics, antidepressants, and SSRIs was 
associated with an increased risk of neonatal admission, but this was not 
statistically significant. 
(3) Being exposed to psychotropics late in pregnancy, and receiving care via 
the MLS were similarly associated with a statistically insignificant risk of 
admission. However, exposure to any antidepressant until delivery, and 
exposure to Methadone, were both significantly associated with increased 
rates of admission, ~1 in 4, and 2 in 5, respectively. 
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Table 5-2 – Admission rates to NNU for different exposure types 
 (N) Admitted 
(%) 
(N) Not admitted 
(%) 
(N) Fisher’s exact test 
(p) 
Total (875) 11.5 (101) 88.5 (774) - 
Exposure 
Unexposed (787) 11.4 (90) 88.6 (697) - 
Any psychotropic (88) 12.5 (11) 87.5 (77) 0.73 
Any AD (85) 12.9 (11) 87.1 (74) 0.72 
Any SSRI (68) 14.7 (10) 85.3 (58) 0.43 
SSRI monotherapy (60) 15.0 (9) 85.0 (51) 0.40 
Methadone (10) 40.0 (4) 60.0 (6) 0.02 
Referred to MLS (26) 19.2 (5) 80.8 (21) 0.21 
Seen by MLS (23) 21.7 (5) 78.3 (18) 0.17 
Late exposure (34) 20.6 (7) 79.4 (27) 0.1 
First trimester 
only 
(41) 2.4 (1) 97.6 (40) 0.00892 
Until delivery 
Any psychotropic (30) 23.3 (7) 76.7 (23) 0.041 
Any AD (29) 24.1 (7) 75.9 (22) 0.036 
Any SSRI (25) 28.0 (7) 72.0 (18) 0.01 
SSRI monotherapy (22) 27.3 (6) 72.7 (16) 0.025 
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Discussion 
It proved somewhat labour-intensive to explore neonatal admissions locally, due 
to the absence of a dedicated electronic database at that time. Paediatric 
administrative colleagues were very helpful in providing some of the data we 
sought, but we were unable to establish and therefore categorise reasons for 
admission to the NNU. Notwithstanding, the lead NNU paediatrician had sight of 
the reasons for all neonatal admissions during our study period, and did not infer 
any significant differences between those exposed to antidepressants and those 
not, with reference either to proportions of preterm births, or diagnoses. 
However, having access to the actual gestation at birth enabled us to check the 
exposure categories to which we had assigned subjects, on the basis of the ISD 
data. This led to 25.0% (3/12) moving, including one who became ‘unexposed’. 
This has implications for the overall validity of our existing conclusions, and 
typifies the inaccuracies inherent in defining when pregnancies start and stop, in 
the absence of relevant data. 
Another issue was those who appeared to commence an antidepressant at a 
higher dose than would be usual (Sertraline 50mg, and Fluoxetine 20mg), 
according to ISD, who had no record of a corresponding prescription being 
dispensed in the preceding six months, and four months (respectively). It 
appears unlikely that a prescriber would initiate these drugs at these doses, 
particularly during pregnancy (if known), and therefore the patients must have 
had access to medication from sources other than Scottish community 
pharmacies, or the ISD data was inaccurate or incomplete. Sources could include 
pharmacies based either in Scottish hospitals or outwith Scotland, or private 
prescriptions. ISD subsequently confirmed that the CHI capture rates for BNF 
Sections 4.2, 4.3, and 4.8 for the period under study were 90.3%, 95.5%, and 
95.6%, respectively, indicating that prescriptions for patients in our cohort may 
have been missed. This could have occurred, for example, if prescribers used 
only DOBs rather than full CHIs. 
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Compared to the baseline admission rate in the “unexposed” of 11.4%, it was 
interesting to note the trend towards higher rates of neonatal admissions in 
those exposed to antidepressants in general, and SSRIs in particular, albeit not 
statistically significant. This could represent a “type II error” due to small 
sample size, and it would be unnecessarily speculative to reach any firm 
conclusions. Nevertheless, while the increased risk of admission associated with 
exposure to Methadone was unsurprising and consistent with other reports, the 
negative association between first trimester exposure only and NNU admission is 
singular and thought provoking (Cleary et al., 2011; Cleary et al., 2012; Greig, 
Ash & Douiri, 2012). It is unclear why mothers who were presumably unwell 
enough to be taking an antidepressant in early pregnancy but stopped should 
subsequently deliver babies with a lower risk of neonatal admission than the 
general population. Reverse causality is one possible explanation, in that 
mothers who were motivated to stop medication for the sake of their baby may 
also have been driven to be generally healthier, but this seems unlikely, 
particularly given the increased risk of depressive relapse in those discontinuing 
antidepressants during pregnancy (Cohen et al., 2006). 
The observation that exposure up until delivery was significantly associated with 
admission is noteworthy, with the associated risk of admission more than 
doubling. Again, in the absence of knowing the reason(s) for admission, the 
explanation remains unclear, although poor neonatal adaptation (neonatal 
adaptation [or abstinence] syndrome [NAS]) is one possibility (Kieviet et al., 
2015). This phenomenon is characterised by time-limited neonatal irritability, 
impaired feeding and sleeping, jitteriness and crying, increased muscle tone, 
gastrointestinal upset, and respiratory distress, and although previously reported 
to affect around 30% of babies exposed to antidepressants in utero, Kieviet et 
al. (2015) reported that up to 64% were affected in their retrospective cohort 
study of 247 women and their infants, although the majority of cases were mild. 
They found an overall admission rate of 21.5%, with 29% of neonates with NAS 
admitted, while only 9% of those without. (Interestingly, SSRIs were associated 
with NAS more than SNRIs or NaSSAs (noradrenergic and specific serotonergic 
antidepressants), but overall drugs less so than feeding – formula feeding was 
associated with higher rates of NAS, implying that ongoing exposure to 
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medication in breast milk may moderate symptoms.) Taken together with our 
findings, this suggests that exposure up until delivery (i.e. not simply “late” 
third trimester exposure per se – see Table 5-2) may put infants at increased risk 
of NAS, and therefore admission to NNU. 
This assumption has influenced some clinicians to withdraw psychotropics in the 
days leading up to the EDD. In addition to the difficulties in predicting EDD with 
any degree of accuracy, this practice is no longer common, at least in part due 
to Warburton, Hertzman and Oberlander (2010), who reported that when 
confounders are controlled for, withdrawing SSRIs prescribed throughout 
pregnancy ~14 days before delivery did not reduce neonatal complications such 
as respiratory or feeding problems (although they did not specifically assess for 
NAS nor include neonatal admission). They concluded that a discontinuation 
syndrome or physiological withdrawal may therefore not fully explain poor 
neonatal adaptation, and that early adverse outcomes may be related to other 
neurodevelopmental effects of both drugs and the indications for which they 
were prescribed. 
One further finding of note was the increased admission rate in those referred 
to/seen by the MLS, almost double the baseline rate, although not statistically 
significant. While this sample did include proportionally more women prescribed 
antidepressants during pregnancy (73.9%, 17/23), and more who were exposed 
late in pregnancy (82.4%, 14/17), than the unexposed population, it was not 
clear that this fully explained the association – five babies born to mothers 
referred to/attending the MLS were admitted to the NNU, three exposed to 
antenatal antidepressants, and two not. 
This observation illustrates one of the key limitations of this pilot – a relatively 
small sample size. To perform meaningful subgroup analyses to explore the 
multitude of relevant common and rare outcomes risks associated with the many 
different types of exposure requires large numbers. 
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Phase 2 Perinatal outcomes in those attending the MLS 
Having established that it was challenging to access the necessary data to 
explore neonatal outcomes for those exposed to antenatal psychotropics in 
Ayrshire, but that those attending the MLS appeared to be at higher risk of 
admission to the NNU, we elected to consider this service in more detail. The 
anticipated advantages included access to diagnoses and their severity, as well 
as select neonatal outcomes, as clinical letters regarding infants of mothers 
attending the MLS who are admitted to the NNU are routinely copied to the MLS 
lead psychiatrist. 
In collaboration with the NNU lead paediatrician, we learned that a new 
electronic database for the NNU, BadgerNet (www.clevermed.com), had been 
implemented, and may be an appropriate source for the clinical details we 
sought. As BadgerNet was introduced in the NNU in late 2012, and was not being 
populated with retrospective data, it was not possible to use it for the existing 
AMU sample. 
Due to uncertainties about the utility of BadgerNet, and the limitations 
experienced with Eclipse, it was agreed that we would access the Scottish Birth 
Record (SBR) simultaneously, a web-based service provided by ISD which aims to 
serve as a single comprehensive repository for neonatal health data for all 
babies born in Scotland, including stillbirths (www.isdscotland.org/Products-
and-Services/Scottish-Birth-Record/). This would allow verification of 
BadgerNet’s accuracy, and compensation for any shortcomings. 
Early/preterm delivery, low birthweight, low APGAR scores, and neonatal 
admissions have been linked with antenatal exposure to maternal depression 
and/or antidepressants (Grote et al., 2010; Jensen et al., 2013; Ross et al., 
2013; Hanley & Oberlander, 2014; Forray, Blackwell & Yonkers, 2015; Gentile, 
2015). A high proportion of those attending the MLS are exposed to both, and 
they appear to be at increased risk of delivering babies who require admission to 
NNU - this was a finding of potential personal importance to mothers, as well as 
significance to the MLS and NNU clinicians. 
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Research questions 
In pregnant women attending the MLS, 
(1) What proportion of neonates required admission to the local neonatal unit 
(NNU)? 
(2) Did exposure to antenatal psychotropics in general, and SSRIs in particular, 
increase the risk of admission, preterm delivery, shorter gestations, low 
birthweight, and/or low APGAR scores? 
(3) Which types of exposure were associated with admission? 
 
Methods 
The MLS records and data collection forms were accessed to identify all women 
who attended the MLS between 1 January and 31 December 2013 (inclusive). We 
used the CHIs to interrogate both BadgerNet and the SBR, with the support of 
administrative staff. Relevant details were entered in to an Excel® spreadsheet 
for analysis, including maternal date seen, psychiatric diagnoses with rating 
scale scores (see below), prescribed and other medication, alcohol and tobacco 
use, and parity; and infant EDD, DOB, mode of delivery, obstetric complications, 
birthweight, gestation, gender, admission to NNU, and APGAR scores. A 
multivariate general linear model was employed to explore the relationships 
between rating scale scores (predictor variables) and gestation at birth, preterm 
delivery (less than 37 weeks/260 days completed gestation, Appendix 4), 
birthweight, APGAR scores, and admission to the NNU (response variables). We 
included exposure to any antidepressants as an additional covariate in the 
model.  
Page 179 of 365 
Approval was granted via Information Governance and the Caldicott Guardian, 
and Healthcare Quality and R&D confirmed that formal ethical approval was not 
required. 
MLS clinicians routinely ask patients to populate a Hospital Anxiety and 
Depression Scale (HADS) at each visit. The HADS is a 14 item self-completed 
outcome measure that rates the severity of both depressive and anxiety 
symptoms via agreement with seven statements related to each, yielding a score 
of between 0 and 3 for every item, i.e. a score out of 21 for depression (HADS-
D), and a score out of 21 for anxiety (HADS-A). Originally developed by Zigmond 
and Snaith (1983) for use in general hospital patients, it places less emphasis on 
non-specific somatic complaints common in other conditions, such as fatigue and 
sleep disturbance. A score >8 on either subscale is generally taken as indicating 
clinically significant depression and/or anxiety (Bjelland et al., 2002). Although 
the HADS has not been satisfactorily validated in perinatal populations, 
nevertheless it has face validity as an appropriate adjunct to standard clinical 
assessment and monitoring (Bocquet & Deruelle, 2014; Brunton et al., 2015; 
Evans, Spiby & Morrell, 2015). However, like other rating scales, it is not clear 
that it is specific for depression/anxiety, and can also be taken as a general 
measure of stress/distress (Pallant & Tennant, 2007). 
APGAR scores, first proposed in 1952, continue to be used to assess heart rate, 
respiratory effort, reflex irritability, muscle tone, and colour one minute and 
five minutes after birth (Jepson, Talashek & Tichy, 1991; ACOG, 2006). Despite 
criticisms and limitations, they remain useful as a predictor of neonatal 
mortality in term infants, and in identifying those in need of cardiopulmonary 
resuscitation (Schmidt et al., 1988; Finster & Wood, 2005). However, they are 
not of value in predicting longer term outcomes, although scores of <8 at one 
minute may be taken as an indicator of potentially clinically significant early 
distress. 
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Contributors 
EJ generated the research questions; planned the methodology; arranged access 
to MLS and NNU data via MC and SK (NNU consultant), respectively; trained, 
supervised and supported LT and SN (junior doctors working in psychiatry) in 
transferring relevant data to Excel®; and completed descriptive statistical 
analysis. RK conducted the multivariate analyses. 
 
Results 
116 women attended the MLS at least once, with 106 being seen during 
pregnancy. Two moved out of Ayrshire before delivering, and data for one of 
these was not available post hoc. Therefore, data were available for 105 
subjects, with details of psychotropic exposure summarised in Table 4-3, and 
timing of exposure for SSRI monotherapy and individual drugs in Table 4-4. Three 
women delivered twins, which were combined into one exposure for the purpose 
of analysing admissions to the NNU, but considered individually when evaluating 
gestations, preterm deliveries, birthweights, and APGAR scores. Diagnoses were 
available for 99 women, with the primary diagnoses given in Table 4-5. As some 
subjects had several HADS scores due to multiple attendances at the MLS, the 
single highest figure was selected for analysis, with the median scores for 
depression and anxiety being 8 (range 0-20), and 12 (range 0-21), respectively. 
HADS-D scores were not available for 13 subjects, and HADS-A scores for 12. 
16.7% (18/108) of the infants were preterm, including all six twins. 
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Table 5-3 - Proportion of women prescribed antenatal medication 
Antenatal medication 
 % (N) 
No psychotropics 24.8 (26) 
Psychotropics 75.2 (79) 
Any antidepressant 71.4 (75) 
Antidepressants only 70.5 (74) 
Any SSRI 59.0 (62) 
SSRIs only 54.3 (57) 
SSRI monotherapy 51.4 (54) 
Citalopram 16.2 (17) 
Escitalopram 1.9 (2) 
Fluoxetine 12.4 (13) 
Paroxetine 0 (0) 
Sertraline 21.0 (22) 
Any TCA 1.0 (1) 
Any SNRI 5.7 (6) 
Other ADs 10.5 (11) 
>1 AD 7.6 (8) 
Any mood stabiliser 1.0 (1) 
Mood stabilisers only 1.0 (1) 
Any antipsychotic 3.8 (4) 
Antipsychotics only 2.9 (3) 
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Table 5-4 - Timing of exposure, by type of psychotropic 
   Timing  Exposure 
 
(N) 
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SSRI monotherapy (54)  19 9 4 7 1 2 2 5 5  9 45 
Citalopram (17)  8 2 0 3 0 1 0 3 0  2 15 
Escitalopram (2)  0 0 2 0 0 0 0 0 0  0 2 
Fluoxetine (13)  4 4 0 2 0 1 0 2 0  4 9 
Paroxetine (0)  0 0 0 0 0 0 0 0 0  0 0 
Sertraline (22)  7 3 2 2 1 0 2 0 5  3 19 
 
 
Admissions to the NNU 
The overall admission rate was 20.0% (21/105), with few statistically significant 
differences between those exposed and unexposed to psychotropics, whether 
taken together as a group, or analysed by subgroup. Preterm delivery was 
associated with increased risk of admission, and exposure to SSRIs only with 
reduced admission rate (Table 4-6). However, exposure to SSRI monotherapy did 
not reach significance, nor did Methadone. There were statistically insignificant 
trends towards lower admission rates in those exposed to psychotropics in 
general, and SSRIs in particular. 
NNU admission rates in those exposed to SSRIs only, those exposed to other 
antidepressants, and those not exposed to antidepressants, were statistically 
significant different using the Freeman-Halton extension of Fisher’s exact test 
for a 2x3 contingency table (Table 4-7). Subsequent dichotomous analysis using 
Fisher’s exact test revealed that this difference was between those exposed to 
SSRIs and those exposed to other antidepressants. 
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Table 5-5 – Primary diagnoses for patients attending the MLS 
Primary diagnoses % (N) Durrani & Cantwell 
(2009) (%) 
Organic, including symptomatic, mental disorders 0 (0) 0.4 
Mental & behavioural disorders due to psychoactive 
substance use 0 (0) 2.5 
Schizophrenia, schizotypal and delusional disorders 1.9 (2) 4.7 
Schizophrenia 1.0 (1) 1.4 
Schizotypal disorder 0 (0) 0.4 
Persistent delusional disorders 0 (0) 0.4 
Acute and transient psychotic disorders 0 (0) 1.4 
Schizoaffective disorder 0 (0) 1.1 
Unspecified non-organic psychosis 1.0 (1) - 
Mood (affective) disorders 62.9 (66) 33.6 
Manic episode 0 (0) - 
Bipolar affective disorder 1.0 (1) 5.1 
Depressive episode/recurrent depressive disorder 61.9 (65) 26.7 (14.8/11.9) 
Persistent mood [affective] disorders 0 (0) 1.8 
Neurotic, stress-related & somatoform disorders 22.9 (24) 16.2 
Phobic/other anxiety disorders 18.1 (19) 7.6 (1.1/6.5) 
Obsessive-compulsive disorder 3.8 (4) 2.9 
Reaction to severe stress, and adjustment disorders 0 (0) 5.4 
Somatoform disorders 1.0 (1) 0.4 
Behavioural syndromes associated with physiological 
disturbances and physical factors 0 (0) 0.4 
Eating disorders 0 (0) - 
Non-organic insomnia 0 (0) - 
Mental and behavioural disorders associated with the 
puerperium, not elsewhere classified 
0 (0) - 
Disorders of adult personality & behaviour 6.7 (7) 3.6 
Specific personality disorder (unspecified) 0 (0) - 
Emotionally unstable personality disorder 6.7 (7) 3.2 
Intentional production or feigning of symptoms or 
disabilities, either physical or psychological [factitious 
disorder] 
0 (0) - 
Mental retardation 0 (0) 0.4 
Premenstrual tension syndrome 0 (0) - 
Factors influencing health status and contact with 
health services 0 (0) - 
Diagnosis not recorded 5.7 (6) - 
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Table 5-6 - Admission rates to NNU for different exposure types 
 (N) Admitted (%) (N) Not admitted (%) (N) Fisher’s exact test (p) 
Total (105) 20.0 (21) 80.0 (84) - 
Exposure 
Unexposed (26) 23.1 (6) 76.9 (20) - 
Any psychotropic (79) 19.0 (15) 81.0 (64) 0.78 
Any AD (75) 18.7 (14) 81.3 (61) 0.60 
Any SSRI (62) 14.5 (9) 85.5 (53) 0.14 
SSRIs only (57) 12.3 (7) 87.7 (50) 0.049 
SSRI monotherapy (54) 13.0 (7) 87.0 (47) 0.09 
Methadone (2) 50.0 (1) 50.0 (1) 0.36 
Late exposure (62) 17.7 (11) 82.3 (51) 0.62 
First trimester only (14) 21.4 (3) 78.6 (11) 0.72 
Preterm delivery (18) 44.4 (8) 55.6 (10) 0.00709 
Until delivery 
Any psychotropic (59) 18.6 (11) 81.4 (48) 1 
Any AD (57) 17.5 (10) 82.5 (47) 0.75 
Any SSRI (49) 14.3 (7) 85.7 (42) 0.24 
SSRIs only (45) 13.3 (6) 86.7 (39) 0.16 
SSRI monotherapy (44) 13.6 (6) 86.4 (38) 0.25 
 
Table 5-7 – Analysis of antidepressant exposures, and admission to the NNU 
 (N) Admitted (%) (N) Not admitted (%) (N) Fisher’s exact test (p) 
Exposure 
SSRIs only (57) 12.3 (7) 87.7 (50)  
Other ADs (18) 38.9 (7) 61.1 (11) 0.0418 
No ADs (30) 23.3 (7) 76.7 (23)  
Dichotomous analyses 
SSRIs only versus other ADs 0.032 
SSRIs only versus no ADs 0.44 
Other ADs versus no ADs 1 
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Gestation, preterm delivery, birthweight, APGAR score, NNU admission and 
relationship(s) to illness severity, and/or exposure to any antidepressant 
The median gestation of infants born to mothers attending the MLS was 276 days 
(range 223-293), median birthweight 3.32 (range 1.4-5.2), and median APGAR 
scores at one minute and five minutes were 9 (range 1-10), and 9 (range 6-10), 
respectively. As noted above, 18 of the babies were preterm (including all six 
twins), and 21 neonates required admission to NNU. 
Since HADS-D and HADS-A were significantly correlated (r=0.704; p<0.001), two 
separate multivariate general linear model analyses were employed to explore 
the effects of HADS-D and HADS-A scores (predictor variables) on gestational 
ages, birthweights, and APGAR scores (outcome variables). We then repeated 
the analysis, using antidepressant use as an additional covariate in both models.  
On the multivariate analysis, without any covariates, there was a significant 
effect of HADS-D (F(3,87)=2.8, p=0.04, ηp=0.09).  On further univariate 
exploration, HADS-D had an inverse relationship with gestational age (p=0.025) 
and birthweight (p=0.006), but not APGAR score (p=0.740), i.e. greater severity 
of self-rated depressive symptoms predicted lower birthweights and shorter 
gestations (Table 5-8).  
Adding “any antidepressant” use as a covariate in the above model did not 
materially affect the results. On multivariate analysis, there was a significant 
effect of HADS-D (p=0.05), but not antidepressant use (p>0.05). On further 
univariate exploration, again HADS-D predicted gestational age (p=0.027) and 
birthweight (p=0.007), but not APGAR score (p=0.745) (Table 5-9). 
On multivariate analysis, there was no significant effect of HADS-A on the 
outcome variables (F(3,87)=0.841, p=0.475, ηp=0.03). 
Given that higher HADS-D score predicted shorter gestational age, we conducted 
an exploratory analysis to see if HADS-D predicted preterm delivery – it did not 
(F(1,93) =1.6; B=0.009; t=1.26; p=0.209). 
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Similarly, we conducted an exploratory analysis to see if HADS-D score predicted 
admission to the NNU. There was no significant relationship between HADS-D and 
admission (F(1,93) <0.001; B<0.001; t=0.008; p=0.994). 
 
Table 5-8 – Multivariate analysis of relationships between HADS-D and select 
outcomes 
Outcome 
variable Parameter B Standard error t Significance (p) 
Partial Eta 
Squared 
Gestation HADS-D -0.557 0.244 -2.286 0.025 0.055 
Birthweight HADS-D -0.037 0.013 -2.817 0.006 0.082 
APGAR score HADS-D 0.011 0.034 0.333 0.740 0.001 
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Table 5-9 - Multivariate analysis of relationships between HADS-D and select 
outcomes, with “any antidepressant” as a covariate 
Outcome 
variable Parameter B Standard error t Significance (p) 
Partial Eta 
Squared 
Gestation Any AD -0.902 3.054 -0.295 0.768 0.001 
 HADS-D -0.552 0.246 -2.248 0.027 0.054 
Birthweight Any AD -0.081 0.163 -0.496 0.621 0.003 
 HADS-D -0.036 0.013 -2.763 0.007 0.080 
APGAR score Any AD 0.022 0.430 0.051 0.959 0.000 
 HADS-D 0.011 0.035 0.327 0.745 0.001 
AD = antidepressant 
 
Results summary 
In pregnant women attending the MLS, 
(1) ~1 in 5 babies required admission to the NNU. 
(2) Exposure to antenatal psychotropics and antidepressants was associated 
with a reduced risk of neonatal admission, but this was not statistically 
significant, except for exposure to SSRIs only (but not SSRI monotherapy). 
(3) Exposure to SSRIs only was associated with a reduced rate of admission, in 
comparison with exposure to other antidepressants, or non-exposure. 
Otherwise psychotropics were not associated with preterm delivery, 
gestation at birth, birthweight, or APGAR scores, although increasing 
severity of depressive symptoms was associated with shorter gestations and 
lower birthweights, and preterm delivery predicted admission to the NNU. 
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Discussion 
Data integrity 
As established in Chapter 3, the MLS records were a reliable record of patients 
seen, while the data collection forms, when completed, were an adequately 
accurate source of data on medication type and timing. Where there were gaps, 
we assumed that no drugs had been taken. Where dates were missing, we used 
EDD to estimate DOB, and gestation seen to estimate date seen. 
BadgerNet proved to be an acceptable repository of relevant details for babies 
admitted to the NNU, although like other databases, not all fields had been 
completed. However, it was a true record of neonatal admissions, and the SBR 
both confirmed and supplemented BadgerNet data, as well as including details 
for infants not admitted to the NNU. Other parameters such as length of stay, 
head circumference, and postpartum haemorrhage were also obtainable. 
Again, when date first seen was compared to the timing of medication changes, 
the majority of prescribing decisions had already been taken before attending 
the MLS. Several patients were seen more than once during pregnancy, and it 
was not possible to correlate the diagnosis and dates of HADS scores with type, 
timing, and dose of medication with any degree of validity. We assumed that 
HADS scores would have a complex relationship with medication, in that some 
patients would remit either spontaneously or with drugs, others would exhibit 
partial recovery, and still others would fail to respond at all (or deteriorate). 
Either partial or non-response could have precipitated a change in medication 
dose or type, and without explanatory documentation, it was not possible to 
establish this retrospectively.  
There were a wide range of values for both the HADS-D and HADS-A, and it was 
encouraging to note that the median HADS-D score was 8, i.e. approaching non-
clinical levels, perhaps indicative of effective therapeutic intervention. 
However, the median HADS-A score was somewhat higher at 12, and although 
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not necessarily consistent with significant neurotic illness, this may reflect the 
general distress levels of expectant mothers attending the MLS. 
Twins were born to three women attending the MLS – each mother was only 
counted once with regards to analysing the relationships between psychotropic 
exposure and neonatal admission, while the details for each twin were included 
for the statistics on gestation, birthweight, and APGAR scores, thereby 
increasing the sample size to 108. 
 
Diagnoses, medication, and outcomes 
In comparison to the PMHS, there were proportionately less women with 
diagnoses of psychotic and bipolar disorders, and more with unipolar depression, 
anxiety, and personality disorder (Table 5-5). This may reflect the different 
resources and remits of the PMHS and the MLS as regional and local services, 
respectively, as the pattern of referrals received by each is similar, with 62% of 
referrals coming from maternity (Durrani & Cantwell, 2009). 
The most common SSRI prescribed was Sertraline, accounting for 40.7% of SSRI 
monotherapy (Table 5-3). Significantly, it was the only psychotropic commenced 
in the third trimester, in five women who all had a primary diagnosis of 
depression. Sertraline is the antidepressant of choice in the MLS, due to its 
generally favourable safety profile in pregnancy and breastfeeding in comparison 
with other antidepressants, in addition to its efficacy and tolerability (Cipriani 
et al., 2009; Taylor, Paton & Kapur, 2015) 
The higher NNU admission rates for infants born to mothers attending the MLS in 
comparison to the general AMU population were again noted, 20.0% (cf. 11.3% of 
those not seen in Phase 1 (Table 5-6). The absolute numbers were low, and 
therefore care over interpretation is required. However, despite 14 of the 21 
babies admitted having been exposed to antenatal psychotropics (all 
antidepressants, and 64.3% SSRIs), this was not a statistically significant 
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difference. In the AMU sample it had appeared that exposure to medication, 
including SSRIs, conferred greater risk of neonatal admission, but the opposite 
trend emerged in this MLS cohort – exposure to SSRIs only was associated with a 
statistically significant lower rate of admission than exposure to other 
psychotropics and non-exposure combined. However, the observation that 
significance disappeared when SSRI monotherapy was analysed raises some 
uncertainties over this interpretation. It should be noted that the absolute 
numbers were small. 
However, overall it appeared that the increased risk of neonatal admission for 
infants of mothers attending the MLS is a true association. The data presented in 
Tables 5-6, 5-7, and 5-8 are consistent with the hypothesis and existing 
observations that psychiatric illnesses are associated with adverse outcomes, 
and that appropriate pharmacological interventions may moderate (or at the 
very least not exacerbate) some of these risks (Wisner et al., 2009; Engelstad et 
al., 2014). Although Malm et al. (2015) did find that antenatal exposure to SSRIs 
was independently associated with a risk of neonatal admission over and above 
the risk attributable to illness, they acknowledged that they had been unable to 
control for illness severity. Moreover, they analysed affective and neurotic 
disorders together, and did not take account of timing or duration of exposure to 
SSRIs. 
It is noteworthy that exposure to SSRIs only was associated with reduced risk of 
admission, and exposure to other antidepressants was associated with an 
increased risk of admission, while neither was linked with other outcomes. 
Rather, severity of depression (but not anxiety) as measured by HADS analysed 
as a continuous variable, was linked with shorter gestations and lower 
birthweights, but not preterm delivery, reduced APGAR scores, or admission. (It 
should be noted that, as illustrated by HADS-D’s association with shorter 
gestations but not increased preterm birth, not all statistically significant 
findings are necessarily of clinical concern.) 
These findings are consistent with the hypothesis that it is severity of illness (for 
which prescribing is a surrogate marker) more than antidepressants that is 
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associated with risk. That exposure to non-SSRIs (mainly SNRIs, Trazodone, and 
Mirtazapine) was associated with an increased risk of admission raises the 
possibilities that these antidepressants cause more adverse effects, or that their 
use indicates either increased depressive severity and/or treatment resistance 
(to SSRIs), or medication (and therefore illness) that predates the current 
pregnancy, thus indicating chronicity. However, further work on a larger sample 
including infants admitted to the NNU is indicated, as both the reasons for 
admission and their associated risk factors remain covert. While it appeared that 
exposure to both unmedicated illness and non-SSRI antidepressants were 
associated with neonatal admission, HADS-D did not predict admission, 
suggesting that other factors may be involved. A larger sample would help to 
explore the consequences of different exposures in more detail, teasing out any 
differences due to severity, duration, and timing of individual disorders and 
drugs. The current consensus is that tricyclic antidepressants, the SNRIs 
Venlafaxine and Duloxetine, the NaSSA Mirtazapine, and Trazodone are broadly 
comparable to SSRIS with regards to perinatal sequelae, although they have 
been studied less than SSRIs, and the few studies that do exist are subject to the 
same caveats and cautions regarding confounding and methodological 
weaknesses (Simoncelli, Martin & Bérard, 2010, Udechuku et al., 2010; 
Grigoriadis et al., 2013; Andrade, 2014; Osborne et al., 2014; Bellantuono et al., 
2015). 
The leitmotif of confounding is woven throughout studies and conclusions 
pertaining to the consequences of antenatal psychiatric disorders and their 
pharmacological treatments. Even where authors claim that known confounding 
factors have been controlled for, there remains interpretative uncertainty. For 
example, while Englestad et al. (2014) list one of their study’s strengths as 
women with depression having “similar disease severity” whether on SSRIs or 
not, they did acknowledge that this could represent symptom reduction due to 
medication in those taking SSRIs, i.e. the group exposed to SSRIs may have had 
more severe depressive illness, which had responded sufficiently to 
antidepressants, thus appearing comparable to the unmedicated subjects. This 
remains a significant challenge to researchers in this area, as randomised-
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controlled studies to ensure parity of illness severity in medication-exposed and 
unexposed groups would be unethical (Barbui & Ostuzzi, 2014). 
It is a reasonable assumption that there are likely to be systematic differences 
between depressed women taking medication, and those not. Current clinical 
practice tends towards using antidepressants when depression is of moderate 
severity or worse, and recommending non-pharmacological interventions in 
milder cases (NICE CG90, 2009). This means that even where rating scales yield 
similar scores in antenatally depressed women exposed and not exposed to 
antidepressants, this is unlikely to indicate that they have had exactly the same 
experience of depressive illness and is consequences throughout pregnancy. 
One way of seeking to address this is via propensity score matching, where one 
adjusts for biased distribution of known covariates between observational 
cohorts by matching subgroups that do not differ significantly with regards to 
these factors (Drake & Fisher, 1995). A seminal study in this regard is Oberlander 
et al. (2008). They interrogated the British Columbia Linked Health Database, 
and identified 119,547 live births between 1 January 1998 and 26 March 2001, 
matched with maternal prescriptions for SSRIs from 1 April 1997 to 31 March 
2002. They defined exposure during pregnancy using the date the drug was 
dispensed plus the number of days for which tablets were supplied to establish 
any overlap with pregnancy, which was estimated from infant birth date and 
length of gestation. The trimesters were taken as from conception until day 92, 
day 93 until day 185, and day 186 until delivery. As per Chambers et al. (1996), 
who first highlighted the potential risks of exposure to SSRIs later in pregnancy 
(defined by continuing into the third trimester/beyond 24 weeks of gestation), 
Oberlander et al. compared neonatal outcomes in those exposed early in 
pregnancy (discontinuing before day 185) and those exposed into the third 
trimester. (One interesting observation is that there is no agreed definition of 
the trimesters of pregnancy, hence we used Oberlander et al’s specification 
throughout – see Appendix 5.) 1.3% (1,575/119,547) were exposed early, and 
1.6% (1925/119,547) late. 
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They found that late exposure was associated with lower birthweights, shorter 
gestations, and increased rates of respiratory distress, but these associations did 
not remain significant following propensity score matching, when they compared 
a subgroup of 429 infants in each exposure group, matched for diagnoses of 
depression, visits to a psychiatrist, and duration of exposure to an SSRI during 
pregnancy (all considered to be proxy markers for depression severity). 
Following this, the only statistically significant findings were that duration of 
exposure to an SSRI during pregnancy was linked with lower birthweights, 
shorter gestations, and increased rates of respiratory distress. SSRI dose was not 
associated with adverse neonatal outcomes, although Roca et al. (2011) 
subsequently reported (after accounting for, but not necessarily controlling for 
maternal illness severity) that higher doses of SSRIs are associated with 
increased rates of preterm birth. 
It appears that antenatal SSRI exposure may contribute to, confound, or curtail 
adverse outcomes, and in the absence of randomised controlled studies to 
establish causality, there remains a need for high quality prospective research 
that takes account of the plethora of parameters that can influence inferences. 
 
Key points 
• ~1 in 10 babies required neonatal admission, and this rate doubled to ~1 in 5 
in those exposed to antenatal maternal depression significant enough to 
warrant referral for specialist care, and/or medication. 
• Antenatal exposure to SSRIs may reduce the risk of some adverse perinatal 
consequences, and increase the risk of others. 
• However, antenatal exposure to SSRIs may also serve as a proxy measure of 
maternal illness severity, which is independently associated with sequelae. 
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Chapter 6 – Methodological issues in determining the 
characteristics and consequences of antenatal exposure to 
SSRIs 
 
Throughout our overview of the literature in Chapter 1, outlining the challenges 
in diagnosing and treating depression, especially perinatally, and the difficulties 
in disentangling the sequelae of antenatal depression from antidepressants; our 
systematic review of publications on the characteristics of antenatal exposure to 
SSRIs in the UK in Chapter 2; our exploration of prescribing patterns and data 
integrity within different perinatal settings using clinical datasets in Chapters 3 
and 4; and our subsequent analyses of select clinical outcomes of fetal exposure 
to depression and antidepressants in Chapter 5; we have highlighted and 
discussed in context diverse methodological issues in this area of research. A 
comprehensive account is beyond the scope of this thesis, as demonstrated by 
Grzeskowiak (2012) in the pursuit of his PhD on “Feasibility of Using Routinely 
Collected Health Data to Examine Long-Term Effects of Medication Use During 
Pregnancy”. Therefore, the focus of this chapter is to summarise and discuss key 
matters relating to mining the UK datasets to determine the characteristics and 
consequences of antenatal exposure to antidepressants in general, and SSRIs in 
particular, in the UK. 
Prospective parents and perinatal practitioners alike desire accurate, reliable 
and up-to-date evidence on how to prevent and treat perinatal depression 
effectively – and safely. Management options and recommendations prefaced 
and enveloped by qualifications such as “In general terms …”, or “As far as we 
know …” are less than reassuring to patients and fall short of professional 
aspirations (Mulder et al., 2012). Clinical practice based on research conclusions 
derived from reviewing individual patients’ records has been at the heart of 
medical research for centuries, and has a long and distinguished profile (Balas et 
al., 2015). This approach is limited, however, by the inadequate statistical 
power of insufficiently large samples to reliably identify small increases in risks 
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of relatively common adverse outcomes, and/or significant sequelae associated 
with rare exposures. The rise of evidence-based medical practice and use of 
epidemiological databases incorporating and linking individual electronic health 
records and other registers over the past few decades has made it possible to 
access millions of records at a time, and has led to the accumulation of vast 
amounts of so-called “big data”. “Big data” merits a big definition, which can be 
simplified as six “Vs”; variety (different datasets with different sources), volume 
(numerous measurements), velocity (contemporaneous or frequent updates), 
value (clinical relevance), variability (longitudinal trends) and veracity (data 
quality) (Andreu-Perez et al., 2015; Baro et al., 2015; Ehrenstein et al., 2017). 
“Big data” can be particularly valuable when exploring rare exposures and 
outcomes, and phenomena not amenable to interventional evaluation. 
However, quantity does not always guarantee quality. In addition to the 
technical, ethical and legal issues surrounding the storage, international sharing 
and use of routinely collected clinical data by researchers (and for purposes) 
unknown to individual patients, suboptimal data integrity due to incomplete, 
invalid, inaccurate, unreliable, out-of-date or inconsistent entries has the 
potential to “amplify systematic error” (Roth et al., 2009; Balas et al., 2015; 
Auffray et al., 2016; Ehrenstein et al., 2017; Lee & Yoon, 2017). As in computer 
science, where “garbage in” equals “garbage out”, inferences based on 
suboptimal datasets are to be avoided. Moreover, statistical does not necessarily 
imply clinical consequence. 
Since 2000 the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) working group has become increasingly influential in 
standardising guideline developers’ grading of the evidence and 
recommendations, and has been used by NICE since 2009, and SIGN since 2013 
[Guyatt et al., 2008a; SIGN, 2013; NICE, 2014]. GRADE has built on the 
established “hierarchy of evidence”, with randomised controlled interventional 
trials (RCTs) representing higher quality data on which to base policy and 
decisions, due to their explicit designs to address and minimise the 
methodological limitations of observational studies, such as those employing 
cohort and case-control designs [Guyatt et al., 2008b]. While observational 
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studies can identify associations between exposures and outcomes, they do not 
prove causality, with chance, bias, confounding and reverse causality mimicking 
true causal relationships (Skapinakis & Lewis, 2001; Rutter, 2007). The use of 
“big data” via epidemiological databases has served to magnify the potential 
both to identify and be misled by small non-causal associations between 
exposures and outcomes, and remains an important (if not convenient and 
necessary) means to answer questions that are difficult to address via 
interventional trials, whether technically, ethically or legally (Ehrenstein et al., 
2017). Assessing the safety, effectiveness and tolerability of antidepressants 
during pregnancy via RCTs is one good example, as many (but not all, e.g. 
Coverdale, McCullough & Chervenak, 2008) hold this to be unethical, mainly due 
to the potential unknown adverse effects on the fetus, and likely impractical 
due to the understandable attitudes and anxieties of mothers-to-be (Healy, 
Mangin & Mintzes, 2010; Turner et al., 2008; Barbui & Ostuzzi, 2014). (RCTs of 
antenatal pharmacological interventions have been possible in certain 
circumstances, which admittedly differ from assessing antidepressants for 
antenatal depression, due to greater certainty about risk:benefit ratios, e.g. 
Unger et al. [2011].) The common practice of using pregnancy as an exclusion 
criterion in RCTs, and the need for statistical power to identify small influences 
on rare outcomes lead inexorably to the use of “big data” in addressing 
questions on the characteristics and consequences of antenatal exposure to 
antidepressants. 
At present, therefore, combining and using the routinely collected longitudinal 
clinical data from millions of records to explore the associations between 
exposure to antenatal depression and antidepressants and outcomes for women 
and offspring remains the primary means of reaching conclusions on which to 
base clinical decisions, necessitating a clear understanding of the 
methodological issues, and consequent uncertainties and caveats. These have 
been described in the literature, with key references including Colvin et al. 
(2011), Bromley et al. (2012), Grzeskowiak, Gilbert & Morrison (2011), 
Grzeskowiak, Gilbert & Morrison (2012a and b) and Colvin et al. (2013). 
Significant areas of challenge in using “big data” are summarised in Table 6-1. 
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Table 6-1 – Methodological issues in using epidemiological data 
Data integrity 
representativeness; missing data; interpreting ambiguities; prospective and 
retrospective data; bias and confounding; technical, ethical and legal challenges 
Defining pregnancy 
beginning and end; spontaneous and induced abortion; live births, stillbirths and 
neonatal deaths 
Defining exposure to antidepressants 
prevalence, type, dose, timing and duration; prescribed, paid for, dispensed and 
ingested; comorbidity and co-prescriptions; genetic, epigenetic and maternal-
obstetric factors 
Relating outcomes to exposures 
underlying illness type and severity, versus intervention characteristics 
 
 
Data integrity 
Data integrity may be defined as the validity, accuracy, reliability, timeliness 
and consistency of the data (Balas et al., 2015). Completeness is implied in this 
definition, although worthy of specific mention. Selecting a study sample 
representative of the general population is the first step in reaching conclusions 
regarding antenatal antidepressants, and presents several challenges. Three 
main data sources described in the perinatal literature are the linking and 
mining of national registers (mainly in Nordic countries, e.g. Jimenez-Solem, 
2014), primary care databases (including in the UK; see Chapter 2), or 
information derived from healthcare insurance and/or claims (commonly in the 
USA, e.g. Hanley & Mintzes, 2014). 
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The limitations of the latter datasets are immediately apparent – socioeconomic 
factors influence outcomes, and patients with private health insurance are not 
directly comparable with those reliant on government funding. For example, 
Hanley and Mintzes (2014) reported that 6.5% of pregnant women with private 
health insurance were exposed to an antidepressant between 2006 and 2011, 
while Huybrechts et al. (2013) found that 8.1% of women eligible for Medicaid  
(a joint federal and state programme that helps to fund healthcare for the less 
affluent) between 2000-2007. However, even within the datasets used there was 
significant temporal, regional, diagnostic and demographic variation – older, 
white women were prescribed antenatal antidepressants more frequently, 
different proportions of those diagnosed with depression received prescriptions 
in different states, and exposure rates varied more than twofold geographically 
(from 6.44% in New York to 15.41% in Idaho). Clearly, conclusions based on 
individual datasets are not necessarily generalisable. Moreover, pooling data 
over time, from different subjects, of varying ethnicities and socioeconomic 
backgrounds, residing in diverse locations, even although they are in a particular 
dataset, simply leads to an overall estimate of the average exposure within that 
population during the time period studied. 
The Nordic registers are more inclusive than their US counterparts, thus ensuring 
that all residents are included, and allowing known confounding factors to be 
taken into account in analyses; therefore, conclusions are relevant to the 
population of the country under consideration. However, they are not exempt 
from other limitations discussed below, including lack of data on women’s 
adherence to dispensed medication, nor pregnancies ending in spontaneous or 
induced abortion (Jimenez-Solem et al., 2013). 
The characteristics of the UK primary care databases have been outlined in 
Chapter 2, with Petersen et al. (2016) providing a summary of their strengths 
and limitations (including that THIN contains slightly more patients who live in 
affluent than CPRD, data is not complete for medication quantities and doses, 
mother:infant data can only be linked if the child is registered at the same 
practice as the mother, and the dates of birth for children under 15 are 
restricted to month and year only – see below). Similar to the Nordic registries, 
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and due to the structure of healthcare in the UK, the CPRD and THIN datasets 
are inclusive and broadly representative of the British population, although do 
not include information about patients not registered with a GP or receiving care 
from other sources, e.g. private or specialist settings. This introduces the 
potential for bias, e.g. by systematically excluding socioeconomically deprived 
patients such as the homeless, more affluent patients accessing private care, or 
more unwell patients requiring specialist management. Each of these could 
influence findings and conclusions in different directions, given that diagnoses of 
and prescriptions for antenatal depression are associated with socioeconomic 
factors, and patients managed in perinatal or psychiatric settings are likely to 
suffer from more severe, chronic and/or complicated depressive illnesses 
necessitating interventions not common in the general population (see Chapters 
1 and 8). Moreover, changes in service provision over time may also affect data 
integrity; for example, pregnant women in the UK no longer require contact with 
their GP to have pregnancy confirmed due to the reliability of over-the-counter 
pregnancy tests and, in recent years, have been able to self-refer for antenatal 
care, thus bypassing their GP, potentially throughout pregnancy. As the data is 
collected prospectively the potential biases associated with retrospective recall 
may be minimised (although not absent – some of the “prospective” information 
collected during clinical contacts is based on the patients’ history); however, 
accessing and interpreting relevant data retrospectively is not always 
straightforward (Margulis et al., 2013). 
Missing data is a significant issue, leading to limitations such as relevant subjects 
being overlooked (e.g. if their pregnancies or prescriptions were not identified 
or recorded) or excluded (e.g. due to strict methodological criteria, such as 
omitting those with certain [comorbid] conditions or co-prescriptions), or 
compensatory measures being employed, such as assumptions about length of 
pregnancy, gestational age at birth, and/or timing of prescriptions) (see Table 2-
2). Again, each of these has the potential to bias findings and conclusions. 
The same is true of ambiguities, such as inconsistent birth details between 
maternal and neonatal records, or translating prescription details for dates, 
doses and number of tablets prescribed and/or dispensed into timing and 
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duration of exposure, in correlation with gestation dates and stages (Chapter 4). 
Some of the most basic parameters foundational to exploring associations 
between antenatal exposure to depression and antidepressants and outcomes 
such as simply identifying pregnancies are not necessarily straightforward. While 
many studies do not go into detail about how exactly they identified pregnancy 
women from datasets such as CPRD and THIN, Cea-Soriano et al. (2013) did, 
demonstrating that categorising subjects as pregnant as opposed to non-
pregnant is not an unambiguous digital process. 
 
Defining pregnancy 
Using THIN to assess medicines prescribed during pregnancy Cea-Soriano et al. 
(2013) defined their study population as women of childbearing age (13-49) who 
were registered with a participating practice for at least one year during the 
study period (1996-2010), including either at least 280 days following the 
recording of their last menstrual period (LMP) or before any date of delivery or 
pregnancy loss (including abortion, termination, ectopic pregnancy, and 
stillbirth [incorporating fetal and neonatal death]). In other words, THIN (and 
other databases do not necessarily provide a data field to indicate “pregnant” as 
opposed to “not pregnant”; pregnancy must be inferred. While several outcomes 
do unequivocally indicate a pregnancy (live birth, pregnancy loss or neonatal 
death), very early miscarriages may be missed, and subjects who were not 
registered throughout pregnancy will be excluded – the former is a practical 
artefact of the dataset itself, and the latter a consequence of researchers using 
exclusion criteria to minimise missing data. Moreover, even apparently 
unequivocal data require checking – Cea-Soriano et al. found that 2% of women 
recorded as experiencing pregnancy loss had subsequent entries indicating live 
birth, suggesting threatened rather than completed miscarriages in the earlier 
entries. 
In an attempt to ensure that their conclusions were accurate, Cea-Soriano et al. 
defined pregnancies in women via three groups: (1) a conception group, where 
Page 201 of 365 
those with an LMP recorded were included if a code consistent with end of 
pregnancy was recorded within 320 days (to capture late deliveries); (2) an end 
of pregnancy group, made up of those with a code for loss or delivery; and (3) an 
other pregnancy codes group, comprised of those without LMP or pregnancy 
outcome data, but with other pregnancy-related codes, e.g. pregnancy tests or 
prenatal visits. 
Cea-Soriano et al. noted that using LMP alone as a marker for pregnancy was 
misleading, as this was not infrequently recorded as part of contraceptive care. 
Therefore, they attempted to link all women with LMP recorded to infants born 
within 180-380 days of that LMP, using THIN’s family identification codes. Again, 
this process involved a degree of estimation and inference, as while mother’s 
dates of delivery may have been recorded accurately, neonates’ dates of birth 
were provided to the researchers as month and year of birth only, to protect 
confidentiality. This necessitated assigning the 15th of the month as the putative 
date of birth for all infants, necessitating further interpretation – if there was 
more than a 30 day discrepancy between mother’s date of delivery and their 
infant’s putative date of birth the latter was used; otherwise, the researchers 
employed the date of delivery. A relatively high proportion of pregnancies 
identified as completed had missing linkage data, again leading to date of 
delivery being used. 
Furthermore, as (by definition) subjects in the end of pregnancy group had no 
LMP date, LMP (i.e. beginning of pregnancy) was simply assumed to be 280 days 
before the date of birth (or date of delivery), unless codes indicated pre- or 
post-term births, in which cases 245 days or 285 days were substituted, 
respectively. Ultimately those with possible pregnancy-related codes (including 
LMP) but no infant linkage were excluded, with the assumption that these codes 
did not imply actual pregnancy. 
Thus it can be seen that simply identifying pregnant women from datasets such 
as THIN is not an unambiguous process. Even where LMP is clearly recorded, this 
does not exclude the potential for individual retrospective recall bias regarding 
exact dates, nor inaccuracies in ultrasonography (as LMP may be calculated or 
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corrected using early scans). Cea-Soriano et al. acknowledged that their 
“conservative” approach may have underestimated the pregnancy rate in THIN, 
and sought to evaluate this by repeating their study, identifying 11% more 
“suspected” pregnancies, but ultimately ending up with the same number of 
subjects for whom data of acceptable accuracy was available. Notably, they 
achieved 88.5% linkage between mothers and infants – this still indicates that 
data for more than one in 10 potential participants were missed. 
In broad terms, therefore, even primary care databases such as THIN, validated 
and viewed as being comprised of high quality data and representative of the 
general population, are not 100% definitive with regards to identifying pregnant 
subjects, nor specifying the beginnings, ends or durations of pregnancies. Thus, 
they are neither exempt from uncertainties nor immune to ambiguities, and 
require careful post-hoc interpretation and algorithmic manipulation. Margulis 
et al. (2015) reviewed the main approaches used by researchers in this area, 
categorising them into five main groups, which, while varying in their strengths, 
complexity and utility, are all associated with unavoidable inaccuracies relating 
to actual gestation length, and therefore prone to introducing bias, e.g. by 
systematically overestimating pregnancy length in pre-term births, which may be 
over-represented in those exposed to antenatal antidepressants (Oberlander et 
al., 2008; Ross et al., 2013). 
Even without reference to databases and registers, precisely defining the 
beginning of pregnancy is challenging clinically and practically, including for 
obstetricians, (Chung et al., 2012). Similar to many perinatal researchers, 
Petersen et al. (2016) took LMP as the start of pregnancy in “accordance with 
clinical practice in the UK”. However, basing gestational age on LMP is not 
exact, as although ovulation occurs 14.6 days later, with fertilisation one day 
after that, and implantation after a further seven days, these are average 
epochs, affected by a variety of factors, including the length of each woman’s 
usual menstrual cycle (Geirsson, 1991). In other words, using gestational age 
(based on LMP, or fetal size in reference to standardised ultrasonographic 
findings) adds an extra 15.6 days (on average) to so-called fertilisation (fetal, 
embryonic) age, potentially artificially inflating estimates of rates of very early 
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fetal exposure to antidepressants prescribed in the weeks before conception. 
Moreover, as the gestational ages associated with even normal, uncomplicated, 
term pregnancies can vary by up to 37 days, it appears clear that it is practically 
impossible to be precise when defining the true beginning of pregnancy using 
LMP alone (Jukic et al., 2013). 
Therefore, using “end of pregnancy” outcomes to define not only the occurrence 
but also the length of pregnancy is perhaps the most useful and accurate 
approach as, if date of mother’s date of delivery/infant’s date of birth and 
infant’s gestational age at birth are recorded, then the start and duration of 
pregnancy can be calculated with a degree of certainty. Depending on data 
outcomes used, ectopic pregnancies, spontaneous miscarriages and induced 
abortions, and stillbirths and neonatal deaths can be identified as well as live 
births, thus minimising biases introduced by excluding these phenomena, given 
that they are associated with exposure to antidepressants (excluding non-live 
births has the potential to lead to underestimates of true overall exposure rates) 
(Ban et al., 2012; Kieler et al., 2014). One further issue to be noted rather than 
addressed is that a high proportion (perhaps up to 70%) of fertilised embryos 
may not implant and therefore result in an identifiable pregnancy - if exposure 
to antidepressants periconception is associated with early pregnancy this may go 
undetected (Smart et al., 1982; Wilcox, Baird & Weinberg, 1999; Wang et al., 
2003). Given the significant difficulties in being accurate to the day regarding 
the start of pregnancy, perhaps taking fertilisation age as the start of pregnancy 
when evaluating exposure to antidepressants would be a reasonably pragmatic 
default, i.e. LMP plus 15 days, or gestational age minus 15 days. No studies to 
date have done this, with even the most methodologically rigorous using 
gestational age to define pregnancy, thus defining exposure a full two weeks 
before an embryo even exists, and three weeks before implantation 
Two further variables related to defining pregnancy merit discussion, both 
relevant to confounding factors: serial pregnancies, and multiple pregnancy. It 
would simplify matters greatly for researchers if all mothers had only one 
pregnancy, and each was singleton. However, given that many of the studies 
span several years, it is not infrequently the case that some women may have 
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several pregnancies, precipitating methodological decisions about how to 
accommodate these. Including more than one pregnancy in the same women 
introduces the potential for bias via clustering, as a past history of an adverse 
outcome is associated with a significantly increased risk of repetition (for a 
detailed discussion see Louis et al., 2006). Failing to take account of this 
statistically, including by simply incorporating obstetric history as a covariate, 
may obscure important exposure:outcome relationships. In an attempt to 
minimise bias due to clustering, some studies exclude multiparous women, or 
select only one pregnancy during the study period, either randomly, or the first 
or last. Others include all pregnancies. This makes it difficult to compare 
different studies, as well as limiting the power to identify potential exposures of 
significance. 
Similar issues affect multiple pregnancy – counting this as one exposure without 
controlling for the reduced growth rates and adverse outcomes in comparison to 
singleton pregnancy introduces one type of bias, while counting each infant as a 
separate outcome introduces another (Grzeskwoiak, Gilbert & Morrison 2012a). 
For these reasons, some researchers elect to include only singleton pregnancies 
in primiparous women when exploring the outcomes of antenatal exposure, not 
least because of the potential adverse effects of multiparity on offspring (Lahti 
et al., 2014). 
In summary, therefore, identifying pregnant women and the timing and duration 
of pregnancy from clinical and administrative datasets for the purpose of 
retrospective research is neither routine nor infallible. The best approach 
appears to be to use outcomes which confirm that pregnancy occurred, e.g. 
ectopic, spontaneous miscarriage, termination of pregnancy, live birth or 
stillbirth, and to use the date of delivery/date of birth and gestation at birth to 
fix the beginning of pregnancy, whether gestational age or fertilisation age. 
Depending on what exposures and/or outcomes are being assessed, either 
singleton or multiple pregnancy, in primiparous or multiparous women, included 
once or serially in the study sample should be considered and described. 
	  
Page 205 of 365 
Defining exposure to antidepressants 
In addition to the challenges in ensuring data integrity and defining pregnancy 
from routinely collected data, characterising antenatal exposure to 
antidepressants is similarly complex. In their paper paper on classifying 
exposures Grzeskowiak, Gilbert and Morrison (2012b) highlight the 
inconsistencies in evaluating dose, duration and timing of exposure; variability in 
categorising exposures (including how to process and analyse women who stop 
medication before or in early pregnancy)’ and assumptions surrounding whether 
medicines dispensed perinatally result in actual fetal exposure. The key issues in 
defining exposure are what and when. 
While it is generally possible to define the type(s) of medication prescribed, it is 
common practice to assess broad outcomes (e.g. any cardiac malformation, 
whether clinically insignificant or life-threatening) of exposure to classes of 
medication (e.g. SSRIs) rather than individual drugs. Although this makes sense 
in terms of increasing sample size, and avoiding the need to take account of 
potentially confounding reasons for clinicians choosing one particular drug over 
another, it assumes that all drugs within that class are similar with regards to 
their teratogenicity and effects on longer term neurodevelopment. As discussed 
in Chapter 5, this is not clearly the case for SSRIs. Partly in relation to this, 
defining rates of exposure is confusing – studies vary in reporting incidence, 
point prevalence and/or period prevalence, depending on which methodology 
they employ to address the specific research question(s) they are seeking to 
address. While establishing total exposure rates, i.e. period prevalence, is useful 
from epidemiological, economic and service provisions perspectives, it is less 
helpful for evaluating outcomes, due to the varying effects of different types of 
exposure at different gestations. 
Detailed data on doses is generally absent from the antenatal literature, not 
because they is not available, but presumably because taking account of doses is 
impractical on a number of levels. Firstly, and as outlined in Chapter 4, the 
actual daily dose taken is not necessarily clear from the prescription data itself. 
Secondly, unless confounding factors such as the underlying diagnosis and illness 
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severity, and maternal adherence and pharmacokinetic issues are taken into 
account, relating doses to outcomes may be misleading. However, SSRI doses do 
represent an important area for future study, as there is evidence of dose-
related teratogenic risks with some SSRIs (higher doses of Paroxetine may be 
associated with a higher risk of cardiac malformations), similar to 
anticonvulsants (Vajda et al., 2004; Bérard et al., 2007). 
Clarity about timing and duration of antenatal antidepressants is critical, 
however, due to concerns about adverse consequences at different 
developmental stages, and/or length of exposure. This is dependent on accurate 
information on gestational age and stage, discussed above. Challenges relating 
to defining timing and duration of exposure have been discussed in Chapter 4, 
and include a wide range of factors. The CPRD and THIN datasets specify when 
prescriptions were issued by the provider, but this is not necessarily the date 
when the medication was dispensed (although this is specified by some sources, 
including ISD), collected or commenced.  Some women may collect their next 
supply of drugs in good time to continue without a break, while others may be 
late, for a variety of legitimate or less than ideal reasons. Unless datasets 
specify the intended daily dose, this and therefore duration cannot necessarily 
be inferred from the quantities and strengths of the tablets supplied. 
Adherence to medication is another obvious complication. Even in the general 
population prescriptions for antidepressants do not translate exactly into 
medication taken – in the Netherlands van Geffen et al. (2009) found that more 
than one in four patients issued with a prescription for an antidepressant either 
did not start it at all, or persisted for less than two weeks, with the elderly, 
those with non-specific symptoms and immigrants two-, three- and five-fold 
more likely to decline treatment, respectively. In Scotland, Beardon et al. 
(1993) reported that around one in four women aged 16-39 did not redeem 
prescriptions, concluding that “observational studies of drug exposure can be 
more accurately estimated from dispensing rather than prescribing data”.  This 
was reinforced by Mabotuwana et al. (2011), who found that while prescribing 
data indicated that 39% of patients demonstrated poor adherence to 
antidepressants, dispensing data revealed poor adherence to be 68%. With 
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specific regards to pregnancy, van Gelder et al. (2012) compared retrospective 
questionnaires on perinatal medication with accurate dispensing records, 
demonstrating a sensitivity of 39% for detecting antidepressants (and a wide 
range of sensitivities for identifying other antenatal drugs), meaning that 
putative recall bias dramatically reduces the utility and validity of retrospective 
data collection for establishing exposure. Skurtveit et al. (2014) reported 
comparable findings, with sensitivity being higher at 66.9% for antidepressants, 
but lower at 27.8% for benzodiazepines prescribed for sleep. Källén, Nilsson and 
Olausson (2011) found that relying on prescription data in early pregnancy can 
lead to overestimates of exposure in comparison with clinical interviews, 
presumably due to erroneously assumed adherence. However, recall bias would 
lead to the opposite error, as may a reluctance to take (or to admit to taking) 
antidepressants during pregnancy – Lupattelli et al. (2015) found that around 
50% of pregnant women adhered poorly to prescribed antidepressants, especially 
those who had more severe depressive symptoms, those who perceived risk to be 
high and/or outweigh benefits, and those who smoked. However, those 
prescribed more than one psychotropic during pregnancy adhered better, 
consistent with the observation that those who perceive benefits to outweigh 
risks demonstrate higher concordance. 
The above issues are particular problems with regards to ascertaining early 
exposure. Knowing exactly when a woman who was prescribed an antidepressant 
before pregnancy started it, took it, and/or discontinued it would, in 
conjunction with actual or retrospectively calculated LMP and/or ultrasound-
estimated gestational age, allow this. However, short of asking each individual 
contemporaneously (or observing, or supervising), there appears to be no 
practical way to improve upon the methods currently employed by the published 
studies, other than to acknowledge their limitations. This obviously affects 
estimates of exposure, with regards to incidence and prevalence, timing and 
duration, and thus accurate assessment of outcomes. 
Even if exposures could be ascertained accurately, this would not obviate the 
issues in categorising exposure types to study outcomes. While stopping 
antidepressants prescribed periconception in the first trimester, or persisting 
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throughout pregnancy are the most common patterns, a substantial proportion 
of patients stop and start at various different gestations, sometimes more than 
once, in addition to being exposed to more than one type of psychotropic 
concurrently or consecutively, as well as non-psychotropics and other 
psychoactive substances, whether legal (including alcohol and tobacco), novel or 
illicit (Riley et al., 2005; Colvin et al., 2011; Huybrechts et al., 2017 – see also 
Chapter 3 and 4). Lumping these disparate exposures together to increase 
statistical power lacks research and ultimately clinical validity, by diluting and 
obscuring potentially significant causal associations between specific exposures 
and sequelae (Grzeskowiak, Gilbert & Morrison, 2011). 
In summary, therefore, accurate classification of exposures is dependent on 
defining the type (which drug, at what dose) and timing (at what gestation(s), 
and for how long), for which data may not be available at the level of accuracy 
or indeed detail required, given that there is no way of confirming 
retrospectively from datasets exactly what dose of medication was taken  and 
when (or if at all). The myriad of confounders discussed in Chapter 1 are 
considered in relation to outcomes (below), with Table 6-2 summarising the 
main factors. At least part of the complexity in this area is that outcomes may 
also act as subsequent exposures and/or confounding factors. 
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Table 6-2 – Select outcomes and exposures/confounders relevant to perinatal 
depression and antidepressants 
 Outcomes* Exposures/confounders 
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l Reduced fecundity 
Ectopic pregnancy 
Miscarriage 
Termination of pregnancy 
Neuroendocrine dysregulation 
Epigenetic phenomena 
Obstetric complications, e.g. reduced fetal, 
growth, eclampsia, operative deliveries 
Stillbirth 
Pre-term delivery 
Low birth weight 
Congenital malformations 
Neonatal adaptation syndrome 
Specific neonatal problems & conditions, 
e.g. respiratory distress 
Feeding difficulties 
Failure to thrive 
Neuroendocrine dysregulation & 
physiological abnormalities 
Attachment difficulties 
Temperament & personality 
Neurodevelopmental delay & deficits 
Socio-emotional, psychomotor, cognitive, 
academic, intellectual & behavioural 
problems 
General health complications 
Childhood/adolescent/adulthood 
psychopathology & mental health problems, 
including depression 
Maternal (& paternal) 
• Genotype 
• Socioeconomic status 
• Age 
• Medical/obstetric history 
• Current health status 
• Depression 
• Smoking, alcohol & substance use 
 
Maternal stress 
 
Depression 
• Severity 
• Chronicity 
• Response to medication 
• Comorbidity 
 
Medication 
• Type 
• Dose 
• Timing 
• Duration 
• Adherence 
• Co-prescriptions 
• Placental transfer of drugs 
 
Fetal genotype 
Early neonatal environment 
* outcomes may also act as subsequent exposures and confounders 	  
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Relating outcomes to exposures 
Compounding the complexity of ensuring data integrity, identifying a 
representative sample population, defining the boundaries of pregnancy and 
categorising exposures are the challenges of relating outcomes to exposures. 
The main issues are specifying the outcomes to be assessed, while minimising 
and accounting for bias and confounding. 
Bias is systematic error that that leads to an incorrect estimate of effect or 
association, while a confounding variable is one that distorts associations 
between exposures and outcomes. Known confounders may be controlled for, 
but unknown confounding factors may lead to bias. Interventional trials 
frequently employ randomisation and blinding to minimise bias and confounding, 
but the observational approaches used to evaluate perinatal exposures and 
outcomes are unable to utilise these. Due to the overlap between the outcomes 
of exposure to antenatal depression and antidepressants, and many of these 
sequelae further confounding associations (e.g. low birthweight and preterm 
delivery, both of which are independently associated with numerous adverse 
outcomes also linked with both antenatal depression and antidepressants), it has 
proven difficult to discriminate between consequences of the underlying 
disorder and its pharmacological treatment. 
It should be noted that neither of these (illness and treatment) is a simple 
digital phenomenon. Just as antidepressant exposure can vary in type, dose, 
timing and duration, depression may fluctuate in severity, chronicity and 
response to treatment. For example (and using a BDI-II cut-off for moderate 
depression as 20), a pregnant woman scoring 20 in the second trimester may 
represent an individual experiencing transient emotional distress, a new onset or 
recurrence of a depressive episode, or an improvement from a score of, say, 40 
two weeks earlier. Equally, a BDI-II score of 20 could represent an unmedicated 
patient who is deteriorating, a patient recently prescribed an SSRI which is 
proving ineffective, or a patient who has improved significantly on a tricyclic 
which was prescribed before pregnancy for a pre-existing and chronic depressive 
illness. As noted in Chapter 5, there are likely to be systematic differences 
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between depressed women taking medication, and those not. Few studies 
investigating antenatal antidepressants have taken account of characteristics of 
the underlying illness (or comorbidity or co-prescriptions for non-psychotropics), 
and none have given comprehensive attention to the all the known factors of 
relevance – this is due in large part to this level of dynamic detail being 
unavailable from the datasets. As per our observations in Chapters 3 and 4, the 
information in the CPRD and THIN was not collected with the aims of the 
researchers in mind (Grzeskowiak, Gilbert & Morrison, 2011).  
In their review and critical appraisal of methodological issues in studying 
consequences of antenatal exposure to SSRIs Grzeskowiak, Gilbert and Morrison 
(2011) noted the above issues, in addition to teasing out specific effects of 
individual SSRIs on discrete outcomes, e.g. Paroxetine and congenital 
malformations. However, on closer inspection even these two apparently clearly 
defined phenomena are heterogeneous groups: Paroxetine exposure needs to be 
defined more precisely in terms of dose, timing and duration, as well as the 
underlying condition for which it was prescribed (presumably, but not 
necessarily depression) and all its characteristics; and “cardiac malformations” 
may include everything from clinically insignificant and self-limiting septal 
defects to major structural pathology associated with stillbirths and/or neonatal 
deaths. Moreover, as those prescribed SSRIs may (for a variety of reasons) be 
monitored more closely during pregnancy (e.g. via detailed ultrasonography), 
and exposed neonates may be admitted more frequently to hospital, it is 
possible that increased rates are more apparent than real, and attributable to 
detection bias. Furthermore, as definitions of congenital malformations vary 
between studies, conclusions and even rates of abnormalities are not necessarily 
comparable. Unmedicated mothers with comparable depression were not used 
as a reference group for comparison, thus meaning that any consequences of 
exposure to antenatal depression may have been misattributed to Paroxetine. 
Similar issues of heterogeneity and detection bias, in addition to confounding, 
apply to exploring associations between antenatal exposure to SSRIs and other 
sequalae, including miscarriage, neonatal outcomes and longer term 
neurodevelopment. Three additional factors that compromise conclusions are 
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the risks of chance findings due to multiple testing and subgroup analyses 
common in the studies, inadequate sample sizes leading to “type II’ errors (with 
attempts to increase sample size leading to heterogeneous exposures), and 
insufficient discrimination between statistically and clinically significant 
findings. Indeed, as Grzeskowiak, Gilbert and Morrison (2011) observe, a 
preferable approach to manage the challenges would be via a prospective cohort 
study, although the costs would be prohibitive, and the losses to follow-up over 
the decades required to address questions regarding longer term outcomes 
would be difficult to minimise. 
 
Summary and conclusions 
Methodological challenges in evaluating the consequences of antenatal exposure 
to SSRIs via retrospective mining of British primary care databases are far from 
insignificant. Some can be managed via careful, detailed and nuanced 
approaches, e.g. defining pregnancy, and classifying broad categories of 
exposure. Actual ingestion of prescribed/dispensed medication cannot be 
confirmed, nor the degree to which drugs were metabolised by individuals, nor 
crossed the placenta to affect fetuses, whose genotypes remain unspecified. 
Many known and all unknown confounding variables cannot be adequately 
controlled for, including factors relating to underlying depression, exposure to 
which is associated with outcomes which overlap with those linked to SSRIs. 
Equally, psychiatric and other comorbidities cannot be accounted for, nor can 
co-prescriptions or tobacco, alcohol or other psychoactive substance use. 
Tensions remain between employing sample sizes large enough to provide 
adequate statistical power to identify clinically significant associations, 
categorising different exposures into meaningful and specific subgroups, and 
caution over chance findings attributable to multiple testing of too many 
subgroups. While researchers have sought to refine methodologies that address 
these issues as far as possible, and existing data provides broad reassurance, 
there remains significant uncertainty about the consequences of antenatal 
exposure to SSRIs. 
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Chapter 7 - Consequences of antenatal exposure to SSRIs: 
Structural neuroimaging 
 
Depression during pregnancy is common, and may be under-recognised and 
undertreated (Geier et al., 2014). Antenatal exposure to untreated depression is 
associated with potentially significant adverse outcomes for both mothers and 
offspring, while antenatal pharmacological treatment may ameliorate some of 
these risks at the expense of increasing others, including long term 
neurodevelopmental consequences, and depression in adulthood (Suri et al., 
2014). Various mechanisms have been postulated as explaining the link between 
maternal antenatal and postnatal depression and sequelae for offspring, 
including neuroendocrine dysregulation, immunological influences, epigenetic 
phenomena, and environmental factors (Field, Diego & Hernandez-Reif, 2006; 
Christian, 2012; Waters et al., 2014). 
One additional mechanism that may also explain the overlapping consequences 
of exposure to both antenatal depression and antidepressants is perturbation of 
serotonin-dependent neurodevelopmental processes via SERT-mediated effects. 
The structural and functional effects of SERT gene polymorphisms are associated 
with increased risk of trait neuroticism and depression (Canli & Lesch, 2007; 
Willner, Scheel-Krüger & Belzung, 2013). Significantly, the murine phenotype 
attributable to congenitally reduced SERT expression and activity associated 
with the “short” SERT allele may be mimicked by early exposure to SSRIs 
(Murphy et al., 2008). This was reported by Ansorge et al. (2004), who 
demonstrated that mice exposed to the SSRI Fluoxetine during developmental 
phases approximating to the third trimester in utero and early postnatal life in 
humans evidenced abnormal emotional behaviours as adults, thought to be 
analogous to anxiety- and depression-like states in humans. As the 
neurodevelopmental consequences of “short” SERT gene alleles are associated 
with anatomical and physiological abnormalities in limbic structures, with 
smaller hippocampal, amygdalar and cingulate cortical volumes, altered 
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functional connectivity between the amygdalae and cingulate cortices, and a 
dysregulated control loop for fear responses, Ansorge et al’s findings suggest 
that the apparent consequences of genetically-mediated attenuated SERT 
function in early life (i.e. trait neuroticism, and the increased risk of adult 
depressive illness) may also be induced by drugs with serotonergic activity 
(Hariri & Weinberger, 2003; Pezawas et al., 2005; Frodl et al., 2008a; Frodl et 
al., 2008b; Kobiella et al., 2011; Little et al., 2014). Of clinical concern is that 
fetal exposure to antidepressants intended to ameliorate antenatal depression 
and its consequences for mothers and babies may actually increase the risk of 
offspring developing depression later in life, via trait neuroticism and associated 
sequelae, by disrupting serotonergically-mediated neurodevelopmental process. 
In other words, does human exposure to antenatal SSRIs predispose to longer-
term risks of developing depression via abnormal limbic neurodevelopment? 
It was in this context that we noted with interest the work of colleagues in the 
Sackler Institute based at Columbia University in New York, USA. They had been 
performing scans on babies born to mothers misusing substances during 
pregnancy, to identify structural neurodevelopmental consequences of exposure 
to opiates in utero. In keeping with our concerns regarding fetal exposure to 
SSRIs they attempted to extend their investigations to depressed mothers to 
investigate early neurodevelopmental effects of antidepressants, but despite 
having a dedicated team and resources, and offering incentives to potential 
participants, they had encountered difficulties in recruiting subjects. The 
reasons for this were unclear. 
As the Glasgow Sackler Institute has a close working relationship with the PMHS, 
which provides care for around 100 women each year taking antidepressants 
during pregnancy, we agreed to try and recruit patients for a similar study in 
Glasgow. Consistent with clinical experience, mums-to-be with mental health 
problems have been reported to overestimate the teratogenicity of prescribed 
medication, with this phenomenon being even more marked in those suffering 
antenatal depression, even to the extent of increasing the likelihood of 
termination of pregnancy (Koren et al., 1989; Walfisch et al., 2011). As women 
taking antenatal antidepressants may feel anxious (and possibly even guilty) 
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about the potential consequences for their babies, we predicted that some at 
least would therefore be motivated to contribute to a study offering neonatal 
neuroimaging to investigate and identify potential sequelae. 
The PMHS appeared to be a viable source of scanning subjects. In 2008 the PMHS 
was located within the Southern General Hospital (SGH) in Glasgow, a large 
teaching hospital with a sizeable maternity service overseeing approximately 
3,500 deliveries annually, alongside a psychiatric service covering both 
inpatients and outpatients. Additionally, the Glasgow Sackler Institute was 
colocated with the Institute of Neurological Sciences (INS), a European centre of 
excellence for neurological clinical care and academic research, with access to 
neuroradiological expertise and an MRI scanner, with research scanning slots 
available and funded. 
As the latest MRI scanning technology (including DTI and MRS) affords an 
opportunity to measure the structural and biochemical consequences of 
perturbation of serotonergic function early in life, we aimed to define the 
effects of fetal exposure to SSRIs on brain anatomy and metabolite 
concentrations by comparing scans in infants born to mothers in three distinct 
categories; (1) healthy controls; (2) women with antenatal depression not 
exposed to antidepressants; and (3) women with antenatal depression who 
received SSRIs during pregnancy. 
We reasoned that the SSRI-exposed phenotype demonstrated in mice by Ansorge 
et al. (2004) might be associated with biomarkers in the form of structural 
changes similar to those seen in humans with “short” SERT alleles. However, 
although limbic structures (hippocampus, amygdala and cingulate gyrus) are 
implicated in affective regulation and have a rich serotonergic innervation, and 
it is feasible that antenatal exposure to SSRIs may interfere with the 
development of this neural circuitry, there are numerous challenges in imaging 
these nuclei in the rapidly developing infant brain, including difficulties in 
keeping subjects sufficiently still, as well as properties of the brain tissue itself 
(Choe et al., 2012; Sled & Nossin-Manor, 2013; Guo et al., 2014; Holland et al., 
2014). As Frodl et al. (2008a) reported an association between “short” SERT 
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alleles (including the “LG” variant which has comparably reduced activity) and 
reduced grey matter volume in all regions studied, and the cerebellum is the 
fastest growing region of the infantile brain, we therefore aimed to assess 
differences in total brain and cerebellar volumes, in addition to amygdalar and 
hippocampal volumes, between the three study groups (Holland et al., 2014). 
 
Key hypotheses 
1. Based on animal models of perinatal SSRI exposure, we hypothesised that 
structural MRI would reveal reduced total brain volume, as well as reduced 
cerebellar, amygdalar and hippocampal volumes, in infants exposed to antenatal 
SSRIs. 
2. Furthermore, we anticipated that DTI measures would demonstrate 
differences in the white matter of SSRI-exposed infants. 
3. Similarly, we predicted that MRS would show significant reductions in N-acetyl 
aspartate (NAA) concentrations in the cerebellums of SSRI-exposed infants. 
 
 
Methods 
 
Subjects 
We aimed to identify primiparous women aged between 18 and 35, with 
uncomplicated singleton pregnancies, booked at the SGH Maternity Unit 
(SGHMU), and/or receiving antenatal psychiatric care via the PMHS. Eligible 
woman would be allocated to one of three discrete study groups: (1) healthy 
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controls, i.e. mentally and physically well, and not prescribed psychotropic 
medication; (2) women with antenatal depression, in the absence of mental or 
physical comorbidity, and not exposed to psychotropics during pregnancy; and 
(3) women taking SSRI monotherapy for uncomplicated antenatal depression. 
Any potential participants with characteristics not consistent with the above 
allocations would be excluded. As it quickly became clear that these criteria 
were too restrictive to allow adequate numbers to be recruited, it was agreed 
that we would allow multiparous women, and those on any antidepressants, to 
participate if they wished. We set out to recruit 10 women into each study group 
for the purposes of this pilot, to generate data, as well as to demonstrate 
feasibility, with the aim of securing grant funding for a proposed bigger study. 
 
Recruitment strategy 
Obstetricians and midwives at the SGH, and psychiatrists and nurses in the PMHS 
were personally informed about our study, including its purposes, practicalities, 
and inclusion criteria. Literature was provided, and their feedback sought. We 
asked these colleagues to tell all antenatal patients about our study, at their 
discretion. Posters were displayed within waiting areas in the SGHMU and the 
PMHS, and information leaflets made available for distribution by clinical staff in 
both locations (Appendix 6 - the first page of the information leaflet was used as 
the poster, printed as size A3, with the leaflets being A3 folded, double-sided, 
i.e. four sides of A4). Moreover, the SGHMU midwives included an information 
leaflet in each Bounty Pregnancy Information Pack compiled (a compendium of 
information and vouchers issued to every mum-to-be booking for antenatal care 
in the UK). 
The posters directed potential participants to speak to their midwife, visit our 
website, and/or email/‘phone/text us for details, while the leaflets gave further 
information about both the reasons for our study, and the practical 
commitments involved. We asked a number of mothers, midwives and colleagues 
to review the wording, pictures and formatting, to ensure that the posters and 
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leaflets were quick to read, easy to assimilate, interesting, and attractive, while 
being factual, accurate, and not misleading. 250 posters and 10,000 information 
leaflets were printed at a cost of £700, paid for from the Sackler budget - 
enough to cover almost three years of deliveries at SGHMU. 
The website www.helpingmums.org.uk gave the same information as the 
leaflets, with a few extra details. It also contained links to the information 
leaflet in Portable Document Format (PDF), as well as another PDF giving 
specific detailed information on the scans themselves (Appendix 7). Finally, the 
website provided a contact page with a form delivered to us via email. The 
website was not submitted to search engines, nor added to online directories, to 
ensure that only women who had seen a poster or received an information 
leaflet would visit (in an attempt to avoid ineligible women outwith our 
recruitment cohort volunteering). We coded the website in the plain text editor 
Smultron using hypertext markup language (HTML), and a free PHP: Hypertext 
Preprocessor (PHP) script for the contact form, and registered the domain name 
via the www.1and1.co.uk hosting service. High resolution royalty-free images 
were purchased from www.iStockphoto.com. (We commenced this study before 
social media such as Facebook became mainstream, but these would now be a 
preferable option for a customisable, easily updated, accessible online 
presence.) The website allowed additional and updated information and 
resources to be added as required, without the costs associated with print 
media. 
The website also provided “brand identity”, in that creating a recognisable 
name and theme for our project may help potential participants to have 
confidence in contacting us, and establish a study persona on which to build 
future research. While we had used the title “Prescribing in Pregnancy: Helping 
Mothers without Harming Babies” when presenting the findings from our initial 
audit, we agreed to change this to “Helping mums, caring for babies”, both to 
soften and de-formalise the maternal descriptor, and to avoid using the lexeme 
“harming”, a term with connotations that, on reflection, we wished to 
disassociate from our work (Julyan, Cavanagh & Cantwell, 2009). 
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Initial contact 
Eligible women could therefore make contact via their midwife or the PMHS 
staff, or directly by text, ‘phone, email or web. This initial interaction was used 
to (arrange a time to) speak by ‘phone, to explain the purpose and practicalities 
of our study, and then to establish some basic details and eligibility if the 
potential participant wished to proceed. Estimated date of delivery (EDD) by 
ultrasound scan was ascertained, and the likely exposure group assignation 
identified, before arranging to meet as soon as possible after booking. If the 
person was willing to proceed to meet in person they were sent a copy of the 
latest version of the approved Information Sheet (Appendix 8), by email or post 
as preferred, to read in advance of meeting. 
 
Antenatal assessment 
In an attempt to make the process as easy as possible for potential participants 
they were assessed at a venue of their choice, although initially our preferred 
option was to use a bookable multipurpose room next to the MRI scanning suite 
within the Department of Neuroradiology, INS, at the SGH. This allowed privacy, 
as well as a limited tour of our facilities, should the woman wish to proceed. 
(The tour was limited, as access to the MR scanning suite was tightly controlled, 
to avoid adverse incidents, and to preserve peace, discretion and confidentiality 
for patients undergoing scans.) If the individual wished to meet at a different 
venue, we sought to facilitate this, with the exception of their home, to 
maintain appropriate ethical and professional boundaries. 
Transport costs were met out of the Sackler Institute budget, and detailed 
directions, travel information and a map were provided. As parking was limited 
at the SGH, we secured agreement from the SGH Facilities Administrators that if 
a mother and baby arrived but could not park, one of the parking attendants 
would arrange a space. Furthermore, as the SGH operated a strict parking policy 
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of no more than four hours for patients or visitors, we obtained assurances that 
our subjects would not be penalised if they breached. 
After meeting, re-explaining our study in greater detail with reference to the 
Information Sheet, and answering any questions, each participant was asked to 
(re-)read the Information Sheet, and then sign and date two copies of the 
Consent Form, which the researcher then countersigned and dated, retaining 
one copy for our records, and giving the other copy to the subject. 
Thereafter we assigned each participant a unique study number to allow later 
anonymisation, and gathered basic epidemiological and clinical data, before 
completing our battery of assessments (see below). To ensure that all relevant 
details were collected, the research team developed an assessment proforma, 
and a checklist (Appendices 9 and 10). Completed paperwork was stored in a 
locked filing cabinet thereafter, except when in transit, or when data were 
being analysed. 
 
Assessment documentation and rating scales 
Given that there were a number of known potential confounding factors 
(including maternal [and fetal] genotype, socioeconomic status, alcohol, 
smoking and substance misuse, family history of affective disorder, life 
experiences, recent/current stressors, and obstetric/fetal outcomes), we 
attempted to capture as many details as possible via the assessment proforma, 
which provided a structure to record essential demographic, contact and clinical 
data. As type, dose, timing, duration, and adherence to psychotropics may 
significantly affect our findings, one specific challenge was how to assess and 
document accurate information on prescribed and other medication during 
pregnancy, as this had been a source of ambiguity and inaccuracy in the PMHS 
and the MLS data collection sheets and clinical records. Therefore, we 
constructed a table with columns for drug name, dose, frequency, and dates 
commenced and changed/stopped, with sufficient rows to accommodate 
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polypharmacy and/or several changes in medication – this allowed accurate 
timing of fetal exposure to medication, and could be easily updated at each 
encounter (although it did not solve the problems of recall bias, poor memory, 
or inaccurate disclosure). Although we acknowledged that there might be 
significant variation in maternal pharmacokinetics, with rate of metabolism, 
serum levels, placental transfer, and fetal cerebrospinal fluid (CSF) levels, that 
would also exert subtle effects on the parameters under scrutiny, assessing 
these was beyond the scope of this study. 
As timing, duration, and severity of depression could similarly affect findings, 
subjects were assessed by experienced clinicians; one higher trainee in 
psychiatry (JM), and a consultant psychiatrist (EJ). As NHS doctors, both were 
experienced in assessing patients with depressive disorders, and in using ICD-10 
criteria to ensure that reliable diagnoses were made. We made this the focus of 
the interview, as clearly a diagnosis of antenatal unipolar depression, in the 
absence of other psychiatric disorders, was essential in assigning subjects to the 
correct group. A retrospective judgment was made for those on antidepressants, 
as the absence of depressive symptoms at the time of assessment would not 
preclude a diagnosis, but rather indicate remission as a consequence of 
pharmacological intervention. We anticipated challenges in allocating some 
participants, as depressive illness and antidepressant pharmacotherapy may not 
persist throughout pregnancy, nor at the same severity or dose (respectively), as 
well as not being mutually exclusive factors, e.g. women may start off well, 
then become depressed, then be prescribed one or more antidepressants, to 
which they may experience variable responses; or start off on medication, then 
stop, then relapse, then restart. We therefore agree to allocate those with any 
experience of antenatal depressive illness but not exposed to medication to the 
depressed unmedicated group, and those on antidepressants (whether depressed 
during pregnancy or not) to the depressed medicated group, discussed below. 
To standardise assessments we initially based our battery of diagnostic 
interviews, rating scales, and psychological tests on that of our Columbia 
University colleagues, namely the Structured Clinical Interview for DSM Axis-I 
disorders (SCID), the Hamilton Rating Scale for Depression (HRSD), the Clinician-
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Administered PTSD Scale for DSM-IV (CAPS), the Stroop Test, and the National 
Adult Reading Test (NART) (Appendix 12). 
The diagnoses based on clinical interview were confirmed via the SCID. The SCID 
is a clinician-administered semi-structured clinical interview based on DSM-IV 
criteria, designed to make reliable diagnoses when used by mental health 
clinicians or trained associates. It presents the DSM-IV criteria for Axis I disorders 
as questions, with accompanying probes and qualifiers, with four levels of 
response rated by the interviewer; ?=inadequate information; 1=absent or false; 
2=subthreshold; and 3=threshold or true. Thus it can generate diagnoses of 
current and historical mood disorder, and is extensively utilised in studies to 
ensure that subjects are correctly diagnosed and allocated. However, it is not 
without controversy or criticism, and can take several hours to complete with 
complicated patients, although as little as 15 minutes in straightforward healthy 
controls (SCID – frequently asked questions www.scid4.org/faq/scidfaq.html 
accessed 21 July 2015).  
The HRSD is an observer-rated scale used to measure depression severity, and is 
the accepted “gold standard” for assessing response to antidepressant therapy.  
It has been validated in various clinical and non-clinical populations, although its 
limitations have been criticised, not least the utility of its total score, and 
redundancy of some of the items (Hamilton, 1960; Gibbons, Clark & Kupfer, 
1993; Faries et al., 2000; Entsuah, Shaffer & Zhang, 2002; Bagby et al., 2004; 
Bech, 2006; Bech, 2012; Leucht et al. 2013). Hamilton’s original 17 items have 
been supplemented by an additional 4 items whose scores are not added to the 
17, and higher scores are taken to indicate increasing severity of depression. 
Variations of the HRSD have been developed in an attempt to address some of 
criticisms and increase its validity and clinical utility, including the HAM-D6, a 
shorter six item scale, the MHRSD, a longer 25 item variant, and the GRID-HAMD, 
which separates frequency of symptoms from severity, as well as providing a 
structured interview guide (Bech et al., 1975; Miller et al., 1985; Williams et 
al., 2008). The HRSD takes an average of 20 minutes to complete, depending on 
the subject.  
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Similar to the SCID, the CAPS is an clinician-administered semi-structured 
interview employed to reliably assess the essential features of post-traumatic 
stress disorder (PTSD), as well as acute stress disorder. Its applications include 
diagnosis, assessment of severity, and monitoring of response to treatment, and 
it is considered to be the “gold standard” in PTSD assessment, and takes 
between 30 and 60 minutes to complete (Blake et al., 1995; Weathers, Keane & 
Davidson, 2001; US Department of Veterans’ Affairs 
www.ptsd.va.gov/professional/assessment/adult-int/caps.asp accessed 21 July 
2015). 
The Stroop test is a non-specific neuropsychological assessment used to 
investigate subjects’ attention, processing speed, and executive functions, by 
firstly reading out loud the names of colours printed in ink of a different colour, 
and then by stating the colour of ink in which each word is printed, regardless of 
the word, e.g. if one saw “BLUE ORANGE PURPLE”, in the first task one would 
say “blue orange purple”, and in the second task, “red green blue”. It is 
immediately apparent that the former is easier than the latter. The Stroop test 
is essentially an interference task, and takes less than 5 minutes to complete 
(Jensen & Rohwer, 1966). 
The NART is utilised to appraise an individual’s premorbid level of intellectual 
functioning, and is to some extent related to demographics and educational 
attainment, as well as abilities that tend to be relatively spared in states of 
cognitive impairment. It is well recognised that pathological mood states can 
have a significant deleterious effect on cognition, and the NART therefore allows 
an estimation of a subject’s baseline functioning, taking around 5 minutes to 
complete (Crawford et al., 1990). 
We reviewed our use of the HRSD, CAPS, Stroop test, and NART during the first 
few assessments, and agreed that they appeared suboptimal in our cohort, not 
least because of the time taken to complete, and what they yielded in terms of 
relevant data. The HRSD places significant emphasis on somatic signs and 
symptoms of depression such as changes in sleep, appetite, weight, and libido, 
as well as fatigue-related features, with 23 (43.4%) of the total 53 points 
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associated with these – normal pregnancy includes all these features, and we 
were concerned that the HRSD had not been validated in pregnancy. After 
reviewing the literature on other depression rating scales (such as the Hospital 
Anxiety and Depression Scale, the Patient Health Questionnaire, the Quick 
Inventory of Depressive Symptomatology, and the Edinburgh Postnatal 
Depression Scale) and establishing that all had limitations in pregnant and non-
pregnant subjects, we sought expert opinion from Drs Roch Cantwell and Ian 
Jones, who agreed that using the Beck Depression Inventory (BDI-II) instead of 
the HRSD would be reasonable, particularly in view of its ease of use, short time 
required for completion, and patient-completed nature (Holcomb et al., 1996; Ji 
et al., 2011; Wang & Gorenstein, 2013; Brunton et al., 2015). Furthermore, as 
the BDI-II has a greater emphasis on cognitive depressive features, it therefore 
has a degree of face validity in antenatal depression (15 [23.8%) of the total 63 
points relate to somatic symptoms). The BDI has also been shown to correlate 
with adverse obstetric/neonatal outcomes (see Chapter 8) (Steer et al., 1992). 
The CAPS appeared redundant, as comorbid PTSD was an exclusion criterion for 
our study, and focusing on severity of anxiety and stress-related features 
appeared more relevant, hence switching to using the Beck Anxiety Inventory 
(BAI) for similar reasons to the BDI-II, and the Holmes-Rahe Social Readjustment 
Rating Scale (SRRS), both self-completed (Holmes & Rahe, 1967; Beck et al., 
1988). These changes saved significant time in assessing subjects, without any 
obvious loss of data relevant to our study, and allowed quick updates at the one 
month and four month scans, when time for maternal re-assessment was limited.  
Table 7-1 summarises the recommended cut-off points for normal, mild, 
moderate, severe, and very severe scores for each of the rating scales, with low, 
moderate, and high risk of illness being shown for the SRRS (Hamilton, 1960; 
Holmes & Rahe, 1967; Beck et al., 1988; Beck et al., 1996). 
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Table 7-1 – Cut-off scores for severity 
Severity HRSD BDI-II BAI  Risk of illness  SRRS 
Normal 0-7 0-13 0-7  Low risk <150 
Mild 8-13 14-19 8-15  Moderate risk 150-299 
Moderate 14-18 20-28 16-25  At risk >299 
Severe 19-22 29-63 26-63    
Very severe >22 - -    
HRSD – Hamilton Rating Scale for Depression; BDI-II – Beck Depression Inventory-II; BAI – Beck 
Anxiety Inventory; SRRS – Social Readjustment Rating Scale 
 
A checklist was utilised to summarise salient points for each participant, as well 
as to minimize omissions. The checklist served as the front sheet in the 
polypocket containing paperwork for each subject, and included the unique 
study number and EDD, a column for each anticipated contact (immediately 
after booking, at the start of the third trimester and at the one month and four 
month scans), rows to note actual dates and gestations, in addition to next 
planned assessment, rows to tick off the consent and each assessment when 
completed at each meeting, a section to categorise subjects by health status 
and antidepressant exposure, and a section for any additional notes (Appendix 
10, and the updated version, Appendix 11). 
 
Timetable 
Existing data indicated that the majority of women taking antenatal 
psychotropics throughout pregnancy are already prescribed them before 
conceiving. We therefore aimed to recruit and assess subjects as early in 
pregnancy as possible, ideally in the second trimester, immediately after 
booking (which tends to take place around 11-13 weeks gestation). This allowed 
us to follow women through a greater proportion of their pregnancies, thus 
reducing recall bias and significant factual omissions and inaccuracies. In 
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particular, this should make our data on prescribed and other drugs more 
accurate. 
However, this also permitted re-assessment of each subject at a standardised 
timepoint, at the start of the third trimester, between 24 and 28 weeks, 
facilitating more consistent comparison of the depression rating scale scores. 
Moreover, a second review allowed completion of any assessments outstanding 
following the first meeting – some subjects were unable to complete them all in 
one interview, especially if unwell, or if their history was complicated. 
Over time, however, and particularly when scanning started and reduced the 
time available for assessing other subjects, it became desirable to rationalise 
the number of antenatal contacts to just two; the initial ‘phone discussion, and 
then a face-to-face assessment at the start of the third trimester. This made it 
less onerous for the participants (and assessors), with no discernible deleterious 
effects on the quality of data collected. However, this may have been related at 
least in part to our recruits mainly being healthy controls (see below). 
At the first meeting, and after informed consent was obtained, we agreed 
provisional scan dates for as close to 44 weeks and 56 weeks gestational age by 
EDD as possible. All future dates were entered into a private “Helping mums” 
Google calendar using the anonymised unique study numbers, accessible only by 
the researchers, with email alerts set up, to prompt contacting subjects in 
advance of each meeting, and ensure that any issues were resolved. For 
example, it sometimes became necessary to reschedule assessments or scans, 
due to accommodating other subjects, the MR scanner being unavailable due to 
servicing or malfunction, or life events affecting participants’ availability. 
 
Rooms and resources 
Another factor was the availability of an assessor, as all scans had to be 
scheduled on Wednesdays between 9am and 1pm. However, this slot did not suit 
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some potential participants. Moreover, it was not always possible to book the 
neuroradiology multipurpose room for assessments at that time, as others 
tended to book the room regularly for various purposes, and booking well in 
advance was not always possible, depending on what stage of pregnancy the 
mums-to-be contacted us, or were able to meet. We therefore met and assessed 
some subjects at their place of work, or in a coffee shop if preferred. However, 
after negotiation with the Sleep Centre Service Manager (the University of 
Glasgow Sleep Centre was hosted within the Sackler Institute until 2012) it 
became possible to use one of the sleep study rooms in the INS for assessments. 
Furthermore, assessing participants at the INS, two floors above the Department 
of Neuroradiology, allowed them to have a limited tour of and orientation to the 
MR scanning suite, a desirable factor in reducing anxiety on the day of the first 
scan. 
 
Supporting staff and colleagues 
As assessments and scanning progressed, it became clear that one researcher 
alone would be unable to complete and supervise all the work involved, 
particularly as timing for both assessments and scans was critical, and meetings 
could not be rescheduled to accommodate limited availability of staff due to 
annual leave, or scans and assessments being booked at the same time. 
Higher Trainees in Psychiatry in the West of Scotland were therefore invited to 
participate in the study. This was of mutual benefit, as trainees are expected to 
obtain research experience. Three doctors volunteered, who shadowed the 
consultant psychiatrist when completing assessments and scans at least twice, in 
addition to receiving detailed tutorials, and ensuring registration/approval with 
the Research Ethics Committee, through submission of their curriculum vitaes, 
before carrying out interviews and supervising scans on their own. JM assessed 
one and supervised scans for three subjects, and FC supervised one scan. 
Page 228 of 365 
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is a non-ionising, non-invasive scanning 
technology that exploits the varying water (H2O) content of different tissues to 
produce high resolution images (Currie et al., 2013a). By subjecting static 
subjects to a strong and uniform magnetic field within the scanner, protons 
(hydrogen atoms) are then “excited” by radiofrequency pulses at a 
characteristic frequency. Magnetic field gradients are further applied to 
facilitate the spatial localisation of the signals. It is these gradients which 
contribute to the noise the MRI scanner produces, which can be considerable 
(>100dB). Following the radiofrequency stimulation and gradient applications, 
radio waves emitted from the subject are detected by a receiver coil. The rate 
at which excited atoms return to baseline provides the contrast between 
different tissues, and can be viewed on a computer screen. Magnetic field 
strength is measured and expressed in teslas (T). MRI scanners utilising field 
strengths of 1.5T are frequently used in humans for clinical diagnostic, staging, 
and monitoring purposes, while 3T scanners are common in research 
environments. Since the beginning of this project 7T MRI systems are being used 
more frequently for research, and there are now more than 50 7T MRI systems 
worldwide. 
Image contrast can be weighted according to what tissues or lesions are under 
study, by altering parameters relating to technical issues such as repetition time 
or echo time, associated with spin-lattice relaxation, and spin-spin relaxation, 
respectively. These are referred to as T1 and T2 (not to be confused with 
teslas). Among other things, T1-weighted images highlight fatty tissues well, for 
general anatomical imaging and in post-contrast examination, while T2-weighted 
scans are useful for demonstrating pathologies such as oedema, inflammation, 
and white matter lesions. 
MRI scans excel in revealing the detail of organs comprised of varying soft tissues 
such as the brain, and can thus yield high resolution data on the size, shape, and 
integrity of intracranial structures. In addition to straightforward spatial and 
volumetric imaging, MRI can also be deployed in demonstrating anatomical 
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connectivity via Diffusion Tensor Imaging (DTI), which detects the anisotropic 
movement of molecules along axons forming white matter tracts (Abhinav et al., 
2014). Magnetic resonance spectroscopy (MRS) can measure cellular metabolism 
(a measure of cell turnover and membrane integrity) via spectral resonances 
associated with different molecules (Currie et al., 2013b). Moreover, functional 
MRI (fMRI) can be used to detect neuronal activity without the need for contrast 
media, using the different signals associated with oxygenated and deoxygenated 
blood flow as a proxy marker for increased cerebral activity. All these 
techniques have been used in studying the developing brain (Rivkin, 2000; Almli, 
Rivkin & McKinstry, 2007; Cascio, Gerig & Piven, 2007; Hunt & Thomas, 2008; 
Marsh, Gerber & Peterson, 2008; Silk & Wood, 2011; Gilmore et al., 2012; Blüml 
et al., 2013; Giedd et al., 2015). 
MRI scanning is, generally speaking, considered to be safe, given that it employs 
non-ionising radiation to produce images. However, due to the strong magnetic 
fields, there were a number of considerations relevant to our project. Firstly, 
ferromagnetic objects are attracted strongly to the centre of the magnet, 
necessitating such potential missiles to be banned from the scan room. 
Secondly, scanning subjects can heat up due to absorbing the radio waves used 
to generate the magnetic fields (although this is monitored by the scanner, and 
scanners are designed to ensure internationally agreed limits are not exceeded). 
And thirdly, although MRI has not been demonstrated to cause tissue damage or 
increase the risk of cancer in humans, it has been associated with minor DNA 
damage similar to that of other ionising imaging modalities (Knuuti et al., 2013). 
Notwithstanding, MRI is considered to be safe for infants, and has even being 
utilised during pregnancy to detect and monitor congenital defects in utero, 
although its use during organogenesis in the first trimester is avoided unless 
essential (Alorainy et al., 2006; Girard & Chaumoitre, 2012). There are no known 
developmental sequelae of MR neuroimaging in neonates (Bulas & Egloff, 2013; 
Tocchio et al., 2015). 
One major challenge, however, is that scanning subjects need to remain as still 
as possible, to allow high quality images to be produced. This is a particular 
issue in imaging neonates, especially given the noise of the gradient coils. 
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Despite providing ear plugs and larger headphones feeding white noise to babies, 
there is still sufficient noise to disturb them, resulting in movement. Many young 
children undergoing MRI are anaesthetised because of the noise and the 
claustrophobic tunnel, but this was not appropriate for our study. The advice of 
our colleagues in Columbia in this regard was invaluable, as detailed in Appendix 
12, and described below. 
We aimed to use structural MRI to measure and compare total brain volume and 
cerebellar volume for all neonates at one month and four months postnatally; to 
use DTI to measure and compare diffusion tensor maps for all neonates at one 
month and four months postnatally; and to use MRS to measure and compare N-
acetyl aspartate for all neonates at one month and four months postnatally. 
 
Preparation for scanning 
One week after the EDD participants were contacted to inquire after their 
health and progress, and to remind them about the provisionally agreed scan 
date. After confirming availability and willingness to proceed, and arranging any 
necessary rescheduling, each received a copy of our leaflet giving detailed 
information about the scan (Appendix 7). Transport arrangements were made, 
with taxis being booked for those without private transport, with advice to 
contact the researcher by text/’phone upon arrival, to provide help in locating a 
parking space, and escorting mother and baby to the scanning suite. Subjects 
were advised to attend between 9am and 9:30am, and to bring baby hungry and 
tired if possible – this proved challenging for those driving to the SGH, as babies 
tend to sleep during car journeys (Knickmeyer et al., 2008). Upon arrival mother 
and baby were welcomed, and put at ease, while ensuring that necessary 
details, such as actual date of delivery (ADD), obstetric, postnatal and neonatal 
particulars and complications, birthweight, exact gestational age in days by EDD 
on the day of the scan, and information on baby’s feeding and sleeping (to 
detect any significant features of neonatal adaptation syndrome) were collected 
and/or updated. Gestational age by EDD was calculated using the “Perfect 
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Wheel” app for iPhone, to ensure accuracy and consistency. Each baby was 
weighed, and his/her head circumference measured, before an MR checklist was 
completed for both neonate and mother (to allow her to enter the scan room 
allow with baby). 
Participants were shown to the anaesthetic preparation room within the MR 
scanning suite, immediately opposite the scan room, and any questions 
answered. At this stage the lighting was dimmed, and babies were changed and 
swaddled. Mothers were advised in advance to bring clothing for them and baby 
appropriate for scanning, i.e. warm and without ferromagnetic fasteners, and 
suitable items were provided for babies where necessary. Foam ear plugs were 
cut to size and taped in position in babies’ ears, and a pulse oximeter probe 
attached to a portable monitor was secured to one foot, before babies were fed 
and burped. Mothers who were bottle-feeding brought their own equipment, and 
a water bath was provided. A judgment was made in each case whether to allow 
babies to fall asleep in the preparation room, and then transfer to the scan 
room, or to be taken in to the scan room before sleep, as babies had to be 
secured in an adult head coil in the scanner by means of foam wedge supports, 
which frequently woke them up. Headphones through which white noise was 
played were fitted, and babies allowed a little time to settle in to a deep sleep 
before scanning started. Mothers were invited to remain in the scan room with 
their babies if they wished, with the option of observing through the viewing 
panel or enjoying a complementary beverage in the nearby canteen. The 
researcher remained with each baby throughout the scans, observing for any 
signs of distress, and monitoring heart rate and blood oxygen saturation. 
Scanning stopped immediately if babies moved or appeared distressed, and 
attempts made to resettle them. Scanning resumed if babies became and 
remained calm, but paused if distress was sustained, and mothers were asked to 
comfort babies initially in the scan room, and then in the preparation room if 
necessary. We reattempted scanning if babies settled once more, and mothers 
consented, but abandoned scanning if not. 
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Scanning protocol 
Eight sequences were performed, as summarised in Table 7-2 (Appendix 13). As 
the imaging parameters prescribed had been carefully considered, to optimise 
comparisons between study groups by minimising the amount of variation and 
error in the subsequent measurements, strict instructions not to alter any 
settings were given to radiology staff, including not to copy slice thicknesses 
across different acquisitions. 
 
Table 7-2 – Scanning sequences 
 
 
Two localising sequences were completed, to establish and correct for head 
position. A 3D sequence followed, corrected and “straightened” sagittally, 
axially and coronally with respect to the localising sequences, as for all 
Sequence Purpose 
Localiser 1 To establish subject position 
Localiser 2 To correct more precisely for head position 
3D IR-FSPGR To acquire total cranium, including total brain volume, optimised 
to capture grey/white matter contrast 
T2 measure (1, 2 and 3) 
(Dual TE, FSE-XL) 
To compare T2 values in brain regions between the study groups 
Asset calibration To allow parallel imaging with the following DTI sequence, 
reducing acquisition time 
DTI To compare diffusion values in brain regions between the study 
groups 
Dual echo T2 FSE-X To measure volume of subcortical structures, including 
hippocampus and amygdala 
MRS To compare metabolite ratios in the cerebellum between the 
study groups 
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subsequent sequences. It acquired the whole head, including the skull. The 3D 
sequence was optimised for grey matter/white matter contrast, to allow 
comparison of averaged volumes/concentrations between study groups. The next 
sequence established T2 values in the brain regions of interest via the 
acquisition of multiple TE value images. Multiple acquisitions were required to 
cover the whole brain. 
Thereafter, an axial asset calibration sequence allowed parallel imaging to be 
employed for the following DTI, significant reducing acquisition time. 
Subsequently, a dual echo T2 sequence focused on subcortical structures, 
acquiring coronal slices anteriorly to posteriorly from the rostral aspect of the 
amygdala to the tail of the hippocampus. An MRS sequence then captured 
metabolite ratios in the cerebellum. The full protocol with accompanying 
diagrams is shown in Appendix 13. 
Imaging parameters were optimised for one month and four month scans, as per 
advice from Columbia (Appendices 14 and 15). If babies moved during image 
acquisition, this was detected either by the researcher in the scan room, or by 
the radiographers, who reviewed the images in real time to screen for any 
obviously suboptimal data. 
We secured agreement from our Columbia colleagues that they would analyse 
the scanning data, due to their resources and expertise. All scans were also 
reviewed by a local consultant paediatric radiologist, to screen for any clinically 
concerning abnormalities. 
 
Project registration and approval 
The scanning project was registered with NHS Greater Glasgow & Clyde Research 
& Development (NHS GGC, R&D), and ethical approval was obtained from the 
local Research Ethics Committee (REC) (Appendix 16). All amendments to the 
protocol were likewise reviewed and approved by the REC. 
Page 234 of 365 
Results 
Forty-six women became known to the study between 13 July 2009 and 28 March 
2012, two who contacted researchers by telephone, 41 via email, and three 
attending the PMHS, who consented to have their details passed on.  Figure 7-1 
depicts a CONSORT-style diagram to summarise the progress of the potential and 
actual participants through the phases of our study. The very first woman to 
make contact with the research team, by email, was excluded during the follow-
up ‘phone call as she was expecting her second child, but this exclusion criterion 
was quickly revised as discussed above. Of the 46 who became known to the 
research team, a few declined to proceed after initial telephone in discussion in 
response to their inquiry, but many simply did not respond to several attempts 
to contact them by ‘phone, email, and/or post, including all those identified via 
the PMHS. 
Although we had intended to recruit 10 women in each group, several factors 
beyond the research team’s control conspired to end scanning in early 2012. 
Firstly, serious illness affected EJ’s family in 2011, and he withdrew for nine 
months to support his wife through treatment. Secondly, in 2012 NHS GGC 
moved paediatric services from the SGH to the Royal Hospital for Sick Children, 
Yorkhill, meaning that we were no longer permitted to scan babies at the INS, 
despite considerable efforts to negotiate alternative arrangements. Thirdly, the 
Department of Neuroradiology acquired a new MRI scanner while the study was 
suspended, introducing another variable in comparing future scans with those 
already acquired. Fourthly, the head of department at the Columbia Sackler 
Institute moved to a new post in a different state, leading to the end of 
collaboration on this project, including our agreement regarding image analysis. 
These issues resulted in there being inadequate time for alternative 
arrangements to be made, and our pilot study was brought to a premature end, 
with insufficient data to allow meaningful comparison between groups, or to 
justify investment in analyses.  
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Figure 7-1 – CONSORT 2010-style flow diagram 
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Of the 46 women, 12 completed the one month scan, with six also completing 
the four month scan, all in the control group. One of those who made initial 
contact by ‘phone did not proceed to assessment, and none of those contacted 
via the PMHS responded to invitations by ‘phone or post. Otherwise, all 
completed all antenatal assessments, except HM015, for whom there was 
insufficient time to finish the SCID at the first meeting. As the “Columbia 
battery” of tests was used from HM001 through HM015, there were no ratings for 
antenatal anxiety or stress until HM016. Table 7-3 summarises the antenatal 
characteristics of the 12 mothers who attending for at least one scan. The 
median age was 33 (range 25-40). Eight of those undergoing scans were in the 
control group, with six being the first child – HM009 was expecting her second 
child, and HM014 had required treatment for an ectopic pregnancy the 
preceding year. HM015, the solitary depressed unmedicated participant, was 
rated as being severely depressed antenatally on the HRSD, although clinically 
she described herself as having felt better in the few weeks immediately prior to 
assessment. The second page of her BDI-II from the one month scan was missing, 
hence no score in Table 7-3. 
HM015, the depressed unmedicated participant, attended for the one month 
scan, but not the scan at four months. Similarly, three depressed medicated 
subjects underwent the first but not the second scan – HM022 had been taking 
Citalopram 20mg since approximately two months before pregnancy, reduced to 
10mg around 14 weeks, and increased back to 20mg daily at 18 weeks; HM030 
had been taking Sertraline 200mg daily for some years prior to conceiving, and 
reduced to 100mg daily until delivering after discovering she was pregnant 
around six weeks gestation; and HM035 had been taking Fluoxetine 20mg daily 
for approximately 10 months before falling pregnant, and stopped between six 
and eight weeks’ gestation. All eight of the controls attended for the one month 
scan, with six undergoing the four month scan, also – two were unable to 
complete the second scan, due to unsettled babies. Only one subject who 
attended for the one month scan (a control) was unable to complete, due to her 
baby being unsettled. Not all sequences were completed even in those attending 
for scans, due to a mixture of babies being unsettled and/or moving too much. 
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Table 7-3 – Antenatal maternal characteristics of those completing scans 
       
Antenatal 
ID Group Age Pregnancy Child EDD ADD Stage Depression Anxiety Stress 
HM006 Control 33 1 1 24/02/10 20/02/10 113 Normal - - 
HM009 Control 33 2 2 07/02/10 29/01/10 192 Normal - - 
HM013 Control 34 1 1 16/05/10 21/05/10 173 Normal - - 
HM014 Control 32 21 1 19/04/10 14/04/10 193 Mild - - 
HM015 Depressed 38 3 3 15/05/10 14/05/10 195 Severe - - 
HM022 Medicated 27 1 1 28/09/10 22/09/10 185 Mild Moderate High 
HM023 Control 39 1 1 06/11/10 21/10/10 179 Normal Mild Low 
HM025 Control 30 1 1 22/02/11 09/03/11 183 Normal Normal Low 
HM030 Medicated 32 4 4 04/04/11 27/03/11 217 Mild Mild Moderate 
HM033 Control 33 1 1 02/07/11 27/06/11 181 Normal Mild Moderate 
HM034 Control 25 1 1 08/07/11 11/07/11 180 Normal Severe Moderate 
HM035 Medicated 40 1 1 25/07/11 21/07/11 163 Normal Normal Low 
EDD = estimated delivery date by ultrasound scan; ADD = actual delivery date; Stage = gestation 
by EDD in days 
1 Previous ectopic pregnancy 
 
 
Table 7-4 presents obstetric outcomes, indicating that all babies were born at 
term (defined as between 269 and 294 days gestation), and all were within 
normal birthweight range (2.5-4.5kg). Postnatal maternal outcomes are 
summarised in Table 7-5, revealing a trend towards improvement in severity 
ratings for those who scored as moderate or worse for depression, anxiety, or 
stress during pregnancy (particularly HM022 and HM034). Tables 7-6 and 7-7 
show neonatal data for the one month and four month scans, respectively. 
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Usable images were generally acquired via the 3D MRI and the MRS sequence, 
e.g. Figure 7-2 and Figure 7-3, but there were technical difficulties with the DTI, 
although useable images were obtained, e.g. Figure 7-4. While some artefacts 
were clearly attributable to infants’ movements, others were not as readily 
explained, and we were unable to resolve all difficulties, not least due to 
scanning and analysis not continuing as planned. 
As most images were from healthy controls, comparative analyses were not 
possible. 
 
Table 7-4 – Obstetric outcomes for those completing scans 
ID Group Stage Weight1 Centile2 Delivery Obstetric complications 
HM006 Control 276 3.97 93% SVD3 None 
HM009 Control 271 3.69 83% SVD None 
HM013 Control 285 3.61 70% Forceps Breech presentation, external 
cephalic version, then forceps due to 
fetal heart rate slowing, then 
increasing 
HM014 Control 275 3.36 60% Elective section Prolonged hypotension 
HM015 Depressed 279 - - Elective section Depressed until ~6 months, then 
recovered 
HM022 Medicated 274 3.69 83% SVD Citalopram 20mg until 14 weeks, 
then 10mg until 18 weeks, then 20mg 
until delivery 
HM023 Control 264 2.50 2% Induced Post-partum haemorrhage, neonatal 
jaundice, admitted to neonatal unit 
for ~36 hours 
HM025 Control 295 3.88 85% Induced, forceps None 
HM030 Medicated 272 3.15 425% SVD Sertraline 200mg until ~6 weeks, 
then 100mg thereafter 
HM033 Control 275 3.49 70% SVD None 
HM034 Control 283 4.05 95% SVD None 
HM035 Medicated 276 3.54 74% Elective section Fluoxetine 20mg stopped between 6-
8 weeks 
Stage = gestation by EDD in days; 1 kilogrammes; 2 According to WHO charts; 3 SVD = spontaneous 
vaginal delivery 
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Table 7-5 – Postnatal maternal outcomes for those completing scans 
  
Scan 1 Scan 2 
ID Group Stage Depression Anxiety Stress Stage Depression Anxiety Stress 
HM006 Control 301 - - - 392 Normal Normal High 
HM009 Control 304 - - - 395 Normal Normal Moderate 
HM013 Control 318 Normal Mild High 395 Normal Normal High 
HM014 Control 310 Normal Normal Moderate 394 Normal Normal Moderate 
HM015 Depressed 305 - Mild High Baby did not settle 
HM022 Medicated 309 Normal Moderate Moderate Cancelled by research team (availability) 
HM023 Control 305 Normal Normal Moderate 389 Normal Normal Moderate 
HM025 Control 309 Normal Normal Low 400 Normal Normal Low 
HM030 Medicated 310 Mild Mild Moderate Baby did not settle 
HM033 Control 312 Normal Mild Moderate Baby did not settle 
HM034 Control 313 Normal Normal Low Baby did not settle 
HM035 Medicated 310 Normal Normal Moderate 401 Normal Normal Moderate 
Stage = gestation by EDD in days 
 
Page 240 of 365 
Table 7-6 – Neonatal outcomes at one month 
ID Group Stage Weight1 Centile2 Head circumference3 Centile2 
HM006 Control 301 4.25 60% 35.7 28% 
HM009 Control 304 4.60 80% 35.5 22% 
HM013 Control 318 4.54 61% 38.0 78% 
HM014 Control 310 4.54 77% 37.0 70% 
HM015 Depressed 305 - - 35.5 22% 
HM022 Medicated 309 4.55 77% - - 
HM023 Control 305 4.05 28% 37.0 46% 
HM025 Control 309 4.70 70% 38.5 88% 
HM030 Medicated 310 - - - - 
HM033 Control 312 4.11 50% 37.5 83% 
HM034 Control 313 4.28 62% 36.2 44% 
HM035 Medicated 310 4.40 69% 37.0 70% 
Stage = gestation by EDD in days; 1 kilogrammes; 2 According to WHO charts; 3 centimetres 
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Table 7-7 – Neonatal outcomes at four months 
ID Group Stage Weight1 Centile2 Head circumference3 Centile2 
HM006 Control 392 6.00 29% - - 
HM009 Control 395 7.00 75% - - 
HM013 Control 395 6.40 21% 41.5 45% 
HM014 Control 394 6.80 67% - - 
HM015 Depressed 382 5.75 18% - - 
HM022 Medicated 407 - - - - 
HM023 Control 389 5.87 6% 41 29% 
HM025 Control 400 7.20 59% 42.3 71% 
HM030 Medicated 394 5.50 10% - - 
HM033 Control 396 5.70 16% 40.7 53% 
HM034 Control 397 - - - - 
HM035 Medicated 401 6.50 53% 42 86% 
Stage = gestation by EDD in days; 1 kilogrammes; 2 According to WHO charts; 3 centimetres 
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Figure 7-2 - 3D MR image from a 1 month scan 
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Figure 7-3 - MRS 1 month scans 
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Figure 7-4 – DT image from a 1 month scan 
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Discussion 
Similar to Columbia, we encountered a number of challenges, leading to our 
intended pilot study recruiting insufficient numbers of women on 
antidepressants in the time available. Notwithstanding, we concluded that our 
recruitment strategy had been at least partially effective. Over a period of 
approximately 30 months, 46 women became known to the research team, with 
all but three alerted to our study via the information leaflet included in the 
Bounty pack. The other three attended the PMHS, and gave permission to their 
clinician for their contact details to be passed on, but none ultimately 
responded to invitations by ‘phone and post to discuss participation with a 
researcher. A total of 25 women were assessed and consented, with the other 21 
being filtered out without the need to meet in person, often following the 
‘phone conversation to discuss the study in more detail – thus, this appeared to 
be an effective strategy that saved time for both potential participants and 
researchers alike. There was a relatively high attrition rate, from the 46 who 
made contact, to the final six who completed the second scan, that was simply 
reflective of the difficulties inherent in conducting research of this nature. 
Although subjects were recruited at a rate of almost one per month on average, 
the majority were controls, followed by mothers with depression on 
antidepressants, and then those with depression not treated pharmacologically, 
in a ratio of 16:7:2. We had anticipated that mothers on antidepressants would 
be the easiest to recruit, on account of both presumed anxiety over the 
potential adverse effects of antenatal exposure and attendance at the PMHS, 
but it was actually mothers with good health and uncomplicated pregnancies 
who demonstrated most interest. When asked informally about their reasons for 
contributing to the study, participants in the control group tended to cite an 
interest in what they perceived to be an exciting project, especially the 
prospect of seeing detailed images of their offspring’s brains, in addition to an 
altruistic desire to contribute to research. Those affected by depression, 
whether medicated or not, focused more on the potential to find answers to 
concerns about the neurodevelopmental effects of fetal exposure to depression 
and its medical treatment, while acknowledging that they and their babies 
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would not benefit directly from this study. It was perhaps not surprising that the 
most difficult group to recruit were the depressed unmedicated women, both on 
account of their likely low motivation associated with their mental illness, and 
also possibly their perception that the study was about the effects of antenatal 
antidepressants, and not about the consequences of untreated depression, too. 
The recruitment strategy could be improved through various amendments. 
Firstly, it is reasonable to assume more healthy controls could be recruited by 
including other nearby maternity units, potentially doubling or even tripling our 
rate of enrollment.  Secondly, informing local GPs and psychiatrists about the 
study would significantly expand the population from which we could identify 
depressed mothers, and those prescribed antidepressants. Thirdly, rewording 
our printed material and web content to emphasise depression during 
pregnancy, whether treated medically or not, as the focus of study may attract 
those not taking antidepressants. 
While we could not be certain why we were unable to recruit any subjects from 
the PMHS, our anticipated main source of depressed mothers, one possible 
explanation is that as the vast majority of the PMHS patients attend later in 
pregnancy, the clinicians may have perceived this to have excluded them from 
the study, especially as initially we aimed to identify potential participants “as 
early in pregnancy as possible”. Although the lead psychiatrist in the PMHS was 
aware of our desire to be as inclusive as possible (and had in fact been the one 
who advised relaxing our exclusion criteria), he was not the only clinician seeing 
patients in the PMHS. The research team did visit the PMHS and updated the 
doctors and nurses due to recruitment being slow, but reviewing the details of 
recruitment from the PMHS would be a fourth option to improve a future study. 
However, our findings in the PMHS detailed in Chapter 3 also suggest that this 
cohort differs from the general maternity population in several ways, and an 
important conclusion is that looking to the PMHS as the only, or even the main, 
source of participants for a study such as ours is not warranted.  
Fifthly, targeting relevant local audiences via social media and virtual groups, 
such as local users of www.netmums.com and www.mumfidential.com may also 
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be an effective way to boost numbers contributing. Moreover, although the 
printed information leaflets proved to be the most successful means of 
contacting potential participants, the Helping mums website was useful in 
establishing the kind of resource with which many people are familiar, and 
which allowed women to contact the research team in an easy, non-threatening 
manner, while also providing the means by which we were able to give 
additional information that could be easily updated, without the need to print 
thousands of new leaflets, and arranged physical distribution. 
Another option to improve recruitment would be to consider offering attractive 
incentives like Columbia.  However, this would bring its own challenges, such as 
securing a source of funding, and the ethical issues involved. As the UK 
healthcare and welfare provisions differ significantly from, and compare 
favourably to, those in the USA, we did not from the impression that offering 
incentives was either necessary nor desirable. Nevertheless, mother did express 
enthusiasm for receiving digital images and a print of their offspring’s scans. 
As presaged above, assessing those who continued to indicate interest following 
the initial ‘phone discussion was associated with some challenges. In the early 
stages of the study in 2009 only one researcher was available to complete the 
assessments, and time for this was limited to Wednesday mornings. However, 
not all participants were free to meet at that time, and thus a degree of 
flexibility was required, particularly as we wished to make the process as easy as 
possible. Additionally, a suitable NHS venue was not always available, and 
therefore some women were seen at work or in a coffee shop. It quickly became 
clear that while the “Columbia battery” of assessments could be completed in 
around 60 to 90 minutes for healthy controls with uncomplicated histories, even 
two hours was insufficient to finish everything for those with less than 
straightforward backgrounds – this was most clearly the case for the depressed 
unmedicated mothers. Moreover, exploring sensitive personal information in a 
coffee shop, or taking up two hours of time for subjects at work or in a café was 
inappropriate, and thus we streamlined the assessments and rating scales as 
previously described, in addition to identifying a room both suitable and 
available at the INS, that also allowed a tour of the scanning suite. 
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Although initially we had planned to identify subjects as early in pregnancy as 
possible, and ideally not long after booking, and then to repeat assessment at 
around 24 weeks gestation to standardise findings to increase the validity of 
comparisons, this appeared to place an unnecessary burden on participants 
without clearly enhancing the quality of the data obtained. Similarly, when 
several women required assessment around the same time (as gestation dictated 
tight timescales), and scans had commenced (which were even more time-
sensitive), it proved extremely challenging (and, on more than one occasion, 
impossible) for one researcher to do all the assessments, while supervising 
scans, too. Recruiting Higher Trainees in Psychiatry proved invaluable in this 
regard, allowing simultaneous assessment and/or scans, with them receiving 
useful research experience in return. Careful consideration was given to training 
and supervising these colleagues, and in general they did an excellent job, not 
least in looking after the participants. However, perhaps inevitably when several 
different researchers were assessing subjects and supervising scans, some data 
could not be found when analyses started (e.g. some maternal and neonatal 
measures in Tables 7-4, 7-5, 7-6, and 7-7. 
Changing the rating scales to self-completed outcome measures saved time in 
assessments, and were also more practical to complete at the one month and 
four month scans – using the HRSD, CAPS, Stroop test and NART, as well as 
reviewing maternal, obstetric, and neonatal histories was not viable. A 
potentially desirable option for similar future studies would be the use of 
electronic self-completed measures at regular intervals throughout pregnancy, 
e.g. online, or via an app, with monthly prompts and automatic plotting, to 
allow further comparison of antenatal trends, and control (to a degree) for the 
confounding influences of severity of antenatal depressed mood, anxiety, and 
stress.  
It proved relatively simple to assign the enrolled subjects to the relevant study 
group, but this would not necessarily always be the case. As our results, 
analyses, and conclusions would have been based on careful comparisons, it was 
necessary to ensure that our study groups represented the different parameters 
under study, while controlling for the many known and unknown confounders as 
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far as possible. For example, in order to accurately characterise any 
neurodevelopmental consequences of medicated and unmedicated antenatal 
maternal depression, one should ideally compare otherwise identical subjects 
who were either completely mentally and physically well and not on any 
medication; with those with depression of similar severity, duration, and 
subtype, but no other health problems or medication; with those on one specific 
type of antidepressant at the same dose throughout pregnancy, and no other 
medication or health problems other than depression. As highlighted above and 
discussed in Chapter 8, even SSRIs differ sufficiently in their pharmacokinetic 
and pharmacodynamics properties to necessitate studying each independently. 
Fluoxetine 20mg taken intermittently for the first six weeks of pregnancy for 
remitted mild reactive depression is not really equivalent to Sertraline 200mg 
taken daily throughout for severe endogenous depression with features that 
persist. Moreover, in order to adequately control for any effects of fetal 
exposure to mental illness, one would prefer to include only women whose 
depression had remitted. Enforcing these strict inclusion criteria would result in 
it taking significantly longer to recruit adequate numbers, even without 
controlling for factors such as parental age, ethnicity, parity, and genotype, 
obstetric complications, and fetal gender. 
The time available to complete the study posed a challenge to completion, even 
without such restrictive measures. We had planned to use the four years 
available to the main researcher for a part-time Doctorate in Medicine, and 
ethical and R&D approval was in place before the MD was registered in October 
2008. However, it took almost one year of preparatory work and waiting before 
the first potential participant made contact in July 2009, and the first scan did 
not take place until March 2010, due to the lag time between identifying a 
subject during pregnancy, and the final four month scan being completed. In a 
ideal case, we would identify the mother at around three months, meaning that 
it would take a total of 10 months to finish each subject. Recruiting at our rate 
of less than one per month would therefore take at least three and a half years 
to study the 30 participants we sought, assuming no complications and the 
correct ratio of subjects, suggesting that unless one could improve the rate of 
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recruitment of those with ideal characteristics, it would take several years to 
complete a study with 10 women in each study group. 
However, less than three years after we recruited our first subject scanning was 
stopped by NHS GGC, in April 2012. This was due to a high level decision related 
to the reconfiguring of paediatric services in anticipation of the centralisation of 
hospital-based care at the new South Glasgow University Hospital (which opened 
in June 2015). Essentially, as clinical paediatric care at the SGH stopped 
between 2012 and 2015, the Department of Neuroradiology no longer performed 
neonatal scans, as there was no longer any provision for emergency life support 
for children who became unwell at the SGH. Although our project only included 
healthy babies, and we did not anticipate any becoming acutely unwell as a 
result of the MR scans, nevertheless we were not allowed to continue. It proved 
very difficult to identify exactly who had taken this decision, or if it could be 
amended for our study. This was a severe blow, and although we negotiated 
with the key stakeholders in radiology, radiography, and paediatrics, we had to 
stop scanning. The last four month scan had been completed in November 2011, 
as there had been a hiatus in recruitment for a few months, but we had 
managed to assess and consent a further six subjects, with their one month 
scans booked between April and September 2012 (three were healthy controls, 
two taking antidepressants, and one depressed unmedicated). The research 
team made significant efforts to negotiate with NHS GGC management via 
supportive consultant paediatric anaesthetists, and to demonstrate safe practice 
that would justify continuing the scans by completing training in paediatric 
immediate life support. However, we were unsuccessful. 
This complication was compounded by the MR scanner used for the study being 
upgraded, meaning that even if we had been able to restart scanning, detailed 
comparisons of existing data with new images would be suboptimal. Moreover, 
the original arrangement for our imaging data to be analysed by Columbia, was 
negated due to their head of department relocating. In other words, numerous 
factors outwith our control or influence conspired to end scanning. 
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Notwithstanding, we were able to review our experiences, and reflect on other, 
theoretically resolvable challenges that should be addressed in advance of any 
future similar study. As access to the scanner was somewhat restrictive, this 
could be addressed by seeking additional ring-fenced research scanning time, 
funded via a grant. Acquiring equipment specifically intended for paediatric (and 
ideally neonatal) application, including MR head coil, and pulse oximeter probe 
would also be desirable. A full time research assistant, or part-time with 
administrative support, would be invaluable in keeping the project running 
smoothly at maximal efficiency, and local in-house image analysis would ensure 
greater control over this critical part of the research. Including a researcher 
with experience of image analysis, both manual and using automated voxel-
based morphometry, although this approach has been criticized (Ashburner & 
Friston, 2000; Bookstein, 2001; Ashburner & Friston, 2001; Ashburner & Friston 
2005). 
In summary, therefore, we attempted an ambitious pilot project, to use 
neonatal MRI to characterise the early neurodevelopmental correlates of 
antenatal exposure to medicated and unmedicated depression in comparison 
with healthy controls. However, a number of potentially surmountable 
challenges were compounded by significant unforeseen obstacles, causing the 
study to end prematurely. 
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Chapter 8 – Synthesis, observations, and future research 
 
Synthesis 
The extent of antidepressant exposure during pregnancy in the samples from the 
three settings we analysed (the Ayrshire Maternity Unit [AMU]) general 
population, the Maternity Liaison Service [MLS] local specialist service, and the 
Glasgow Perinatal Mental Health Service [PMHS] regional specialist service) is 
presented in Figure 8-1. All values are expressed as percentages of the total 
sample size (875 from AMU, 105 for the MLS, and 627 for the PMHS), with figures 
for the AMU corrected forthwith following reanalysis by gestation as discussed in 
Chapter 5. (NB As per Margulis, Kang & Hammad [2014] [Figure 2-3], the total 
prevalence of exposure to any antidepressant was lower than the addition of 
SSRIs, TCAs, and other antidepressants, as some women in each sample were 
exposed to more than one type of antidepressant – the total percentages were 
9.7% for AMU, 71.4% for the MLS, and 37.5% for the PMHS.) 
Several observations can be made. Firstly, the proportion of pregnant women 
exposed to antidepressants in the AMU sample was higher than has been 
reported in the general British population. Petersen et al. (2011), Margulis, Kang 
and Hammad (2014) and Charlton et al. (2015) all reported overall prevalence of 
antidepressant prescribing as <6% antenatally. However, it should be reiterated 
that they all based their estimates on prescriptions issued during pregnancy, and 
did not include potential exposure to medication prescribed and taken 
periconception. Moreover, their values represent averaged prevalence over 
several years, during which time prescribing may have increased. Our figures 
were more up-to-date, included exposure even in early pregnancy, and 
accounted for all live/stillbirths, i.e. did not exclude participants on the basis of 
missing data before pregnancy. 
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Figure 8-1 – Prevalence of antidepressants in pregnancy 
 
ADs = antidepressants; TCAs = tricyclics; SSRIs = selective serotonin reuptake inhibitors 
 
Secondly, the overall proportion of women exposed to antidepressants in each 
setting varied significantly, with more attending the specialist services receiving 
medication. This was expected, although almost twice as many women seen via 
the MLS took medication as those in the PMHS. While this may appear 
counterintuitive, it is likely to be related to their respective remits – as per 
Tables 3-3 and 5-5 the PMHS provides care for more women with psychosis and 
bipolar disorders, and the MLS for a significantly greater proportion with 
affective and neurotic disorders, particularly depression. Moreover, the data for 
the PMHS spans 2002 to 2009, whereas the MLS data is for 2013. 
Thirdly, as per the literature, the majority of antidepressant prescriptions during 
pregnancy were for SSRIs, regardless of setting (80.0%, 82.7%, and 74.5% in the 
AMU, MLS, and PMHS, respectively). There was a higher prevalence of TCAs in 
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the AMU sample compared with the MLS, but this is explainable on the basis that 
the majority of TCAs were “low dose” Amitriptyline, likely prescribed for non-
psychiatric indications (Petersen et al., 2011). A relatively higher proportion of 
PMHS attendees were prescribed TCAs, possibly reflecting higher levels of 
“treatment resistance” requiring alternatives to SSRIs, chronicity or 
comorbidity. The greater levels of “other” antidepressants seen in the MLS 
sample were due to SNRIs (5.7%, 6/105 - Venlafaxine and Duloxetine 2.9% each), 
Trazodone (5.7%, 6/105), and Mirtazapine (4.8%, 5/105). 
Figure 8-2 presents the relative proportion of individual SSRIs taken by patients 
receiving monotherapy in each setting. The most obvious differences lie in the 
greater exposure to Sertraline and lesser exposure to Fluoxetine in the MLS, 
compared to both AMU and the PMHS, and the higher rates of Paroxetine 
prescribing in the PMHS. Following the US Food and Drug Administration’s 
warning in 2005 about Paroxetine’s potential for teratogenic effects (but not 
other SSRIs), prescribers moved away from using Paroxetine in pregnancy, and 
this increased proportion in the PMHS sample may simply represent a historical 
artifact (Stone et al., 2009). 
Figure 8-3 Illustrates timing of exposure to SSRI monotherapy, which was largely 
representative of other antidepressants. Again, themes and differences between 
the samples emerge. ~45% of the AMU and PMHS patients stopped in the first 
trimester, while this was true of only 16.6% of the MLS attendees. ~50% more 
women seen via the MLS were exposed to SSRIs throughout pregnancy than in the 
PMHS, and more than double the proportion in the AMU sample. ~20% of those 
seen via MLS or the PMHS commenced medication during the second and third 
trimesters, compared with 5% of the general population. A significant proportion 
of the AMU and MLS subjects followed a ‘stop-start’ pattern, but less so in the 
PMHS sample (possibly only an apparent difference due to simplification during 
documentation using the data collection forms). As discussed above, as most 
prescribing decisions are taken in the first trimester before being seen in the 
MLS or PMHs, whether made by patients or prescribers, these serve more as 
proxy markers for other factors, such as severity of illness, and relapse. For 
example, one might predict that relatively more women who stop in the first  
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 Figure 8-2 – Exposure to individual SSRIs 
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Figure 8-3 – Timing of exposure to SSRIs 
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trimester will be seen in a specialist service later in pregnancy, as they are at 
increased risk of relapse, and there may be uncertainty or concerns over 
restarting medication. 
Equally, the higher proportion of women taking an SSRI throughout pregnancy 
seen in the MLS may reflect referrer-specific issues, e.g. a referral to the MLS 
from AMU due to concerns that medication is unnecessary as the patient appears 
well, when further assessment leads to the conclusion that her current good 
mental health is attributable to ongoing pharmacological intervention. 
 
Figure 8-4 – Timing of exposure to SSRIs – early or late 
 
 
Consistent with the above observations, third trimester (“late”) exposure to 
SSRIs was less common than earlier exposure in the AMU sample, although not to 
the same extent as the literature pertaining to the UK, where reductions in 
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excess of 50% have been described (Figures 8-4 and 2-3) (Petersen et al., 2011; 
Margulis, Kang & Hammad, 2014; Charlton et al., 2015). Once more, the PMHS 
figures appeared intermediate between AMU and the MLS, most likely due to the 
diagnostic make-up of the sample. 
A more detailed breakdown is given in Figure 8-5, where the percentage exposed 
in each trimester in each service is summarised (T1, T2, and T3, respectively). 
T0 represents those exposed at the time of conception, and is not comparable to 
other studies, which reported figures for prescriptions issued in the three or six 
months before pregnancy, and hence included those additional women who stop 
antidepressants prior to conceiving – this may explain the absence of significant 
reduction between T0 and T1 presented here (Figures 8-5 and 2-3). 
Notwithstanding, the trend seen in the AMU sample was similar to those 
reported, with almost a 50% reduction in exposure from T1 to T2, followed by a 
further reduction in T3. In contrast, however, there was a much smaller drop in 
exposure rate from T1 to T2 in MLS attendees, and an increase in T3. Once 
more, the figures for the PMHS sample were intermediate. 
These findings suggest that further research into exposures in specialist 
perinatal mental health settings may be a valuable complement to those based 
on data from the general population, both as an enriched source of exposures to 
illnesses, treatments, and confounders, and as a valuable aid to those making 
prescribing decision in such settings. This can be seen most clearly in our 
findings regarding outcomes. Expectant mothers and those caring for them need 
to know that babies born to those attending specialist psychiatric care may be at 
significantly increased risk of early morbidity of sufficient severity to warrant 
neonatal admission. Although admission rates appeared to be higher in those 
exposed to SSRIs in the AMU sample, the outcomes in the MLS sample pointed to 
illness severity being a more important predictor than exposure to medication. 
Rates of admission for different exposures in AMU and the MLS are shown in 
Figure 8-6. 
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Figure 8-5 – Timing of exposure to SSRIs by trimester 
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Figure 8-6 – Neonatal admission rates for select exposures 
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Additionally, the effects of depression severity and the moderating influence of 
antidepressants on gestation and birthweight merit further exploration, as 
although the associations we found between them and HADS-D and were 
statistically significant, it does not necessarily follow that they were clinically 
significant. Importantly, HADS-D did not predict admission, nor preterm 
delivery. 
 
Observations 
Perinatal depression, both antenatal and postnatal, remains an important 
clinical condition, with potentially far-reaching consequences for mothers and 
babies, in addition to the wider family, health services, and society in general. 
Optimal management necessitates relevant data, and this is still lacking in many 
areas. While a not insignificant amount is known about risk factors for and 
consequences of perinatal depression, we have less comprehensive knowledge 
about the advantages and disadvantages of antenatal antidepressants and, in the 
absence of adequate empirical data, current clinical practice and 
recommendations are largely based on extrapolation from findings of studies 
outwith pregnancy, retrospective observations, and expert consensus. We still 
are not absolutely certain how common depressive illness is during pregnancy, 
and foundational to the gaps in our knowledge in this specialist area are the 
intertwined issues of our lack of comprehension about the pathophysiologies of 
depression, our limitations in elucidating how antidepressants actually work, and 
our relative ignorance about the mechanisms underlying the intergenerational 
transmission of illness and risk. Most facts we do have are consistent with the 
overall positive zeitgeist with regards to the role of antenatal antidepressants, 
but there is still much to learn, and no place for complacency. 
Notwithstanding, we can be confident that perinatal depression and related 
problems (including anxiety and stress) and their consequences  are common and 
concerning, and that the therapeutic advantages of antidepressants appear to 
outweigh their risks for at least some expectant mothers and their offspring. 
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The account outlined above raises a number of important issues that suggest 
current and future priorities with regards to clinical care and research. 
 
Clinical considerations 
As discussed in Chapter 1, we do not know exactly how to conceptualise 
depression, nor even how to define clear and valid boundaries between normal 
depressive symptoms and a pathological state. It is unsurprising, therefore, that 
we are not clear about the prevalence of depression during pregnancy. 
 
The validity, reliability, and utility of diagnosing depression 
DSM is widely used in both clinical practice and research, and indeed, evidence-
based recommendations about management are largely based on the outcomes 
of studies founded on DSM criteria. However, in addition to the limitations of 
DSM criteria in diagnosing major depression within and outwith pregnancy 
outlined in Chapter 1, when Regier et al. (2013) assessed the test-retest 
reliability of categorical diagnoses using DSM-5 operational criteria they 
concluded that the reliability of a diagnosis of major depressive disorder made 
by independent clinicians was “questionable”, with a pooled intraclass kappa of 
0.28 (0.20-0.35 95% confidence interval). (The individual kappas for the four 
different sites included were 0.13, 0.25, 0.27, and 0.42, i.e. three out of the 
four were categorised as “unacceptable” or “questionable”.) 
If DSM (or any other operational) criteria are neither valid nor reliable and 
cannot consistently discriminate between pathology and physiology, of what 
value are they? This is critical question to which there is no final answer. Parker 
(2000) critiques the unitarian conceptualisation of depression as being on a 
continuum, and the inadequacy of operational criteria in distinguishing between 
aetiologically distinct subtypes. Memorably, he compares classifying depression 
on the basis of symptoms to distinguishing between cars by using tyre size, 
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indicating that depressive symptoms shared between different underlying causes 
are a poor basis on which to judge severity of illness, or evaluate the 
effectiveness of different interventions. Parker uses the example of 
breathlessness, pointing out that we would not and should not measure the 
efficacy of a treatment that addresses only one underling cause, e.g. an 
antibiotic, in a heterogeneous sample made up of those with asthma, pulmonary 
embolus, and heart failure, in addition to pneumonia (Parker, 2009).  In this 
context, counting symptoms to diagnose depression and/or rate its severity 
appears of limited relevance, despite being the approach adopted by both DSM-5 
and ICD-10. Parker (2006) goes so far as to state that DSM and ICD-10 “have 
outlived their usefulness”, with de Leon (2015) stating that DSM-III had 
“devastating consequences” that “put European psychiatry to sleep”, and 
describing DSM-5 as a “dead end”. However, Parker’s views have been critiqued 
(and perhaps marginalised), with Goldney (2006) reaching more optimistic 
conclusions (Fahy, 2002). 
Despite the limitations of operational criteria with regards to validity and 
reliability, Kendell and Jablensky (2003) contend that diagnoses do not have to 
be valid to be useful. We know that whatever depression criteria, structured 
clinical interviews, or rating scales are measuring, whether general distress, 
anxiety, or true depression, nevertheless they can be useful in identifying those 
at increased risk, and in monitoring response to treatment, as diagnoses and 
scores do correlate with outcomes. In other words, there is both validity and 
utility in our current clinical and research assessment tools, despite their 
shortcomings. It is noteworthy that Steer et al. (1992) reported that when they 
analysed Beck Depression Inventory scores as a continuous variable, they found 
that the risk of adverse outcomes (preterm deliveries, low birthweights, or 
small-for-gestational age babies) increased by “5-7% . . . for each point the BDI 
total score increased”. This suggests that, in addition to using cut-off scores to 
determine “caseness”, using continuous measures of 
depression/anxiety/distress, i.e. allostatic load, may be a clinically appropriate 
and relevant used of validated rating scales. Parker et al. (2015) call for this use 
of the EPDS, as highlighted in Chapter 1. 
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One final point regarding qualitative versus quantitative measures in evaluating 
depression is that, despite Parker’s (2009) compelling argument that 
interventions for depression should be matched to the underlying pathology for 
maximum effect, nevertheless, studies continue to indicate that using 
depressive subtypes does not predict response to antidepressants, consistent 
with Kendell and Jablensky’s (2003) observation that even the boundaries 
between psychiatric disorders are not well demarcated, and that variation in 
symptoms appears to be dimensional (Arnow et al., 2015).  
 
Screening for perinatal depression 
Given the uncertainties pertaining to diagnosing whatever we think we mean by 
“depression”, it is hardly surprising that some have questioned the validity of 
screening for a condition we cannot define. It is still unclear whether or not 
screening for depression is effective in improving outcomes in primary care 
(Thombs & Ziegelstein, 2014). Thombs et al. (2014) conducted a systematic 
review of perinatal depression screening and outcomes, and found only one 
eligible postnatal study, on which they opined that final conclusions should not 
be based, due to methodological limitations. Despite the challenges and 
uncertainties, Milgrom and Gemmill (2014) are more optimistic about screening 
for perinatal depression, given that it is “serious, prevalent, under-detected and 
treatable”, and “a tolerable screening procedure of known accuracy is 
available”. 
Guidelines vary in their recommendations, while recognising the limitations of 
the current evidence. The American College of Obstetricians and Gynecologists 
(ACOG) recommend screening all women perinatally, while Australian guidelines 
recommend universal screening at least once both antenatally and postnatally – 
both countries recommend the use of a validated rating scale, with the 
Edinburgh Postnatal Depression Scale (EPDS) comparing favourably to 
alternatives (Austin et al., 2011; ACOG, 2015). British guidelines also 
recommend antenatal and postnatal screening, with an emphasis on clinical 
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inquiry via psychosocial assessment and specific questions (essentially the PHQ-
2), and to “consider using” rating scales (such as the EPDS) as “part of a 
subsequent assessment”, “an aid to clinical monitoring” and “to facilitate 
discussion of emotional issues”, rather than as the primary means of screening 
(NICE CG192, 2014; SIGN, 2012). Interestingly, although UK guidelines emphasise 
reliance on the PHQ-2, Austin et al. (2011) reported that the EPDS is superior. 
The different emphases appear related to the relative strengths and weaknesses 
of clinical inquiry and rating scales – neither is invulnerable to false positives or 
false negatives. The SIGN guidelines in particular take account of this, not least 
by emphasising the importance of a longitudinal perspective, whereby those who 
screen positive are followed up in two weeks to detect persisting symptoms 
(Matthey & Ross-Hamid, 2012; SIGN, 2012). It is noteworthy that Cameron, 
Lawton and Reid (2009) found that Scottish GPs (who were aware of the study) 
“rated depression” in 52% of patients who independently “screened positive” for 
“probable depression” (HADS ≥11), 24% of those with “possible depression” 
(HADS 8-10), and 8% of those with “no depression” (HADS <8), suggesting that 
GPs are circumspect in diagnosing depressive illness (and in prescribing 
antidepressants), placing symptoms and distress in clinical context. 
Despite the lack of conclusive evidence, the available guidelines make sensible 
use of what we do know, and the emphases on awareness of risk factors and 
need for screening, shared documentation and management plans, prompt 
review of antenatal medication, and referral to specialist services where 
indicated, are welcome. 
However, as evidenced by our findings that many women are exposed to 
antidepressants (and other psychotropics) periconception, and make decisions 
about continuing or stopping early in pregnancy, before/without the benefits of 
medical advice, guidelines also recognise the desirability of anticipating 
pregnancy. The recommendations by both SIGN (2012) and the updated NICE 
CG192 guidelines (2014) include that medication prescribed to those of 
“childbearing potential” should be accompanied by relevant information on risks 
and benefits, advice on contraception, and consideration of discontinuing if 
pregnancy is planned. 
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Anticipating unplanned pregnancy 
This direction is important, given that a significant proportion of pregnancies are 
unplanned and/or unintended. It has been reported that more than 50% of all 
pregnancies in the UK and the US are unplanned, with possibly even higher rates 
in women with mental illness (associated with increased adverse consequences), 
although research using different methodology and terminology suggests that the 
true figure lies somewhere between one in three, and one in six (Barkla et al., 
2000; O’Sullivan et al., 2005; Lakha & Glasier, 2006; Wellings et al. 2013). 
However, it should be noted that rates appear to vary significantly between 
different age groups, with almost half of pregnancies in women aged 16-19 being 
described as unplanned, and clear differences between those terminating their 
pregnancies, and those continuing. For example, almost nine in ten of those 
undergoing abortion reported their pregnancies as unplanned, compared with 
less than one in ten of those proceeding to delivery. And more than one third of 
women completing pregnancy describe conceiving as unintended, although not 
necessarily unplanned. Falling pregnant is ultimately not entirely subject to 
human planning. 
It follows, therefore, that all depressed women of childbearing potential should 
be treated with the same degree of vigilance, skill and tenacity as their 
expectant counterparts, as some may fall pregnant unexpectedly, and the stakes 
are high for mother and child. Indeed, in depressed women, unplanned 
pregnancy is a risk for unplanned antidepressant discontinuation, with 
consequent risk of relapse, and resumption of medication in more than 50% 
(Cohen et al., 2006; Roca et al., 2013). As in pregnancy clinicians are caring for 
two distinct patients with different needs and vulnerabilities, the fundamental 
and primary principle of western medicine, primum non nocere (“first do no 
harm”), reminds doctors that prescribing medication for pregnant women may 
be associated with a variety of significant risks to the developing fetus in both 
the short and longer term, including chronic disability (Herranz, 2002). 
Thalidomide remains a vivid illustration of the frightening potential for 
prescribers with good intentions to cause significant and extensive harm 
(Rasmussen, 2012). 
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Managing perinatal depression 
A full review and discussion on the management of perinatal depression is 
beyond the scope of this thesis, and excellent evidence-based guidelines and 
reviews are available (SIGN, 2012; Howard et al., 2014; NICE, 2014; Ray & 
Stowe, 2014; Taylor, Paton & Kapur, 2015; McAllister-Williams et al., 2017). In 
the absence of evidence specific to antenatal medication, all concur that good 
practice during pregnancy is modeled on good practice outwith, in that one 
should prescribe when clinically indicated (in itself difficult to define), using the 
least number of drugs at their lowest effective doses, involving the patient and 
her family in the decisions, with a joint weighing of the potential benefits and 
risks of treating and not treating. While adverse outcomes have been reported to 
be associated with all currently available individual drugs and their classes, 
nevertheless (with the exception of Paroxetine, and occasionally Venlafaxine), 
no antidepressants are absolutely contraindicated or advised against, and SSRIs, 
TCAs, and SNRIs are recommended by the current NICE guidelines. Of course, 
choice of medication is specific to each individual, and balance is required – 
while no drug should be prescribed for longer than necessary, or at a higher dose 
than necessary, it is important that treatment is of adequate dose and duration, 
as being exposed to a medication at an inadequate dose or for too short a period 
merely increases risk rather than addressing it, and relapse following cessation 
of treatment is not uncommon (Weisskopf et al., 2015). 
Koren (2012) uses the title, “Depression in pregnancy: Time to stop terrifying 
pregnant women”, to emphasise the importance of treating antenatal depression 
effectively. While there are known and unknown risks associated with antenatal 
antidepressants, it is not the case that we are complacently advocating the 
indiscriminate use of toxic placebos. Rather, we are thoughtfully recommending 
nuanced and individually-tailored effective evidence-based interventions to 
women suffering from significant illnesses that have the potential for both 
mortality and morbidity, in both mothers and babies, in the short and long term. 
Of course, non-pharmacological interventions should also be considered as 
clinically indicated, and both psychosocial management and other physical 
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treatments have been discussed (Richards & Payne, 2013; Dennis, 2014; Stuart & 
Koleva, 2014; Kim et al., 2015). Unfortunately, however, there is often even less 
evidence to guide decisions on these perinatally than there is for 
antidepressants. 
 
Future research 
In this thesis and series of related pilot studies we have reviewed the 
international literature and analysed local data, to ascertain both our current 
status and the future feasibility of research regarding the characteristics and 
consequences of antenatal exposure to SSRIs. We have noted the 
methodological, practical, and ethical challenges in studying this area; the 
complex interactions between antenatal antidepressants and the perinatal 
depression for which they are prescribed; the grievous issue of confounding; and 
the (often extensive) gaps in and uncertainty over our knowledge to date. 
Our observations have highlighted both established facts, and outstanding 
questions that remain unanswered. Several future lines of inquiry suggest 
themselves, and have been identified numerous times by different authors. 
There is an ongoing pressing need to identify exactly what exposures, at what 
stages of pregnancy, are associated with what clinically relevant outcomes, and 
for whom. 
In light of so many variables, and the relative frequency of different outcomes 
(some common, some rare), the ongoing use of large database linkage studies is 
appealing (Stewart, 2014). The advantages of “big data” are many, including the 
potential for large numbers to facilitate adequate statistical power, the 
inclusion of all subjects within a population, a longitudinal perspective across 
individuals’ lives, and a relatively cost-effective and economic retrospective tool 
for addressing health-related queries. 
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However, there are also numerous disadvantages, as discussed throughout this 
thesis, and by Munk-Jørgensen et al. (2014) in general, and Grzeskowiak, Gilbert 
and Morrison (2013) regarding the use of administrative databases to explore 
perinatal exposures and outcomes in particular. These include (but are not 
necessarily limited to) biased, non-representative populations due to inclusion 
criteria and/or missing data; details of exposures and outcomes that are one or 
more steps removed from the clinical truth; a lack of explanatory power, in that 
only associations can be demonstrated, and not causality; a tendency towards 
finding statistical rather than clinical significance; and the inability to control 
for unknown confounders. Moreover, due to the sheer numbers involved, there is 
the risk of problematic heterogeneity, in that factors that should be assessed 
independently are often lumped together. All must be carefully considered and 
addressed in future research. 
Some of these issues are illustrated clearly by antenatal antidepressants. In the 
order of disadvantages given above, many of the studies referenced above have 
been based on skewed populations (e.g. insurance-related, or live births only), 
and have excluded any for whom not all data was available (sometime >50% of 
the original sample); have identified medication prescribed/dispensed/paid for 
rather than medication actually taken; have focused on exposure to medication 
in isolation from exposure to the condition for which it was prescribed; have 
highlighted ‘cardiac abnormalities’ as an adverse outcome, regardless of how 
clinically significant; and have not taken into account other known contributors 
to the risks under study, including psychosocial stress. 
One major problem is the lack of precision with regards to both exposures and 
outcomes. Antidepressants are not a homogeneous group, with congruent effects 
(Ciraulo, Shader & Greenblatt, 2011). For example, SSRIs alone vary considerably 
pharmacokinetically, pharmacodynamically, and pharmacogenetically, are 
known to cross the placenta to different degrees, and are not necessarily equally 
efficacious, with a complex interaction with serotonin transporter genotype 
(Hendrick et al., 2003; Serretti & Artioloi, 2004; Serretti et al., 2007; Cipriani et 
al., 2009; Kato & Serretti, 2010; Ababneh, Ritchie & Webster, 2012; Altieri et 
al., 2014). Similarly, as discussed in Chapters 4 and 6, different risks may be 
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associated with different SSRIs, but grouping together heterogeneous outcomes 
such as “major malformations” may mask some true associations, e.g. the 
Reefhuis/Bérard discrepancy (Reefhuis et al., 2015; Bérard, Zhao and Sheehy, 
2015). 
Several factors must be considered when addressing/avoiding these issues. Not 
necessarily in order of importance, these include collecting data prospectively 
and longitudinally, in inclusive and representative samples of sufficient size, 
with an adequate level of detail and accuracy, for specific exposures and 
specific short term and long term outcomes, that can be analysed statistically. 
The preferred approach is to use prospective rather than retrospective data, and 
to collect all information desired for analysis on an intentional basis. This 
observation was presaged almost 40 years ago by Doering and Stewart (1978), 
and reiterated by Wisner et al. (2009), specifically with regards to evaluating 
outcomes associated with individual SSRIs. It ensures that all necessary data is 
available in a format that can be accessed and used, however, demands 
proactive intentionality, time, resources, and funding. Both the administrative 
databases synthesised by ISD, and the data collection forms used in the PMHS 
and the MLS can serve as a convenient source of prospectively gathered data, 
collected on a routine basis. However, the data collection forms and their 
associated processes would require revision to render them less open to 
idiosyncratic and subtotal completion and ambiguity, to ensure that they are 
always filled for each patient, and updated at each contact. 
This segues into a related issue – the data must be longitudinal. While cross-
sectional studies can provide a snapshot in time, it is clear that antenatal 
exposures are dynamic, and fluctuate unpredictably in individuals throughout 
pregnancy. This was illustrated by our findings regarding prescribing changes 
during pregnancy, and one of the motivators underlying the studies by Petersen 
et al. (2011), Margulis, Kang and Hammad (2014) and Charlton et al. (2015). 
However, it is not only drugs that change during pregnancy. Illnesses vary, too, 
as does objective and subjective stress (Matthey & Ross-Hamid, 2012; Parker et 
al., 2015). As severity of illness may be even more predictive of adverse 
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outcomes than exposure to medication, it is desirable if not necessary that the 
longitudinal courses of exposure to both illness severity and stress, and also 
known confounders such as comorbid medical conditions and associated 
medication, and other psychoactive substances such as alcohol, tobacco and 
non-prescription drugs, are estimated. As many of these details are not captured 
by administrative databases, there remains a need for planned prospective, 
longitudinal, observational data collection, ideally in clinical settings such as the 
PMHS and the MLS. 
While ISD can provide data representative of the whole population, and thus 
contribute to inferences relevant to all, including background baseline norms, 
there are some advantages in closer scrutiny of the different populations seen by 
the PMHS and the MLS. These include smaller numbers at increased risk of both 
exposures and adverse outcomes, as well as the potential to collate more 
relevant data from the detailed and comprehensive assessments carried out by 
the respective specialist teams. Moreover, longitudinal information on illness, 
stress, and medication, as well as known confounders is routinely documented. 
Organising and structuring the documentation to facilitate easier retrospective 
analysis, while dovetailing with any mandatory local templates, and avoiding 
unnecessary duplication, would be a route to achieving a powerful valuable 
repository of knowledge. Databases from the PMHS and the MLS would have the 
potential to provide knowledge directly applicable to the patients seen, e.g. 
increased neonatal admission rates, and the likely impact of associated 
medication. 
As well as having access to sufficient details in larger enough and representative 
samples, data would of course have to be accurate. This may entail utilising 
more than one source of information, e.g. combining local details from forms, 
letters, and electronic records such as Eclipse, FACE, SAMS, and BadgerNet, with 
centralized ISD figures, to permit verification. This would have the advantages 
of allowing clinicians to compare their findings with what official sources 
indicate, and give an estimate of issues such as adherence over time. 
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Such data linkage and cross-checking, while time-consuming, would foster 
confidence in the level of detail achieved for statistical analysis. While it would 
not allow access to information such as maternal and fetal genotype, nor the 
exact level of fetal exposure to drugs, nevertheless, it would permit better 
confirmation of whether drugs prescribed and dispensed were actually, at what 
doses, when, and how consistently. Estimates of adherence during pregnancy are 
generally fairly high (although findings and conclusions are affected by a variety 
of methodological issues, such as non-representative populations, e.g. >80% 
reporting a planned pregnancy), but some studies suggest that up to half of 
pregnant women prescribed psychotropics may not take medication as 
prescribed, especially those with more severe depressive symptoms (Bosman et 
al., 2014; Lupattelli et al., 2015). Critically, it would also be possible to 
establish exact gestation at each data timepoint, a necessary prerequisite to 
define exposure type, but one that is challenging to achieve retrospectively from 
large databases (Margulis et al., 2015). While some have simply assumed a 
uniform duration for all pregnancies, it is clear that the majority of pregnancies 
will not last exactly 280 days, and this can lead to inaccuracies in defining 
exposure, as discussed and illustrated in our AMU sample, affecting 25% of those 
for whom actual gestational age at birth could be calculated (Chapters 4 and 5). 
As noted above, future research also needs to use specific exposures and 
outcomes, as it cannot be assumed that even the same antidepressant, at the 
same dose, for the same duration, and for the same indication, will be 
associated with the same outcome(s) in different women. Moreover, as many of 
the existing studies simply report categorical outcomes for group exposures, it is 
critical that these are teased apart. For example, despite the methodological 
robustness of Oberlander et al’s 2008 study, it is imperative to note that almost 
40% of the women in their sample were exposed to Paroxetine, indicating that 
their findings and conclusions are not necessarily relevant to patients attending 
the MLS now, when Paroxetine is scarcely used. 
Another challenge in observational studies of perinatal exposures and outcomes 
is that many are either very common or extremely rare, and therefore large 
numbers are required to establish statistically significant relationships. While 
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this is true in the general population, the enriched samples in the PMHS and the 
MLS afford opportunities to explore more specific and exaggerated exposures 
and outcomes, while accounting for known confounders to some extent, using 
appropriate multivariate analyses. 
One final factor of note is that while short term health outcomes have been 
relatively straightforward to study, longer term consequences, and particularly 
non-health outcomes, may be less specific and/or easy to establish, e.g. suicide, 
criminality, academic/vocational achievement, fertility, etc. 
Comprehensive exploration of these factors requires follow-up over decades, 
and extensive linkage across “electronic patient records and other population-
based datasets”, e.g. social, criminal justice, and educational databases, with 
all the associated practical and ethical challenges. The Farr Institute @ Scotland 
(www.farrinstitute.org, formerly the Scottish Health Informatics Programme) has 
the potential to contribute to this aspiration, although it is yet early in its 
inception (Pavis & Morris, 2015). 
 
Future research proposals 
In light of this several future directions for research emerge. 
Firstly, scanning. Despite the barriers we experienced in completing our pilot, 
we noted with interest that Dr Michael Craig, Senior Lecturer in Reproductive 
and Developmental Psychiatry at Kings College London, received funding to 
conduct a similar MR study based on virtually identical hypotheses; that prenatal 
depression is a risk factor for structural and functional abnormalities in limbic 
brain regions (Craig, 2015). Collaboration and sharing our experience may prove 
fruitful. 
Secondly, it appears wise to repeat and extend our retrospective analyses in the 
MLS, by including more patients over several years to confirm our findings, 
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further refining our methodology, and exploring reasons for admissions to the 
NNU in more detail. 
Thirdly, it would be relevant to characterise reasons for admission to the NNU in 
the general population, both to provide a context in which to place the MLS 
findings, and to fill the gap in the literature – we were unable to find a recent 
paper addressing this. 
However, it must be acknowledged that these plans cannot address one of the 
most important questions; what are the long term consequences of exposure to 
antenatal depression and/or antenatal antidepressants? 
While the gold standard would be to undertake a prospective cohort study, this 
would be costly in terms of years, resources, and finances. A more efficient 
option would be to mine the ALSPAC data. 
The Avon Longitudinal Study of Parents and Children (ALSPAC, 
www.bristol.ac.uk/alspac/) began in the early 1990s, and has collected a wide 
range of health, social, and other data for over 14,000 mothers and their 
children since. It is “the most detailed study of its kind in the world”, with over 
1000 academic publications, and we have confirmed that it would be possible to 
access their dataset retrospectively to establish details of antenatal depression 
and medication, and maternal and child outcomes, in addition to key known 
confounders (Appendix 17). Although at one point we considered incorporating 
ALSPAC data into our research, we were advised that this proposal would merit a 
doctoral project in its own right. We will prepare the groundwork for this, and 
apply for funding, in anticipation of identifying a suitable researcher. 
However, our aspiration is to set up a prospective cohort study, initially within 
the MLS, and thereafter in the AMU. The ultimate goal is a Scotland- or UK-wide 
register of antenatal exposure to depression and antidepressants, modeled on 
the successful UK Epilepsy and Pregnancy register, which has yielded valuable 
information on the risks of antenatal anticonvulsants 
(www.epilepsyandpregnancy.co.uk/home.htm). This will involve reviewing the 
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processes surrounding the assessment and review of patients attending the MLS, 
and revising the data collection form to ensure that all relevant details are 
captured in an unambiguous way. Moreover, to prevent forms from being left 
uncompleted or incomplete, we are considering the possibility of devising a 
bespoke perinatal assessment template, thus ensuring both that clinical 
assessment and documentation are comprehensive, and that all details relevant 
to our research questions are collected and updated at each contact. In addition 
to this being a paper proforma, it is possible that an electronic FACE template 
could be produced, which would facilitate efficient automated data extraction 
into an Excel® spreadsheet for ease of analysis. This would allow data linkage 
via CHIs. 
Making prospective data collection part of routine clinical practice within the 
MLS can be justified on the grounds of providing and evidencing excellent care, 
and will provide an accurate and accessible resource for answering some key 
research questions. In particular, establishing the practice of regular and routine 
self-rating of symptoms via validated rating scales may inform management 
through monitoring illness severity and response to treatment, and facilitate 
timely decisions about interventions. Although well-established in clinical 
psychology, the use of mood diaries in unipolar depression to monitor response 
to medication has not been well-studied. Notwithstanding, there is significant 
face validity in employing rating scales as an adjunct to clinical assessment, and 
some hold that involving patients in their own care is empowering, and likely to 
lead to better outcomes (Bauer et al., 2006). Therefore, asking the MLS patients 
to complete a mood rating scale every two or four weeks would help to establish 
data on the longitudinal course of their symptoms in relationship to treatment, 
and provide sufficient detail to allow a more nuanced analysis of the 
relationships between illness, treatment, and outcomes. 
Diagnosing depression is difficult, as it defies decisive definition. However, as 
numerous studies indicate that whatever “depression” rating scales are 
measuring antenatally, it correlates with perinatal outcomes, we propose that 
alongside ‘care as usual’ in the MLS, with clinical diagnoses and treatment 
decisions, one or more outcome measures be routinely employed (Steer et al., 
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1992). Ideally, in addition to being valid, these should be both brief and patient-
completed. While evidence exists to support the use of most available rating 
scales outwith pregnancy, Ji et al’s (2011) findings indicate that interpretation 
must be intelligent, and Parker et al. (2015) advise against imposing cut-off 
points on continuous measures. Scores derived from rating scales should 
therefore be analysed as a continuous predictor variable, rather than 
categorical. Although the PHQ-2 (Patient Health Questionnaire-2, the two 
questions recommended by NICE and coded on Eclipse) and the EPDS are perhaps 
the most sensitive screening tools for antenatal depression, it is not clear which 
rating scales are best for gauging severity and/or most sensitive to change in 
response to medication (Austin et al., 2011). Therefore, we propose a 
systematic review of studies on depression rating scales in pregnancy, with 
particular reference to their properties in rating severity and sensitivity to 
change. Meantime, continuing to use the HADS appears reasonable. 
Measuring depression and describing medication in detail during pregnancy, and 
linking with obstetric and paediatric outcomes, will help to establish a 
potentially fruitful research culture and effort within the MLS, enhancing clinical 
care. However, the patients attending the MLS are not representative of the 
general population. (They are, of course, representative of pregnant women 
with depression and/or prescribed antidepressants requiring psychiatric care.) 
As not all mums-to-be exposed to depression or antidepressants in Ayrshire are 
referred to or seen via the MLS, it is important to consider what further research 
would be desirable and feasible within AMU, with the potential for extension to 
the rest of Scotland and the UK once methodology, infrastructure, and funding 
are established. This is where our proposal regarding an Ayrshire Register of 
Depression and Antidepressants in Pregnancy is relevant, and again, this will 
involve a considerable investment of time, money, and resources. It is therefore 
best taken forward by a dedicated and appropriately funded research team, 
rather than relying on full time clinicians, although the lessons learned from and 
experience with the MLS research will provide a key foundation. Following the 
completion of our current programme of research, we plan to work towards such 
an undertaking in Ayrshire 
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Until then, as per guidelines, we recommend that all women booking at AMU are 
screened for depressive symptoms using the PHQ-2 (or the EPDS), and that any 
for whom there are concerns, and/or any on antidepressants, are referred to or 
discussed with the MLS. 
 
Conclusions 
This thesis describes the background to, findings of, and conclusions from a 
series of pilot studies exploring the characteristics and consequences of 
antenatal exposure to SSRIs, and related factors. Chapter 1 provides an overview 
of some key issues pertaining to perinatal depression. Chapter 2 gives Chapter 3 
outlines the characteristics of antenatal psychiatric medication in a regional 
specialist mental health service, with Chapter 4 describing complementary 
findings in general and local specialist settings. Chapter 5 highlights certain 
outcomes associated with exposure to antenatal depression and antidepressants, 
and Chapter 6 discusses key methodological issues in using “big data” to 
investigate perinatal outcomes and exposures. Chapter 7 presents challenges in 
neuroimaging structural sequelae in infants exposed in utero. This chapter 
provides a synthetic summary of key findings, and proposals for future research. 
Antenatal depressive symptoms and illness are common, as are antenatal 
antidepressants, taken by nearly one in 10 pregnant women in the local Scottish 
population. Exposure to either depression or antidepressants is associated with 
diverse adverse outcomes for mothers and babies, but much remains unknown, 
particularly the long term sequelae. While current clinical guidelines provide 
apposite and sage recommendations on the basis of the available evidence, 
further research is needed to confirm detailed characteristics of both antenatal 
depression and antidepressants, and their consequences. The retrospective 
interrogation of population-based datasets has hitherto yielded much 
illumination, yet there remains a significant need for more comprehensive, 
detailed, and accurate information on which to base the information available to 
pregnant women, and the care they receive. Intentional prospective longitudinal 
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clinical data collection has an important role to play in ensuring that we 
continue to help mothers, while caring for their babies. 
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Appendix 1 – Systematic review search strategy 
Database Strategy Date 
searched 
Results 
Medline & 
Embase 
(SSRIs) 
Database: Ovid MEDLINE(R) 1946 to Present with Daily Update, Embase <1974 to 
2016 October 07> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     "selective serotonin reuptake inhibitors".mp. [mp=ti, ab, ot, nm, hw, kf, px, 
rx, ui, tn, dm, mf, dv, kw, fs] (15258) 
2     "Serotonin and Noradrenaline Reuptake Inhibitors"/ (4622) 
3     Serotonin Uptake Inhibitors/ (58591) 
4     serotonin noradrenalin reuptake inhibitor/ (4539) 
5     serotonin uptake inhibitors/ (58591) 
6     citalopram/ or fluoxetine/ (63464) 
7     Fluvoxamine/ (13908) 
8     Paroxetine/ (28850) 
9     Sertraline/ (25059) 
10     (citalopram or cipramil).ti,ab. (10018) 
11     (dapoxetine or prilegy).ti,ab. (412) 
12     (escitalopram or cipralex).ti,ab. (4800) 
13     (fluoxetine or prozac or oxactin).ti,ab. (23682) 
14     (fluvoxamine or faverin).ti,ab. (5440) 
15     (paroxetine or seroxat).ti,ab. (11525) 
16     (sertraline or lustral).ti,ab. (8668) 
17     ssri.ti,ab. (12886) 
18     sri.ti,ab. (14001) 
19     ssris.ti,ab. (14044) 
20     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 
16 or 17 or 18 or 19 (145561) 
21     pregnan*.ti,ab. (911901) 
22     exp Pregnancy/ (1514688) 
23     Pregnant Women/ (59352) 
24     exp pregnancy/ (1514688) 
25     pregnant woman/ (74025) 
26     womb.ti,ab. (1518) 
27     fetal.ti,ab. (456149) 
28     exp Fetus/ (341613) 
29     fetus/ (267489) 
30     foetal.ti,ab. (34371) 
31     Prenatal Exposure Delayed Effects/ (41776) 
32     prenatal exposure/ (44025) 
33     ant*natal.ti,ab. (61688) 
34     per*natal.ti,ab. (130630) 
35     pr*natal.ti,ab. (166818) 
36     "in utero".mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, tn, dm, mf, dv, kw, 
fs] (52142) 
37     intr*uterine.ti,ab. (100138) 
38     fetus.ti,ab. (125716) 
39     foetus.ti,ab. (13488) 
40     21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 
34 or 35 or 36 or 37 or 38 or 39 (2143160) 
41     exp Great Britain/ (335856) 
42     (national health service* or nhs*).ti,ab,in. (300770) 
43     (english not ((published or publication* or translat* or written or language* 
or speak* or literature or citation*) adj5 english)).ti,ab. (50100) 
44     (gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or 
united kingdom* or (england* not "new england") or northern ireland* or northern 
irish* or scotland* or scottish* or ((wales or "south wales") not "new south wales") 
or welsh*).ti,ab,jw,in. (4035796) 
45     (bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not 
alabama*) or bradford or "bradford's" or brighton or "brighton's" or bristol or 
"bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or 
(canterbury not zealand*) or ("canterbury's" not zealand*) or chelmsford or 
"chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry 
or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or 
("durham's" not (carolina* or nc)) or ely or "ely's" or exeter or "exeter's" or 
gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not 
nebraska*) or ("lincoln's" not nebraska*) or (liverpool not (new south wales* or 
nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* or 
10/10/16 485 
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ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or 
"manchester's" or (newcastle not (new south wales* or nsw)) or ("newcastle's" not 
(new south wales* or nsw)) or norwich or "norwich's" or nottingham or 
"nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or 
plymouth or "plymouth's" or portsmouth or "portsmouth's" or preston or 
"preston's" or ripon or "ripon's" or salford or "salford's" or salisbury or "salisbury's" 
or sheffield or "sheffield's" or southampton or "southampton's" or st albans or 
stoke or "stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield 
or "wakefield's" or wells or westminster or "westminster's" or winchester or 
"winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or 
boston* or harvard*)) or (york not ("new york*" or ny or ontario* or ont or 
toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))).ti,ab,in. (2847979) 
46     (bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st 
asaph or "st asaph's" or st davids or swansea or "swansea's").ti,ab,in. (112223) 
47     (aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or 
"edinburgh's" or glasgow or "glasgow's" or inverness or (perth not australia*) or 
("perth's" not australia*) or stirling or "stirling's").ti,ab,in. (402187) 
48     (armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or 
londonderry or "londonderry's" or derry or "derry's" or newry or 
"newry's").ti,ab,in. (51324) 
49     or/41-48 (4882671) 
50     (exp africa/ or exp americas/ or exp antarctic regions/ or exp arctic 
regions/ or exp asia/ or exp australia/ or exp oceania/) not (exp great britain/ 
or europe/) (5137913) 
51     49 not 50 (4614740) 
52     United Kingdom/ (609021) 
53     (national health service* or nhs*).ti,ab,in,ad. (347509) 
54     (english not ((published or publication* or translat* or written or language* 
or speak* or literature or citation*) adj5 english)).ti,ab. (50100) 
55     (gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or 
united kingdom* or (england* not "new england") or northern ireland* or northern 
irish* or scotland* or scottish* or ((wales or "south wales") not "new south wales") 
or welsh*).ti,ab,jw,in,ad. (4087026) 
56     (bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not 
alabama*) or bradford or "bradford's" or brighton or "brighton's" or bristol or 
"bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or 
(canterbury not zealand*) or ("canterbury's" not zealand*) or chelmsford or 
"chelmsford's" or chester or "chester's" or chichester or "chichester's" or coventry 
or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or 
("durham's" not (carolina* or nc)) or ely or "ely's" or exeter or "exeter's" or 
gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not 
nebraska*) or ("lincoln's" not nebraska*) or (liverpool not (new south wales* or 
nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* or 
ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or 
"manchester's" or (newcastle not (new south wales* or nsw)) or ("newcastle's" not 
(new south wales* or nsw)) or norwich or "norwich's" or nottingham or 
"nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or 
plymouth or "plymouth's" or portsmouth or "portsmouth's" or preston or 
"preston's" or ripon or "ripon's" or salford or "salford's" or salisbury or "salisbury's" 
or sheffield or "sheffield's" or southampton or "southampton's" or st albans or 
stoke or "stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield 
or "wakefield's" or wells or westminster or "westminster's" or winchester or 
"winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or 
boston* or harvard*)) or (york not ("new york*" or ny or ontario* or ont or 
toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))).ti,ab,in,ad. (2865308) 
57     (bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st 
asaph or "st asaph's" or st davids or swansea or "swansea's").ti,ab,in,ad. (112799) 
58     (aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or 
"edinburgh's" or glasgow or "glasgow's" or inverness or (perth not australia*) or 
("perth's" not australia*) or stirling or "stirling's").ti,ab,in,ad. (404171) 
59     (armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or 
londonderry or "londonderry's" or derry or "derry's" or newry or 
"newry's").ti,ab,in,ad. (51518) 
60     or/52-59 (5007306) 
61     (exp "arctic and antarctic"/ or exp oceanic regions/ or exp western 
hemisphere/ or exp africa/ or exp asia/ or exp "australia and new zealand"/) not 
(united kingdom/ or europe/) (3589895) 
62     60 not 61 (4787301) 
63     51 or 62 (4842059) 
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64     20 and 40 and 63 (637) 
65     remove duplicates from 64 (538) 
66     limit 65 to english language (525) 
67     limit 66 to human (485) 
68     limit 67 to humans (485) 
Cochrane 
(SSRIs) 
ID Search Hits 
#1 "selective serotonin reuptake inhibitors":ti,ab,kw  (Word variations 
have been searched) 1566 
#2 MeSH descriptor: [Serotonin and Noradrenaline Reuptake Inhibitors] 
explode all trees 1 
#3 MeSH descriptor: [Serotonin Uptake Inhibitors] explode all trees
 2660 
#4 MeSH descriptor: [Fluvoxamine] explode all trees 371 
#5 MeSH descriptor: [Paroxetine] explode all trees 827 
#6 MeSH descriptor: [Sertraline] explode all trees 721 
#7 (citalopram or cipramil):ti,ab  1035 
#8 (dapoxetine or prilegy):ti,ab  48 
#9 escitalopram or cipralex:ti,ab,kw  (Word variations have been 
searched) 958 
#10 (fluoxetine or Prozac or oxactin):ti,ab  2420 
#11 (fluvoxamine or faverin):ti,ab  676 
#12 (paroxetine or seroxat):ti,ab  1834 
#13 (sertraline or lustral):ti,ab  1482 
#14 ssri:ti,ab  1157 
#15 sri:ti,ab  370 
#16 ssris:ti,ab  837 
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 
or #13 or #14 or #15 or #16  9375 
#18 pregnan*:ti,ab  21005 
#19 MeSH descriptor: [Pregnancy] explode all trees 6437 
#20 MeSH descriptor: [Pregnant Women] explode all trees 131 
#21 womb:ti,ab  174 
#22 (fetal or foetal):ti,ab  5427 
#23 MeSH descriptor: [Fetus] explode all trees 1657 
#24 MeSH descriptor: [Prenatal Exposure Delayed Effects] explode all trees
 301 
#25 ant*natal:ti,ab  2131 
#26 per*natal:ti,ab  2642 
#27 pr*natal:ti,ab  1973 
#28 intr*uterine:ti,ab,kw  (Word variations have been searched) 3009 
#29 pr*natal:ti,ab  1973 
#30 (fetus or foetus):ti,ab  1300 
#31 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or 
#28 or #29 or #30  30290 
#32 #17 and #31  53 
#33 MeSH descriptor: [Great Britain] explode all trees 6368 
#34 (uk or gb or nhs):ti,ab,pt  11279 
#35 "national health service"  2519 
#36 (England or Scotland or Ireland or wales):ti,ab,pt  4917 
#37 #33 or #34 or #35 or #36  20928 
#38 #32 and #37  3 
10/10/16 3 
Web of 
Science 
(SSRIs) 
# 10 99  #8 AND #4  
Refined by: 
COUNTRIES/TERRITORIES: ( IRELAND 
OR SCOTLAND OR ENGLAND OR WALES 
)  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 9 1,529  #8 AND #4  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 8 386,258  #7 OR #6 OR #5  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 7 13,790  TOPIC: ("in utero")  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
11/10/16 99 
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# 6 118,986  TOPIC: (pr*natal or ant*natal or 
per*natal or intr*uterine)  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 5 351,576  TOPIC: (pregnan* or womb or fetal or 
foetal or fetus or foetus)  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 4 35,426  #3 OR #2 OR #1  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 3 19,938  TOPIC: (citalopram or fluoxetine or 
fluvoxamine or paroxetine or 
sertraline or cipramil or dapoxetine or 
prilegy or escitalopram or cipralex or 
prozac or oxactin or faverin or seroxat 
or lustral)  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 2 116  TOPIC: ("serotonin and noradrenaline 
reuptake inhibitors")  
Timespan=All years 
Search language=Auto    
Select to 
combine 
sets.  
Select to 
delete 
this set. 
 
 
# 1 22,088  TOPIC: ("selective serotonin reuptake 
inhibitors") OR TOPIC: ("serotonin 
uptake inhibitors") OR TOPIC: (SSRIs or 
SRI or SSRI)  
Timespan=All years 
Search language=Auto    
  
 
TRIP 
(SSRIs) 
("selective serotonin reuptake inhibitors" or "serotonin uptake inhibitors" or 
citalopram or cipramil or dapoxetine or prilegy or escitalopram or cipralex or 
fluoxetine or prozac or oxactin or fluvoxamine or faverin or paroxetine or 
seroxat or sertraline or lustral or ssri or ssris or sri) AND (pregnan* or womb or 
fetal or foetal or fetus or foetus or prenatal or antenatal or perinatal or "in 
utero" or intrauterine) AND (uk or "united kingdom" or gb or "great britain" or 
england or scotland or ireland or wales) 
11/10/2016 366 (0 
selected) 
Opengrey 
(SSRIs) 
("selective serotonin reuptake inhibitors" OR "serotonin uptake inhibitors" OR 
citalopram OR fluoxetine OR fluvoxamine OR paroxetine OR sertraline OR 
cipramil OR dapoxetine OR prilegy OR escitalopram OR cipralex OR prozac OR 
oxactin OR faverin OR seroxat OR sertraline OR lustral OR ssri OR sri OR ssris) 
AND (pregnan* OR womb OR fetal OR foetal OR fetus OR foetus OR prenatal OR 
antenatal OR perinatal OR "in utero" OR intrauterine) AND (uk OR gb OR "united 
kingdom" OR "great britain" OR scotland OR engalnd OR ireland OR wales) 
11/10/2016 3 (0 
selected) 
PROSPERO 
(SSRIs)  
#1"selective serotonin reuptake inhibitors" or "serotonin uptake inhibitors" 
 38 
 
#2MeSH DESCRIPTOR Serotonin Uptake Inhibitors EXPLODE ALL TREES 15 
 
#3MeSH DESCRIPTOR Serotonin and Noradrenaline Reuptake Inhibitors EXPLODE 
ALL TREES 1 
 
#4citalopram or fluoxetine or fluvoxamine or paroxetine or sertraline or cipramil 
or dapoxetine or prilegy or escitalopram or cipralex or prozac or oxactin or 
faverin or seroxat or sertraline or lustral 59 
11/10/2016 23 
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#5ssri or ssris or sri 146 
 
#6#5 OR #4 OR #3 OR #2 OR #1 182 
 
#7pregnan* 1793 
 
#8MeSH DESCRIPTOR Pregnancy EXPLODE ALL TREES 882 
 
#9MeSH DESCRIPTOR Pregnant Women EXPLODE ALL TREES 9 
 
#10womb or fetal or foetal or fetus or foetus  528 
 
#11ant*natal or per*natal or pr*natal or intr*uterine  718 
 
#12"in utero"  55 
 
#13#12 OR #11 OR #10 OR #9 OR #8 OR #7 2125 
 
#14#6 AND #13  23 
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Appendix 3 – Psychotropics 
BNF Section Category  Class Drug Dose range 
(daily)1 
4.2.1 and 4.2.2 Antipsychotics Typical Benperidol 0.25-1.5mg 
Typical Chlorpromazine 75-1000mg 
Typical Flupentixol 1-18mg 
Typical Haloperidol 1-30mg 
Typical Levomepromazine 25-1000mg 
Typical Pericyazine 75-300mg 
Typical Perphenazine 12-24mg 
Typical Pimozide 2-20mg 
Typical Prochlorperazine 15-100mg 
Typical Promazine 400-800mg 
Typical Sulpiride 400-2400mg 
Typical Trifluoperazine 10-15mg 
Typical Zuclopenthixol 20-150mg 
Atypical Amisulpride 400-1200mg 
Atypical Aripiprazole 10-30mg 
Atypical Clozapine 200-900mg 
Atypical Olanzapine 10-20mg 
Atypical Palperidone 3-12mg 
Atypical Quetiapine 300-800mg 
Atypical Risperidone 2-16mg 
4.2.3 
(see also 4.8.1) 
Mood stabilisers - Carbamazepine 200-2000mg 
- Valproate 600-2500mg 
- Lithium As per serum 
level 
4.3 Antidepressants TCA Amitriptyline 10-200mg 
TCA Clomipramine 10-250mg 
TCA Dosulepin 75-225mg 
TCA Doxepin 75-300mg 
TCA Imipramine 75-300mg 
TCA Lofepramine 140-210mg 
TCA Nortriptyline 10-150mg 
TCA Trimipramine 50-300mg 
TCA-related Mianserin 30-90mg 
TCA-related Trazodone 150-600mg 
MAOi Phenelzine 45-90mg 
MAOi Isocarboxazid 30-60mg 
MAOi Tranylcypromine 20-30mg 
RIMA Moclobemide 300-600mg 
SSRI Citalopram 10-40mg 
SSRI Escitalopram 5-20mg 
SSRI Fluoxetine 20-60mg 
SSRI Fluvoxamne 50-300mg 
SSRI Paroxetine 10-60mg 
SSRI Sertraline 50-200mg 
SNRI Duloxetine 60-120mg 
NaSSA Mirtazapine 15-45mg 
NARI Reboxetine 8-12mg 
SNRI Venlafaxine 75-375mg 
4.8.1 Antiepileptics - Lamotrigine 100-500mg 
1 oral doses licensed in adults, for various indications including psychotic, affective and neurotic 
disorders 
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Appendix 5 – Defining the trimesters of pregnancy 
The trimesters of pregnancy have no agreed definition, and are used for 
convenience to stage a continuous process. Apart from the brain, organs are 
largely complete by the end of the first trimester, with growth and maturation 
characterising the second and third trimesters. Pregnancy is defined as lasting 
280 days (normal range 260-294) from the first day of the last menstrual period, 
and we took the timing of the trimesters to be as follows: 
 
Days Weeks Trimester 
1-7 1 1 
8-14 2 1 
15-21 3 1 
22-28 4 1 
29-35 5 1 
36-42 6 1 
43-49 7 1 
50-56 8 1 
57-63 9 1 
64-70 10 1 
71-77 11 1 
78-84 12 1 
85-91 13 1 
92-98 14 2 
99-105 15 2 
106-112 16 2 
113-119 17 2 
120-126 18 2 
127-133 19 2 
134-140 20 2 
141-147 21 2 
148-154 22 2 
155-161 23 2 
162-168 24 2 
169-175 25 2 
176-182 26 2 
183-189 27 3 
190-196 28 3 
197-203 29 3 
204-210 30 3 
211-217 31 3 
218-224 32 3 
225-231 33 3 
232-238 34 3 
239-245 35 3 
246-252 36 3 
253-259 37 3 
260-266 38 3 
267-273 39 3 
274-280 40 3 
281-287 41 3 
288-294 42 3 
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Appendix 7 – Scan information leaflet 
	Version 1 - 1 October 2009  
Helping mums, 
caring for babies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information 
about the MRI scan 
 
 
Please read carefully 
Page 293 of 365 
	Version 1 - 1 October 2009  
Where to come 
 
• Institute of Neurological Sciences, Zone 3, Southern General 
Hospital (see accompanying map on page 5). 
• Turn right after entering the building, and enter the 
Department of Neuroradiology (next to Aroma coffee). 
• Call/text Everett on 07985 956997 or ask at the reception 
desk - I’ll be expecting you. 
 
 
 
 
 
 
When to come 
 
• Please try to come around 9:30am. 
• Let me know if you need transport. 
• If you need a parking space, please call/text Everett on 
07985-956997 when you arrive. 
 
 
 
 
 
 
What to bring 
 
• Please bring a swaddling blanket. 
• MRI uses magnets, so baby’s clothes musn’t have any metal 
poppers or fasteners. 
• We will provide clean clothes and blankets if you don’t have 
anything suitable. 
• Please bring nappies and wipes. 
• If baby is bottle-fed, please bring a feed with you. 
• As the scan room can feel cool, please bring a cardigan or 
jumper for yourself. 
• You may want to bring something to read during the scan. 
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Feeding and sleeping 
 
• It’s great if baby can come to the scan hungry and tired! 
• Then baby can feed and go to sleep. 
• This is because we need baby to stay still during the scan to 
get the best pictures we can. 
• So please try to keep baby awake when coming to the scan. 
• If baby sleeps on the way to hospital, we might not be able to 
do the scan. 
• If baby wants fed before coming to the Southern, please try 
to give a half feed, saving the rest for just before the scan. 
 
 
 
What actually happens? 
 
• We’ll meet you, and go to a room next to the MRI scanner. 
• We’ll check that it’s OK to do the scan. 
• We’ll give baby a check-up, by asking about feeding and 
sleeping, and by measuring head circumference. 
• Baby’s nappy and clothes can be changed (if necessary). 
• We’ll use ear pads and a hat for baby, to keep him/her warm 
and to keep things quiet for sleeping. 
• Baby can then be swaddled and fed. 
• When baby is sleeping, he/she can go in the MRI scanner. 
• The scan will take around 45 minutes to 1 hour to complete, 
and we may have to pause or stop if baby moves. 
• During the scan you can stay in the room with baby or be 
nearby while speaking to one of us. 
• We will keep a close eye on baby during the scan to make 
sure that everything is OK, including heart rate. 
• It’s natural to feel a bit anxious during the first scan. 
• If you have any questions at any time, just ask. 
• After the scan we will send the data to one of our specialist 
colleagues for checking. 
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Information about MRI scans 
 
• MRI stands for Magnetic Resonance Imaging. 
• MRI produces images of the inside of the body without using 
X-rays. 
• It works by using a strong magnet, radio waves and a 
computer. 
• You will be asked to complete a safety checklist for baby. 
• You will be asked to complete the safety checklist, too. 
 
 
 
 
 
Please note that the department 
does not have childminding facilities 
 
 
 
 
Contact details 
 
Web www.helpingmums.org.uk 
 
Email info@helpingmums.org.uk 
 
Tel 07985-956997 
 
Institute of Health & Wellbeing 
College of Medical, Veterinary & Life Sciences 
University of Glasgow 
Sackler Institute of Psychobiological Research 
Southern General Hospital 
Glasgow G41 5TF 
 
 
                 in association with 
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MRI STUDIES OF INFANTS EXPOSED PRENATALLY TO DEPRESSION AND 
ANTIDEPRESSANTS  
 
INFORMATION SHEET Version 4 20/04/09 
 
We are asking you to help with research that is being carried out by the University of Glasgow and 
NHS Greater Glasgow & Clyde. The research project aims to explore whether there are any effects of 
depression and antidepressant medication on the developing brain and on behaviour in babies. 
 
 
What we are asking you to do 
 
We would like to review your clinical records, carry out a clinical interview,  measure your baby’s 
heart rate and do some psychological tests during your pregnancy. Once baby is born we would like to 
carry out a brain scan on your baby at aged 1 month and again at 4 months. The type of brain scan is 
MRI.  
 
In order to decide whether or not you wish to enroll yourself and your child, you should know about the 
risks and benefits of participating. This information sheet provides the essential details about this 
project. If you would like to know more, a member of the research team will also discuss the project 
with you and answer any of your questions about the project. This discussion will go over all aspects of 
the study, including its purpose, its procedures, any risks of participating, the potential benefits of 
participating. Once you understand the study, you will be asked if you are willing to enrol yourself and 
the baby in the study. If so, you will be asked to sign a consent form. 
 
Alternatives to Participation 
 
You do not need to participate in this research. The information gathered in this study is for research 
purposes and is not intended to guide the care for you or the infant.  
 
Description of Procedures 
 
The study will be conducted following your antenatal visit and at the Southern General Hospital in 
Glasgow (or other location suitable to you). There is no treatment involved for you or the baby. 
Information is being collected for research purposes only. 
The project is a 2-year study.  
1) Clinical information, gathered through personal interviews, will address your medical, 
emotional, and medication-use history.   
2) Physical examination, neurological evaluation, and MRI scan of the baby 1 month and 4 
months after birth. 
3) Standardized developmental and psychological tests will be administered to you and your baby 
at each visit. We will also observe your baby’s behaviours.   
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1. Your Clinical Interviews, Baby’s Heart Rate & Psychological Tests 
This set of interviews generally takes no more than 2 hours. Questions will be asked about your 
medical and emotional history, family life, support systems, relationships, parenting beliefs and 
practices, and history of medication use. In addition, we are requesting permission to review the 
clinical and hospital charts for you and the baby. 
We would also like to measure baby’s heart rate. This will be done using a non-invasive monitor 
(Monica AN24), consisting of a unit the size of an MP3 player worn around your neck with 5 leads 
attached to your tummy. This can be done while the other assessments are being made.  
 
 
 
2. The Baby’s MRI Scan 
 
At aged 1 month, the baby will receive a physical, neurological, and behavioural examination that will 
take about 40 minutes. At a time that is convenient for you and the baby, you and the baby will be 
escorted to the MRI scanner. A member of the research team will explain the MRI procedure in detail 
before the scan and will be present throughout the entire scan. A paediatrician will also be present with 
the baby throughout the entire scan. 
 
 
The baby’s breathing and heart rate will be monitored throughout the scan. This is done to ensure the 
complete safety of the baby during the scan, and not because the scan will affect the baby’s heart or 
breathing in any way. We will also give the baby earplugs as well as earmuffs to help dampen the 
sound of the scanner and be sure that the baby can sleep soundly through the scan. You will then feed 
and swaddle the baby, and together with the study team, we will move the baby while sleeping into the 
scanner.   
 
For the MRI scan, the baby will lie on a padded table that moves into a doughnut-shaped magnet. The 
baby is unlikely to feel any discomfort at all during the scan, although the machine can be noisy during 
the scan. The noises are usually knocking or buzzing sounds, which the ear muffs will help to dampen 
for the baby. This knocking is the magnet taking pictures. We will give you ear plugs to block out most 
of the noise as well. You, the technologist operating the scanner, and the paediatrician will be able to 
see the baby during the scan, and we will all be able to hear if the baby wakes up and cries. You may 
stay in the room with the baby during the entire scan, which will take approximately 60 minutes once 
the scan begins.  If you decide that you do not want to be in the room during the scan, you are welcome 
to bring a friend or family member to sit in the room with the baby.  
  
Within 1 month of the MRI scan, the scan will receive a clinical reading and any significant results will 
be shared with you and a physician of your choice. 
 
For the second scan, we will contact you when baby is just about to turn 4 months. 
 
Scanning the baby twice will allow us to see the growth and development of the baby’s brain as it 
changes during the first year of life.  The procedure for the rescan will be exactly the same as that of 
the first scan.  The second scan will take approximately 60 minutes. You can be with the baby in the 
scan room.   
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Risks and Inconveniences 
 
Clinical Interviews & Examinations: The risks of the interviews (for you), neuropsychological 
testing (for you and the child), and physical examinations (for the baby) are few. These procedures do 
take time to complete, so we have built in short breaks to minimize fatigue. You can stop at any time, 
and we can offer the sessions in 2 appointments if you so desire.  You do not have to answer all 
questions if they make you uncomfortable. 
 
MRI:  The long-term effects of being placed in a magnet of this strength (3 Tesla) are unknown, but 
you should be aware that there have been no reports of any ill long-term effects caused by magnets of 
the same or even higher strength. Except for people who have some types of metallic implants, we 
know of no health hazard from the MRI scan. The scan can be noisy, and so we will provide ear plugs 
and ear muffs for your baby to reduce that noise level. If he or she cries, the scan will be interrupted 
and the baby will be attended to immediately. You and the study team, or a person of your choice will 
remain with the baby throughout the entire scan to ensure optimal comfort.  The additional scan does 
not put the baby at greater risk.  The risk is the same as with the first MRI scan.  
 
Benefits  
 
The MRI pictures, clinical interviews, physical examinations, and neuropsychological tests are unlikely 
to be of direct benefit to you or the child.  While MRI scans are sometimes done for clinical purposes, 
the kind of MRI scan you will have as part of this study is for research purposes only. Nevertheless, 
these scans will be checked by a consultant radiologist and if any clinically significant findings happen 
to be detected on the MRI scan, or if we detect clinically significant findings on the neuropsychological 
tests or clinical interviews regarding you or the child’s psychological well-being, we will provide you 
with that information and appropriate referrals will be made for treatment.  Finally, the findings of this 
study could add to our understanding of the effects that exposure to illness or medication during 
pregnancy has on brain development, and this knowledge could one day benefit other children in 
similar situations. 
 
Confidentiality 
 
Information obtained in this study, as well as information from the baby’s hospital chart review, is 
strictly confidential unless the law requires disclosure.  You will be assigned a research number, rather 
than your name, which will be recorded on data we collect about you and the baby. All of this data will 
be secured under lock and key. Your name will not be used in the reporting of information in 
publications or conference presentations.  
 
 
 
 
Research Standards and Rights of Participants  
 
Participation in this research study is voluntary.  If you decide not to participate, or if you later decide 
to stop participating, neither you nor the child will lose any benefits to which you are otherwise 
entitled.  A decision not to participate will not effect the treatment of you or the child in any way. 
Should you wish to consult an independent doctor further about this study. 
 
Dr Michael Smith would be available at: Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE. 
Telephone  0141 884 5122 
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Appendix 12 - Visit to the Sackler Institute, Columbia 
University, New York, USA 
	
Professor Jonathan Cavanagh (JC), Dr John McLean (JMcL), and Dr Everett Julyan 
(EJ) visited the Sackler Institute, Columbia University, New York, in September 
2009, spending time with various collaborators over a three day period. Although 
we planned to observe a scan from start until finish, this proved impossible as 
the scanner was “down” pending maintenance. We were advised that we should 
expect this to be a common problem in Glasgow. 
Despite this, it had been arranged that a participant would attend with her 
baby, and go through the entire process without scanning actually taking place, 
so that we could understand each stage. We learned that women were recruited 
via the New York-Presbyterian Hospital (NYPH), a university teaching hospital 
ranked among the top 10 hospitals in the USA (US News and World Report, 2015 
http://health.usnews.com). It is affiliated with two Ivy League medical schools, 
Columbia and Cornell, and has over 2,400 beds, dispersed between a number of 
sites, including the Morgan Stanley Children’s Hospital (MGCH), where the 
scanning took place. The MGCH serves a wide metropolitan area in Manhattan, 
including the deprived area of Harlem, from which many scanning subjects were 
recruited, especially those using prescribed and non-prescribed opiates during 
pregnancy. 
MSCH obstetricians, midwives and paediatricians were involved in identifying 
potential participants antenatally, and women were offered an incentive of 
vouchers for baby products worth $100 to take part in the study. A battery of 
maternal assessments and rating scales were completed at least once during 
pregnancy, including a standard psychiatric history, the Structured Clinical 
Interview for DSM-IV-TR Axis I disorders (SCID-I/NP), the Hamilton Rating Scale 
for Depression (HRSD), the Clinician-Administered PTSD Scale for DSM-IV (CAPS), 
the Stroop Test, and the National Adult Reading Test (NART). 
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Women were invited to attend with their babies between 43 and 46 weeks 
gestational age by scan, and to present at the research location between 9am 
and 10am. As neonates spend most of their time sleeping, punctuated by short 
periods of feeding and activity, women were advised to bring their babies hungry 
and tired, by keeping their babies awake from the time they woke up in the 
morning until arriving at the scanning suite, and unfed for at least 3 hours, with 
the expectation and intention that they would then be ready to feed, and then 
more likely to sleep during the scan. Our colleagues had one full time researcher 
dedicated to looking after the mothers and babies, in addition to support from 
radiographers, radiologists, physicists, paediatricians, other research staff, and 
administrative infrastructure. Moreover, they had daily access to a MRI scanner 
dedicated solely to research. 
Prior to scanning, each mother was interviewed to update the assessments and 
rating scales, with a specific emphasis on prescribed and other drugs, and 
maternal mood, alongside general questions about her baby’s health, 
development, feeding and sleeping. The infant’s weight was noted, and both 
mother and baby had an MRI checklist completed, to ensure safety, with all 
ferromagnetic materials being removed at that point (mothers were encouraged 
to enter the scan room, and even stay with their little one throughout the scan 
if they wished). Babies had their diapers changed, were tightly swaddled, and 
had ear protectors fitted. They were then fed by breast or bottle, winded, and 
allowed to fall asleep, before being carried into the scan room and placed on 
the MR bed. 
When the scanner was functional, various scan sequences to establish 
positioning, total brain volume, regional volumes, white matter integrity, and 
cell metabolism were completed, lasting 45-60 minutes. We were advised to 
expect babies to wake up frequently during the scans, particularly when moving 
from one sequence to another (heralded by periods of sudden silence, then a 
sudden change in noise pattern, often associated with a startle response from 
the babies). Our colleagues explained that they often set aside a whole day for 
each scan, and recommended that we plan for the same, including that we 
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retain the option to invite each mother back the following day if the scans had 
not been completed successfully. 
JMcL then spent time with the physicists, clarifying their scanning protocols, and 
learning from their experiences of unsuccessful scans, technical challenges, and 
how to overcome these, while EJ practiced his swaddling technique under 
supervision. EJ was advised to “look after” the mothers and babies well, and to 
seek to be reassuring throughout the day of the scans, as most mothers would be 
anxious to some degree. It was thought particularly important to leave plenty of 
time for the scans, as working under the pressure of time would not be 
conducive to avoiding anxiety, and in particular to allow sufficient time to 
repeat sequences several times. There was also extensive discussion about the 
differences between the Columbia research, and that to which we were aspiring 
in Glasgow, and caution advised about the likely success of our endeavours, due 
to the significant disparity in resources. Our New York colleagues were uncertain 
about our ability to complete the proposed scanning, as EJ as the main 
researcher would be attempting the study in only 4 hours per week (Wednesdays 
9am to 1pm) as part of “Supporting Professional Activities” time in his job plan 
as a fulltime NHS Consultant Psychiatrist, without dedicated research or 
administrative support. Similarly, JMcL would be the only physicist involved, and 
although we had input from colleagues in radiography, radiology, and midwifery, 
our resources were significantly less than those of our Columbia collaborators. 
Moreover, the MRI scanner we planned to use was an NHS unit, used for clinical 
healthcare in addition to research, and there would be no option to scan outwith 
the allotted slot, nor invite participants back the following day. Furthermore, 
we were advised to source accommodation and storage, for assessments, 
preparation, and equipment, as it was not clear if these would be available in 
Glasgow. 
We discussed the best stage at which to scan, and were advised that as early as 
possible between 43 and 46 weeks gestational age by antenatal ultrasound scan 
was advisable, as this would allow us to compare findings between the USA and 
the UK, in addition to this being a stage at which babies were as likely as any to 
sleep throughout the scans. As babies tend to sleep in 40-45 minutes cycles we 
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learned that it was advisable to keep the combined scan sequences below this 
target duration, and/or to allow adequate time for breaks, and that we should 
be ready to start scanning as soon as the baby was soundly asleep. It was 
recommended that we change each baby before feeding, to avoid subsequent 
nappy changes waking him/her up, and to swaddle and secure ear protectors 
before feeding for the same reason. We were also advised to ask mothers to 
bring a cardigan for themselves in case they wanted to stay in the scan room 
throughout, as the ambient temperature is low due to the cryogenic agents used 
to optimise superconduction of the electromagnetic coils. 
As any results and conclusions would be based on comparative findings between 
our three proposed study groups, we were also advised to scan each baby twice, 
to allow comparison of developmental trajectories, i.e. growth differences 
between each group. This would allow not only a snapshot of structural, tract 
and spectroscopy parameters in each group of subjects at one month, but also 
relative changes between each group, in addition to within each subject. We 
were recommended to consider rescanning at four months postnatally, ~56 
weeks gestational age, as after this time contrast and discrimination are 
diminished in T1-weighted scans due to changes in the developing brain 
parenchyma, and also as infants become increasingly less likely to complete MR 
scans without anaesthesia beyond this age.  
Other recommendations included obtaining paediatric advice and support, 
especially with regards to monitoring babies while in the MR scanner, via 
electrocardiography, oximetry, and temperature checking using neonate-
appropriate equipment. Clinically competent staff should also be on hand, in 
case of unforeseen events or emergencies. To put mothers at ease we were 
advised to give as much detailed and specific information in advance as possible, 
including exactly what should/would happen on the day of the scan, including 
exactly who would be there, and also a tour of the scanning suite during 
antenatal assessment. We would need access to a suitable room in which to 
assess mums-to-be, as well as a space to use to prepare for the scans. MR-safe 
equipment would need to be provided (vests without metal fasteners, clothes, 
hats, blankets, and nappies), and wipes, bottle warmers, and beverages 
Page 307 of 365 
available for mums, too. We would also require secure clean storage for our 
apparatus, and means of laundering and sterilising paraphernalia. 
We were encouraged to consider what incentives we could offer potential 
participants, e.g. free samples or vouchers for baby items, or a print of one of 
the scans, and to think about what prospective follow-up we should put in place, 
to monitor long term clinically relevant outcomes. We were advised to review 
scans immediately, while mother and baby were still present, to ensure 
adequate scan data acquisition. Other suggestions included incorporating 
measures of antenatal and postnatal distress, via maternal rating scales and 
fetal/neonatal heart rate variability and salivary/urinary cortisol, and even 
maternal/fetal genotyping via cord blood, to take account of SERT and BDNF 
polymorphisms known to influence neurodevelopment. 
We were advised to be alert to child abuse issues, e.g. shaken baby syndrome, 
and to ensure that all scans would be reviewed by an appropriately experienced 
radiologist, with a clear plan in place to manage any incidental pathological 
findings. In view of our limited resources, we were encouraged to think about 
involving others on a voluntary basis, e.g. undergraduate medical and 
intercalating students for audits, and postgraduate trainees in psychiatry, 
psychology, paediatric, obstetrics & gynaecology, and/or radiology to assist in 
maternal assessments and supervising scans. 
Above all, we were advised to standardise all measures as much as possible, 
without sacrificing patient participation or data acquisition, e.g. completing 
rating scales and scans in all subjects at comparable time points. 
After returning to Glasgow, we met with the Glasgow PMHS lead psychiatrist, to 
discuss the way forward. As per the advice received, we developed our 
hypotheses and aims as detailed above. 
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Appendix 13 – Scanning protocol 
On the MRI select Babies 1 Month or Babies 4 Month protocol depending on the 
age of the infant. 
NB: Please note, the imaging parameters prescribed for all the following 
imaging sequences described have been carefully considered and should not 
be changed. This is to facilitate the optimum comparison between study 
groups by minimising the amount of variation and error in the subsequent 
measurements that will be made. Similarly, one should follow this imaging 
protocol such that images are planned consistently throughout the study. 
NB: Copy Rx may be used throughout to replicate slice orientations only. I.e. 
do not copy slice thicknesses etc across different acquisitions. 
Localiser 1: Use the longer (42s), quieter localiser 
Localiser 2: Re-run the longer (42s), quieter localiser correcting for baby head 
position 
Sequence: 3D IR-FSPGR 
Plan: This axial oblique acquisition should be planned with respect to the AC-PC 
points on the sagittal localiser image. The planned acquisition should also be 
corrected on the coronal localiser (relative to temporal horns), and axial 
localiser (relative to inter-hemisphere boundary) planes such that it is ‘straight’. 
The acquisition should include the whole head, i.e. include skull as well as 
brain. Care must be taken to avoid image wrap. 
Purpose: This 3D acquisition has been prescribed to optimise the grey matter/ 
white matter contrast (GM/WM), hence the longer than normal (adult) inversion 
time for this neonatal study. The 3D acquisition will be used to create group 
averaged template neonatal images which will allow GM and WM volumes and 
concentrations to be compared across study groups. 
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Sequence: T2 measures (1, 2 and 3) (Dual TE, FSE-XL) 
Plan: This axial oblique acquisition should be planned with respect to the AC-PC 
points on the sagittal localiser image. The planned acquisition should also be 
corrected on the coronal localiser (relative to temporal horns), and axial 
localiser (relative to inter-hemisphere boundary) planes such that it is ‘straight’. 
These scans are relatively short, but multiple acquisitions will necessary to cover 
the whole brain. NB: maximise number of slices per acquisition number (~ 6 
slices x 4 acquisitions to cover whole head) 
Purpose: T2 values change rapidly in early life. We aim to compare T2 values in 
different regions of the brain across the three groups in this study (normal, 
depressed/ unmedicated, depressed/medicated). To obtain T2 values, multiple 
TE value images are acquired. 
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Asset Calibration: 
Plan: This must be planned as a straight axial acquisition and cover the entire 
field of view 
Purpose: Acquiring the asset image enables parallel imaging to be used with the 
subsequent DTI acquisition. This results in the DTI acquisition being significantly 
less time to acquire. 
Sequence: DTI (Single shot, DW-EPI, b = 600, 3 x b0 acquisitions, 11 diffusion 
directions) 
Plan: This axial oblique acquisition should be planned with respect to the AC-PC 
points on the sagittal localiser image. The planned acquisition should also be 
corrected on the coronal localiser (relative to temporal horns), and axial 
localiser (relative to inter-hemisphere boundary) planes such that it is ‘straight’.  
NB: Following ‘Save series’ and ‘Download’, the transmitter gain (TG) must 
be amended. Run ‘Manual prescan’ the TG is likely to be around 160, this 
should be set to 85, modify the value and then let manual prescan continue 
to run for a few seconds, then click ‘apply’. 
Run the Scan 
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Purpose: Brain diffusion values change rapidly in early life. We aim to compare 
diffusion values in different regions of the brain across the three groups in this 
study. 
 
Sequence: Dual echo T2 FSE-XL (For mid-brain structure volume 
measurements) 
Plan: This coronal acquisition should be planned perpendicular to the 
hippocampus. The slices should cover anterior to posteriorly the amygdala to the 
tail of the hippocampus. 
Purpose: The coronal acquisition will allow mid-brain structures such as the 
amygdala and hippocampus to be measured such that the size of these 
structures can be compared between the three groups in the study.  
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Sequence: MRS (Magnetic Resonance Spectroscopy) 
Plan: The 3cm (R/L) x 1cm (A/P) x 2cm (S/I) single voxel should be placed within 
the white matter of the cerebellum, centred on the inter-hemispheric boundary. 
Plan on the T1 3D, T2 FSE and/or localiser images, use 2 or 3 planes. Save a 
screenshot of the voxel position (Go to image browser screen > right click on 
background > service tools > command line > type gimp). 
Purpose: We aim to compare metabolite ratios in the cerebellum, a key area in 
brain development, between the three groups in this study. 
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Appendix 14 – Parameters for one month scans 
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Appendix 15 – Parameters for four month scans 
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Appendix 16 – Ethical approval 
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Appendix 17 – Email correspondence re: ALSPAC 
From: Kate Northstone <Kate.Northstone@bristol.ac.uk> 
Subject: Fwd: FW: Informal enquiry - ALSPAC data on long term consequence 
of antenatal antidepressants 
Date: 26 February 2013 20:51:49 GMT 
To: everett@julyan.co.uk 
Reply-To: Kate.Northstone@bristol.ac.uk 
 
Dear Everett, 
 
Further to the message below: Yes, it is most likely that this project would be 
feasible. To be sure and to obtain formal approval you need to complete a 
proposal form (http://www.bristol.ac.uk/alspac/researchers/data-access/) and 
submit to alspac-exec@bristol.ac.uk. We have a standard access fee, which is 
currently £702. THe medication data may be tricky in that it is highly 
identifiable in it's raw state (from text responses to Qs) and additional work will 
be required to identify the exact drugs that you would require and to create 
relevant indicator variables - additional informaiton would be provide on this if 
your project was approved.  A standard data request takes two weeks from the 
time that a 'clean' request is made to the team. 
 
Kind regards 
Kate 
 
Dr Kate Northstone 
Senior Research Fellow  
 
ALSPAC (Children of the 90s) 
School of Social and Community Medicine 
University of Bristol 
Oakfield House 
Oakfield Grove 
Bristol 
BS8 2BN     
 
Tel: +44 (0) 117 3310040 
Fax: +44 (0) 117 3310080 
Follow us on Twitter @CO90s 
 
 
From: T Everett Julyan [mailto:everett@julyan.co.uk] 
Sent: 26 February 2013 12:40 
To: alspac-exec@bristol.ac.uk 
Subject: Informal enquiry - ALSPAC data on long term consequence of antenatal 
antidepressants 
 
Dear Sir/Madam 
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I wish to make an informal enquiry re: accessing the ALSPAC data to determine 
the long term consequences of antenatal exposure to antidepressants. I am a 
consultant psychiatrist in Ayrshire, Scotland, with a research interest in the 
neurodevelopmental effects of psychotropics. I am currently working towards an 
MD via the University of Glasgow, and am considering accessing ALSPAC data as 
part of this. 
 
I wish to acquire data on the parameters below, and have gleaned from your 
website that much of this is likely to be available. I would be happy to 'phone to 
discuss this enquiry further, but wonder: 
 
1. Is this feasible? 
2. How much would it cost? 
3. What would be the timescale(s) involved? 
 
Thank you. 
Everett Julyan 
  
Parameters 
  
Mother 
General 
Age 
Socioeconomic status 
Parity 
Depression/anxiety during pregnancy (timing, severity, self-reported or 
clinician-diagnosed?) 
Psychotropic medication during pregnancy (what, dose, timing, self-reported 
or confirmed from records) 
Other medication during pregnancy 
Substances/alcohol during pregnancy (what, dose, timing) 
Postnatal depression 
Breastfeeding +/- psychotropic medication 
Obstetric 
Antenatal issues - infections, bleeding, other significant complications 
Labour complications - length, PROM, streptococcal infection, pyrexia 
Haemorrhage (antenatal, pre/intra/post-partum) 
Delayed discharge 
  
Child 
Neonatal 
APGARs, birth weight, gestational age, pulmonary hypertension, adaptation 
syndrome (abnormal sleep or feeding, irritability) 
Major congenital malformations 
Other/minor congenital malformations 
Admission to SCBU/NICU 
Childhood 
Medical history (significant childhood illnesses, depression, anxiety, contact 
with mental health services, other referrals to secondary care or hospital 
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admissions) 
Forensic issues (criminal charges) 
Substance misuse 
Educational outcomes (SATS, GCSEs/A levels, further/higher education, 
qualifications) 
Vocational (employment/unemployment post-education) 
Relationships (any consistent/pervasive difficulties) 
Social functioning 
_________________________ 
Dr T Everett Julyan 
Consultant Psychiatrist 
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